prediction_file,target_file,field_name,evaluation_method,scoring_type,tp,fp,fn,tn,expected,actual
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,title,exact,string,1,0,0,0,Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy,Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,title,levenshtein,string,1,0,0,0,Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy,Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,abstract,exact,string,0,0,1,0,"Background Hypophosphatemia occurs in up to 80% of the patients during continuous renal replacement therapy (CRRT). Phosphate supplementation is time-consuming and the phosphate level might be dangerously low before normophosphatemia is re-established. This study evaluated the possibility to prevent hypophosphatemia during CRRT treatment by using a new commercially available phosphate-containing dialysis fluid. Methods Forty-two heterogeneous intensive care unit patients, admitted between January 2007 and July 2008, undergoing hemodiafiltration, were treated with a new Gambro dialysis solution with 1.2 mM phosphate (Phoxilium) or with standard medical treatment (Hemosol B0). The patients were divided into three groups: group 1 (n=14) receiving standard medical treatment and intravenous phosphate supplementation as required, group 2 (n=14) receiving the phosphate solution as dialysate solution and Hemosol B0 as replacement solution and group 3 (n=14) receiving the phosphate-containing solution as both dialysate and replacement solutions. Results Standard medical treatment resulted in hypophosphatemia in 11 of 14 of the patients (group 1) compared with five of 14 in the patients receiving phosphate solution as the dialysate solution and Hemosol B0 as the replacement solution (group 2). Patients treated with the phosphate-containing dialysis solution (group 3) experienced stable serum phosphate levels throughout the study. Potassium, ionized calcium, magnesium, pH, pCO2 and bicarbonate remained unchanged throughout the study. Conclusion The new phosphate-containing replacement and dialysis solution reduces the variability of serum phosphate levels during CRRT and eliminates the incidence of hypophosphatemia.",
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,abstract,levenshtein,string,0,0,1,0,"Background Hypophosphatemia occurs in up to 80% of the patients during continuous renal replacement therapy (CRRT). Phosphate supplementation is time-consuming and the phosphate level might be dangerously low before normophosphatemia is re-established. This study evaluated the possibility to prevent hypophosphatemia during CRRT treatment by using a new commercially available phosphate-containing dialysis fluid. Methods Forty-two heterogeneous intensive care unit patients, admitted between January 2007 and July 2008, undergoing hemodiafiltration, were treated with a new Gambro dialysis solution with 1.2 mM phosphate (Phoxilium) or with standard medical treatment (Hemosol B0). The patients were divided into three groups: group 1 (n=14) receiving standard medical treatment and intravenous phosphate supplementation as required, group 2 (n=14) receiving the phosphate solution as dialysate solution and Hemosol B0 as replacement solution and group 3 (n=14) receiving the phosphate-containing solution as both dialysate and replacement solutions. Results Standard medical treatment resulted in hypophosphatemia in 11 of 14 of the patients (group 1) compared with five of 14 in the patients receiving phosphate solution as the dialysate solution and Hemosol B0 as the replacement solution (group 2). Patients treated with the phosphate-containing dialysis solution (group 3) experienced stable serum phosphate levels throughout the study. Potassium, ionized calcium, magnesium, pH, pCO2 and bicarbonate remained unchanged throughout the study. Conclusion The new phosphate-containing replacement and dialysis solution reduces the variability of serum phosphate levels during CRRT and eliminates the incidence of hypophosphatemia.",
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,keywords,exact,set,0,0,0,1,,
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,keywords,levenshtein,set,0,0,0,1,,
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,author_surnames,exact,set,0,1,0,0,"BROMAN, CARLSSON, FRIBERG, GODALY, WIESLANDER","Broman, Carlsson, Friberg, Godaly, Wieslander"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,author_surnames,levenshtein,set,0,1,0,0,"BROMAN, CARLSSON, FRIBERG, GODALY, WIESLANDER","Broman, Carlsson, Friberg, Godaly, Wieslander"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,first_author_surname,exact,string,0,1,0,0,BROMAN,Broman
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,first_author_surname,levenshtein,string,0,1,0,0,BROMAN,Broman
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,author_full_names,exact,set,0,1,0,0,"A WIESLANDER, G GODALY, H FRIBERG, M BROMAN, O CARLSSON","A Wieslander, G Godaly, H Friberg, M Broman, O Carlsson"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,author_full_names,levenshtein,set,0,1,0,0,"A WIESLANDER, G GODALY, H FRIBERG, M BROMAN, O CARLSSON","A Wieslander, G Godaly, H Friberg, M Broman, O Carlsson"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,first_author_full_name,exact,string,0,1,0,0,M BROMAN,M Broman
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,first_author_full_name,levenshtein,string,0,1,0,0,M BROMAN,M Broman
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,affiliation_strings,exact,set,1,0,0,0,"Department of Anaesthesiology and Intensive Care, Lund University Hospital, Lund, Sweden, Gambro Lundia AB, Lund, Sweden","Department of Anaesthesiology and Intensive Care, Lund University Hospital, Lund, Sweden, Gambro Lundia AB, Lund, Sweden"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,affiliation_strings,levenshtein,set,1,0,0,0,"Department of Anaesthesiology and Intensive Care, Lund University Hospital, Lund, Sweden, Gambro Lundia AB, Lund, Sweden","Department of Anaesthesiology and Intensive Care, Lund University Hospital, Lund, Sweden, Gambro Lundia AB, Lund, Sweden"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,affiliation_institution,exact,set,1,0,0,0,"Department of Anaesthesiology and Intensive Care, Lund University Hospital, Gambro Lundia AB","Department of Anaesthesiology and Intensive Care, Lund University Hospital, Gambro Lundia AB"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,affiliation_institution,levenshtein,set,1,0,0,0,"Department of Anaesthesiology and Intensive Care, Lund University Hospital, Gambro Lundia AB","Department of Anaesthesiology and Intensive Care, Lund University Hospital, Gambro Lundia AB"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,section_titles,exact,list,0,1,0,0,"Methods, Fluid composition and study design, Patients and CRRT treatments, Clinical parameters of the patients, Statistics, Results, Discussion","Methods, Fluid composition and study design, Patients and CRRT treatments, Clinical parameters of the patients, Statistics, Results, Hypophosphatemia prevention during CRRT, Discussion"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,section_titles,levenshtein,list,0,1,0,0,"Methods, Fluid composition and study design, Patients and CRRT treatments, Clinical parameters of the patients, Statistics, Results, Discussion","Methods, Fluid composition and study design, Patients and CRRT treatments, Clinical parameters of the patients, Statistics, Results, Hypophosphatemia prevention during CRRT, Discussion"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,tables,exact,table,0,1,0,0,"[[["""", ""Hemosol B0 (mmol/l)"", ""Phosphate containingdialysis solution (mmol/l)""], [""Bicarbonate"", ""32"", ""30""], [""Lactate"", ""3"", ""0""], [""Calcium"", ""1.75"", ""1.25""], [""Magnesium"", ""0.5"", ""0.6""], [""Potassium"", ""0"", ""4""], [""Sodium"", ""140"", ""140""], [""Phosphate"", ""0"", ""1.2""], [""Chloride"", ""109.5"", ""115.9""]], [[""Main diagnoses"", ""Group 1"", ""Group 2"", ""Group 3""], [""Septic shock"", ""5"", ""8"", ""7""], [""Pneumonia"", ""2"", ""1"", ""0""], [""Cardiac insufficiency"", ""0"", ""0"", ""3""], [""Cardiac arrest"", ""1"", ""0"", ""2""], [""Major intoxication"", ""1"", ""0"", ""1""], [""Rupture of aortic aneurysm"", ""0"", ""0"", ""2""], [""Myocardial infarction"", ""0"", ""0"", ""1""], [""Cardiogenic shock"", ""0"", ""0"", ""1""], [""Sclerosis cholangitis"", ""0"", ""0"", ""1""], [""Unspecified respiratory failure"", ""1"", ""0"", ""0""], [""Obstructing malignant intestinal tumour"", ""1"", ""0"", ""0""], [""Epilepsy"", ""1"", ""0"", ""0""], [""Unspecified muscle disease"", ""0"", ""0"", ""1""]], [["""", ""Group 1"", ""Group 2"", ""Group 3""], [""Demographics*""], [""Age (years)"", ""63 (43\u201386)"", ""68 (37\u201388)"", ""67 (53\u201383)""], [""Weight (kg)"", ""80 (53\u2013116)"", ""86 (56\u2013124)"", ""79 (41\u2013130)""], [""Male sex, n (%)"", ""7 (50)"", ""7 (50)"", ""5 (36)""], [""APACHE II*"", ""28.1 (19\u201344)"", ""26 (13\u201336)"", ""23.2 (15\u201329)""], [""RIFLE score, points*,\u2020"", ""37"", ""39"", ""39""], [""Delivered CRRT*""], [""CRRT treatment duration (h)"", ""82 (17\u2013278)"", ""115 (37\u2013207)"", ""96 (29\u2013210)""], [""CRRT treatment mode"", ""CVVHDF"", ""CVVHDF"", ""CVVHDF""], [""Effluent flow (ml/kg/h) calculated on active treatment time*,\u2021"", ""23.7 (13\u201345)"", ""21.9 (15\u201330)"", ""18 (10\u201320)""], [""Proportion of ordered dose delivered*"", ""85.3%"", ""87.5%"", ""91.8%""], [""Anticoagulation*"", ""None 3"", ""None 2"", ""None 2""], ["""", ""Heparine 9"", ""Heparine 11"", ""Heparine 10""], ["""", ""Prostacycline 1"", ""Prostacycline 1"", ""Prostacycline 2""], [""Phosphate supplementation\u00a7 (mmol/CRRT treatment day)"", ""11 (0\u201335)"", ""3 (0\u201313)"", ""0 (0)""]], [[""Group"", ""Group 1"", ""Group 2"", ""Group 3""], ["""", ""Before"", ""During"", ""Before"", ""During"", ""Before"", ""During""], [""Phosphate*"", ""1.90"", ""0.99"", ""1.54"", ""1.20"", ""1.83"", ""1.43""], [""Ionized Ca\u2020"", ""1.10"", ""1.24"", ""1.13"", ""1.19"", ""1.11"", ""1.15""], [""pH\u2021"", ""7.24"", ""7.40"", ""7.30"", ""7.36"", ""7.32"", ""7.36""], [""pCO2\u2021"", ""5.59"", ""5.27"", ""5.81"", ""5.77"", ""6.51"", ""5.27""], [""Bicarbonate\u00a7"", ""18"", ""24"", ""21"", ""23"", ""21"", ""22""]], [[""Day on CRRT"", ""Before"", ""1"", ""2"", ""3"", ""4"", ""5""], [""Sodium*"", ""134.0 \u00b1 5"", ""135.0 \u00b1 3"", ""135.2 \u00b1 2"", ""135.0 \u00b1 2"", ""135.7 \u00b1 2"", ""135.8 \u00b1 3""], [""Potassium\u2020"", ""4.06 \u00b1 0.5"", ""4.10 \u00b1 0.4"", ""4.14 \u00b1 0.3"", ""4.23 \u00b1 0.3"", ""4.39 \u00b1 0.4"", ""4.49 \u00b1 0.5""], [""Ionised calcium\u2021"", ""1.11 \u00b1 0.08"", ""1.10 \u00b1 0.05"", ""1.15 \u00b1 0.07"", ""1.17 \u00b1 0.06"", ""1.16 \u00b1 0.05"", ""1.17 \u00b1 0.06""], [""Magnesium\u2020"", ""1.1 \u00b1 0.4"", ""1.0 \u00b1 0.2"", ""1.1 \u00b1 0.2"", ""0.7 \u00b1 0.2"", ""0.9 \u00b1 0.1"", ""1.0 \u00b1 0.3""]]]","[[], [], [], [], []]"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,tables,levenshtein,table,0,1,0,0,"[[["""", ""Hemosol B0 (mmol/l)"", ""Phosphate containingdialysis solution (mmol/l)""], [""Bicarbonate"", ""32"", ""30""], [""Lactate"", ""3"", ""0""], [""Calcium"", ""1.75"", ""1.25""], [""Magnesium"", ""0.5"", ""0.6""], [""Potassium"", ""0"", ""4""], [""Sodium"", ""140"", ""140""], [""Phosphate"", ""0"", ""1.2""], [""Chloride"", ""109.5"", ""115.9""]], [[""Main diagnoses"", ""Group 1"", ""Group 2"", ""Group 3""], [""Septic shock"", ""5"", ""8"", ""7""], [""Pneumonia"", ""2"", ""1"", ""0""], [""Cardiac insufficiency"", ""0"", ""0"", ""3""], [""Cardiac arrest"", ""1"", ""0"", ""2""], [""Major intoxication"", ""1"", ""0"", ""1""], [""Rupture of aortic aneurysm"", ""0"", ""0"", ""2""], [""Myocardial infarction"", ""0"", ""0"", ""1""], [""Cardiogenic shock"", ""0"", ""0"", ""1""], [""Sclerosis cholangitis"", ""0"", ""0"", ""1""], [""Unspecified respiratory failure"", ""1"", ""0"", ""0""], [""Obstructing malignant intestinal tumour"", ""1"", ""0"", ""0""], [""Epilepsy"", ""1"", ""0"", ""0""], [""Unspecified muscle disease"", ""0"", ""0"", ""1""]], [["""", ""Group 1"", ""Group 2"", ""Group 3""], [""Demographics*""], [""Age (years)"", ""63 (43\u201386)"", ""68 (37\u201388)"", ""67 (53\u201383)""], [""Weight (kg)"", ""80 (53\u2013116)"", ""86 (56\u2013124)"", ""79 (41\u2013130)""], [""Male sex, n (%)"", ""7 (50)"", ""7 (50)"", ""5 (36)""], [""APACHE II*"", ""28.1 (19\u201344)"", ""26 (13\u201336)"", ""23.2 (15\u201329)""], [""RIFLE score, points*,\u2020"", ""37"", ""39"", ""39""], [""Delivered CRRT*""], [""CRRT treatment duration (h)"", ""82 (17\u2013278)"", ""115 (37\u2013207)"", ""96 (29\u2013210)""], [""CRRT treatment mode"", ""CVVHDF"", ""CVVHDF"", ""CVVHDF""], [""Effluent flow (ml/kg/h) calculated on active treatment time*,\u2021"", ""23.7 (13\u201345)"", ""21.9 (15\u201330)"", ""18 (10\u201320)""], [""Proportion of ordered dose delivered*"", ""85.3%"", ""87.5%"", ""91.8%""], [""Anticoagulation*"", ""None 3"", ""None 2"", ""None 2""], ["""", ""Heparine 9"", ""Heparine 11"", ""Heparine 10""], ["""", ""Prostacycline 1"", ""Prostacycline 1"", ""Prostacycline 2""], [""Phosphate supplementation\u00a7 (mmol/CRRT treatment day)"", ""11 (0\u201335)"", ""3 (0\u201313)"", ""0 (0)""]], [[""Group"", ""Group 1"", ""Group 2"", ""Group 3""], ["""", ""Before"", ""During"", ""Before"", ""During"", ""Before"", ""During""], [""Phosphate*"", ""1.90"", ""0.99"", ""1.54"", ""1.20"", ""1.83"", ""1.43""], [""Ionized Ca\u2020"", ""1.10"", ""1.24"", ""1.13"", ""1.19"", ""1.11"", ""1.15""], [""pH\u2021"", ""7.24"", ""7.40"", ""7.30"", ""7.36"", ""7.32"", ""7.36""], [""pCO2\u2021"", ""5.59"", ""5.27"", ""5.81"", ""5.77"", ""6.51"", ""5.27""], [""Bicarbonate\u00a7"", ""18"", ""24"", ""21"", ""23"", ""21"", ""22""]], [[""Day on CRRT"", ""Before"", ""1"", ""2"", ""3"", ""4"", ""5""], [""Sodium*"", ""134.0 \u00b1 5"", ""135.0 \u00b1 3"", ""135.2 \u00b1 2"", ""135.0 \u00b1 2"", ""135.7 \u00b1 2"", ""135.8 \u00b1 3""], [""Potassium\u2020"", ""4.06 \u00b1 0.5"", ""4.10 \u00b1 0.4"", ""4.14 \u00b1 0.3"", ""4.23 \u00b1 0.3"", ""4.39 \u00b1 0.4"", ""4.49 \u00b1 0.5""], [""Ionised calcium\u2021"", ""1.11 \u00b1 0.08"", ""1.10 \u00b1 0.05"", ""1.15 \u00b1 0.07"", ""1.17 \u00b1 0.06"", ""1.16 \u00b1 0.05"", ""1.17 \u00b1 0.06""], [""Magnesium\u2020"", ""1.1 \u00b1 0.4"", ""1.0 \u00b1 0.2"", ""1.1 \u00b1 0.2"", ""0.7 \u00b1 0.2"", ""0.9 \u00b1 0.1"", ""1.0 \u00b1 0.3""]]]","[[], [], [], [], []]"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,table_strings,exact,list,0,1,0,0,"Hemosol B0 (mmol/l) Phosphate containingdialysis solution (mmol/l) Bicarbonate 32 30 Lactate 3 0 Calcium 1.75 1.25 Magnesium 0.5 0.6 Potassium 0 4 Sodium 140 140 Phosphate 0 1.2 Chloride 109.5 115.9, Main diagnoses Group 1 Group 2 Group 3 Septic shock 5 8 7 Pneumonia 2 1 0 Cardiac insufficiency 0 0 3 Cardiac arrest 1 0 2 Major intoxication 1 0 1 Rupture of aortic aneurysm 0 0 2 Myocardial infarction 0 0 1 Cardiogenic shock 0 0 1 Sclerosis cholangitis 0 0 1 Unspecified respiratory failure 1 0 0 Obstructing malignant intestinal tumour 1 0 0 Epilepsy 1 0 0 Unspecified muscle disease 0 0 1, Group 1 Group 2 Group 3 Demographics* Age (years) 63 (43–86) 68 (37–88) 67 (53–83) Weight (kg) 80 (53–116) 86 (56–124) 79 (41–130) Male sex, n (%) 7 (50) 7 (50) 5 (36) APACHE II* 28.1 (19–44) 26 (13–36) 23.2 (15–29) RIFLE score, points*,† 37 39 39 Delivered CRRT* CRRT treatment duration (h) 82 (17–278) 115 (37–207) 96 (29–210) CRRT treatment mode CVVHDF CVVHDF CVVHDF Effluent flow (ml/kg/h) calculated on active treatment time*,‡ 23.7 (13–45) 21.9 (15–30) 18 (10–20) Proportion of ordered dose delivered* 85.3% 87.5% 91.8% Anticoagulation* None 3 None 2 None 2 Heparine 9 Heparine 11 Heparine 10 Prostacycline 1 Prostacycline 1 Prostacycline 2 Phosphate supplementation§ (mmol/CRRT treatment day) 11 (0–35) 3 (0–13) 0 (0), Group Group 1 Group 2 Group 3 Before During Before During Before During Phosphate* 1.90 0.99 1.54 1.20 1.83 1.43 Ionized Ca† 1.10 1.24 1.13 1.19 1.11 1.15 pH‡ 7.24 7.40 7.30 7.36 7.32 7.36 pCO2‡ 5.59 5.27 5.81 5.77 6.51 5.27 Bicarbonate§ 18 24 21 23 21 22, Day on CRRT Before 1 2 3 4 5 Sodium* 134.0 ± 5 135.0 ± 3 135.2 ± 2 135.0 ± 2 135.7 ± 2 135.8 ± 3 Potassium† 4.06 ± 0.5 4.10 ± 0.4 4.14 ± 0.3 4.23 ± 0.3 4.39 ± 0.4 4.49 ± 0.5 Ionised calcium‡ 1.11 ± 0.08 1.10 ± 0.05 1.15 ± 0.07 1.17 ± 0.06 1.16 ± 0.05 1.17 ± 0.06 Magnesium† 1.1 ± 0.4 1.0 ± 0.2 1.1 ± 0.2 0.7 ± 0.2 0.9 ± 0.1 1.0 ± 0.3","Hemosol B0 (mmol/l) Phosphate containing dialysis solution (mmol/l) Bicarbonate 32 30 Lactate 3 0 Calcium 1.75 1.25 Magnesium 0.5 0.6 Potassium 0 4 Sodium 140 140 Phosphate 0 1.2 Chloride 109.5 115.9, Main diagnoses leading to intensive care of the study groups. Main diagnoses Group 1 Group 2 Group 3 Septic shock 5 8 7 Pneumonia 2 1 0 Cardiac insufficiency 0 0 3 Cardiac arrest 1 0 2 Major intoxication 1 0 1 Rupture of aortic aneurysm 0 0 2 Myocardial infarction 0 0 1 Cardiogenic shock 0 0 1 Sclerosis cholangitis 0 0 1 Unspecified respiratory failure 1 0 0 Obstructing malignant intestinal tumour 1 0 0 Epilepsy 1 0 0 Unspecified muscle disease 0 0 1, Group 1 Group 2 Group 3, Day on CRRT Before 1 2 3 4 5 Sodium* 134.0 AE 5 135.0 AE 3 135.2 AE 2 135.0 AE 2 135.7 AE 2 135.8 AE 3 Potassiumw 4.06 AE 0.5 4.10 AE 0.4 4.14 AE 0.3 4.23 AE 0.3 4.39 AE 0.4 4.49 AE 0.5 Ionised calciumz 1.11 AE 0.08 1.10 AE 0.05 1.15 AE 0.07 1.17 AE 0.06 1.16 AE 0.05 1.17 AE 0.06 Magnesiumw 1.1 AE 0.4 1.0 AE 0.2 1.1 AE 0.2 0.7 AE 0.2 0.9 AE 0.1 1.0 AE 0.3 *P, Serum values (mmol/l, kPa) during CRRT with the phosphate- containing dialysis fluid. Group Group 1 Group 2 Group 3 Before During Before During Before During Phosphate* 1.90 0.99 1.54 1.20 1.83 1.43 Ionized Caw 1.10 1.24 1.13 1.19 1.11 1.15 pHz 7.24 7.40 7.30 7.36 7.32 7.36 pCO 2 z 5.59 5.27 5.81 5.77 6.51 5.27 Bicarbonate § 18 24 21 23 21 22"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,table_strings,levenshtein,list,0,1,0,0,"Hemosol B0 (mmol/l) Phosphate containingdialysis solution (mmol/l) Bicarbonate 32 30 Lactate 3 0 Calcium 1.75 1.25 Magnesium 0.5 0.6 Potassium 0 4 Sodium 140 140 Phosphate 0 1.2 Chloride 109.5 115.9, Main diagnoses Group 1 Group 2 Group 3 Septic shock 5 8 7 Pneumonia 2 1 0 Cardiac insufficiency 0 0 3 Cardiac arrest 1 0 2 Major intoxication 1 0 1 Rupture of aortic aneurysm 0 0 2 Myocardial infarction 0 0 1 Cardiogenic shock 0 0 1 Sclerosis cholangitis 0 0 1 Unspecified respiratory failure 1 0 0 Obstructing malignant intestinal tumour 1 0 0 Epilepsy 1 0 0 Unspecified muscle disease 0 0 1, Group 1 Group 2 Group 3 Demographics* Age (years) 63 (43–86) 68 (37–88) 67 (53–83) Weight (kg) 80 (53–116) 86 (56–124) 79 (41–130) Male sex, n (%) 7 (50) 7 (50) 5 (36) APACHE II* 28.1 (19–44) 26 (13–36) 23.2 (15–29) RIFLE score, points*,† 37 39 39 Delivered CRRT* CRRT treatment duration (h) 82 (17–278) 115 (37–207) 96 (29–210) CRRT treatment mode CVVHDF CVVHDF CVVHDF Effluent flow (ml/kg/h) calculated on active treatment time*,‡ 23.7 (13–45) 21.9 (15–30) 18 (10–20) Proportion of ordered dose delivered* 85.3% 87.5% 91.8% Anticoagulation* None 3 None 2 None 2 Heparine 9 Heparine 11 Heparine 10 Prostacycline 1 Prostacycline 1 Prostacycline 2 Phosphate supplementation§ (mmol/CRRT treatment day) 11 (0–35) 3 (0–13) 0 (0), Group Group 1 Group 2 Group 3 Before During Before During Before During Phosphate* 1.90 0.99 1.54 1.20 1.83 1.43 Ionized Ca† 1.10 1.24 1.13 1.19 1.11 1.15 pH‡ 7.24 7.40 7.30 7.36 7.32 7.36 pCO2‡ 5.59 5.27 5.81 5.77 6.51 5.27 Bicarbonate§ 18 24 21 23 21 22, Day on CRRT Before 1 2 3 4 5 Sodium* 134.0 ± 5 135.0 ± 3 135.2 ± 2 135.0 ± 2 135.7 ± 2 135.8 ± 3 Potassium† 4.06 ± 0.5 4.10 ± 0.4 4.14 ± 0.3 4.23 ± 0.3 4.39 ± 0.4 4.49 ± 0.5 Ionised calcium‡ 1.11 ± 0.08 1.10 ± 0.05 1.15 ± 0.07 1.17 ± 0.06 1.16 ± 0.05 1.17 ± 0.06 Magnesium† 1.1 ± 0.4 1.0 ± 0.2 1.1 ± 0.2 0.7 ± 0.2 0.9 ± 0.1 1.0 ± 0.3","Hemosol B0 (mmol/l) Phosphate containing dialysis solution (mmol/l) Bicarbonate 32 30 Lactate 3 0 Calcium 1.75 1.25 Magnesium 0.5 0.6 Potassium 0 4 Sodium 140 140 Phosphate 0 1.2 Chloride 109.5 115.9, Main diagnoses leading to intensive care of the study groups. Main diagnoses Group 1 Group 2 Group 3 Septic shock 5 8 7 Pneumonia 2 1 0 Cardiac insufficiency 0 0 3 Cardiac arrest 1 0 2 Major intoxication 1 0 1 Rupture of aortic aneurysm 0 0 2 Myocardial infarction 0 0 1 Cardiogenic shock 0 0 1 Sclerosis cholangitis 0 0 1 Unspecified respiratory failure 1 0 0 Obstructing malignant intestinal tumour 1 0 0 Epilepsy 1 0 0 Unspecified muscle disease 0 0 1, Group 1 Group 2 Group 3, Day on CRRT Before 1 2 3 4 5 Sodium* 134.0 AE 5 135.0 AE 3 135.2 AE 2 135.0 AE 2 135.7 AE 2 135.8 AE 3 Potassiumw 4.06 AE 0.5 4.10 AE 0.4 4.14 AE 0.3 4.23 AE 0.3 4.39 AE 0.4 4.49 AE 0.5 Ionised calciumz 1.11 AE 0.08 1.10 AE 0.05 1.15 AE 0.07 1.17 AE 0.06 1.16 AE 0.05 1.17 AE 0.06 Magnesiumw 1.1 AE 0.4 1.0 AE 0.2 1.1 AE 0.2 0.7 AE 0.2 0.9 AE 0.1 1.0 AE 0.3 *P, Serum values (mmol/l, kPa) during CRRT with the phosphate- containing dialysis fluid. Group Group 1 Group 2 Group 3 Before During Before During Before During Phosphate* 1.90 0.99 1.54 1.20 1.83 1.43 Ionized Caw 1.10 1.24 1.13 1.19 1.11 1.15 pHz 7.24 7.40 7.30 7.36 7.32 7.36 pCO 2 z 5.59 5.27 5.81 5.77 6.51 5.27 Bicarbonate § 18 24 21 23 21 22"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,table_labels,exact,list,0,1,0,0,"Table 1, Table 2, Table 3, Table 5, Table 4","Table 1 Fluid composition., Table 2, Table 3 Baseline characteristics of study patients and delivered CRRT., Table 4 Serum solute concentrations (mmol/l) during CRRT with the phosphate containing dialysis fluid for patients in group 3., Table 5"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,table_labels,levenshtein,list,0,1,0,0,"Table 1, Table 2, Table 3, Table 5, Table 4","Table 1 Fluid composition., Table 2, Table 3 Baseline characteristics of study patients and delivered CRRT., Table 4 Serum solute concentrations (mmol/l) during CRRT with the phosphate containing dialysis fluid for patients in group 3., Table 5"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,table_captions,exact,list,0,1,0,0,"Fluid composition., Main diagnoses leading to intensive care of the study groups., Baseline characteristics of study patients and delivered CRRT., Serum values (mmol/l, kPa) during CRRT with the phosphate-containing dialysis fluid., Serum solute concentrations (mmol/l) during CRRT with the phosphate containing dialysis fluid for patients in group 3.",", , , , "
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,table_captions,levenshtein,list,0,1,0,0,"Fluid composition., Main diagnoses leading to intensive care of the study groups., Baseline characteristics of study patients and delivered CRRT., Serum values (mmol/l, kPa) during CRRT with the phosphate-containing dialysis fluid., Serum solute concentrations (mmol/l) during CRRT with the phosphate containing dialysis fluid for patients in group 3.",", , , , "
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,table_label_captions,exact,list,0,1,0,0,"Table 1 Fluid composition., Table 2 Main diagnoses leading to intensive care of the study groups., Table 3 Baseline characteristics of study patients and delivered CRRT., Table 5 Serum values (mmol/l, kPa) during CRRT with the phosphate-containing dialysis fluid., Table 4 Serum solute concentrations (mmol/l) during CRRT with the phosphate containing dialysis fluid for patients in group 3.","Table 1 Fluid composition., Table 2, Table 3 Baseline characteristics of study patients and delivered CRRT., Table 4 Serum solute concentrations (mmol/l) during CRRT with the phosphate containing dialysis fluid for patients in group 3., Table 5"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,table_label_captions,levenshtein,list,0,1,0,0,"Table 1 Fluid composition., Table 2 Main diagnoses leading to intensive care of the study groups., Table 3 Baseline characteristics of study patients and delivered CRRT., Table 5 Serum values (mmol/l, kPa) during CRRT with the phosphate-containing dialysis fluid., Table 4 Serum solute concentrations (mmol/l) during CRRT with the phosphate containing dialysis fluid for patients in group 3.","Table 1 Fluid composition., Table 2, Table 3 Baseline characteristics of study patients and delivered CRRT., Table 4 Serum solute concentrations (mmol/l) during CRRT with the phosphate containing dialysis fluid for patients in group 3., Table 5"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,first_reference_fields,exact,list,0,1,0,0,"[u'1', u'Troyanov', u'S', u'Geadah', u'D', u'Ghannoum', u'M', u'Cardinal', u'J', u'Leblanc', u'M', u'Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy', u'Intensive Care Med', u'2004', u'30', u'1662', u'5', u'15156308']","[u'Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy', u'S', u'Troyanov', u'D', u'Geadah', u'M', u'Ghannoum', u'J', u'Cardinal', u'M', u'Leblanc', u'Intensive Care Med', u'30', u'', u'']"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,first_reference_fields,levenshtein,list,1,0,0,0,"[u'1', u'Troyanov', u'S', u'Geadah', u'D', u'Ghannoum', u'M', u'Cardinal', u'J', u'Leblanc', u'M', u'Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy', u'Intensive Care Med', u'2004', u'30', u'1662', u'5', u'15156308']","[u'Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy', u'S', u'Troyanov', u'D', u'Geadah', u'M', u'Ghannoum', u'J', u'Cardinal', u'M', u'Leblanc', u'Intensive Care Med', u'30', u'', u'']"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,first_reference_title,exact,string,1,0,0,0,Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy,Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,first_reference_title,levenshtein,string,1,0,0,0,Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy,Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_fields,exact,list,0,1,0,0,"[u'1', u'Troyanov', u'S', u'Geadah', u'D', u'Ghannoum', u'M', u'Cardinal', u'J', u'Leblanc', u'M', u'Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy', u'Intensive Care Med', u'2004', u'30', u'1662', u'5', u'15156308'], [u'2', u'Marik', u'PE', u'Bedigian', u'MK', u'Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study', u'Arch Surg', u'1996', u'131', u'1043', u'7', u'8857900'], [u'3', u'Bugg', u'NC', u'Jones', u'JA', u'Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit', u'Anaesthesia', u'1998', u'53', u'895', u'902', u'9849285'], [u'4', u'Skulberg', u'A', u'Sr.', u'Glucose: a potential killer', u'Acta Anaesthesiol Scand', u'2009', u'53', u'684', u'19419367'], [u'5', u'Peppers', u'MP', u'Geheb', u'M', u'Desai', u'T', u'Endocrine crises. Hypophosphatemia and hyperphosphatemia', u'Crit Care Clin', u'1991', u'7', u'201', u'14', u'2007215'], [u'6', u'Elisaf', u'MS', u'Siamopoulos', u'KC', u'Mechanisms of hypophosphataemia in alcoholic patients', u'Int J Clin Pract', u'1997', u'51', u'501', u'3', u'9536603'], [u'7', u'Zazzo', u'JF', u'Troche', u'G', u'Ruel', u'P', u'Maintenant', u'J', u'High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function', u'Intensive Care Med', u'1995', u'21', u'826', u'31', u'8557871'], [u'8', u'Tan', u'HK', u'Bellomo', u'R', u""M'Pis"", u'DA', u'Ronco', u'C', u'Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration', u'Int J Artif Organs', u'2001', u'24', u'186', u'91', u'11394697'], [u'9', u'Baldwin', u'I', u'Naka', u'T', u'Koch', u'B', u'Fealy', u'N', u'Bellomo', u'R', u'A pilot randomised controlled comparison of continuous veno-venous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance', u'Intensive Care Med', u'2007', u'33', u'830', u'5', u'17384931'], [u'10', u'Shor', u'R', u'Halabe', u'A', u'Rishver', u'S', u'Tilis', u'Y', u'Matas', u'Z', u'Fux', u'A', u'Boaz', u'M', u'Weinstein', u'J', u'Severe hypophosphatemia in sepsis as a mortality predictor', u'Ann Clin Lab Sci', u'2006', u'36', u'67', u'72', u'16501239'], [u'11', u'Stoff', u'JS', u'Phosphate homeostasis and hypophosphatemia', u'Am J Med', u'1982', u'72', u'489', u'95', u'7036738'], [u'12', u'Brown', u'GR', u'Greenwood', u'JK', u'Drug- and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill', u'Ann Pharmacother', u'1994', u'28', u'626', u'32', u'8069002'], [u'13', u'Bollaert', u'PE', u'Levy', u'B', u'Nace', u'L', u'Laterre', u'PF', u'Larcan', u'A', u'Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock', u'Chest', u'1995', u'107', u'1698', u'701', u'7781370'], [u'14', u'Paterson', u'CR', u'Hypophosphataemia: a dangerous disorder', u'Nutrition', u'1996', u'12', u'540', u'1', u'8878151'], [u'15', u'Paula', u'FJ', u'Plens', u'AE', u'Foss', u'MC', u'Effects of hypophosphatemia on glucose tolerance and insulin secretion', u'Horm Metab Res', u'1998', u'30', u'281', u'4', u'9660090'], [u'16', u'Ravenscroft', u'AJ', u'Valentine', u'JM', u'Knappett', u'PA', u'Severe hypophosphataemia and insulin resistance in diabetic ketoacidosis', u'Anaesthesia', u'1999', u'54', u'198', u'10215720'], [u'17', u'Weber', u'U', u'Huppe', u'T', u'Niehaus', u'L', u'CT and MRI in severe hypophosphataemia with central nervous system involvement', u'Neuroradiology', u'2000', u'42', u'112', u'4', u'10663486'], [u'18', u'Darsee', u'JR', u'Nutter', u'DO', u'Reversible severe congestive cardiomyopathy in three cases of hypophosphatemia', u'Ann Intern Med', u'1978', u'89', u'867', u'70', u'363007'], [u'19', u'Aubier', u'M', u'Murciano', u'D', u'Lecocguic', u'Y', u'Viires', u'N', u'Jacquens', u'Y', u'Squara', u'P', u'Pariente', u'R', u'Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure', u'N Engl J Med', u'1985', u'313', u'420', u'4', u'3860734'], [u'20', u'Williams', u'JD', u'Topley', u'N', u'Craig', u'KJ', u'Mackenzie', u'RK', u'Pischetsrieder', u'M', u'Lage', u'C', u'Passlick-Deetjen', u'J', u'The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane', u'Kidney Int', u'2004', u'66', u'408', u'18', u'15200450'], [u'21', u'Gatchalian', u'RA', u'Popli', u'A', u'Ejaz', u'AA', u'Leehey', u'DJ', u'Kjellstrand', u'CM', u'Ing', u'TS', u'Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate', u'Am J Kidney Dis', u'2000', u'36', u'1262', u'6', u'11096051'], [u'22', u'Santiago', u'MJ', u'Lopez-Herce', u'J', u'Urbano', u'J', u'Bellon', u'JM', u'del Castillo', u'J', u'Carrillo', u'A', u'Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children', u'Kidney Int', u'2009', u'75', u'312', u'6', u'19002217'], [u'23', u'Janssen van Doorn', u'K', u'Spapen', u'H', u'Geers', u'C', u'Diltoer', u'M', u'Shabana', u'W', u'Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?', u'Acta Anaesthesiol Scand', u'2008', u'52', u'1259', u'64', u'18823466'], [u'24', u'Lentz', u'RD', u'Brown', u'DM', u'Kjellstrand', u'CM', u'Treatment of severe hypophosphatemia', u'Ann Intern Med', u'1978', u'89', u'941', u'4', u'102230'], [u'25', u'Vannatta', u'JB', u'Whang', u'R', u'Papper', u'S', u'Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient', u'Arch Intern Med', u'1981', u'141', u'885', u'7', u'7235807'], [u'26', u'Vannatta', u'JB', u'Andress', u'DL', u'Whang', u'R', u'Papper', u'S', u'High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia', u'South Med J', u'1983', u'76', u'1424', u'6', u'6635736'], [u'27', u'Kingston', u'M', u""Al-Siba'i"", u'MB', u'Treatment of severe hypophosphatemia', u'Crit Care Med', u'1985', u'13', u'16', u'8', u'3965243'], [u'28', u'Sacks', u'GS', u'Walker', u'J', u'Dickerson', u'RN', u'Kudsk', u'KA', u'Brown', u'RO', u'Observations of hypophosphatemia and its management in nutrition support', u'Nutr Clin Pract', u'1994', u'9', u'105', u'8', u'8078444'], [u'29', u'Clark', u'CL', u'Sacks', u'GS', u'Dickerson', u'RN', u'Kudsk', u'KA', u'Brown', u'RO', u'Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial', u'Crit Care Med', u'1995', u'23', u'1504', u'11', u'7664552'], [u'30', u'Rosen', u'GH', u'Boullata', u'JI', u""O'Rangers"", u'EA', u'Enow', u'NB', u'Shin', u'B', u'Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia', u'Crit Care Med', u'1995', u'23', u'1204', u'10', u'7600828'], [u'31', u'Perreault', u'MM', u'Ostrop', u'NJ', u'Tierney', u'MG', u'Efficacy and safety of intravenous phosphate replacement in critically ill patients', u'Ann Pharmacother', u'1997', u'31', u'683', u'8', u'9184705'], [u'32', u'Charron', u'T', u'Bernard', u'F', u'Skrobik', u'Y', u'Simoneau', u'N', u'Gagnon', u'N', u'Leblanc', u'M', u'Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia', u'Intensive Care Med', u'2003', u'29', u'1273', u'8', u'12845429'], [u'33', u'Barak', u'V', u'Schwartz', u'A', u'Kalickman', u'I', u'Nisman', u'B', u'Gurman', u'G', u'Shoenfeld', u'Y', u'Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines', u'Am J Med', u'1998', u'104', u'40', u'7', u'9528718'], [u'34', u'Walker', u'K', u'Dallas Hall', u'W', u'Hurst', u'W', u'Stoneham', u'M', u'Serum inorganic phosphate', u'Clinical methods', u'1990', u'London', u'Butterworth Publishers', u'895', u'9'], [u'35', u'Morimatsu', u'H', u'Uchino', u'S', u'Bellomo', u'R', u'Ronco', u'C', u'Continuous veno-venous hemodiafiltration or hemofiltration: impact on calcium, phosphate and magnesium concentrations', u'Int J Artif Organs', u'2002', u'25', u'512', u'9', u'12117290'], [u'36', u'Kraus', u'MA', u'Selection of dialysate and replacement fluids and management of electrolyte and acid\u2013base disturbances', u'Semin Dial', u'2009', u'22', u'137', u'40', u'19426416']","[u'Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy', u'S', u'Troyanov', u'D', u'Geadah', u'M', u'Ghannoum', u'J', u'Cardinal', u'M', u'Leblanc', u'Intensive Care Med', u'30', u'', u''], [u'Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study', u'P', u'E', u'Marik', u'M', u'K', u'Bedigian', u'Arch Surg', u'131', u'', u''], [u'Pathophysiology, effects and management on the intensive care unit', u'N', u'C', u'Bugg', u'J', u'A', u'Jones', u'Hypophosphataemia', u'Anaesthesia', u'53', u'', u''], [u'Glucose: a potential killer', u'A', u'Skulberg', u'Sr', u'Acta Anaesthesiol Scand', u'53', u'684', u''], [u'Endocrine crises. Hypophosphatemia and hyperphosphatemia', u'M', u'P', u'Peppers', u'M', u'Geheb', u'T', u'Desai', u'Crit Care Clin', u'7', u'', u''], [u'Mechanisms of hypophosphataemia in alcoholic patients', u'M', u'S', u'Elisaf', u'K', u'C', u'Siamopoulos', u'Int J Clin Pract', u'51', u'', u''], [u'High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function', u'J', u'F', u'Zazzo', u'G', u'Troche', u'P', u'Ruel', u'J', u'Maintenant', u'Intensive Care Med', u'21', u'', u''], [u'Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration', u'H', u'K', u'Tan', u'R', u'Bellomo', u'M', u'Pis', u'D', u'A', u'Ronco', u'C', u'Int J Artif Organs', u'24', u'', u''], [u'A pilot randomised controlled comparison of continuous venovenous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance', u'I', u'Baldwin', u'T', u'Naka', u'B', u'Koch', u'N', u'Fealy', u'R', u'Bellomo', u'Intensive Care Med', u'33', u'', u''], [u'Severe hypophosphatemia in sepsis as a mortality predictor', u'R', u'Shor', u'A', u'Halabe', u'S', u'Rishver', u'Y', u'Tilis', u'Z', u'Matas', u'A', u'Fux', u'M', u'Boaz', u'J', u'Weinstein', u'Ann Clin Lab Sci', u'36', u'', u''], [u'Phosphate homeostasis and hypophosphatemia', u'J', u'S', u'Stoff', u'Am J Med', u'72', u'', u''], [u'Drug-and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill', u'G', u'R', u'Brown', u'J', u'K', u'Greenwood', u'Ann Pharmacother', u'28', u'', u''], [u'Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock', u'P', u'E', u'Bollaert', u'B', u'Levy', u'L', u'Nace', u'P', u'F', u'Laterre', u'A', u'Larcan', u'Chest', u'107', u'', u''], [u'Hypophosphataemia: a dangerous disorder', u'C', u'R', u'Paterson', u'Nutrition', u'12', u'', u''], [u'Effects of hypophosphatemia on glucose tolerance and insulin secretion', u'F', u'J', u'Paula', u'A', u'E', u'Plens', u'M', u'C', u'Foss', u'Horm Metab Res', u'30', u'', u''], [u'Severe hypophosphataemia and insulin resistance in diabetic ketoacidosis', u'A', u'J', u'Ravenscroft', u'J', u'M', u'Valentine', u'P', u'A', u'Knappett', u'Anaesthesia', u'54', u''], [u'CT and MRI in severe hypophosphataemia with central nervous system involvement', u'U', u'Weber', u'T', u'Huppe', u'L', u'Niehaus', u'Neuroradiology', u'42', u'', u''], [u'Reversible severe congestive cardiomyopathy in three cases of hypophosphatemia', u'J', u'R', u'Darsee', u'D', u'O', u'Nutter', u'Ann Intern Med', u'89', u'', u''], [u'Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure', u'M', u'Aubier', u'D', u'Murciano', u'Y', u'Lecocguic', u'N', u'Viires', u'Y', u'Jacquens', u'P', u'Squara', u'R', u'Pariente', u'N Engl J Med', u'313', u'', u''], [u'The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane', u'J', u'D', u'Williams', u'N', u'Topley', u'K', u'J', u'Craig', u'R', u'K', u'Mackenzie', u'M', u'Pischetsrieder', u'C', u'Lage', u'J', u'Passlick-Deetjen', u'Kidney Int', u'66', u'', u''], [u'Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate', u'R', u'A', u'Gatchalian', u'A', u'Popli', u'A', u'A', u'Ejaz', u'D', u'J', u'Leehey', u'C', u'M', u'Kjellstrand', u'T', u'S', u'Ing', u'Am J Kidney Dis', u'36', u'', u''], [u'Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children', u'M', u'J', u'Santiago', u'J', u'Lopez-Herce', u'Urbano', u'J', u'Bellon', u'J', u'M', u'Del Castillo', u'J', u'Carrillo', u'A', u'Kidney Int', u'75', u'', u''], [u'Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?', u'K', u'Janssen Van Doorn', u'H', u'Spapen', u'C', u'Geers', u'M', u'Diltoer', u'W', u'Shabana', u'Acta Anaesthesiol Scand', u'52', u'', u''], [u'Treatment of severe hypophosphatemia', u'R', u'D', u'Lentz', u'D', u'M', u'Brown', u'C', u'M', u'Kjellstrand', u'Ann Intern Med', u'89', u'', u''], [u'Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient', u'J', u'B', u'Vannatta', u'R', u'Whang', u'S', u'Papper', u'Arch Intern Med', u'141', u'', u''], [u'High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia', u'J', u'B', u'Vannatta', u'D', u'L', u'Andress', u'R', u'Whang', u'S', u'Papper', u'South Med J', u'76', u'', u''], [u'Treatment of severe hypophosphatemia', u'M', u'Kingston', u'Al-Siba&apos;i Mb', u'Crit Care Med', u'13', u'', u''], [u'Observations of hypophosphatemia and its management in nutrition support', u'G', u'S', u'Sacks', u'J', u'Walker', u'R', u'N', u'Dickerson', u'K', u'A', u'Kudsk', u'R', u'O', u'Brown', u'Nutr Clin Pract', u'9', u'', u''], [u'Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial', u'C', u'L', u'Clark', u'G', u'S', u'Sacks', u'R', u'N', u'Dickerson', u'K', u'A', u'Kudsk', u'R', u'O', u'Brown', u'Crit Care Med', u'23', u'', u''], [u'Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia', u'G', u'H', u'Rosen', u'J', u'I', u'Boullata', u'O', u'&apos;rangers', u'E', u'A', u'Enow', u'N', u'B', u'Shin', u'B', u'Crit Care Med', u'23', u'', u''], [u'Efficacy and safety of intravenous phosphate replacement in critically ill patients', u'M', u'M', u'Perreault', u'N', u'J', u'Ostrop', u'M', u'G', u'Tierney', u'Ann Pharmacother', u'31', u'', u''], [u'Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia', u'T', u'Charron', u'F', u'Bernard', u'Y', u'Skrobik', u'N', u'Simoneau', u'N', u'Gagnon', u'M', u'Leblanc', u'Intensive Care Med', u'29', u'', u''], [u'Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines', u'V', u'Barak', u'A', u'Schwartz', u'I', u'Kalickman', u'B', u'Nisman', u'G', u'Gurman', u'Y', u'Shoenfeld', u'Am J Med', u'104', u'', u''], [u'Serum inorganic phosphate', u'K', u'Walker', u'Dallas', u'Hall', u'W', u'Hurst', u'W', u'Stoneham M', u'', u'Butterworth Publishers', u'', u'London'], [u'Continuous veno-venous hemodiafiltration or hemofiltration: impact on calcium, phosphate and magnesium concentrations', u'H', u'Morimatsu', u'S', u'Uchino', u'R', u'Bellomo', u'C', u'Ronco', u'Int J Artif Organs', u'25', u'', u''], [u'Selection of dialysate and replacement fluids and management of electrolyte and acid-base disturbances', u'M', u'A', u'Kraus', u'Semin Dial', u'22', u'', u'']"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_fields,levenshtein,list,0,1,0,0,"[u'1', u'Troyanov', u'S', u'Geadah', u'D', u'Ghannoum', u'M', u'Cardinal', u'J', u'Leblanc', u'M', u'Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy', u'Intensive Care Med', u'2004', u'30', u'1662', u'5', u'15156308'], [u'2', u'Marik', u'PE', u'Bedigian', u'MK', u'Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study', u'Arch Surg', u'1996', u'131', u'1043', u'7', u'8857900'], [u'3', u'Bugg', u'NC', u'Jones', u'JA', u'Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit', u'Anaesthesia', u'1998', u'53', u'895', u'902', u'9849285'], [u'4', u'Skulberg', u'A', u'Sr.', u'Glucose: a potential killer', u'Acta Anaesthesiol Scand', u'2009', u'53', u'684', u'19419367'], [u'5', u'Peppers', u'MP', u'Geheb', u'M', u'Desai', u'T', u'Endocrine crises. Hypophosphatemia and hyperphosphatemia', u'Crit Care Clin', u'1991', u'7', u'201', u'14', u'2007215'], [u'6', u'Elisaf', u'MS', u'Siamopoulos', u'KC', u'Mechanisms of hypophosphataemia in alcoholic patients', u'Int J Clin Pract', u'1997', u'51', u'501', u'3', u'9536603'], [u'7', u'Zazzo', u'JF', u'Troche', u'G', u'Ruel', u'P', u'Maintenant', u'J', u'High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function', u'Intensive Care Med', u'1995', u'21', u'826', u'31', u'8557871'], [u'8', u'Tan', u'HK', u'Bellomo', u'R', u""M'Pis"", u'DA', u'Ronco', u'C', u'Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration', u'Int J Artif Organs', u'2001', u'24', u'186', u'91', u'11394697'], [u'9', u'Baldwin', u'I', u'Naka', u'T', u'Koch', u'B', u'Fealy', u'N', u'Bellomo', u'R', u'A pilot randomised controlled comparison of continuous veno-venous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance', u'Intensive Care Med', u'2007', u'33', u'830', u'5', u'17384931'], [u'10', u'Shor', u'R', u'Halabe', u'A', u'Rishver', u'S', u'Tilis', u'Y', u'Matas', u'Z', u'Fux', u'A', u'Boaz', u'M', u'Weinstein', u'J', u'Severe hypophosphatemia in sepsis as a mortality predictor', u'Ann Clin Lab Sci', u'2006', u'36', u'67', u'72', u'16501239'], [u'11', u'Stoff', u'JS', u'Phosphate homeostasis and hypophosphatemia', u'Am J Med', u'1982', u'72', u'489', u'95', u'7036738'], [u'12', u'Brown', u'GR', u'Greenwood', u'JK', u'Drug- and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill', u'Ann Pharmacother', u'1994', u'28', u'626', u'32', u'8069002'], [u'13', u'Bollaert', u'PE', u'Levy', u'B', u'Nace', u'L', u'Laterre', u'PF', u'Larcan', u'A', u'Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock', u'Chest', u'1995', u'107', u'1698', u'701', u'7781370'], [u'14', u'Paterson', u'CR', u'Hypophosphataemia: a dangerous disorder', u'Nutrition', u'1996', u'12', u'540', u'1', u'8878151'], [u'15', u'Paula', u'FJ', u'Plens', u'AE', u'Foss', u'MC', u'Effects of hypophosphatemia on glucose tolerance and insulin secretion', u'Horm Metab Res', u'1998', u'30', u'281', u'4', u'9660090'], [u'16', u'Ravenscroft', u'AJ', u'Valentine', u'JM', u'Knappett', u'PA', u'Severe hypophosphataemia and insulin resistance in diabetic ketoacidosis', u'Anaesthesia', u'1999', u'54', u'198', u'10215720'], [u'17', u'Weber', u'U', u'Huppe', u'T', u'Niehaus', u'L', u'CT and MRI in severe hypophosphataemia with central nervous system involvement', u'Neuroradiology', u'2000', u'42', u'112', u'4', u'10663486'], [u'18', u'Darsee', u'JR', u'Nutter', u'DO', u'Reversible severe congestive cardiomyopathy in three cases of hypophosphatemia', u'Ann Intern Med', u'1978', u'89', u'867', u'70', u'363007'], [u'19', u'Aubier', u'M', u'Murciano', u'D', u'Lecocguic', u'Y', u'Viires', u'N', u'Jacquens', u'Y', u'Squara', u'P', u'Pariente', u'R', u'Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure', u'N Engl J Med', u'1985', u'313', u'420', u'4', u'3860734'], [u'20', u'Williams', u'JD', u'Topley', u'N', u'Craig', u'KJ', u'Mackenzie', u'RK', u'Pischetsrieder', u'M', u'Lage', u'C', u'Passlick-Deetjen', u'J', u'The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane', u'Kidney Int', u'2004', u'66', u'408', u'18', u'15200450'], [u'21', u'Gatchalian', u'RA', u'Popli', u'A', u'Ejaz', u'AA', u'Leehey', u'DJ', u'Kjellstrand', u'CM', u'Ing', u'TS', u'Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate', u'Am J Kidney Dis', u'2000', u'36', u'1262', u'6', u'11096051'], [u'22', u'Santiago', u'MJ', u'Lopez-Herce', u'J', u'Urbano', u'J', u'Bellon', u'JM', u'del Castillo', u'J', u'Carrillo', u'A', u'Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children', u'Kidney Int', u'2009', u'75', u'312', u'6', u'19002217'], [u'23', u'Janssen van Doorn', u'K', u'Spapen', u'H', u'Geers', u'C', u'Diltoer', u'M', u'Shabana', u'W', u'Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?', u'Acta Anaesthesiol Scand', u'2008', u'52', u'1259', u'64', u'18823466'], [u'24', u'Lentz', u'RD', u'Brown', u'DM', u'Kjellstrand', u'CM', u'Treatment of severe hypophosphatemia', u'Ann Intern Med', u'1978', u'89', u'941', u'4', u'102230'], [u'25', u'Vannatta', u'JB', u'Whang', u'R', u'Papper', u'S', u'Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient', u'Arch Intern Med', u'1981', u'141', u'885', u'7', u'7235807'], [u'26', u'Vannatta', u'JB', u'Andress', u'DL', u'Whang', u'R', u'Papper', u'S', u'High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia', u'South Med J', u'1983', u'76', u'1424', u'6', u'6635736'], [u'27', u'Kingston', u'M', u""Al-Siba'i"", u'MB', u'Treatment of severe hypophosphatemia', u'Crit Care Med', u'1985', u'13', u'16', u'8', u'3965243'], [u'28', u'Sacks', u'GS', u'Walker', u'J', u'Dickerson', u'RN', u'Kudsk', u'KA', u'Brown', u'RO', u'Observations of hypophosphatemia and its management in nutrition support', u'Nutr Clin Pract', u'1994', u'9', u'105', u'8', u'8078444'], [u'29', u'Clark', u'CL', u'Sacks', u'GS', u'Dickerson', u'RN', u'Kudsk', u'KA', u'Brown', u'RO', u'Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial', u'Crit Care Med', u'1995', u'23', u'1504', u'11', u'7664552'], [u'30', u'Rosen', u'GH', u'Boullata', u'JI', u""O'Rangers"", u'EA', u'Enow', u'NB', u'Shin', u'B', u'Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia', u'Crit Care Med', u'1995', u'23', u'1204', u'10', u'7600828'], [u'31', u'Perreault', u'MM', u'Ostrop', u'NJ', u'Tierney', u'MG', u'Efficacy and safety of intravenous phosphate replacement in critically ill patients', u'Ann Pharmacother', u'1997', u'31', u'683', u'8', u'9184705'], [u'32', u'Charron', u'T', u'Bernard', u'F', u'Skrobik', u'Y', u'Simoneau', u'N', u'Gagnon', u'N', u'Leblanc', u'M', u'Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia', u'Intensive Care Med', u'2003', u'29', u'1273', u'8', u'12845429'], [u'33', u'Barak', u'V', u'Schwartz', u'A', u'Kalickman', u'I', u'Nisman', u'B', u'Gurman', u'G', u'Shoenfeld', u'Y', u'Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines', u'Am J Med', u'1998', u'104', u'40', u'7', u'9528718'], [u'34', u'Walker', u'K', u'Dallas Hall', u'W', u'Hurst', u'W', u'Stoneham', u'M', u'Serum inorganic phosphate', u'Clinical methods', u'1990', u'London', u'Butterworth Publishers', u'895', u'9'], [u'35', u'Morimatsu', u'H', u'Uchino', u'S', u'Bellomo', u'R', u'Ronco', u'C', u'Continuous veno-venous hemodiafiltration or hemofiltration: impact on calcium, phosphate and magnesium concentrations', u'Int J Artif Organs', u'2002', u'25', u'512', u'9', u'12117290'], [u'36', u'Kraus', u'MA', u'Selection of dialysate and replacement fluids and management of electrolyte and acid\u2013base disturbances', u'Semin Dial', u'2009', u'22', u'137', u'40', u'19426416']","[u'Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy', u'S', u'Troyanov', u'D', u'Geadah', u'M', u'Ghannoum', u'J', u'Cardinal', u'M', u'Leblanc', u'Intensive Care Med', u'30', u'', u''], [u'Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study', u'P', u'E', u'Marik', u'M', u'K', u'Bedigian', u'Arch Surg', u'131', u'', u''], [u'Pathophysiology, effects and management on the intensive care unit', u'N', u'C', u'Bugg', u'J', u'A', u'Jones', u'Hypophosphataemia', u'Anaesthesia', u'53', u'', u''], [u'Glucose: a potential killer', u'A', u'Skulberg', u'Sr', u'Acta Anaesthesiol Scand', u'53', u'684', u''], [u'Endocrine crises. Hypophosphatemia and hyperphosphatemia', u'M', u'P', u'Peppers', u'M', u'Geheb', u'T', u'Desai', u'Crit Care Clin', u'7', u'', u''], [u'Mechanisms of hypophosphataemia in alcoholic patients', u'M', u'S', u'Elisaf', u'K', u'C', u'Siamopoulos', u'Int J Clin Pract', u'51', u'', u''], [u'High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function', u'J', u'F', u'Zazzo', u'G', u'Troche', u'P', u'Ruel', u'J', u'Maintenant', u'Intensive Care Med', u'21', u'', u''], [u'Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration', u'H', u'K', u'Tan', u'R', u'Bellomo', u'M', u'Pis', u'D', u'A', u'Ronco', u'C', u'Int J Artif Organs', u'24', u'', u''], [u'A pilot randomised controlled comparison of continuous venovenous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance', u'I', u'Baldwin', u'T', u'Naka', u'B', u'Koch', u'N', u'Fealy', u'R', u'Bellomo', u'Intensive Care Med', u'33', u'', u''], [u'Severe hypophosphatemia in sepsis as a mortality predictor', u'R', u'Shor', u'A', u'Halabe', u'S', u'Rishver', u'Y', u'Tilis', u'Z', u'Matas', u'A', u'Fux', u'M', u'Boaz', u'J', u'Weinstein', u'Ann Clin Lab Sci', u'36', u'', u''], [u'Phosphate homeostasis and hypophosphatemia', u'J', u'S', u'Stoff', u'Am J Med', u'72', u'', u''], [u'Drug-and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill', u'G', u'R', u'Brown', u'J', u'K', u'Greenwood', u'Ann Pharmacother', u'28', u'', u''], [u'Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock', u'P', u'E', u'Bollaert', u'B', u'Levy', u'L', u'Nace', u'P', u'F', u'Laterre', u'A', u'Larcan', u'Chest', u'107', u'', u''], [u'Hypophosphataemia: a dangerous disorder', u'C', u'R', u'Paterson', u'Nutrition', u'12', u'', u''], [u'Effects of hypophosphatemia on glucose tolerance and insulin secretion', u'F', u'J', u'Paula', u'A', u'E', u'Plens', u'M', u'C', u'Foss', u'Horm Metab Res', u'30', u'', u''], [u'Severe hypophosphataemia and insulin resistance in diabetic ketoacidosis', u'A', u'J', u'Ravenscroft', u'J', u'M', u'Valentine', u'P', u'A', u'Knappett', u'Anaesthesia', u'54', u''], [u'CT and MRI in severe hypophosphataemia with central nervous system involvement', u'U', u'Weber', u'T', u'Huppe', u'L', u'Niehaus', u'Neuroradiology', u'42', u'', u''], [u'Reversible severe congestive cardiomyopathy in three cases of hypophosphatemia', u'J', u'R', u'Darsee', u'D', u'O', u'Nutter', u'Ann Intern Med', u'89', u'', u''], [u'Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure', u'M', u'Aubier', u'D', u'Murciano', u'Y', u'Lecocguic', u'N', u'Viires', u'Y', u'Jacquens', u'P', u'Squara', u'R', u'Pariente', u'N Engl J Med', u'313', u'', u''], [u'The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane', u'J', u'D', u'Williams', u'N', u'Topley', u'K', u'J', u'Craig', u'R', u'K', u'Mackenzie', u'M', u'Pischetsrieder', u'C', u'Lage', u'J', u'Passlick-Deetjen', u'Kidney Int', u'66', u'', u''], [u'Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate', u'R', u'A', u'Gatchalian', u'A', u'Popli', u'A', u'A', u'Ejaz', u'D', u'J', u'Leehey', u'C', u'M', u'Kjellstrand', u'T', u'S', u'Ing', u'Am J Kidney Dis', u'36', u'', u''], [u'Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children', u'M', u'J', u'Santiago', u'J', u'Lopez-Herce', u'Urbano', u'J', u'Bellon', u'J', u'M', u'Del Castillo', u'J', u'Carrillo', u'A', u'Kidney Int', u'75', u'', u''], [u'Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?', u'K', u'Janssen Van Doorn', u'H', u'Spapen', u'C', u'Geers', u'M', u'Diltoer', u'W', u'Shabana', u'Acta Anaesthesiol Scand', u'52', u'', u''], [u'Treatment of severe hypophosphatemia', u'R', u'D', u'Lentz', u'D', u'M', u'Brown', u'C', u'M', u'Kjellstrand', u'Ann Intern Med', u'89', u'', u''], [u'Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient', u'J', u'B', u'Vannatta', u'R', u'Whang', u'S', u'Papper', u'Arch Intern Med', u'141', u'', u''], [u'High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia', u'J', u'B', u'Vannatta', u'D', u'L', u'Andress', u'R', u'Whang', u'S', u'Papper', u'South Med J', u'76', u'', u''], [u'Treatment of severe hypophosphatemia', u'M', u'Kingston', u'Al-Siba&apos;i Mb', u'Crit Care Med', u'13', u'', u''], [u'Observations of hypophosphatemia and its management in nutrition support', u'G', u'S', u'Sacks', u'J', u'Walker', u'R', u'N', u'Dickerson', u'K', u'A', u'Kudsk', u'R', u'O', u'Brown', u'Nutr Clin Pract', u'9', u'', u''], [u'Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial', u'C', u'L', u'Clark', u'G', u'S', u'Sacks', u'R', u'N', u'Dickerson', u'K', u'A', u'Kudsk', u'R', u'O', u'Brown', u'Crit Care Med', u'23', u'', u''], [u'Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia', u'G', u'H', u'Rosen', u'J', u'I', u'Boullata', u'O', u'&apos;rangers', u'E', u'A', u'Enow', u'N', u'B', u'Shin', u'B', u'Crit Care Med', u'23', u'', u''], [u'Efficacy and safety of intravenous phosphate replacement in critically ill patients', u'M', u'M', u'Perreault', u'N', u'J', u'Ostrop', u'M', u'G', u'Tierney', u'Ann Pharmacother', u'31', u'', u''], [u'Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia', u'T', u'Charron', u'F', u'Bernard', u'Y', u'Skrobik', u'N', u'Simoneau', u'N', u'Gagnon', u'M', u'Leblanc', u'Intensive Care Med', u'29', u'', u''], [u'Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines', u'V', u'Barak', u'A', u'Schwartz', u'I', u'Kalickman', u'B', u'Nisman', u'G', u'Gurman', u'Y', u'Shoenfeld', u'Am J Med', u'104', u'', u''], [u'Serum inorganic phosphate', u'K', u'Walker', u'Dallas', u'Hall', u'W', u'Hurst', u'W', u'Stoneham M', u'', u'Butterworth Publishers', u'', u'London'], [u'Continuous veno-venous hemodiafiltration or hemofiltration: impact on calcium, phosphate and magnesium concentrations', u'H', u'Morimatsu', u'S', u'Uchino', u'R', u'Bellomo', u'C', u'Ronco', u'Int J Artif Organs', u'25', u'', u''], [u'Selection of dialysate and replacement fluids and management of electrolyte and acid-base disturbances', u'M', u'A', u'Kraus', u'Semin Dial', u'22', u'', u'']"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_title,exact,list,0,1,0,0,"Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy, Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study, Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit, Glucose: a potential killer, Endocrine crises. Hypophosphatemia and hyperphosphatemia, Mechanisms of hypophosphataemia in alcoholic patients, High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function, Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration, A pilot randomised controlled comparison of continuous veno-venous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance, Severe hypophosphatemia in sepsis as a mortality predictor, Phosphate homeostasis and hypophosphatemia, Drug- and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill, Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock, Hypophosphataemia: a dangerous disorder, Effects of hypophosphatemia on glucose tolerance and insulin secretion, Severe hypophosphataemia and insulin resistance in diabetic ketoacidosis, CT and MRI in severe hypophosphataemia with central nervous system involvement, Reversible severe congestive cardiomyopathy in three cases of hypophosphatemia, Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure, The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane, Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate, Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children, Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?, Treatment of severe hypophosphatemia, Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient, High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia, Treatment of severe hypophosphatemia, Observations of hypophosphatemia and its management in nutrition support, Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial, Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia, Efficacy and safety of intravenous phosphate replacement in critically ill patients, Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia, Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines, Serum inorganic phosphate, Continuous veno-venous hemodiafiltration or hemofiltration: impact on calcium, phosphate and magnesium concentrations, Selection of dialysate and replacement fluids and management of electrolyte and acid–base disturbances","Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy, Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study, Pathophysiology, effects and management on the intensive care unit, Glucose: a potential killer, Endocrine crises. Hypophosphatemia and hyperphosphatemia, Mechanisms of hypophosphataemia in alcoholic patients, High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function, Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration, A pilot randomised controlled comparison of continuous venovenous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance, Severe hypophosphatemia in sepsis as a mortality predictor, Phosphate homeostasis and hypophosphatemia, Drug-and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill, Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock, Hypophosphataemia: a dangerous disorder, Effects of hypophosphatemia on glucose tolerance and insulin secretion, Severe hypophosphataemia and insulin resistance in diabetic ketoacidosis, CT and MRI in severe hypophosphataemia with central nervous system involvement, Reversible severe congestive cardiomyopathy in three cases of hypophosphatemia, Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure, The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane, Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate, Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children, Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?, Treatment of severe hypophosphatemia, Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient, High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia, Treatment of severe hypophosphatemia, Observations of hypophosphatemia and its management in nutrition support, Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial, Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia, Efficacy and safety of intravenous phosphate replacement in critically ill patients, Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia, Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines, , Continuous veno-venous hemodiafiltration or hemofiltration: impact on calcium, phosphate and magnesium concentrations, Selection of dialysate and replacement fluids and management of electrolyte and acid-base disturbances"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_title,levenshtein,list,0,1,0,0,"Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy, Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study, Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit, Glucose: a potential killer, Endocrine crises. Hypophosphatemia and hyperphosphatemia, Mechanisms of hypophosphataemia in alcoholic patients, High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function, Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration, A pilot randomised controlled comparison of continuous veno-venous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance, Severe hypophosphatemia in sepsis as a mortality predictor, Phosphate homeostasis and hypophosphatemia, Drug- and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill, Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock, Hypophosphataemia: a dangerous disorder, Effects of hypophosphatemia on glucose tolerance and insulin secretion, Severe hypophosphataemia and insulin resistance in diabetic ketoacidosis, CT and MRI in severe hypophosphataemia with central nervous system involvement, Reversible severe congestive cardiomyopathy in three cases of hypophosphatemia, Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure, The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane, Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate, Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children, Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?, Treatment of severe hypophosphatemia, Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient, High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia, Treatment of severe hypophosphatemia, Observations of hypophosphatemia and its management in nutrition support, Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial, Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia, Efficacy and safety of intravenous phosphate replacement in critically ill patients, Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia, Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines, Serum inorganic phosphate, Continuous veno-venous hemodiafiltration or hemofiltration: impact on calcium, phosphate and magnesium concentrations, Selection of dialysate and replacement fluids and management of electrolyte and acid–base disturbances","Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy, Refeeding hypophosphatemia in critically ill patients in an intensive care unit. A prospective study, Pathophysiology, effects and management on the intensive care unit, Glucose: a potential killer, Endocrine crises. Hypophosphatemia and hyperphosphatemia, Mechanisms of hypophosphataemia in alcoholic patients, High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function, Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafiltration, A pilot randomised controlled comparison of continuous venovenous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance, Severe hypophosphatemia in sepsis as a mortality predictor, Phosphate homeostasis and hypophosphatemia, Drug-and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill, Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock, Hypophosphataemia: a dangerous disorder, Effects of hypophosphatemia on glucose tolerance and insulin secretion, Severe hypophosphataemia and insulin resistance in diabetic ketoacidosis, CT and MRI in severe hypophosphataemia with central nervous system involvement, Reversible severe congestive cardiomyopathy in three cases of hypophosphatemia, Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure, The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane, Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate, Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children, Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?, Treatment of severe hypophosphatemia, Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient, High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia, Treatment of severe hypophosphatemia, Observations of hypophosphatemia and its management in nutrition support, Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial, Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia, Efficacy and safety of intravenous phosphate replacement in critically ill patients, Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia, Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines, , Continuous veno-venous hemodiafiltration or hemofiltration: impact on calcium, phosphate and magnesium concentrations, Selection of dialysate and replacement fluids and management of electrolyte and acid-base disturbances"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_year,exact,list,0,1,0,0,"2004, 1996, 1998, 2009, 1991, 1997, 1995, 2001, 2007, 2006, 1982, 1994, 1995, 1996, 1998, 1999, 2000, 1978, 1985, 2004, 2000, 2009, 2008, 1978, 1981, 1983, 1985, 1994, 1995, 1995, 1997, 2003, 1998, 1990, 2002, 2009","2004, 1996, 1998, 2009, 1991, 1997, 1995, 2001, 2007, 2006, 1982, 1994, 1995, 1996, 1998, 0198, 2000, 1978, 1985, 2004, 2000, 2009, 2008, 1978, 1981, 1983, 1985, 1994, 1995, 1995, 1997, 2003, 1998, 1990, 2002, 2009"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_year,levenshtein,list,0,1,0,0,"2004, 1996, 1998, 2009, 1991, 1997, 1995, 2001, 2007, 2006, 1982, 1994, 1995, 1996, 1998, 1999, 2000, 1978, 1985, 2004, 2000, 2009, 2008, 1978, 1981, 1983, 1985, 1994, 1995, 1995, 1997, 2003, 1998, 1990, 2002, 2009","2004, 1996, 1998, 2009, 1991, 1997, 1995, 2001, 2007, 2006, 1982, 1994, 1995, 1996, 1998, 0198, 2000, 1978, 1985, 2004, 2000, 2009, 2008, 1978, 1981, 1983, 1985, 1994, 1995, 1995, 1997, 2003, 1998, 1990, 2002, 2009"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_source,exact,list,0,1,0,0,"Intensive Care Med, Arch Surg, Anaesthesia, Acta Anaesthesiol Scand, Crit Care Clin, Int J Clin Pract, Intensive Care Med, Int J Artif Organs, Intensive Care Med, Ann Clin Lab Sci, Am J Med, Ann Pharmacother, Chest, Nutrition, Horm Metab Res, Anaesthesia, Neuroradiology, Ann Intern Med, N Engl J Med, Kidney Int, Am J Kidney Dis, Kidney Int, Acta Anaesthesiol Scand, Ann Intern Med, Arch Intern Med, South Med J, Crit Care Med, Nutr Clin Pract, Crit Care Med, Crit Care Med, Ann Pharmacother, Intensive Care Med, Am J Med, Clinical methods, Int J Artif Organs, Semin Dial","Intensive Care Med, Arch Surg, Anaesthesia, Acta Anaesthesiol Scand, Crit Care Clin, Int J Clin Pract, Intensive Care Med, Int J Artif Organs, Intensive Care Med, Ann Clin Lab Sci, Am J Med, Ann Pharmacother, Chest, Nutrition, Horm Metab Res, Anaesthesia, Neuroradiology, Ann Intern Med, N Engl J Med, Kidney Int, Am J Kidney Dis, Kidney Int, Acta Anaesthesiol Scand, Ann Intern Med, Arch Intern Med, South Med J, Crit Care Med, Nutr Clin Pract, Crit Care Med, Crit Care Med, Ann Pharmacother, Intensive Care Med, Am J Med, , Int J Artif Organs, Semin Dial"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_source,levenshtein,list,0,1,0,0,"Intensive Care Med, Arch Surg, Anaesthesia, Acta Anaesthesiol Scand, Crit Care Clin, Int J Clin Pract, Intensive Care Med, Int J Artif Organs, Intensive Care Med, Ann Clin Lab Sci, Am J Med, Ann Pharmacother, Chest, Nutrition, Horm Metab Res, Anaesthesia, Neuroradiology, Ann Intern Med, N Engl J Med, Kidney Int, Am J Kidney Dis, Kidney Int, Acta Anaesthesiol Scand, Ann Intern Med, Arch Intern Med, South Med J, Crit Care Med, Nutr Clin Pract, Crit Care Med, Crit Care Med, Ann Pharmacother, Intensive Care Med, Am J Med, Clinical methods, Int J Artif Organs, Semin Dial","Intensive Care Med, Arch Surg, Anaesthesia, Acta Anaesthesiol Scand, Crit Care Clin, Int J Clin Pract, Intensive Care Med, Int J Artif Organs, Intensive Care Med, Ann Clin Lab Sci, Am J Med, Ann Pharmacother, Chest, Nutrition, Horm Metab Res, Anaesthesia, Neuroradiology, Ann Intern Med, N Engl J Med, Kidney Int, Am J Kidney Dis, Kidney Int, Acta Anaesthesiol Scand, Ann Intern Med, Arch Intern Med, South Med J, Crit Care Med, Nutr Clin Pract, Crit Care Med, Crit Care Med, Ann Pharmacother, Intensive Care Med, Am J Med, , Int J Artif Organs, Semin Dial"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_volume,exact,list,1,0,0,0,"30, 131, 53, 53, 7, 51, 21, 24, 33, 36, 72, 28, 107, 12, 30, 54, 42, 89, 313, 66, 36, 75, 52, 89, 141, 76, 13, 9, 23, 23, 31, 29, 104, , 25, 22","30, 131, 53, 53, 7, 51, 21, 24, 33, 36, 72, 28, 107, 12, 30, 54, 42, 89, 313, 66, 36, 75, 52, 89, 141, 76, 13, 9, 23, 23, 31, 29, 104, , 25, 22"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_volume,levenshtein,list,1,0,0,0,"30, 131, 53, 53, 7, 51, 21, 24, 33, 36, 72, 28, 107, 12, 30, 54, 42, 89, 313, 66, 36, 75, 52, 89, 141, 76, 13, 9, 23, 23, 31, 29, 104, , 25, 22","30, 131, 53, 53, 7, 51, 21, 24, 33, 36, 72, 28, 107, 12, 30, 54, 42, 89, 313, 66, 36, 75, 52, 89, 141, 76, 13, 9, 23, 23, 31, 29, 104, , 25, 22"
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_fpage,exact,list,0,1,0,0,"1662, 1043, 895, 684, 201, 501, 826, 186, 830, 67, 489, 626, 1698, 540, 281, 198, 112, 867, 420, 408, 1262, 312, 1259, 941, 885, 1424, 16, 105, 1504, 1204, 683, 1273, 40, 895, 512, 137",", , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , "
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_fpage,levenshtein,list,0,1,0,0,"1662, 1043, 895, 684, 201, 501, 826, 186, 830, 67, 489, 626, 1698, 540, 281, 198, 112, 867, 420, 408, 1262, 312, 1259, 941, 885, 1424, 16, 105, 1504, 1204, 683, 1273, 40, 895, 512, 137",", , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , "
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_lpage,exact,list,0,1,0,0,"5, 7, 902, , 14, 3, 31, 91, 5, 72, 95, 32, 701, 1, 4, , 4, 70, 4, 18, 6, 6, 64, 4, 7, 6, 8, 8, 11, 10, 8, 8, 7, 9, 9, 40",", , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , "
aas0055-0039.grobid-tei.xml,aas0055-0039.nxml,reference_lpage,levenshtein,list,0,1,0,0,"5, 7, 902, , 14, 3, 31, 91, 5, 72, 95, 32, 701, 1, 4, , 4, 70, 4, 18, 6, 6, 64, 4, 7, 6, 8, 8, 11, 10, 8, 8, 7, 9, 9, 40",", , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , "
d-67-00463.grobid-tei.xml,d-67-00463.nxml,title,exact,string,0,1,0,0,Pi sampling: a methodical and flexible approach to initial macromolecular crystallization screening,Biological Crystallography Pi sampling: a methodical and flexible approach to initial macromolecular crystallization screening
d-67-00463.grobid-tei.xml,d-67-00463.nxml,title,levenshtein,string,0,1,0,0,Pi sampling: a methodical and flexible approach to initial macromolecular crystallization screening,Biological Crystallography Pi sampling: a methodical and flexible approach to initial macromolecular crystallization screening
d-67-00463.grobid-tei.xml,d-67-00463.nxml,abstract,exact,string,0,1,0,0,"Pi sampling, derived from the incomplete factorial approach, is an effort to maximize the diversity of macromolecular crystallization conditions and to facilitate the preparation of 96-condition initial screens.The Pi sampling method is derived from the incomplete factorial approach to macromolecular crystallization screen design. The resulting ‘Pi screens’ have a modular distribution of a given set of up to 36 stock solutions. Maximally diverse conditions can be produced by taking into account the properties of the chemicals used in the formulation and the concentrations of the corresponding solutions. The Pi sampling method has been implemented in a web-based application that generates screen formulations and recipes. It is particularly adapted to screens consisting of 96 different conditions. The flexibility and efficiency of Pi sampling is demonstrated by the crystallization of soluble proteins and of an integral membrane-protein sample.",The Pi sampling method is derived from the incomplete factorial approach to macromolecular crystallization screen design. The resulting 'Pi screens' have a modular distribution of a given set of up to 36 stock solutions. Maximally diverse conditions can be produced by taking into account the properties of the chemicals used in the formulation and the concentrations of the corresponding solutions. The Pi sampling method has been implemented in a web-based application that generates screen formulations and recipes. It is particularly adapted to screens consisting of 96 different conditions. The flexibility and efficiency of Pi sampling is demonstrated by the crystallization of soluble proteins and of an integral membrane-protein sample.
d-67-00463.grobid-tei.xml,d-67-00463.nxml,abstract,levenshtein,string,0,1,0,0,"Pi sampling, derived from the incomplete factorial approach, is an effort to maximize the diversity of macromolecular crystallization conditions and to facilitate the preparation of 96-condition initial screens.The Pi sampling method is derived from the incomplete factorial approach to macromolecular crystallization screen design. The resulting ‘Pi screens’ have a modular distribution of a given set of up to 36 stock solutions. Maximally diverse conditions can be produced by taking into account the properties of the chemicals used in the formulation and the concentrations of the corresponding solutions. The Pi sampling method has been implemented in a web-based application that generates screen formulations and recipes. It is particularly adapted to screens consisting of 96 different conditions. The flexibility and efficiency of Pi sampling is demonstrated by the crystallization of soluble proteins and of an integral membrane-protein sample.",The Pi sampling method is derived from the incomplete factorial approach to macromolecular crystallization screen design. The resulting 'Pi screens' have a modular distribution of a given set of up to 36 stock solutions. Maximally diverse conditions can be produced by taking into account the properties of the chemicals used in the formulation and the concentrations of the corresponding solutions. The Pi sampling method has been implemented in a web-based application that generates screen formulations and recipes. It is particularly adapted to screens consisting of 96 different conditions. The flexibility and efficiency of Pi sampling is demonstrated by the crystallization of soluble proteins and of an integral membrane-protein sample.
d-67-00463.grobid-tei.xml,d-67-00463.nxml,keywords,exact,set,0,0,1,0,"GPCR, incomplete factorial approach, initial screen formulation, macromolecular crystallization, membrane-protein crystallization, modular distribution",
d-67-00463.grobid-tei.xml,d-67-00463.nxml,keywords,levenshtein,set,0,0,1,0,"GPCR, incomplete factorial approach, initial screen formulation, macromolecular crystallization, membrane-protein crystallization, modular distribution",
d-67-00463.grobid-tei.xml,d-67-00463.nxml,author_surnames,exact,set,1,0,0,0,"Gorrec, Lebon, Palmer, Warne","Gorrec, Lebon, Palmer, Warne"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,author_surnames,levenshtein,set,1,0,0,0,"Gorrec, Lebon, Palmer, Warne","Gorrec, Lebon, Palmer, Warne"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,first_author_surname,exact,string,1,0,0,0,Gorrec,Gorrec
d-67-00463.grobid-tei.xml,d-67-00463.nxml,first_author_surname,levenshtein,string,1,0,0,0,Gorrec,Gorrec
d-67-00463.grobid-tei.xml,d-67-00463.nxml,author_full_names,exact,set,0,1,0,0,"Colin M. Palmer, Fabrice Gorrec, Guillaume Lebon, Tony Warne","Colin M Palmer, Fabrice Gorrec, Guillaume Lebon, Tony Warne"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,author_full_names,levenshtein,set,1,0,0,0,"Colin M. Palmer, Fabrice Gorrec, Guillaume Lebon, Tony Warne","Colin M Palmer, Fabrice Gorrec, Guillaume Lebon, Tony Warne"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,first_author_full_name,exact,string,1,0,0,0,Fabrice Gorrec,Fabrice Gorrec
d-67-00463.grobid-tei.xml,d-67-00463.nxml,first_author_full_name,levenshtein,string,1,0,0,0,Fabrice Gorrec,Fabrice Gorrec
d-67-00463.grobid-tei.xml,d-67-00463.nxml,affiliation_strings,exact,set,0,1,0,0,"MRC Laboratory of Molecular Biology, England","Acta Crystallographica Section D, MRC Laboratory of Molecular Biology, Hills Road, CB2 0QH, Cambridge, England Correspondence"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,affiliation_strings,levenshtein,set,0,1,0,0,"MRC Laboratory of Molecular Biology, England","Acta Crystallographica Section D, MRC Laboratory of Molecular Biology, Hills Road, CB2 0QH, Cambridge, England Correspondence"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,affiliation_institution,exact,set,0,1,0,0,MRC Laboratory of Molecular Biology,"Acta Crystallographica Section D, MRC Laboratory of Molecular Biology"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,affiliation_institution,levenshtein,set,0,1,0,0,MRC Laboratory of Molecular Biology,"Acta Crystallographica Section D, MRC Laboratory of Molecular Biology"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,section_titles,exact,list,0,1,0,0,"Introduction, Methods, Pi sampling, Pi Sampler, Pi minimal screen preparation and crystallization assays with commercially available soluble proteins, Pi-PEG screen preparation and crystallization assays with a GPCR, Results, Discussion, Pi sampling, The Pi minimal screen, The Pi-PEG screen, Conclusions","Introduction, Figure 2, Methods, Pi sampling, Pi Sampler, Pi minimal screen preparation and crystallization assays with commercially available soluble proteins, Pi-PEG screen preparation and crystallization assays with a GPCR, Set, Results, Discussion, The Pi minimal screen, The Pi-PEG screen, Conclusions"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,section_titles,levenshtein,list,0,1,0,0,"Introduction, Methods, Pi sampling, Pi Sampler, Pi minimal screen preparation and crystallization assays with commercially available soluble proteins, Pi-PEG screen preparation and crystallization assays with a GPCR, Results, Discussion, Pi sampling, The Pi minimal screen, The Pi-PEG screen, Conclusions","Introduction, Figure 2, Methods, Pi sampling, Pi Sampler, Pi minimal screen preparation and crystallization assays with commercially available soluble proteins, Pi-PEG screen preparation and crystallization assays with a GPCR, Set, Results, Discussion, The Pi minimal screen, The Pi-PEG screen, Conclusions"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,tables,exact,table,0,1,0,0,,"[[], [], [], []]"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,tables,levenshtein,table,0,1,0,0,,"[[], [], [], []]"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,table_strings,exact,list,0,1,0,0,,"Details of the samples used with the Pi minimal screen (Table 1) and number of crystallization hits. TEN, buffer consisting of 20 mM 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris), 1 mM ethylene- diaminetetraacetic acid (EDTA), 1 mM sodium azide and 200 mM sodium chloride. Protein Concentration (mg ml À1 ) MW (kDa) Source and code Buffer/preparation Hits Lysozyme 10.0 14.4 Sigma L6876 Deionized water 56 Concanavalin A 7.0 26.5 Sigma L7647 TEN pH 8.5 16 Glucose isomerase 33.0 43.0 Hampton HR7-102 See product user guide 11 Xylanase 36.0 21.0 Hampton HR7-106 See product user guide 8 Ferritin 50-150 440.0 Fluka 96701 As supplied by the manufacturer 8 Catalase 12.6 62.5 Sigma C3155 Deionized water 6 Citrate synthase 10.0 49.0 Sigma C3260 TEN pH 8.5 5 Lipase B 25.0 35.0 Hampton HR7-099 Deionized water 4 Ribonuclease A 30.0 13.7 Sigma R5503 Deionized water 1 Thaumatin 30.0 22.0 Sigma T7638 Deionized water 1 Sum 116, Hits per condition' observed and corresponding results expected with the binomial distribution (Pi minimal screen). Hits/condition Observed Expected 0 21 26.5 1 45 36.4 2 20 22.5 3 or more 10 10.6 Sum 96 96, Set 1 Set 2 Set 3 Well ID Name Conc. Unit ID Name Conc. Unit ID Name Conc. Unit F6 6 Cacodylate pH 6.5 0.15 M E Potassium thiocyanate 0.030 M P PEG 20 000 18.0 %(w/v) F7 7 MOPS pH 7.0 0.15 M F Sodium iodide 0.060 M Q PEG 1000 52.0 %(w/v) F8 8 HEPES pH 7.5 0.15 M G Propanediol 3.000 %(v/v) R Sodium chloride 2.7 M F9 9 Tris pH 8.0 0.15 M H Calcium chloride 0.030 M S PEG 4000 42.0 %(w/v) F10 10 TAPS pH 8.5 0.15 M I Ethylene glycol 3.000 %(v/v) T Lithium sulfate 1.4 M F11 11 AMPD/Tris pH 9.0 0.15 M J Sodium potassium tartrate 0.030 M U PEG MME 5000 35.0 %(w/v) F12 12 CAPSO pH 9.5 0.15 M K MPD 3.000 %(v/v) V Glycerol 62.0 %(w/v) G1 1 Formate pH 4.0 0.15 M G Propanediol 2.000 %(v/v) M Phosphate 1.1 M G2 2 Acetate pH 4.5 0.15 M H N PEG MME 550 45.00 %(v/v) G3 3 Malate pH 5.0 0.15 M I Ethylene glycol 2.000 %(v/v) O Ammonium nitrate 3.7 M G4 4 Citrate pH 5.5 0.15 M J Sodium potassium tartrate 0.020 M P PEG 20 000 19.0 %(w/v) G5 5 MES pH 6.0 0.15 M K MPD 2.000 %(v/v) Q PEG 1000 56.0 %(w/v) G6 6 Cacodylate pH 6.5 0.15 M L 2-Butanol 2.000 %(v/v) R Sodium chloride 3.0 M G7 7 MOPS pH 7.0 0.15 M A Potassium bromide 0.040 M S PEG 4000 45.0 %(w/v) G8 8 HEPES pH 7.5 0.15 M B PEG 300 2.000 %(v/v) T Lithium sulfate 1.5 M G9 9 Tris pH 8.0 0.15 M C Magnesium sulfate 0.040 M U PEG MME 5000 38.0 %(w/v) G10 10 TAPS pH 8.5 0.15 M D Sodium fluoride 0.008 M V Glycerol 67.0 %(w/v) G11 11 AMPD/Tris pH 9.0 0.15 M E Potassium thiocyanate 0.020 M W Ammonium sulfate 2.6 M G12 12 CAPSO pH 9.5 0.15 M F Sodium iodide 0.040 M X PEG 8000 38.0 %(w/v) H1 1 Formate pH 4.0 0.15 M B PEG 300 1.000 %(v/v) O Ammonium nitrate 4.0 M H2 2 Acetate pH 4.5 0.15 M C Magnesium sulfate 0.020 M P PEG 20 000 20.0 %(w/v) H3 3 Malate pH 5.0 0.15 M D Sodium fluoride 0.004 M Q PEG 1000 60.0 %(w/v) H4 4 Citrate pH 5.5 0.15 M E Potassium thiocyanate 0.010 M R Sodium chloride 3.2 M H5 5 MES pH 6.0 0.15 M F Sodium iodide 0.020 M S PEG 4000 48.0 %(w/v) H6 6 Cacodylate pH 6.5 0.15 M G Propanediol 1.000 %(v/v) T Lithium sulfate 1.6 M H7 7 MOPS pH 7.0 0.15 M H Calcium chloride 0.010 M U PEG MME 5000 40.0 %(w/v) H8 8 HEPES pH 7.5 0.15 M I Ethylene glycol 1.000 %(v/v) V Glycerol 72.0 %(w/v) H9 9 Tris pH 8.0 0.15 M J Sodium potassium tartrate 0.010 M W Ammonium sulfate 2.8 M H10 10 TAPS pH 8.5 0.15 M K MPD 1.000 %(v/v) X PEG 8000 40.0 %(w/v) H11 11 AMPD/Tris pH 9.0 0.15 M L 2-Butanol 1.000 %(v/v) M Phosphate 1.2 M H12 12 CAPSO pH 9.5 0.15 M A Potassium bromide 0.020 M N PEG MME 550 48.00 %(v/v), Set 1 Set 2 Set 3 Well ID Name Conc. Unit ID Name Conc. Unit ID Name Conc. Unit A1 1 Acetate pH 4.8 0.05 M A PEG 200 22.5 %(v/v) M A2 2 Acetate pH 5.2 0.05 M B PEG 300 20.0 %(v/v) N A3 3 MES pH 5.6 0.05 M C PEG MME 350 20.0 %(v/v) O A4 4 MES pH 6.0 0.05 M D PEG 400 20.0 %(v/v) P A5 5 ADA pH 6.4 0.05 M E PEG MME 550 20.0 %(v/v) Q A6 6 ADA pH 6.8 0.05 M F PEG 600 20.0 %(v/v) R A7 7 HEPES pH 7.1 0.05 M G PEG 1000 17.5 %(w/v) S A8 8 HEPES pH 7.3 0.05 M H PEG 1500 17.5 %(w/v) T A9 9 Tris pH 7.6 0.05 M I PEG 2000 15.0 %(w/v) U A10 10 Tris pH 8.0 0.05 M J PEG MME 2000 15.0 %(w/v) V A11 11 Bicine pH 8.4 0.05 M K PEG 3000 15.0 %(w/v) W A12 12 Bicine pH 8.8 0.05 M L PEG 4000 15.0 %(w/v) X B1 1 Acetate pH 4.8 0.05 M H PEG 1500 15.0 %(w/v) O PEG 4000 3.6 %(w/v) B2 2 Acetate pH 5.2 0.05 M I PEG 2000 12.9 %(w/v) P PEG 200 6.4 %(v/v) B3 3 MES pH 5.6 0.05 M J PEG MME 2000 12.9 %(w/v) Q PEG 300 5.7 %(v/v) B4 4 MES pH 6.0 0.05 M K PEG 3000 12.9 %(w/v) R PEG MME 350 5.7 %(v/v) B5 5 ADA pH 6.4 0.05 M L PEG 4000 12.9 %(w/v) S PEG 400 5.7 %(v/v) B6 6 ADA pH 6.8 0.05 M A PEG 200 19.3 %(v/v) T PEG MME 550 5.7 %(v/v) B7 7 HEPES pH 7.1 0.05 M B PEG 300 17.1 %(v/v) U PEG 600 5.7 %(v/v) B8 8 HEPES pH 7.3 0.05 M C PEG MME 350 17.1 %(v/v) V PEG 1000 5.0 %(w/v) B9 9 Tris pH 7.6 0.05 M D PEG 400 17.1 %(v/v) W PEG 1500 5.0 %(w/v) B10 10 Tris pH 8.0 0.05 M E PEG MME 550 17.1 %(v/v) X PEG 2000 4.3 %(w/v) B11 11 Bicine pH 8.4 0.05 M F PEG 600 17.1 %(v/v) M PEG MME 2000 4.3 %(w/v) B12 12 Bicine pH 8.8 0.05 M G PEG 1000 15.0 %(w/v) N PEG 3000 4.3 %(w/v) C1 1 Acetate pH 4.8 0.05 M C PEG MME 350 14.3 %(v/v) Q PEG 300 11.4 %(v/v) C2 2 Acetate pH 5.2 0.05 M D PEG 400 14.3 %(v/v) R PEG MME 350 11.4 %(v/v) C3 3 MES pH 5.6 0.05 M E PEG MME 550 14.3 %(v/v) S PEG 400 11.4 %(v/v) C4 4 MES pH 6.0 0.05 M F PEG 600 14.3 %(v/v) T PEG MME 550 11.4 %(v/v) C5 5 ADA pH 6.4 0.05 M G PEG 1000 12.5 %(w/v) U PEG 600 11.4 %(v/v) C6 6 ADA pH 6.8 0.05 M H PEG 1500 12.5 %(w/v) V PEG 1000 10.0 %(w/v) C7 7 HEPES pH 7.1 0.05 M I PEG 2000 10.7 %(w/v) W PEG 1500 10.0 %(w/v) C8 8 HEPES pH 7.3 0.05 M J PEG MME 2000 10.7 %(w/v) X PEG 2000 8.6 %(w/v) C9 9 Tris pH 7.6 0.05 M K PEG 3000 10.7 %(w/v) M PEG MME 2000 8.6 %(w/v) C10 10 Tris pH 8.0 0.05 M L PEG 4000 10.7 %(w/v) N PEG 3000 8.6 %(w/v) C11 11 Bicine pH 8.4 0.05 M A PEG 200 16.1 %(v/v) O PEG 4000 7.1 %(w/v) C12 12 Bicine pH 8.8 0.05 M B PEG 300 14.3 %(v/v) P PEG 200 12.9 %(v/v) D1 1 Acetate pH 4.8 0.05 M J PEG MME 2000 8.6 %(w/v) S PEG 400 17.1 %(w/v) D2 2 Acetate pH 5.2 0.05 M K PEG 3000 8.6 %(w/v) T PEG MME 550 17.1 %(v/v) D3 3 MES pH 5.6 0.05 M L PEG 4000 8.6 %(w/v) U PEG 600 17.1 %(v/v) D4 4 MES pH 6.0 0.05 M A PEG 200 12.9 %(v/v) V PEG 1000 15.0 %(w/v) D5 5 ADA pH 6.4 0.05 M B PEG 300 11.4 %(v/v) W PEG 1500 15.0 %(w/v) D6 6 ADA pH 6.8 0.05 M C PEG MME 350 11.4 %(v/v) X PEG 2000 12.9 %(w/v) D7 7 HEPES pH 7.1 0.05 M D PEG 400 11.4 %(v/v) M PEG MME 2000 12.9 %(w/v) D8 8 HEPES pH 7.3 0.05 M E PEG MME 550 11.4 %(v/v) N PEG 3000 12.9 %(w/v) D9 9 Tris pH 7.6 0.05 M F PEG 600 11.4 %(v/v) O PEG 4000 10.7 %(w/v) D10 10 Tris pH 8.0 0.05 M G PEG 1000 10.0 %(w/v) P PEG 200 19.3 %(v/v) D11 11 Bicine pH 8.4 0.05 M H PEG 1500 10.0 %(w/v) Q PEG 300 17.1 %(v/v) D12 12 Bicine pH 8.8 0.05 M I PEG 2000 8.6 %(w/v) R PEG MME 350 17.1 %(v/v) E1 1 Acetate pH 4.8 0.05 M E PEG MME 550 8.6 %(v/v) U PEG 600 22.9 %(v/v) E2 2 Acetate pH 5.2 0.05 M F PEG 600 8.6 %(v/v) V PEG 1000 20.0 %(w/v) E3 3 MES pH 5.6 0.05 M G PEG 1000 7.5 %(w/v) W PEG 1500 20.0 %(w/v) E4 4 MES pH 6.0 0.05 M H PEG 1500 7.5 %(w/v) X PEG 2000 17.1 %(w/v) E5 5 ADA pH 6.4 0.05 M I PEG 2000 6.4 %(w/v) M PEG MME 2000 17.1 %(w/v) E6 6 ADA pH 6.8 0.05 M J PEG MME 2000 6.4 %(w/v) N PEG 3000 17.1 %(w/v) E7 7 HEPES pH 7.1 0.05 M K PEG 3000 6.4 %(w/v) O PEG 4000 14.3 %(w/v) E8 8 HEPES pH 7.3 0.05 M L PEG 4000 6.4 %(w/v) P PEG 200 25.7 %(v/v) E9 9 Tris pH 7.6 0.05 M A PEG 200 9.6 %(v/v) Q PEG 300 22.9 %(v/v) E10 10 Tris pH 8.0 0.05 M B PEG 300 8.6 %(v/v) R PEG MME 350 22.9 %(v/v) E11 11 Bicine pH 8.4 0.05 M C PEG MME 350 8.6 %(v/v) S PEG 400 22.9 %(v/v) E12 12 Bicine pH 8.8 0.05 M D PEG 400 8.6 %(v/v) T PEG MME 550 22.9 %(v/v) F1 1 Acetate pH 4.8 0.05 M L PEG 4000 4.3 %(w/v) W PEG 1500 25.0 %(w/v) F2 2 Acetate pH 5.2 0.05 M A PEG 200 6.4 %(v/v) X PEG 2000 21.4 %(w/v) F3 3 MES pH 5.6 0.05 M B PEG 300 5.7 %(v/v) M PEG MME 2000 21.4 %(w/v) F4 4 MES pH 6.0 0.05 M C PEG MME 350 5.7 %(v/v) N PEG 3000 21.4 %(w/v) F5 5 ADA pH 6.4 0.05 M D PEG 400 5.7 %(v/v) O PEG 4000 17.9 %(w/v) F6 6 ADA pH 6.8 0.05 M E PEG MME 550 5.7 %(v/v) P PEG 200 32.1 %(v/v) F7 7 HEPES pH 7.1 0.05 M F PEG 600 5.7 %(v/v) Q PEG 300 28.6 %(v/v) F8 8 HEPES pH 7.3 0.05 M G PEG 1000 5.0 %(w/v) R PEG MME 350 28.6 %(v/v) F9 9 Tris pH 7.6 0.05 M H PEG 1500 5.0 %(w/v) S PEG 400 28.6 %(v/v)"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,table_strings,levenshtein,list,0,1,0,0,,"Details of the samples used with the Pi minimal screen (Table 1) and number of crystallization hits. TEN, buffer consisting of 20 mM 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris), 1 mM ethylene- diaminetetraacetic acid (EDTA), 1 mM sodium azide and 200 mM sodium chloride. Protein Concentration (mg ml À1 ) MW (kDa) Source and code Buffer/preparation Hits Lysozyme 10.0 14.4 Sigma L6876 Deionized water 56 Concanavalin A 7.0 26.5 Sigma L7647 TEN pH 8.5 16 Glucose isomerase 33.0 43.0 Hampton HR7-102 See product user guide 11 Xylanase 36.0 21.0 Hampton HR7-106 See product user guide 8 Ferritin 50-150 440.0 Fluka 96701 As supplied by the manufacturer 8 Catalase 12.6 62.5 Sigma C3155 Deionized water 6 Citrate synthase 10.0 49.0 Sigma C3260 TEN pH 8.5 5 Lipase B 25.0 35.0 Hampton HR7-099 Deionized water 4 Ribonuclease A 30.0 13.7 Sigma R5503 Deionized water 1 Thaumatin 30.0 22.0 Sigma T7638 Deionized water 1 Sum 116, Hits per condition' observed and corresponding results expected with the binomial distribution (Pi minimal screen). Hits/condition Observed Expected 0 21 26.5 1 45 36.4 2 20 22.5 3 or more 10 10.6 Sum 96 96, Set 1 Set 2 Set 3 Well ID Name Conc. Unit ID Name Conc. Unit ID Name Conc. Unit F6 6 Cacodylate pH 6.5 0.15 M E Potassium thiocyanate 0.030 M P PEG 20 000 18.0 %(w/v) F7 7 MOPS pH 7.0 0.15 M F Sodium iodide 0.060 M Q PEG 1000 52.0 %(w/v) F8 8 HEPES pH 7.5 0.15 M G Propanediol 3.000 %(v/v) R Sodium chloride 2.7 M F9 9 Tris pH 8.0 0.15 M H Calcium chloride 0.030 M S PEG 4000 42.0 %(w/v) F10 10 TAPS pH 8.5 0.15 M I Ethylene glycol 3.000 %(v/v) T Lithium sulfate 1.4 M F11 11 AMPD/Tris pH 9.0 0.15 M J Sodium potassium tartrate 0.030 M U PEG MME 5000 35.0 %(w/v) F12 12 CAPSO pH 9.5 0.15 M K MPD 3.000 %(v/v) V Glycerol 62.0 %(w/v) G1 1 Formate pH 4.0 0.15 M G Propanediol 2.000 %(v/v) M Phosphate 1.1 M G2 2 Acetate pH 4.5 0.15 M H N PEG MME 550 45.00 %(v/v) G3 3 Malate pH 5.0 0.15 M I Ethylene glycol 2.000 %(v/v) O Ammonium nitrate 3.7 M G4 4 Citrate pH 5.5 0.15 M J Sodium potassium tartrate 0.020 M P PEG 20 000 19.0 %(w/v) G5 5 MES pH 6.0 0.15 M K MPD 2.000 %(v/v) Q PEG 1000 56.0 %(w/v) G6 6 Cacodylate pH 6.5 0.15 M L 2-Butanol 2.000 %(v/v) R Sodium chloride 3.0 M G7 7 MOPS pH 7.0 0.15 M A Potassium bromide 0.040 M S PEG 4000 45.0 %(w/v) G8 8 HEPES pH 7.5 0.15 M B PEG 300 2.000 %(v/v) T Lithium sulfate 1.5 M G9 9 Tris pH 8.0 0.15 M C Magnesium sulfate 0.040 M U PEG MME 5000 38.0 %(w/v) G10 10 TAPS pH 8.5 0.15 M D Sodium fluoride 0.008 M V Glycerol 67.0 %(w/v) G11 11 AMPD/Tris pH 9.0 0.15 M E Potassium thiocyanate 0.020 M W Ammonium sulfate 2.6 M G12 12 CAPSO pH 9.5 0.15 M F Sodium iodide 0.040 M X PEG 8000 38.0 %(w/v) H1 1 Formate pH 4.0 0.15 M B PEG 300 1.000 %(v/v) O Ammonium nitrate 4.0 M H2 2 Acetate pH 4.5 0.15 M C Magnesium sulfate 0.020 M P PEG 20 000 20.0 %(w/v) H3 3 Malate pH 5.0 0.15 M D Sodium fluoride 0.004 M Q PEG 1000 60.0 %(w/v) H4 4 Citrate pH 5.5 0.15 M E Potassium thiocyanate 0.010 M R Sodium chloride 3.2 M H5 5 MES pH 6.0 0.15 M F Sodium iodide 0.020 M S PEG 4000 48.0 %(w/v) H6 6 Cacodylate pH 6.5 0.15 M G Propanediol 1.000 %(v/v) T Lithium sulfate 1.6 M H7 7 MOPS pH 7.0 0.15 M H Calcium chloride 0.010 M U PEG MME 5000 40.0 %(w/v) H8 8 HEPES pH 7.5 0.15 M I Ethylene glycol 1.000 %(v/v) V Glycerol 72.0 %(w/v) H9 9 Tris pH 8.0 0.15 M J Sodium potassium tartrate 0.010 M W Ammonium sulfate 2.8 M H10 10 TAPS pH 8.5 0.15 M K MPD 1.000 %(v/v) X PEG 8000 40.0 %(w/v) H11 11 AMPD/Tris pH 9.0 0.15 M L 2-Butanol 1.000 %(v/v) M Phosphate 1.2 M H12 12 CAPSO pH 9.5 0.15 M A Potassium bromide 0.020 M N PEG MME 550 48.00 %(v/v), Set 1 Set 2 Set 3 Well ID Name Conc. Unit ID Name Conc. Unit ID Name Conc. Unit A1 1 Acetate pH 4.8 0.05 M A PEG 200 22.5 %(v/v) M A2 2 Acetate pH 5.2 0.05 M B PEG 300 20.0 %(v/v) N A3 3 MES pH 5.6 0.05 M C PEG MME 350 20.0 %(v/v) O A4 4 MES pH 6.0 0.05 M D PEG 400 20.0 %(v/v) P A5 5 ADA pH 6.4 0.05 M E PEG MME 550 20.0 %(v/v) Q A6 6 ADA pH 6.8 0.05 M F PEG 600 20.0 %(v/v) R A7 7 HEPES pH 7.1 0.05 M G PEG 1000 17.5 %(w/v) S A8 8 HEPES pH 7.3 0.05 M H PEG 1500 17.5 %(w/v) T A9 9 Tris pH 7.6 0.05 M I PEG 2000 15.0 %(w/v) U A10 10 Tris pH 8.0 0.05 M J PEG MME 2000 15.0 %(w/v) V A11 11 Bicine pH 8.4 0.05 M K PEG 3000 15.0 %(w/v) W A12 12 Bicine pH 8.8 0.05 M L PEG 4000 15.0 %(w/v) X B1 1 Acetate pH 4.8 0.05 M H PEG 1500 15.0 %(w/v) O PEG 4000 3.6 %(w/v) B2 2 Acetate pH 5.2 0.05 M I PEG 2000 12.9 %(w/v) P PEG 200 6.4 %(v/v) B3 3 MES pH 5.6 0.05 M J PEG MME 2000 12.9 %(w/v) Q PEG 300 5.7 %(v/v) B4 4 MES pH 6.0 0.05 M K PEG 3000 12.9 %(w/v) R PEG MME 350 5.7 %(v/v) B5 5 ADA pH 6.4 0.05 M L PEG 4000 12.9 %(w/v) S PEG 400 5.7 %(v/v) B6 6 ADA pH 6.8 0.05 M A PEG 200 19.3 %(v/v) T PEG MME 550 5.7 %(v/v) B7 7 HEPES pH 7.1 0.05 M B PEG 300 17.1 %(v/v) U PEG 600 5.7 %(v/v) B8 8 HEPES pH 7.3 0.05 M C PEG MME 350 17.1 %(v/v) V PEG 1000 5.0 %(w/v) B9 9 Tris pH 7.6 0.05 M D PEG 400 17.1 %(v/v) W PEG 1500 5.0 %(w/v) B10 10 Tris pH 8.0 0.05 M E PEG MME 550 17.1 %(v/v) X PEG 2000 4.3 %(w/v) B11 11 Bicine pH 8.4 0.05 M F PEG 600 17.1 %(v/v) M PEG MME 2000 4.3 %(w/v) B12 12 Bicine pH 8.8 0.05 M G PEG 1000 15.0 %(w/v) N PEG 3000 4.3 %(w/v) C1 1 Acetate pH 4.8 0.05 M C PEG MME 350 14.3 %(v/v) Q PEG 300 11.4 %(v/v) C2 2 Acetate pH 5.2 0.05 M D PEG 400 14.3 %(v/v) R PEG MME 350 11.4 %(v/v) C3 3 MES pH 5.6 0.05 M E PEG MME 550 14.3 %(v/v) S PEG 400 11.4 %(v/v) C4 4 MES pH 6.0 0.05 M F PEG 600 14.3 %(v/v) T PEG MME 550 11.4 %(v/v) C5 5 ADA pH 6.4 0.05 M G PEG 1000 12.5 %(w/v) U PEG 600 11.4 %(v/v) C6 6 ADA pH 6.8 0.05 M H PEG 1500 12.5 %(w/v) V PEG 1000 10.0 %(w/v) C7 7 HEPES pH 7.1 0.05 M I PEG 2000 10.7 %(w/v) W PEG 1500 10.0 %(w/v) C8 8 HEPES pH 7.3 0.05 M J PEG MME 2000 10.7 %(w/v) X PEG 2000 8.6 %(w/v) C9 9 Tris pH 7.6 0.05 M K PEG 3000 10.7 %(w/v) M PEG MME 2000 8.6 %(w/v) C10 10 Tris pH 8.0 0.05 M L PEG 4000 10.7 %(w/v) N PEG 3000 8.6 %(w/v) C11 11 Bicine pH 8.4 0.05 M A PEG 200 16.1 %(v/v) O PEG 4000 7.1 %(w/v) C12 12 Bicine pH 8.8 0.05 M B PEG 300 14.3 %(v/v) P PEG 200 12.9 %(v/v) D1 1 Acetate pH 4.8 0.05 M J PEG MME 2000 8.6 %(w/v) S PEG 400 17.1 %(w/v) D2 2 Acetate pH 5.2 0.05 M K PEG 3000 8.6 %(w/v) T PEG MME 550 17.1 %(v/v) D3 3 MES pH 5.6 0.05 M L PEG 4000 8.6 %(w/v) U PEG 600 17.1 %(v/v) D4 4 MES pH 6.0 0.05 M A PEG 200 12.9 %(v/v) V PEG 1000 15.0 %(w/v) D5 5 ADA pH 6.4 0.05 M B PEG 300 11.4 %(v/v) W PEG 1500 15.0 %(w/v) D6 6 ADA pH 6.8 0.05 M C PEG MME 350 11.4 %(v/v) X PEG 2000 12.9 %(w/v) D7 7 HEPES pH 7.1 0.05 M D PEG 400 11.4 %(v/v) M PEG MME 2000 12.9 %(w/v) D8 8 HEPES pH 7.3 0.05 M E PEG MME 550 11.4 %(v/v) N PEG 3000 12.9 %(w/v) D9 9 Tris pH 7.6 0.05 M F PEG 600 11.4 %(v/v) O PEG 4000 10.7 %(w/v) D10 10 Tris pH 8.0 0.05 M G PEG 1000 10.0 %(w/v) P PEG 200 19.3 %(v/v) D11 11 Bicine pH 8.4 0.05 M H PEG 1500 10.0 %(w/v) Q PEG 300 17.1 %(v/v) D12 12 Bicine pH 8.8 0.05 M I PEG 2000 8.6 %(w/v) R PEG MME 350 17.1 %(v/v) E1 1 Acetate pH 4.8 0.05 M E PEG MME 550 8.6 %(v/v) U PEG 600 22.9 %(v/v) E2 2 Acetate pH 5.2 0.05 M F PEG 600 8.6 %(v/v) V PEG 1000 20.0 %(w/v) E3 3 MES pH 5.6 0.05 M G PEG 1000 7.5 %(w/v) W PEG 1500 20.0 %(w/v) E4 4 MES pH 6.0 0.05 M H PEG 1500 7.5 %(w/v) X PEG 2000 17.1 %(w/v) E5 5 ADA pH 6.4 0.05 M I PEG 2000 6.4 %(w/v) M PEG MME 2000 17.1 %(w/v) E6 6 ADA pH 6.8 0.05 M J PEG MME 2000 6.4 %(w/v) N PEG 3000 17.1 %(w/v) E7 7 HEPES pH 7.1 0.05 M K PEG 3000 6.4 %(w/v) O PEG 4000 14.3 %(w/v) E8 8 HEPES pH 7.3 0.05 M L PEG 4000 6.4 %(w/v) P PEG 200 25.7 %(v/v) E9 9 Tris pH 7.6 0.05 M A PEG 200 9.6 %(v/v) Q PEG 300 22.9 %(v/v) E10 10 Tris pH 8.0 0.05 M B PEG 300 8.6 %(v/v) R PEG MME 350 22.9 %(v/v) E11 11 Bicine pH 8.4 0.05 M C PEG MME 350 8.6 %(v/v) S PEG 400 22.9 %(v/v) E12 12 Bicine pH 8.8 0.05 M D PEG 400 8.6 %(v/v) T PEG MME 550 22.9 %(v/v) F1 1 Acetate pH 4.8 0.05 M L PEG 4000 4.3 %(w/v) W PEG 1500 25.0 %(w/v) F2 2 Acetate pH 5.2 0.05 M A PEG 200 6.4 %(v/v) X PEG 2000 21.4 %(w/v) F3 3 MES pH 5.6 0.05 M B PEG 300 5.7 %(v/v) M PEG MME 2000 21.4 %(w/v) F4 4 MES pH 6.0 0.05 M C PEG MME 350 5.7 %(v/v) N PEG 3000 21.4 %(w/v) F5 5 ADA pH 6.4 0.05 M D PEG 400 5.7 %(v/v) O PEG 4000 17.9 %(w/v) F6 6 ADA pH 6.8 0.05 M E PEG MME 550 5.7 %(v/v) P PEG 200 32.1 %(v/v) F7 7 HEPES pH 7.1 0.05 M F PEG 600 5.7 %(v/v) Q PEG 300 28.6 %(v/v) F8 8 HEPES pH 7.3 0.05 M G PEG 1000 5.0 %(w/v) R PEG MME 350 28.6 %(v/v) F9 9 Tris pH 7.6 0.05 M H PEG 1500 5.0 %(w/v) S PEG 400 28.6 %(v/v)"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,table_labels,exact,list,0,1,0,0,,"Table 2, Table 3 ', Table 3 (continued), Table 4 Final formulation of the Pi-PEG screen."
d-67-00463.grobid-tei.xml,d-67-00463.nxml,table_labels,levenshtein,list,0,1,0,0,,"Table 2, Table 3 ', Table 3 (continued), Table 4 Final formulation of the Pi-PEG screen."
d-67-00463.grobid-tei.xml,d-67-00463.nxml,table_captions,exact,list,0,1,0,0,,", , , "
d-67-00463.grobid-tei.xml,d-67-00463.nxml,table_captions,levenshtein,list,0,1,0,0,,", , , "
d-67-00463.grobid-tei.xml,d-67-00463.nxml,table_label_captions,exact,list,0,1,0,0,,"Table 2, Table 3 ', Table 3 (continued), Table 4 Final formulation of the Pi-PEG screen."
d-67-00463.grobid-tei.xml,d-67-00463.nxml,table_label_captions,levenshtein,list,0,1,0,0,,"Table 2, Table 3 ', Table 3 (continued), Table 4 Final formulation of the Pi-PEG screen."
d-67-00463.grobid-tei.xml,d-67-00463.nxml,first_reference_fields,exact,list,0,1,0,0,"[u'J. Appl. Cryst.', u'39']","[u'', u'V', u'Berejnov', u'N', u'S', u'Husseini', u'O', u'A', u'Alsaied', u'R', u'E', u'Thorne', u'J. Appl. Cryst', u'39', u'', u'']"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,first_reference_fields,levenshtein,list,1,0,0,0,"[u'J. Appl. Cryst.', u'39']","[u'', u'V', u'Berejnov', u'N', u'S', u'Husseini', u'O', u'A', u'Alsaied', u'R', u'E', u'Thorne', u'J. Appl. Cryst', u'39', u'', u'']"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,first_reference_title,exact,string,0,0,0,1,,
d-67-00463.grobid-tei.xml,d-67-00463.nxml,first_reference_title,levenshtein,string,0,0,0,1,,
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_fields,exact,list,0,1,0,0,"[u'J. Appl. Cryst.', u'39'], [u'Methods Mol. Biol.', u'363'], [u'J. Appl. Cryst.', u'34'], [u'J. Biol. Chem.', u'254'], [u'Cell', u'141'], [u'J. Appl. Cryst.', u'20'], [u'Proc. Natl Acad. Sci. USA', u'90'], [u'Acta Cryst.', u'58'], [u'Cryst. Growth Des.', u'11'], [u'J. Appl. Cryst.', u'24'], [u'Bioinformatics', u'20'], [u'Proteins', u'51'], [u'Protein Sci.', u'18'], [u'Proc. Natl Acad. Sci. USA', u'93'], [u'Protein Sci.', u'12'], [u'J. Biol. Chem.', u'251'], [u'Eur. J. Biochem.', u'189'], [u'et al.', u'Acta Cryst.', u'67'], [u'J. Struct. Biol.', u'142'], [u'History of Mathematics.'], [u'Prog. Biophys. Mol. Biol.', u'88'], [u'Nature (London)', u'454'], [u'Protein Expr. Purif.', u'65']","[u'', u'V', u'Berejnov', u'N', u'S', u'Husseini', u'O', u'A', u'Alsaied', u'R', u'E', u'Thorne', u'J. Appl. Cryst', u'39', u'', u''], [u'', u'T', u'Bergfors', u'Methods Mol. Biol', u'363', u'', u''], [u'', u'A', u'M', u'Brzozowski', u'J', u'Walton', u'J. Appl. Cryst', u'34', u'', u''], [u'', u'C', u'W', u'Carter', u'C', u'W', u'Carter', u'J. Biol. Chem', u'254', u'', u''], [u'', u'O', u'B', u'Clarke', u'A', u'T', u'Caputo', u'A', u'P', u'Hill', u'J', u'I', u'Vandenberg', u'B', u'J', u'Smith', u'J', u'M', u'Gulbis', u'Cell', u'141', u'', u''], [u'', u'M', u'J', u'Cox', u'P', u'C', u'Weber', u'J. Appl. Cryst', u'20', u'', u''], [u'J', u'A', u'Doudna', u'C', u'Grosshans', u'A', u'Gooding', u'C', u'E', u'Kundrot', u'Proc. Natl Acad. Sci. USA', u'Natl Acad. Sci. USA', u'', u'90', u''], [u'', u'E', u'L', u'Forsythe', u'D', u'L', u'Maxwell', u'M', u'Pusey', u'Acta Cryst', u'58', u'', u''], [u'', u'T', u'Hedderich', u'M', u'Marcia', u'J', u'K\xf6 Pke', u'H', u'Michel', u'Cryst. Growth Des', u'11', u'', u''], [u'', u'J', u'Jancarik', u'S.-H', u'Kim', u'J. Appl. Cryst', u'24', u'', u''], [u'', u'K', u'A', u'Kantardjieff', u'B', u'Rupp', u'Bioinformatics', u'20', u'', u''], [u'', u'M', u'S', u'Kimber', u'F', u'Vallee', u'S', u'Houston', u'A', u'Necakov', u'T', u'Skarina', u'E', u'Evdokimova', u'S', u'Beasley', u'D', u'Christendat', u'A', u'Savchenko', u'C', u'H', u'Arrowsmith', u'M', u'Vedadi', u'M', u'Gerstein', u'A', u'M', u'Edwards', u'Proteins', u'51', u'', u''], [u'', u'M', u'Koszelak-Rosenblum', u'A', u'Krol', u'N', u'Mozumdar', u'K', u'Wunsch', u'A', u'Ferin', u'E', u'Cook', u'C', u'K', u'Veatch', u'R', u'Nagel', u'J', u'R', u'Luft', u'G', u'T', u'Detitta', u'M', u'G', u'Malkowski', u'Protein Sci', u'18', u'', u''], [u'E', u'M', u'Landau', u'J', u'P', u'Rosenbusch', u'Proc. Natl Acad. Sci', u'USA, 93', u'', u''], [u'', u'M', u'J', u'Lemieux', u'J', u'Song', u'M', u'J', u'Kim', u'Y', u'Huang', u'A', u'Villa', u'M', u'Auer', u'X.-D', u'Li', u'D.-N', u'Wang', u'Protein Sci', u'12', u'', u''], [u'', u'A', u'Mcpherson', u'J. Biol. Chem', u'251', u'', u''], [u'', u'A', u'Mcpherson', u'Eur. J. Biochem', u'189', u'', u''], [u'', u'C', u'Morris', u'Acta Cryst', u'67', u'', u''], [u'', u'B', u'Rupp', u'J. Struct. Biol', u'142', u'', u''], [u'D', u'E', u'Smith', u'History of Mathematics', u'New York', u'Dover Publications', u''], [u'', u'D', u'Stock', u'O', u'Perisic', u'J', u'L\xf6 We', u'Prog. Biophys. Mol. Biol', u'88', u'', u''], [u'', u'T', u'Warne', u'M', u'J', u'Serrano-Vega', u'J', u'G', u'Baker', u'R', u'Moukhametzianov', u'P', u'C', u'Edwards', u'R', u'Henderson', u'A', u'G', u'Leslie', u'C', u'G', u'Tate', u'G', u'F', u'Schertler', u'Nature', u'454', u'', u''], [u'', u'T', u'Warne', u'M', u'J', u'Serrano-Vega', u'C', u'G', u'Tate', u'G', u'F', u'Schertler', u'Protein Expr. Purif', u'65', u'', u'']"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_fields,levenshtein,list,0,1,0,0,"[u'J. Appl. Cryst.', u'39'], [u'Methods Mol. Biol.', u'363'], [u'J. Appl. Cryst.', u'34'], [u'J. Biol. Chem.', u'254'], [u'Cell', u'141'], [u'J. Appl. Cryst.', u'20'], [u'Proc. Natl Acad. Sci. USA', u'90'], [u'Acta Cryst.', u'58'], [u'Cryst. Growth Des.', u'11'], [u'J. Appl. Cryst.', u'24'], [u'Bioinformatics', u'20'], [u'Proteins', u'51'], [u'Protein Sci.', u'18'], [u'Proc. Natl Acad. Sci. USA', u'93'], [u'Protein Sci.', u'12'], [u'J. Biol. Chem.', u'251'], [u'Eur. J. Biochem.', u'189'], [u'et al.', u'Acta Cryst.', u'67'], [u'J. Struct. Biol.', u'142'], [u'History of Mathematics.'], [u'Prog. Biophys. Mol. Biol.', u'88'], [u'Nature (London)', u'454'], [u'Protein Expr. Purif.', u'65']","[u'', u'V', u'Berejnov', u'N', u'S', u'Husseini', u'O', u'A', u'Alsaied', u'R', u'E', u'Thorne', u'J. Appl. Cryst', u'39', u'', u''], [u'', u'T', u'Bergfors', u'Methods Mol. Biol', u'363', u'', u''], [u'', u'A', u'M', u'Brzozowski', u'J', u'Walton', u'J. Appl. Cryst', u'34', u'', u''], [u'', u'C', u'W', u'Carter', u'C', u'W', u'Carter', u'J. Biol. Chem', u'254', u'', u''], [u'', u'O', u'B', u'Clarke', u'A', u'T', u'Caputo', u'A', u'P', u'Hill', u'J', u'I', u'Vandenberg', u'B', u'J', u'Smith', u'J', u'M', u'Gulbis', u'Cell', u'141', u'', u''], [u'', u'M', u'J', u'Cox', u'P', u'C', u'Weber', u'J. Appl. Cryst', u'20', u'', u''], [u'J', u'A', u'Doudna', u'C', u'Grosshans', u'A', u'Gooding', u'C', u'E', u'Kundrot', u'Proc. Natl Acad. Sci. USA', u'Natl Acad. Sci. USA', u'', u'90', u''], [u'', u'E', u'L', u'Forsythe', u'D', u'L', u'Maxwell', u'M', u'Pusey', u'Acta Cryst', u'58', u'', u''], [u'', u'T', u'Hedderich', u'M', u'Marcia', u'J', u'K\xf6 Pke', u'H', u'Michel', u'Cryst. Growth Des', u'11', u'', u''], [u'', u'J', u'Jancarik', u'S.-H', u'Kim', u'J. Appl. Cryst', u'24', u'', u''], [u'', u'K', u'A', u'Kantardjieff', u'B', u'Rupp', u'Bioinformatics', u'20', u'', u''], [u'', u'M', u'S', u'Kimber', u'F', u'Vallee', u'S', u'Houston', u'A', u'Necakov', u'T', u'Skarina', u'E', u'Evdokimova', u'S', u'Beasley', u'D', u'Christendat', u'A', u'Savchenko', u'C', u'H', u'Arrowsmith', u'M', u'Vedadi', u'M', u'Gerstein', u'A', u'M', u'Edwards', u'Proteins', u'51', u'', u''], [u'', u'M', u'Koszelak-Rosenblum', u'A', u'Krol', u'N', u'Mozumdar', u'K', u'Wunsch', u'A', u'Ferin', u'E', u'Cook', u'C', u'K', u'Veatch', u'R', u'Nagel', u'J', u'R', u'Luft', u'G', u'T', u'Detitta', u'M', u'G', u'Malkowski', u'Protein Sci', u'18', u'', u''], [u'E', u'M', u'Landau', u'J', u'P', u'Rosenbusch', u'Proc. Natl Acad. Sci', u'USA, 93', u'', u''], [u'', u'M', u'J', u'Lemieux', u'J', u'Song', u'M', u'J', u'Kim', u'Y', u'Huang', u'A', u'Villa', u'M', u'Auer', u'X.-D', u'Li', u'D.-N', u'Wang', u'Protein Sci', u'12', u'', u''], [u'', u'A', u'Mcpherson', u'J. Biol. Chem', u'251', u'', u''], [u'', u'A', u'Mcpherson', u'Eur. J. Biochem', u'189', u'', u''], [u'', u'C', u'Morris', u'Acta Cryst', u'67', u'', u''], [u'', u'B', u'Rupp', u'J. Struct. Biol', u'142', u'', u''], [u'D', u'E', u'Smith', u'History of Mathematics', u'New York', u'Dover Publications', u''], [u'', u'D', u'Stock', u'O', u'Perisic', u'J', u'L\xf6 We', u'Prog. Biophys. Mol. Biol', u'88', u'', u''], [u'', u'T', u'Warne', u'M', u'J', u'Serrano-Vega', u'J', u'G', u'Baker', u'R', u'Moukhametzianov', u'P', u'C', u'Edwards', u'R', u'Henderson', u'A', u'G', u'Leslie', u'C', u'G', u'Tate', u'G', u'F', u'Schertler', u'Nature', u'454', u'', u''], [u'', u'T', u'Warne', u'M', u'J', u'Serrano-Vega', u'C', u'G', u'Tate', u'G', u'F', u'Schertler', u'Protein Expr. Purif', u'65', u'', u'']"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_title,exact,list,1,0,0,0,", , , , , , , , , , , , , , , , , , , , , , ",", , , , , , , , , , , , , , , , , , , , , , "
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_title,levenshtein,list,1,0,0,0,", , , , , , , , , , , , , , , , , , , , , , ",", , , , , , , , , , , , , , , , , , , , , , "
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_year,exact,list,0,1,0,0,", , , , , , , , , , , , , , , , , , , , , , ","2006, 2007, 2001, 1979, 2010, 1987, 1993, 2002, 2011, 1991, 2004, 2003, 2009, 1996, 2003, 1976, 1990, 2011, 2003, 1958, 2005, 2008, 2009"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_year,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , , , , , , , , , , ","2006, 2007, 2001, 1979, 2010, 1987, 1993, 2002, 2011, 1991, 2004, 2003, 2009, 1996, 2003, 1976, 1990, 2011, 2003, 1958, 2005, 2008, 2009"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_source,exact,list,0,1,0,0,", , , , , , , , , , , , , , , , , , , , , , ","J. Appl. Cryst, Methods Mol. Biol, J. Appl. Cryst, J. Biol. Chem, Cell, J. Appl. Cryst, , Acta Cryst, Cryst. Growth Des, J. Appl. Cryst, Bioinformatics, Proteins, Protein Sci, , Protein Sci, J. Biol. Chem, Eur. J. Biochem, Acta Cryst, J. Struct. Biol, , Prog. Biophys. Mol. Biol, Nature, Protein Expr. Purif"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_source,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , , , , , , , , , , ","J. Appl. Cryst, Methods Mol. Biol, J. Appl. Cryst, J. Biol. Chem, Cell, J. Appl. Cryst, , Acta Cryst, Cryst. Growth Des, J. Appl. Cryst, Bioinformatics, Proteins, Protein Sci, , Protein Sci, J. Biol. Chem, Eur. J. Biochem, Acta Cryst, J. Struct. Biol, , Prog. Biophys. Mol. Biol, Nature, Protein Expr. Purif"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_volume,exact,list,0,1,0,0,", , , , , , , , , , , , , , , , , , , , , , ","39, 363, 34, 254, 141, 20, 90, 58, 11, 24, 20, 51, 18, , 12, 251, 189, 67, 142, , 88, 454, 65"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_volume,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , , , , , , , , , , ","39, 363, 34, 254, 141, 20, 90, 58, 11, 24, 20, 51, 18, , 12, 251, 189, 67, 142, , 88, 454, 65"
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_fpage,exact,list,1,0,0,0,", , , , , , , , , , , , , , , , , , , , , , ",", , , , , , , , , , , , , , , , , , , , , , "
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_fpage,levenshtein,list,1,0,0,0,", , , , , , , , , , , , , , , , , , , , , , ",", , , , , , , , , , , , , , , , , , , , , , "
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_lpage,exact,list,1,0,0,0,", , , , , , , , , , , , , , , , , , , , , , ",", , , , , , , , , , , , , , , , , , , , , , "
d-67-00463.grobid-tei.xml,d-67-00463.nxml,reference_lpage,levenshtein,list,1,0,0,0,", , , , , , , , , , , , , , , , , , , , , , ",", , , , , , , , , , , , , , , , , , , , , , "
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,title,exact,string,0,1,0,0,"3-Allyl-1-{[3-(4-nitro­phen­yl)-4,5-dihydro-1,3-oxazol-5-yl]meth­yl}-1H-anthra[1,2-d]imidazole-2,6,11(3H)-trione","E67, o1363-o1364 Acta Cryst"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,title,levenshtein,string,0,1,0,0,"3-Allyl-1-{[3-(4-nitro­phen­yl)-4,5-dihydro-1,3-oxazol-5-yl]meth­yl}-1H-anthra[1,2-d]imidazole-2,6,11(3H)-trione","E67, o1363-o1364 Acta Cryst"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,abstract,exact,string,0,1,0,0,"The mol­ecular structure of the title compound, C28H20N4O6, consists of three fused six-membered rings (A,B,C) and one five-membered ring (D). The latter is linked to an isoxazole ring (E) via a methyl­ene unit. A 4-nitro-phenyl substituent (F) is attached to the isoxazole. The fused five and six-membered rings (C,D) are almost coplanar with an r.m.s. deviation of 0.0345 Å and make a dihedral angle of 9.40 (8)° with ring A. The isoxazole and 4-nitro-phenyl rings (E,F) are also almost coplanar with the imidazole and the fused adjacent ring (C,D), forming a dihedral angle of 11.4 (6)°. The crystal packing displays inter­molecular C—H⋯O hydrogen bonding. An intra­molecular C—H⋯O inter­action also occurs.","Key indicators: single-crystal X-ray study; T = 296 K; mean (C-C) = 0.003 A ˚ ; R factor = 0.040; wR factor = 0.111; data-to-parameter ratio = 14.1. The molecular structure of the title compound, C 28 H 20 N 4 O 6 , consists of three fused six-membered rings (A,B,C) and one five-membered ring (D). The latter is linked to an isoxazole ring (E) via a methylene unit. A 4-nitro-phenyl substituent (F) is attached to the isoxazole. The fused five and six-membered rings (C,D) are almost coplanar with an r.m.s. deviation of 0.0345 A ˚ and make a dihedral angle of 9.40 (8) with ring A. The isoxazole and 4-nitro-phenyl rings (E,F) are also almost coplanar with the imidazole and the fused adjacent ring (C,D), forming a dihedral angle of 11.4 (6). The crystal packing displays intermolecular C-HÁ Á ÁO hydrogen bonding. An intramolecular C-HÁ Á ÁO interaction also occurs."
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,abstract,levenshtein,string,0,1,0,0,"The mol­ecular structure of the title compound, C28H20N4O6, consists of three fused six-membered rings (A,B,C) and one five-membered ring (D). The latter is linked to an isoxazole ring (E) via a methyl­ene unit. A 4-nitro-phenyl substituent (F) is attached to the isoxazole. The fused five and six-membered rings (C,D) are almost coplanar with an r.m.s. deviation of 0.0345 Å and make a dihedral angle of 9.40 (8)° with ring A. The isoxazole and 4-nitro-phenyl rings (E,F) are also almost coplanar with the imidazole and the fused adjacent ring (C,D), forming a dihedral angle of 11.4 (6)°. The crystal packing displays inter­molecular C—H⋯O hydrogen bonding. An intra­molecular C—H⋯O inter­action also occurs.","Key indicators: single-crystal X-ray study; T = 296 K; mean (C-C) = 0.003 A ˚ ; R factor = 0.040; wR factor = 0.111; data-to-parameter ratio = 14.1. The molecular structure of the title compound, C 28 H 20 N 4 O 6 , consists of three fused six-membered rings (A,B,C) and one five-membered ring (D). The latter is linked to an isoxazole ring (E) via a methylene unit. A 4-nitro-phenyl substituent (F) is attached to the isoxazole. The fused five and six-membered rings (C,D) are almost coplanar with an r.m.s. deviation of 0.0345 A ˚ and make a dihedral angle of 9.40 (8) with ring A. The isoxazole and 4-nitro-phenyl rings (E,F) are also almost coplanar with the imidazole and the fused adjacent ring (C,D), forming a dihedral angle of 11.4 (6). The crystal packing displays intermolecular C-HÁ Á ÁO hydrogen bonding. An intramolecular C-HÁ Á ÁO interaction also occurs."
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,keywords,exact,set,0,0,0,1,,
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,keywords,levenshtein,set,0,0,0,1,,
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,author_surnames,exact,set,0,1,0,0,"Afrakssou, Capet, El Ammari, Haoudi, Rolando","Afrakssou, Ammari, Capet, Haoudi, Rolando"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,author_surnames,levenshtein,set,0,1,0,0,"Afrakssou, Capet, El Ammari, Haoudi, Rolando","Afrakssou, Ammari, Capet, Haoudi, Rolando"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,first_author_surname,exact,string,1,0,0,0,Afrakssou,Afrakssou
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,first_author_surname,levenshtein,string,1,0,0,0,Afrakssou,Afrakssou
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,author_full_names,exact,set,1,0,0,0,"Amal Haoudi, Christian Rolando, Frédéric Capet, Lahcen El Ammari, Zahra Afrakssou","Amal Haoudi, Christian Rolando, Frédéric Capet, Lahcen El Ammari, Zahra Afrakssou"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,author_full_names,levenshtein,set,1,0,0,0,"Amal Haoudi, Christian Rolando, Frédéric Capet, Lahcen El Ammari, Zahra Afrakssou","Amal Haoudi, Christian Rolando, Frédéric Capet, Lahcen El Ammari, Zahra Afrakssou"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,first_author_full_name,exact,string,1,0,0,0,Zahra Afrakssou,Zahra Afrakssou
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,first_author_full_name,levenshtein,string,1,0,0,0,Zahra Afrakssou,Zahra Afrakssou
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,affiliation_strings,exact,set,0,1,0,0,"France, Morocco","Faculté des Sciences et Techniques, Laboratoire de Chimie Organique Appliquée, Université Sidi Mohamed Ben Abdallah, Route d'Immouzzer, BP 2202 Fès, Morocco, Faculté des Sciences, Acta Crystallographica Section E, Laboratoire de Chimie du Solide Appliquée, Université Mohammed V-Agdal, Avenue Ibn Battouta, BP 1014, Rabat, Morocco Correspondence, USR 3290 Miniaturisation pour l'Analyse, la Synthèse et la Protéomique, Université Lille-1, 59655 Villeneuve d'Ascq Cedex, France,, Unité de Catalyse et de Chimie du Solide (UCCS), UMR 8181, Ecole Nationale Supérieure de Chimie de Lille, France"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,affiliation_strings,levenshtein,set,0,1,0,0,"France, Morocco","Faculté des Sciences et Techniques, Laboratoire de Chimie Organique Appliquée, Université Sidi Mohamed Ben Abdallah, Route d'Immouzzer, BP 2202 Fès, Morocco, Faculté des Sciences, Acta Crystallographica Section E, Laboratoire de Chimie du Solide Appliquée, Université Mohammed V-Agdal, Avenue Ibn Battouta, BP 1014, Rabat, Morocco Correspondence, USR 3290 Miniaturisation pour l'Analyse, la Synthèse et la Protéomique, Université Lille-1, 59655 Villeneuve d'Ascq Cedex, France,, Unité de Catalyse et de Chimie du Solide (UCCS), UMR 8181, Ecole Nationale Supérieure de Chimie de Lille, France"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,affiliation_institution,exact,set,0,1,0,0,,"Faculté des Sciences et Techniques, Laboratoire de Chimie Organique Appliquée, Université Sidi Mohamed Ben Abdallah, Faculté des Sciences, Acta Crystallographica Section E, Laboratoire de Chimie du Solide Appliquée, Université Mohammed V-Agdal, USR 3290 Miniaturisation pour l'Analyse, la Synthèse et la Protéomique, Université Lille-1, Unité de Catalyse et de Chimie du Solide (UCCS), UMR 8181, Ecole Nationale Supérieure de Chimie de Lille"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,affiliation_institution,levenshtein,set,0,1,0,0,,"Faculté des Sciences et Techniques, Laboratoire de Chimie Organique Appliquée, Université Sidi Mohamed Ben Abdallah, Faculté des Sciences, Acta Crystallographica Section E, Laboratoire de Chimie du Solide Appliquée, Université Mohammed V-Agdal, USR 3290 Miniaturisation pour l'Analyse, la Synthèse et la Protéomique, Université Lille-1, Unité de Catalyse et de Chimie du Solide (UCCS), UMR 8181, Ecole Nationale Supérieure de Chimie de Lille"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,section_titles,exact,list,0,1,0,0,"Related literature, Experimental, , Crystal data, Data collection, Refinement, , Supplementary Material","Related literature, Experimental, C. Rolando and L. El Ammari, Comment, Figures"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,section_titles,levenshtein,list,0,1,0,0,"Related literature, Experimental, , Crystal data, Data collection, Refinement, , Supplementary Material","Related literature, Experimental, C. Rolando and L. El Ammari, Comment, Figures"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,tables,exact,table,0,1,0,0,,"[[], []]"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,tables,levenshtein,table,0,1,0,0,,"[[], []]"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,table_strings,exact,list,0,1,0,0,,"Hydrogen-bond geometry (A ˚ , ). D-HÁ Á ÁA D -H HÁ Á ÁA D Á Á ÁA D -HÁ Á ÁA C7-H7Á Á ÁO1 i 0.93 2.60 3.516 (2) 169 C18-H18BÁ Á ÁO2 ii 0.97 2.37 3.333 (2) 170 C26-H26BÁ Á ÁO1 i 0.97 2.55 3.379 (3) 144 C16-H16AÁ Á ÁO2 0.97 2.10 2.902 (2) 141 Symmetry codes: (, Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 ) x y z U iso */U eq C1 0.6321 (2) 0.82375 (9) 0.19097 (19) 0.0612 (5) C2 0.85135 (19) 0.84194 (8) 0.35084 (17) 0.0552 (4) C3 0.81023 (17) 0.89317 (8) 0.27367 (15) 0.0502 (4) C4 0.90411 (17) 0.94182 (7) 0.30538 (15) 0.0475 (4) C5 1.04177 (18) 0.93398 (7) 0.40936 (15) 0.0505 (4) C6 1.0776 (2) 0.88249 (8) 0.48157 (16) 0.0593 (5) H6 1.1683 0.8794 0.5498 0.071* C7 0.9829 (2) 0.83582 (8) 0.45530 (17) 0.0622 (5) H7 1.0064 0.8018 0.5055 0.075* C8 1.1555 (2) 0.97997 (8) 0.44241 (17) 0.0574 (4) C9 1.1231 (2) 1.03401 (8) 0.36364 (17) 0.0556 (4) C10 0.98508 (19) 1.04342 (7) 0.26723 (16) 0.0527 (4) C11 0.86591 (19) 1.00068 (8) 0.24546 (16) 0.0524 (4) C12 1.2303 (2) 1.07627 (9) 0.3858 (2) 0.0712 (5) supplementary materials sup-4 H12 1.3224 1.0703 0.4505 0.085* C13 1.2012 (3) 1.12668 (10) 0.3127 (2) 0.0793 (6) H13 1.2730 1.1550 0.3292 0.095* C14 1.0663 (3) 1.13554 (9) 0.2151 (2) 0.0754 (6) H14 1.0482 1.1692 0.1641 0.090* C15 0.9574 (2) 1.09440 (8) 0.19255 (19) 0.0651 (5) H15 0.8658 1.1008 0.1275 0.078* C16 0.59135 (18) 0.91052 (8) 0.05248 (16) 0.0576 (5) H16A 0.5982 0.9527 0.0669 0.069* H16B 0.4900 0.8995 0.0226 0.069* C17 0.64489 (18) 0.89559 (9) −0.05152 (17) 0.0588 (5) H17 0.6223 0.8546 −0.0797 0.071* C18 0.58172 (18) 0.93738 (8) −0.16582 (17) 0.0617 (5) H18A 0.5628 0.9177 −0.2474 0.074* H18B 0.4935 0.9560 −0.1695 0.074* C19 0.70447 (18) 0.98060 (8) −0.13153 (16) 0.0553 (4) C20 0.69973 (18) 1.03873 (8) −0.18912 (16) 0.0546 (4) C21 0.5711 (2) 1.06028 (9) −0.28290 (18) 0.0640 (5) H21 0.4882 1.0370 −0.3120 0.077* C22 0.5655 (2) 1.11605 (9) −0.33315 (19) 0.0701 (5) H22 0.4792 1.1305 −0.3955 0.084* C23 0.6886 (2) 1.15008 (8) −0.2904 (2) 0.0662 (5) C24 0.8184 (2) 1.12962 (10) −0.1991 (2) 0.0727 (6) H24 0.9011 1.1530 −0.1718 0.087* C25 0.8234 (2) 1.07410 (9) −0.14903 (19) 0.0655 (5) H25 0.9106 1.0599 −0.0875 0.079* C26 0.7429 (2) 0.74050 (9) 0.3414 (2) 0.0749 (6) H26A 0.6442 0.7270 0.3176 0.090* H26B 0.7923 0.7385 0.4351 0.090* C27 0.8169 (2) 0.70030 (9) 0.2829 (2) 0.0776 (6) H27 0.8222 0.6608 0.3062 0.093* C28 0.8743 (3) 0.71473 (12) 0.2031 (3) 0.0922 (7) H28A 0.8718 0.7537 0.1768 0.111* H28B 0.9182 0.6862 0.1720 0.111* N1 0.67395 (14) 0.88059 (7) 0.17487 (13) 0.0554 (4) N2 0.73969 (16) 0.80148 (7) 0.30080 (15) 0.0633 (4) N3 0.82302 (15) 0.96221 (7) −0.04143 (14) 0.0606 (4) N4 0.6801 (3) 1.20974 (9) −0.3438 (2) 0.0907 (6) O1 0.52115 (15) 0.79872 (6) 0.12021 (14) 0.0768 (4) O2 0.73990 (14) 1.01619 (6) 0.18463 (13) 0.0677 (4) O3 1.27476 (15) 0.97262 (6) 0.53085 (13) 0.0835 (4) O4 0.80057 (12) 0.90603 (6) 0.00001 (12) 0.0663 (4) O5 0.5638 (2) 1.22624 (8) −0.4262 (2) 0.1111 (6) O6 0.7864 (2) 1.24061 (9) −0.3026 (3) 0.1445 (9) Atomic displacement parameters (Å 2 ) U supplementary materials sup-5"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,table_strings,levenshtein,list,0,1,0,0,,"Hydrogen-bond geometry (A ˚ , ). D-HÁ Á ÁA D -H HÁ Á ÁA D Á Á ÁA D -HÁ Á ÁA C7-H7Á Á ÁO1 i 0.93 2.60 3.516 (2) 169 C18-H18BÁ Á ÁO2 ii 0.97 2.37 3.333 (2) 170 C26-H26BÁ Á ÁO1 i 0.97 2.55 3.379 (3) 144 C16-H16AÁ Á ÁO2 0.97 2.10 2.902 (2) 141 Symmetry codes: (, Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 ) x y z U iso */U eq C1 0.6321 (2) 0.82375 (9) 0.19097 (19) 0.0612 (5) C2 0.85135 (19) 0.84194 (8) 0.35084 (17) 0.0552 (4) C3 0.81023 (17) 0.89317 (8) 0.27367 (15) 0.0502 (4) C4 0.90411 (17) 0.94182 (7) 0.30538 (15) 0.0475 (4) C5 1.04177 (18) 0.93398 (7) 0.40936 (15) 0.0505 (4) C6 1.0776 (2) 0.88249 (8) 0.48157 (16) 0.0593 (5) H6 1.1683 0.8794 0.5498 0.071* C7 0.9829 (2) 0.83582 (8) 0.45530 (17) 0.0622 (5) H7 1.0064 0.8018 0.5055 0.075* C8 1.1555 (2) 0.97997 (8) 0.44241 (17) 0.0574 (4) C9 1.1231 (2) 1.03401 (8) 0.36364 (17) 0.0556 (4) C10 0.98508 (19) 1.04342 (7) 0.26723 (16) 0.0527 (4) C11 0.86591 (19) 1.00068 (8) 0.24546 (16) 0.0524 (4) C12 1.2303 (2) 1.07627 (9) 0.3858 (2) 0.0712 (5) supplementary materials sup-4 H12 1.3224 1.0703 0.4505 0.085* C13 1.2012 (3) 1.12668 (10) 0.3127 (2) 0.0793 (6) H13 1.2730 1.1550 0.3292 0.095* C14 1.0663 (3) 1.13554 (9) 0.2151 (2) 0.0754 (6) H14 1.0482 1.1692 0.1641 0.090* C15 0.9574 (2) 1.09440 (8) 0.19255 (19) 0.0651 (5) H15 0.8658 1.1008 0.1275 0.078* C16 0.59135 (18) 0.91052 (8) 0.05248 (16) 0.0576 (5) H16A 0.5982 0.9527 0.0669 0.069* H16B 0.4900 0.8995 0.0226 0.069* C17 0.64489 (18) 0.89559 (9) −0.05152 (17) 0.0588 (5) H17 0.6223 0.8546 −0.0797 0.071* C18 0.58172 (18) 0.93738 (8) −0.16582 (17) 0.0617 (5) H18A 0.5628 0.9177 −0.2474 0.074* H18B 0.4935 0.9560 −0.1695 0.074* C19 0.70447 (18) 0.98060 (8) −0.13153 (16) 0.0553 (4) C20 0.69973 (18) 1.03873 (8) −0.18912 (16) 0.0546 (4) C21 0.5711 (2) 1.06028 (9) −0.28290 (18) 0.0640 (5) H21 0.4882 1.0370 −0.3120 0.077* C22 0.5655 (2) 1.11605 (9) −0.33315 (19) 0.0701 (5) H22 0.4792 1.1305 −0.3955 0.084* C23 0.6886 (2) 1.15008 (8) −0.2904 (2) 0.0662 (5) C24 0.8184 (2) 1.12962 (10) −0.1991 (2) 0.0727 (6) H24 0.9011 1.1530 −0.1718 0.087* C25 0.8234 (2) 1.07410 (9) −0.14903 (19) 0.0655 (5) H25 0.9106 1.0599 −0.0875 0.079* C26 0.7429 (2) 0.74050 (9) 0.3414 (2) 0.0749 (6) H26A 0.6442 0.7270 0.3176 0.090* H26B 0.7923 0.7385 0.4351 0.090* C27 0.8169 (2) 0.70030 (9) 0.2829 (2) 0.0776 (6) H27 0.8222 0.6608 0.3062 0.093* C28 0.8743 (3) 0.71473 (12) 0.2031 (3) 0.0922 (7) H28A 0.8718 0.7537 0.1768 0.111* H28B 0.9182 0.6862 0.1720 0.111* N1 0.67395 (14) 0.88059 (7) 0.17487 (13) 0.0554 (4) N2 0.73969 (16) 0.80148 (7) 0.30080 (15) 0.0633 (4) N3 0.82302 (15) 0.96221 (7) −0.04143 (14) 0.0606 (4) N4 0.6801 (3) 1.20974 (9) −0.3438 (2) 0.0907 (6) O1 0.52115 (15) 0.79872 (6) 0.12021 (14) 0.0768 (4) O2 0.73990 (14) 1.01619 (6) 0.18463 (13) 0.0677 (4) O3 1.27476 (15) 0.97262 (6) 0.53085 (13) 0.0835 (4) O4 0.80057 (12) 0.90603 (6) 0.00001 (12) 0.0663 (4) O5 0.5638 (2) 1.22624 (8) −0.4262 (2) 0.1111 (6) O6 0.7864 (2) 1.24061 (9) −0.3026 (3) 0.1445 (9) Atomic displacement parameters (Å 2 ) U supplementary materials sup-5"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,table_labels,exact,list,0,1,0,0,,"Table 1, Refinement . Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > 2σ(F 2 ) is used only for calculating R- factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.11 U 22 U 33 U 12 U 13 U 23"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,table_labels,levenshtein,list,0,1,0,0,,"Table 1, Refinement . Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > 2σ(F 2 ) is used only for calculating R- factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.11 U 22 U 33 U 12 U 13 U 23"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,table_captions,exact,list,0,1,0,0,,", "
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,table_captions,levenshtein,list,0,1,0,0,,", "
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,table_label_captions,exact,list,0,1,0,0,,"Table 1, Refinement . Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > 2σ(F 2 ) is used only for calculating R- factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.11 U 22 U 33 U 12 U 13 U 23"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,table_label_captions,levenshtein,list,0,1,0,0,,"Table 1, Refinement . Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > 2σ(F 2 ) is used only for calculating R- factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.11 U 22 U 33 U 12 U 13 U 23"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,first_reference_fields,exact,list,0,1,0,0,"[u'Acta Cryst.', u'66']","[u'', u'Z', u'Afrakssou', u'Y', u'K', u'Rodi', u'H', u'Zouihri', u'E', u'M', u'Essassi', u'S', u'W', u'Ng', u'Acta Cryst', u'66', u'1851', u'']"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,first_reference_fields,levenshtein,list,1,0,0,0,"[u'Acta Cryst.', u'66']","[u'', u'Z', u'Afrakssou', u'Y', u'K', u'Rodi', u'H', u'Zouihri', u'E', u'M', u'Essassi', u'S', u'W', u'Ng', u'Acta Cryst', u'66', u'1851', u'']"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,first_reference_title,exact,string,0,0,0,1,,
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,first_reference_title,levenshtein,string,0,0,0,1,,
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_fields,exact,list,0,1,0,0,"[u'Acta Cryst.', u'66'], [u'J. Ethnopharmacol.', u'72'], [u'Antivir. Res.', u'28'], [u'APEX2', u'SAINT-Plus', u'SADABS'], [u'Food Chem. Toxicol.', u'45'], [u'J. Am. Chem. Soc.', u'97'], [u'J. Appl. Cryst.', u'30'], [u'J. Med. Chem.', u'46'], [u'J. Ethnopharmacol.', u'91'], [u'Cancer Lett.', u'182'], [u'Acta Cryst.', u'64'], [u'Mutat. Res.', u'347'], [u'Biochem. Pharmacol.', u'70'], [u'Thermochim. Acta', u'429'], [u'Food Chem.', u'70']","[u'', u'Z', u'Afrakssou', u'Y', u'K', u'Rodi', u'H', u'Zouihri', u'E', u'M', u'Essassi', u'S', u'W', u'Ng', u'Acta Cryst', u'66', u'1851', u''], [u'', u'S', u'K', u'Agarwal', u'S', u'S', u'Singh', u'S', u'Verma', u'S', u'Kumar', u'J. Ethnopharmacol', u'72', u'', u''], [u'', u'D', u'L', u'Barnard', u'D', u'W', u'Fairbairn', u'K', u'L', u'O&apos;neill', u'T', u'L', u'Gage', u'R', u'W', u'Sidwell', u'Antivir. Res', u'28', u'', u''], [u'APEX2, SAINT-Plus and SADABS', u'Bruker', u'', u'Bruker AXS Inc', u'Madison, Wisconsin, USA'], [u'', u'S', u'H', u'Chen', u'K', u'Y', u'Lin', u'C', u'C', u'Chang', u'C', u'L', u'Fang', u'C', u'P', u'Lin', u'Food Chem. Toxicol', u'45', u'', u''], [u'', u'D', u'Cremer', u'J', u'A', u'Pople', u'J. Am. Chem. Soc', u'97', u'', u''], [u'', u'L', u'J', u'Farrugia', u'H', u'S', u'Haug', u'J', u'F', u'Chiou', u'Y', u'Fong', u'C', u'C', u'Hou', u'Y', u'C', u'Lu', u'J', u'Y', u'Wang', u'J', u'W', u'Shih', u'Y', u'R', u'Pan', u'J', u'J', u'Lin', u'J. Appl. Cryst', u'30', u'', u'', u'J. Med. Chem.'], [u'', u'A', u'Iizuka', u'O', u'T', u'Iijima', u'K', u'Kondo', u'H', u'Itakura', u'F', u'Yoshie', u'H', u'Miyamoto', u'M', u'Kubo', u'M', u'Higuchi', u'H', u'Takeda', u'T', u'Matsumiy', u'J. Ethnopharmacol', u'91', u'', u''], [u'', u'J', u'Koyamaa', u'I', u'Morita', u'K', u'Tagahara', u'Y', u'Nobukuni', u'T', u'Mukainaka', u'M', u'Kuchide', u'H', u'Tokuda', u'H', u'Nishino', u'Cancer Lett', u'182', u'', u''], [u'', u'G', u'M', u'Sheldrick', u'Acta Cryst', u'64', u'', u''], [u'', u'S', u'Simi', u'S', u'Morelli', u'P', u'G', u'Gervasi', u'G', u'Rainaldi', u'Mutat. Res', u'347', u'', u''], [u'', u'Y', u'T', u'Su', u'H', u'L', u'Chang', u'S', u'K', u'Shyue', u'S', u'L', u'Hsu', u'Biochem. Pharmacol', u'70', u'', u''], [u'', u'Y', u'W', u'Wu', u'W', u'Y', u'Gao', u'X', u'H', u'Xiao', u'Y', u'Liu', u'Thermochim. Acta', u'429', u'', u''], [u'', u'G', u'C', u'Yen', u'P', u'D', u'Duh', u'D', u'Y', u'Chuang', u'Food Chem', u'70', u'', u'']"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_fields,levenshtein,list,0,1,0,0,"[u'Acta Cryst.', u'66'], [u'J. Ethnopharmacol.', u'72'], [u'Antivir. Res.', u'28'], [u'APEX2', u'SAINT-Plus', u'SADABS'], [u'Food Chem. Toxicol.', u'45'], [u'J. Am. Chem. Soc.', u'97'], [u'J. Appl. Cryst.', u'30'], [u'J. Med. Chem.', u'46'], [u'J. Ethnopharmacol.', u'91'], [u'Cancer Lett.', u'182'], [u'Acta Cryst.', u'64'], [u'Mutat. Res.', u'347'], [u'Biochem. Pharmacol.', u'70'], [u'Thermochim. Acta', u'429'], [u'Food Chem.', u'70']","[u'', u'Z', u'Afrakssou', u'Y', u'K', u'Rodi', u'H', u'Zouihri', u'E', u'M', u'Essassi', u'S', u'W', u'Ng', u'Acta Cryst', u'66', u'1851', u''], [u'', u'S', u'K', u'Agarwal', u'S', u'S', u'Singh', u'S', u'Verma', u'S', u'Kumar', u'J. Ethnopharmacol', u'72', u'', u''], [u'', u'D', u'L', u'Barnard', u'D', u'W', u'Fairbairn', u'K', u'L', u'O&apos;neill', u'T', u'L', u'Gage', u'R', u'W', u'Sidwell', u'Antivir. Res', u'28', u'', u''], [u'APEX2, SAINT-Plus and SADABS', u'Bruker', u'', u'Bruker AXS Inc', u'Madison, Wisconsin, USA'], [u'', u'S', u'H', u'Chen', u'K', u'Y', u'Lin', u'C', u'C', u'Chang', u'C', u'L', u'Fang', u'C', u'P', u'Lin', u'Food Chem. Toxicol', u'45', u'', u''], [u'', u'D', u'Cremer', u'J', u'A', u'Pople', u'J. Am. Chem. Soc', u'97', u'', u''], [u'', u'L', u'J', u'Farrugia', u'H', u'S', u'Haug', u'J', u'F', u'Chiou', u'Y', u'Fong', u'C', u'C', u'Hou', u'Y', u'C', u'Lu', u'J', u'Y', u'Wang', u'J', u'W', u'Shih', u'Y', u'R', u'Pan', u'J', u'J', u'Lin', u'J. Appl. Cryst', u'30', u'', u'', u'J. Med. Chem.'], [u'', u'A', u'Iizuka', u'O', u'T', u'Iijima', u'K', u'Kondo', u'H', u'Itakura', u'F', u'Yoshie', u'H', u'Miyamoto', u'M', u'Kubo', u'M', u'Higuchi', u'H', u'Takeda', u'T', u'Matsumiy', u'J. Ethnopharmacol', u'91', u'', u''], [u'', u'J', u'Koyamaa', u'I', u'Morita', u'K', u'Tagahara', u'Y', u'Nobukuni', u'T', u'Mukainaka', u'M', u'Kuchide', u'H', u'Tokuda', u'H', u'Nishino', u'Cancer Lett', u'182', u'', u''], [u'', u'G', u'M', u'Sheldrick', u'Acta Cryst', u'64', u'', u''], [u'', u'S', u'Simi', u'S', u'Morelli', u'P', u'G', u'Gervasi', u'G', u'Rainaldi', u'Mutat. Res', u'347', u'', u''], [u'', u'Y', u'T', u'Su', u'H', u'L', u'Chang', u'S', u'K', u'Shyue', u'S', u'L', u'Hsu', u'Biochem. Pharmacol', u'70', u'', u''], [u'', u'Y', u'W', u'Wu', u'W', u'Y', u'Gao', u'X', u'H', u'Xiao', u'Y', u'Liu', u'Thermochim. Acta', u'429', u'', u''], [u'', u'G', u'C', u'Yen', u'P', u'D', u'Duh', u'D', u'Y', u'Chuang', u'Food Chem', u'70', u'', u'']"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_title,exact,list,0,1,0,0,", , , , , , , , , , , , , , ",", , , , , , , , , , , , , "
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_title,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , , ",", , , , , , , , , , , , , "
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_year,exact,list,0,1,0,0,", , , , , , , , , , , , , , ","2010, 2000, 1995, 2009, 2007, 1975, 1997, 2004, 2002, 2008, 1995, 2005, 2005, 2000"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_year,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , , ","2010, 2000, 1995, 2009, 2007, 1975, 1997, 2004, 2002, 2008, 1995, 2005, 2005, 2000"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_source,exact,list,0,1,0,0,", , , , , , , , , , , , , , ","Acta Cryst, J. Ethnopharmacol, Antivir. Res, , Food Chem. Toxicol, J. Am. Chem. Soc, J. Appl. Cryst, J. Ethnopharmacol, Cancer Lett, Acta Cryst, Mutat. Res, Biochem. Pharmacol, Thermochim. Acta, Food Chem"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_source,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , , ","Acta Cryst, J. Ethnopharmacol, Antivir. Res, , Food Chem. Toxicol, J. Am. Chem. Soc, J. Appl. Cryst, J. Ethnopharmacol, Cancer Lett, Acta Cryst, Mutat. Res, Biochem. Pharmacol, Thermochim. Acta, Food Chem"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_volume,exact,list,0,1,0,0,", , , , , , , , , , , , , , ","66, 72, 28, , 45, 97, 30, 91, 182, 64, 347, 70, 429, 70"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_volume,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , , ","66, 72, 28, , 45, 97, 30, 91, 182, 64, 347, 70, 429, 70"
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_fpage,exact,list,0,1,0,0,", , , , , , , , , , , , , , ",", , , , , , , , , , , , , "
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_fpage,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , , ",", , , , , , , , , , , , , "
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_lpage,exact,list,0,1,0,0,", , , , , , , , , , , , , , ",", , , , , , , , , , , , , "
e-67-o1363.grobid-tei.xml,e-67-o1363.nxml,reference_lpage,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , , ",", , , , , , , , , , , , , "
f-67-00344.grobid-tei.xml,f-67-00344.nxml,title,exact,string,0,1,0,0,"Refolding, crystallization and preliminary X-ray crystallographic study of the whole extracellular regions of nectins","Structural Biology and Crystallization Communications Refolding, crystallization and preliminary X-ray crystallographic study of the whole extracellular regions of nectins"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,title,levenshtein,string,0,1,0,0,"Refolding, crystallization and preliminary X-ray crystallographic study of the whole extracellular regions of nectins","Structural Biology and Crystallization Communications Refolding, crystallization and preliminary X-ray crystallographic study of the whole extracellular regions of nectins"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,abstract,exact,string,0,1,0,0,"The whole extracellular regions of nectin-1 (nectin-1-EC) and nectin-2 (nectin-2-EC) were expressed in E. coli as inclusion bodies, solubilized in 8 M urea and then refolded by rapid dilution. Refolded nectin-1-EC and nectin-2-EC were subsequently purified using three chromatographic steps and crystallized by the hanging-drop vapour-diffusion method.The nectin family of Ca2+-independent immunoglobulin-like cell–cell adhesion molecules contains four members. Nectins, which have three Ig-like domains in their extracellular region, form cell–cell adherens junctions cooperatively with cadherins. The whole extracellular regions of nectin-1 (nectin-1-EC) and nectin-­2 (nectin-2-EC) were expressed in Escherichia coli as inclusion bodies, solubilized in 8 M urea and then refolded by rapid dilution into refolding solution. The refolded proteins were subsequently purified by three chromatographic steps and crystallized using the hanging-drop vapour-diffusion method. The nectin-1-EC crystals belonged to space group P213 and the nectin-2-EC crystals belonged to space group P6122 or P6522.","The nectin family of Ca 2+-independent immunoglobulin-like cell-cell adhesion molecules contains four members. Nectins, which have three Ig-like domains in their extracellular region, form cell-cell adherens junctions cooperatively with cadherins. The whole extracellular regions of nectin-1 (nectin-1-EC) and nectin-2 (nectin-2-EC) were expressed in Escherichia coli as inclusion bodies, solubilized in 8 M urea and then refolded by rapid dilution into refolding solution. The refolded proteins were subsequently purified by three chromato-graphic steps and crystallized using the hanging-drop vapour-diffusion method. The nectin-1-EC crystals belonged to space group P2 1 3 and the nectin-2-EC crystals belonged to space group P6 1 22 or P6 5 22."
f-67-00344.grobid-tei.xml,f-67-00344.nxml,abstract,levenshtein,string,0,1,0,0,"The whole extracellular regions of nectin-1 (nectin-1-EC) and nectin-2 (nectin-2-EC) were expressed in E. coli as inclusion bodies, solubilized in 8 M urea and then refolded by rapid dilution. Refolded nectin-1-EC and nectin-2-EC were subsequently purified using three chromatographic steps and crystallized by the hanging-drop vapour-diffusion method.The nectin family of Ca2+-independent immunoglobulin-like cell–cell adhesion molecules contains four members. Nectins, which have three Ig-like domains in their extracellular region, form cell–cell adherens junctions cooperatively with cadherins. The whole extracellular regions of nectin-1 (nectin-1-EC) and nectin-­2 (nectin-2-EC) were expressed in Escherichia coli as inclusion bodies, solubilized in 8 M urea and then refolded by rapid dilution into refolding solution. The refolded proteins were subsequently purified by three chromatographic steps and crystallized using the hanging-drop vapour-diffusion method. The nectin-1-EC crystals belonged to space group P213 and the nectin-2-EC crystals belonged to space group P6122 or P6522.","The nectin family of Ca 2+-independent immunoglobulin-like cell-cell adhesion molecules contains four members. Nectins, which have three Ig-like domains in their extracellular region, form cell-cell adherens junctions cooperatively with cadherins. The whole extracellular regions of nectin-1 (nectin-1-EC) and nectin-2 (nectin-2-EC) were expressed in Escherichia coli as inclusion bodies, solubilized in 8 M urea and then refolded by rapid dilution into refolding solution. The refolded proteins were subsequently purified by three chromato-graphic steps and crystallized using the hanging-drop vapour-diffusion method. The nectin-1-EC crystals belonged to space group P2 1 3 and the nectin-2-EC crystals belonged to space group P6 1 22 or P6 5 22."
f-67-00344.grobid-tei.xml,f-67-00344.nxml,keywords,exact,set,0,0,1,0,"adherens junctions, cell-adhesion molecules, immunoglobulin-like domains",
f-67-00344.grobid-tei.xml,f-67-00344.nxml,keywords,levenshtein,set,0,0,1,0,"adherens junctions, cell-adhesion molecules, immunoglobulin-like domains",
f-67-00344.grobid-tei.xml,f-67-00344.nxml,author_surnames,exact,set,1,0,0,0,"Nakagawa, Narita, Sakisaka, Suzuki, Takai, Yamamoto","Nakagawa, Narita, Sakisaka, Suzuki, Takai, Yamamoto"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,author_surnames,levenshtein,set,1,0,0,0,"Nakagawa, Narita, Sakisaka, Suzuki, Takai, Yamamoto","Nakagawa, Narita, Sakisaka, Suzuki, Takai, Yamamoto"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,first_author_surname,exact,string,1,0,0,0,Narita,Narita
f-67-00344.grobid-tei.xml,f-67-00344.nxml,first_author_surname,levenshtein,string,1,0,0,0,Narita,Narita
f-67-00344.grobid-tei.xml,f-67-00344.nxml,author_full_names,exact,set,1,0,0,0,"Atsushi Nakagawa, Hirotaka Narita, Mamoru Suzuki, Toshiaki Sakisaka, Yasunori Yamamoto, Yoshimi Takai","Atsushi Nakagawa, Hirotaka Narita, Mamoru Suzuki, Toshiaki Sakisaka, Yasunori Yamamoto, Yoshimi Takai"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,author_full_names,levenshtein,set,1,0,0,0,"Atsushi Nakagawa, Hirotaka Narita, Mamoru Suzuki, Toshiaki Sakisaka, Yasunori Yamamoto, Yoshimi Takai","Atsushi Nakagawa, Hirotaka Narita, Mamoru Suzuki, Toshiaki Sakisaka, Yasunori Yamamoto, Yoshimi Takai"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,first_author_full_name,exact,string,1,0,0,0,Hirotaka Narita,Hirotaka Narita
f-67-00344.grobid-tei.xml,f-67-00344.nxml,first_author_full_name,levenshtein,string,1,0,0,0,Hirotaka Narita,Hirotaka Narita
f-67-00344.grobid-tei.xml,f-67-00344.nxml,affiliation_strings,exact,set,0,1,0,0,"Kobe University Graduate School of Medicine, Japan, Osaka University, Japan","Acta Crystallographica Section F, Division of Membrane Dynamics, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, 650-0017, Kobe, Japan,, Division of Molecular and Cellular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 650-0017, Kobe, Japan Correspondence, Institute for Protein Research, Laboratory of Supramolecular Crystallography, Research Center for Structural and Functional Proteomics, Osaka University, 565-0871, Suita, Japan"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,affiliation_strings,levenshtein,set,0,1,0,0,"Kobe University Graduate School of Medicine, Japan, Osaka University, Japan","Acta Crystallographica Section F, Division of Membrane Dynamics, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, 650-0017, Kobe, Japan,, Division of Molecular and Cellular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 650-0017, Kobe, Japan Correspondence, Institute for Protein Research, Laboratory of Supramolecular Crystallography, Research Center for Structural and Functional Proteomics, Osaka University, 565-0871, Suita, Japan"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,affiliation_institution,exact,set,0,1,0,0,"Kobe University Graduate School of Medicine, Osaka University","Acta Crystallographica Section F, Division of Membrane Dynamics, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Division of Molecular and Cellular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, Institute for Protein Research, Laboratory of Supramolecular Crystallography, Research Center for Structural and Functional Proteomics, Osaka University"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,affiliation_institution,levenshtein,set,0,1,0,0,"Kobe University Graduate School of Medicine, Osaka University","Acta Crystallographica Section F, Division of Membrane Dynamics, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Division of Molecular and Cellular Biology, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, Institute for Protein Research, Laboratory of Supramolecular Crystallography, Research Center for Structural and Functional Proteomics, Osaka University"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,section_titles,exact,list,1,0,0,0,"Introduction, Materials and methods, Protein expression and purification of inclusion bodies, Optimization of refolding conditions and protein purification, Crystallization, Data collection, Results and discussion","Introduction, Materials and methods, Protein expression and purification of inclusion bodies, Optimization of refolding conditions and protein purification, Crystallization, Data collection, Results and discussion"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,section_titles,levenshtein,list,1,0,0,0,"Introduction, Materials and methods, Protein expression and purification of inclusion bodies, Optimization of refolding conditions and protein purification, Crystallization, Data collection, Results and discussion","Introduction, Materials and methods, Protein expression and purification of inclusion bodies, Optimization of refolding conditions and protein purification, Crystallization, Data collection, Results and discussion"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,tables,exact,table,0,1,0,0,,[[]]
f-67-00344.grobid-tei.xml,f-67-00344.nxml,tables,levenshtein,table,0,1,0,0,,[[]]
f-67-00344.grobid-tei.xml,f-67-00344.nxml,table_strings,exact,list,0,1,0,0,,"Human nectin-1 extracellular region Mouse nectin-2 extracellular region Beamline BL44XU, SPring-8 BL44XU, SPring-8 Space group P2 1 3 P6 1 22 or P6 5 22 Unit-cell parameters (A ˚ ) a = b = c = 164.9 a = b = 79.3, c = 235.4 Wavelength (A ˚ ) 0.90000 0.90000 Detector DIP6040 DIP6040 Crystal-to-detector distance (mm) 540 400 Rotation range per image ( ) 0.5 1.0 Total rotation range ( ) 6 0 7 0 Exposure time per image (s) 20 2 Resolution range (A ˚ ) 50.00-2.80 (2.90-2.80) 50.00-2.55 (2.59-2.55) Total no. of observations 137039 (13666) 61011 (3039) No. of unique reflections 36109 (3504) 14654 (707) Completeness (%) 97.9 (96.8) 98.2 (96.8) hIi/h(I)i 19.4 (4.3) 21.8 (3.6) Multiplicity 3.8 (3.9) 4.2 (4.3) R merge † 0.068 (0.358) 0.061 (0.396) Overall B factor from Wilson plot (A ˚ 2 ) 85.5 58.1 † R merge = P hkl P i jI i ðhklÞ À hIðhklÞij= P hkl P i I i ðhklÞ, where hI(hkl)i is the mean intensity of symmetry-equivalent reflections."
f-67-00344.grobid-tei.xml,f-67-00344.nxml,table_strings,levenshtein,list,0,1,0,0,,"Human nectin-1 extracellular region Mouse nectin-2 extracellular region Beamline BL44XU, SPring-8 BL44XU, SPring-8 Space group P2 1 3 P6 1 22 or P6 5 22 Unit-cell parameters (A ˚ ) a = b = c = 164.9 a = b = 79.3, c = 235.4 Wavelength (A ˚ ) 0.90000 0.90000 Detector DIP6040 DIP6040 Crystal-to-detector distance (mm) 540 400 Rotation range per image ( ) 0.5 1.0 Total rotation range ( ) 6 0 7 0 Exposure time per image (s) 20 2 Resolution range (A ˚ ) 50.00-2.80 (2.90-2.80) 50.00-2.55 (2.59-2.55) Total no. of observations 137039 (13666) 61011 (3039) No. of unique reflections 36109 (3504) 14654 (707) Completeness (%) 97.9 (96.8) 98.2 (96.8) hIi/h(I)i 19.4 (4.3) 21.8 (3.6) Multiplicity 3.8 (3.9) 4.2 (4.3) R merge † 0.068 (0.358) 0.061 (0.396) Overall B factor from Wilson plot (A ˚ 2 ) 85.5 58.1 † R merge = P hkl P i jI i ðhklÞ À hIðhklÞij= P hkl P i I i ðhklÞ, where hI(hkl)i is the mean intensity of symmetry-equivalent reflections."
f-67-00344.grobid-tei.xml,f-67-00344.nxml,table_labels,exact,list,0,1,0,0,,Table 1 Data-collection statistics. Values in parentheses are for the highest resolution shell.
f-67-00344.grobid-tei.xml,f-67-00344.nxml,table_labels,levenshtein,list,0,1,0,0,,Table 1 Data-collection statistics. Values in parentheses are for the highest resolution shell.
f-67-00344.grobid-tei.xml,f-67-00344.nxml,table_captions,exact,list,0,0,0,1,,
f-67-00344.grobid-tei.xml,f-67-00344.nxml,table_captions,levenshtein,list,0,0,0,1,,
f-67-00344.grobid-tei.xml,f-67-00344.nxml,table_label_captions,exact,list,0,1,0,0,,Table 1 Data-collection statistics. Values in parentheses are for the highest resolution shell.
f-67-00344.grobid-tei.xml,f-67-00344.nxml,table_label_captions,levenshtein,list,0,1,0,0,,Table 1 Data-collection statistics. Values in parentheses are for the highest resolution shell.
f-67-00344.grobid-tei.xml,f-67-00344.nxml,first_reference_fields,exact,list,0,1,0,0,"[u'J. Virol.', u'72']","[u'', u'F', u'Cocchi', u'L', u'Menotti', u'P', u'Mirandola', u'M', u'Lopez', u'G', u'Campadelli-Fiume', u'J. Virol', u'72', u'', u'']"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,first_reference_fields,levenshtein,list,1,0,0,0,"[u'J. Virol.', u'72']","[u'', u'F', u'Cocchi', u'L', u'Menotti', u'P', u'Mirandola', u'M', u'Lopez', u'G', u'Campadelli-Fiume', u'J. Virol', u'72', u'', u'']"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,first_reference_title,exact,string,0,0,0,1,,
f-67-00344.grobid-tei.xml,f-67-00344.nxml,first_reference_title,levenshtein,string,0,0,0,1,,
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_fields,exact,list,0,1,0,0,"[u'J. Virol.', u'72'], [u'Acta Cryst.', u'50'], [u'Science', u'280'], [u'Nature Rev. Mol. Cell Biol.', u'11'], [u'J. Virol.', u'74'], [u'Proc. Jpn Acad. Ser. B Phys. Biol. Sci.', u'86'], [u'IUBMB Life', u'58'], [u'Methods Enzymol.', u'276'], [u'J. Virol.', u'75'], [u'Annu. Rev. Cell Dev. Biol.', u'24'], [u'Cancer Sci.', u'94'], [u'Nature Rev. Mol. Cell Biol.', u'9'], [u'Virology', u'246'], [u'Proc. Natl Acad. Sci. USA', u'105']","[u'', u'F', u'Cocchi', u'L', u'Menotti', u'P', u'Mirandola', u'M', u'Lopez', u'G', u'Campadelli-Fiume', u'J. Virol', u'72', u'', u''], [u'', u'Collaborative Computational Project, Number', u'4', u'', u'', u'Acta Cryst.'], [u'', u'R', u'J', u'Geraghty', u'C', u'Krummenacher', u'G', u'H', u'Cohen', u'R', u'J', u'Eisenberg', u'P', u'G', u'Spear', u'Science', u'280', u'', u''], [u'', u'T', u'J', u'Harris', u'U', u'Tepass', u'Nature Rev. Mol. Cell Biol', u'11', u'', u''], [u'', u'M', u'Lopez', u'F', u'Cocchi', u'L', u'Menotti', u'E', u'Avitabile', u'P', u'Dubreuil', u'G', u'Campadellifiume', u'J. Virol', u'74', u'', u''], [u'', u'H', u'Ogita', u'Y', u'Rikitake', u'J', u'Miyoshi', u'Y', u'Takai', u'Proc. Jpn Acad. Ser. B Phys. Biol. Sci', u'86', u'', u''], [u'', u'H', u'Ogita', u'Y', u'Takai', u'IUBMB Life', u'58', u'', u''], [u'', u'Z', u'Otwinowski', u'W', u'Minor', u'Methods Enzymol', u'276', u'', u''], [u'', u'T', u'Sakisaka', u'T', u'Taniguchi', u'H', u'Nakanishi', u'K', u'Takahashi', u'M', u'Miyahara', u'W', u'Ikeda', u'S', u'Yokoyama', u'Y.-F', u'Peng', u'K', u'Yamanishi', u'Y', u'Takai', u'J. Virol', u'75', u'', u''], [u'', u'Y', u'Takai', u'W', u'Ikeda', u'H', u'Ogita', u'Y', u'Rikitake', u'Annu. Rev. Cell Dev. Biol', u'24', u'', u''], [u'', u'Y', u'Takai', u'K', u'Irie', u'K', u'Shimizu', u'T', u'Sakisaka', u'W', u'Ikeda', u'Cancer Sci', u'94', u'', u''], [u'', u'Y', u'Takai', u'J', u'Miyoshi', u'W', u'Ikeda', u'H', u'Ogita', u'Nature Rev. Mol. Cell Biol', u'9', u'', u''], [u'', u'M', u'S', u'Warner', u'R', u'J', u'Geraghty', u'W', u'M', u'Martinez', u'R', u'I', u'Montgomery', u'J', u'C', u'Whitbeck', u'R', u'Xu', u'R', u'J', u'Eisenberg', u'G', u'H', u'Cohen', u'P', u'G', u'Spear', u'Virology', u'246', u'', u''], [u'P', u'Zhang', u'S', u'Mueller', u'M', u'C', u'Morais', u'C', u'M', u'Bator', u'V', u'D', u'Bowman', u'S', u'Hafenstein', u'E', u'Wimmer', u'M', u'G', u'Rossmann', u'Proc. Natl Acad. Sci. USA, 105', u'Natl Acad. Sci. USA, 105', u'', u'']"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_fields,levenshtein,list,1,0,0,0,"[u'J. Virol.', u'72'], [u'Acta Cryst.', u'50'], [u'Science', u'280'], [u'Nature Rev. Mol. Cell Biol.', u'11'], [u'J. Virol.', u'74'], [u'Proc. Jpn Acad. Ser. B Phys. Biol. Sci.', u'86'], [u'IUBMB Life', u'58'], [u'Methods Enzymol.', u'276'], [u'J. Virol.', u'75'], [u'Annu. Rev. Cell Dev. Biol.', u'24'], [u'Cancer Sci.', u'94'], [u'Nature Rev. Mol. Cell Biol.', u'9'], [u'Virology', u'246'], [u'Proc. Natl Acad. Sci. USA', u'105']","[u'', u'F', u'Cocchi', u'L', u'Menotti', u'P', u'Mirandola', u'M', u'Lopez', u'G', u'Campadelli-Fiume', u'J. Virol', u'72', u'', u''], [u'', u'Collaborative Computational Project, Number', u'4', u'', u'', u'Acta Cryst.'], [u'', u'R', u'J', u'Geraghty', u'C', u'Krummenacher', u'G', u'H', u'Cohen', u'R', u'J', u'Eisenberg', u'P', u'G', u'Spear', u'Science', u'280', u'', u''], [u'', u'T', u'J', u'Harris', u'U', u'Tepass', u'Nature Rev. Mol. Cell Biol', u'11', u'', u''], [u'', u'M', u'Lopez', u'F', u'Cocchi', u'L', u'Menotti', u'E', u'Avitabile', u'P', u'Dubreuil', u'G', u'Campadellifiume', u'J. Virol', u'74', u'', u''], [u'', u'H', u'Ogita', u'Y', u'Rikitake', u'J', u'Miyoshi', u'Y', u'Takai', u'Proc. Jpn Acad. Ser. B Phys. Biol. Sci', u'86', u'', u''], [u'', u'H', u'Ogita', u'Y', u'Takai', u'IUBMB Life', u'58', u'', u''], [u'', u'Z', u'Otwinowski', u'W', u'Minor', u'Methods Enzymol', u'276', u'', u''], [u'', u'T', u'Sakisaka', u'T', u'Taniguchi', u'H', u'Nakanishi', u'K', u'Takahashi', u'M', u'Miyahara', u'W', u'Ikeda', u'S', u'Yokoyama', u'Y.-F', u'Peng', u'K', u'Yamanishi', u'Y', u'Takai', u'J. Virol', u'75', u'', u''], [u'', u'Y', u'Takai', u'W', u'Ikeda', u'H', u'Ogita', u'Y', u'Rikitake', u'Annu. Rev. Cell Dev. Biol', u'24', u'', u''], [u'', u'Y', u'Takai', u'K', u'Irie', u'K', u'Shimizu', u'T', u'Sakisaka', u'W', u'Ikeda', u'Cancer Sci', u'94', u'', u''], [u'', u'Y', u'Takai', u'J', u'Miyoshi', u'W', u'Ikeda', u'H', u'Ogita', u'Nature Rev. Mol. Cell Biol', u'9', u'', u''], [u'', u'M', u'S', u'Warner', u'R', u'J', u'Geraghty', u'W', u'M', u'Martinez', u'R', u'I', u'Montgomery', u'J', u'C', u'Whitbeck', u'R', u'Xu', u'R', u'J', u'Eisenberg', u'G', u'H', u'Cohen', u'P', u'G', u'Spear', u'Virology', u'246', u'', u''], [u'P', u'Zhang', u'S', u'Mueller', u'M', u'C', u'Morais', u'C', u'M', u'Bator', u'V', u'D', u'Bowman', u'S', u'Hafenstein', u'E', u'Wimmer', u'M', u'G', u'Rossmann', u'Proc. Natl Acad. Sci. USA, 105', u'Natl Acad. Sci. USA, 105', u'', u'']"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_title,exact,list,1,0,0,0,", , , , , , , , , , , , , ",", , , , , , , , , , , , , "
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_title,levenshtein,list,1,0,0,0,", , , , , , , , , , , , , ",", , , , , , , , , , , , , "
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_year,exact,list,0,1,0,0,", , , , , , , , , , , , , ","1998, 1994, 1998, 2010, 2000, 2010, 2006, 1997, 2001, 2008, 2003, 2008, 1998, 2008"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_year,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , ","1998, 1994, 1998, 2010, 2000, 2010, 2006, 1997, 2001, 2008, 2003, 2008, 1998, 2008"
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_source,exact,list,0,1,0,0,", , , , , , , , , , , , , ","J. Virol, Collaborative Computational Project, Number, Science, Nature Rev. Mol. Cell Biol, J. Virol, Proc. Jpn Acad. Ser. B Phys. Biol. Sci, IUBMB Life, Methods Enzymol, J. Virol, Annu. Rev. Cell Dev. Biol, Cancer Sci, Nature Rev. Mol. Cell Biol, Virology, "
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_source,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , ","J. Virol, Collaborative Computational Project, Number, Science, Nature Rev. Mol. Cell Biol, J. Virol, Proc. Jpn Acad. Ser. B Phys. Biol. Sci, IUBMB Life, Methods Enzymol, J. Virol, Annu. Rev. Cell Dev. Biol, Cancer Sci, Nature Rev. Mol. Cell Biol, Virology, "
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_volume,exact,list,0,1,0,0,", , , , , , , , , , , , , ","72, 4, 280, 11, 74, 86, 58, 276, 75, 24, 94, 9, 246, "
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_volume,levenshtein,list,0,1,0,0,", , , , , , , , , , , , , ","72, 4, 280, 11, 74, 86, 58, 276, 75, 24, 94, 9, 246, "
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_fpage,exact,list,1,0,0,0,", , , , , , , , , , , , , ",", , , , , , , , , , , , , "
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_fpage,levenshtein,list,1,0,0,0,", , , , , , , , , , , , , ",", , , , , , , , , , , , , "
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_lpage,exact,list,1,0,0,0,", , , , , , , , , , , , , ",", , , , , , , , , , , , , "
f-67-00344.grobid-tei.xml,f-67-00344.nxml,reference_lpage,levenshtein,list,1,0,0,0,", , , , , , , , , , , , , ",", , , , , , , , , , , , , "
sobs89-975.grobid-tei.xml,sobs89-975.nxml,title,exact,string,1,0,0,0,Camera trocar lifting in office gasless laparoscopic sterilization under local anesthesia,Camera trocar lifting in office gasless laparoscopic sterilization under local anesthesia
sobs89-975.grobid-tei.xml,sobs89-975.nxml,title,levenshtein,string,1,0,0,0,Camera trocar lifting in office gasless laparoscopic sterilization under local anesthesia,Camera trocar lifting in office gasless laparoscopic sterilization under local anesthesia
sobs89-975.grobid-tei.xml,sobs89-975.nxml,abstract,exact,string,0,1,0,0,"We evaluated 35 cases of a mechanical approach to abdominal wall lifting, used in office-based gasless laparoscopic sterilization under local anesthesia. Lifting of the abdominal wall, using the camera trocar as an anchoring device and complemented by suprapubic lifting by means of a towel clamp, led to passive intra-abdominal air filling, giving sufficient space to identify, anesthetize, coagulate and cut the Fallopian tubes. Only mild sedation was necessary. All women walked to and from the operating room. All had successful tubal ligation. The overall satisfaction rate was 97%. The mechanical lifting moment was not painful. With the exception of one woman with failed tubal anesthesia, all women had a low mean pain score of 2.6 (VAS 0–10). No complications occurred except one wound infection. The costs were < ¼ of those of traditional laparoscopic sterilization and office hysteroscopic sterilization. This approach is effective for office-based laparoscopic sterilization. Room air, two strings and a needle replace active gas insufflation and narcosis.","We evaluated 35 cases of a mechanical approach to abdominal wall lifting, used in office-based gasless laparoscopic sterilization under local anesthesia. Lifting of the abdominal wall, using the camera trocar as an anchoring device and complemented by suprapubic lifting by means of a towel clamp, led to passive intra-abdominal air filling, giving sufficient space to identify, anesthetize, coagulate and cut the Fallopian tubes. Only mild sedation was necessary. All women walked to and from the operating room. All had successful tubal ligation. The overall satisfaction rate was 97%. The mechanical lifting moment was not painful. With the exception of one woman with failed tubal anesthesia, all women had a low mean pain score of 2.6 (VAS 0-10). No complications occurred except one wound infection. The costs were £ 1 / 4 of those of traditional laparoscopic sterilization and office hysteroscopic sterilization. This approach is effective for office-based laparoscopic sterilization. Room air, two strings and a needle replace active gas insufflation and narcosis."
sobs89-975.grobid-tei.xml,sobs89-975.nxml,abstract,levenshtein,string,1,0,0,0,"We evaluated 35 cases of a mechanical approach to abdominal wall lifting, used in office-based gasless laparoscopic sterilization under local anesthesia. Lifting of the abdominal wall, using the camera trocar as an anchoring device and complemented by suprapubic lifting by means of a towel clamp, led to passive intra-abdominal air filling, giving sufficient space to identify, anesthetize, coagulate and cut the Fallopian tubes. Only mild sedation was necessary. All women walked to and from the operating room. All had successful tubal ligation. The overall satisfaction rate was 97%. The mechanical lifting moment was not painful. With the exception of one woman with failed tubal anesthesia, all women had a low mean pain score of 2.6 (VAS 0–10). No complications occurred except one wound infection. The costs were < ¼ of those of traditional laparoscopic sterilization and office hysteroscopic sterilization. This approach is effective for office-based laparoscopic sterilization. Room air, two strings and a needle replace active gas insufflation and narcosis.","We evaluated 35 cases of a mechanical approach to abdominal wall lifting, used in office-based gasless laparoscopic sterilization under local anesthesia. Lifting of the abdominal wall, using the camera trocar as an anchoring device and complemented by suprapubic lifting by means of a towel clamp, led to passive intra-abdominal air filling, giving sufficient space to identify, anesthetize, coagulate and cut the Fallopian tubes. Only mild sedation was necessary. All women walked to and from the operating room. All had successful tubal ligation. The overall satisfaction rate was 97%. The mechanical lifting moment was not painful. With the exception of one woman with failed tubal anesthesia, all women had a low mean pain score of 2.6 (VAS 0-10). No complications occurred except one wound infection. The costs were £ 1 / 4 of those of traditional laparoscopic sterilization and office hysteroscopic sterilization. This approach is effective for office-based laparoscopic sterilization. Room air, two strings and a needle replace active gas insufflation and narcosis."
sobs89-975.grobid-tei.xml,sobs89-975.nxml,keywords,exact,set,1,0,0,0,"Female sterilization, endoscopic surgery, gasless, laparoscopy, local anesthesia, office, surgical techniques","Female sterilization, endoscopic surgery, gasless, laparoscopy, local anesthesia, office, surgical techniques"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,keywords,levenshtein,set,1,0,0,0,"Female sterilization, endoscopic surgery, gasless, laparoscopy, local anesthesia, office, surgical techniques","Female sterilization, endoscopic surgery, gasless, laparoscopy, local anesthesia, office, surgical techniques"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,author_surnames,exact,set,0,1,0,0,Bergström,"Gynecologica, Obstetricia"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,author_surnames,levenshtein,set,0,1,0,0,Bergström,"Gynecologica, Obstetricia"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,first_author_surname,exact,string,0,1,0,0,Bergström,Obstetricia
sobs89-975.grobid-tei.xml,sobs89-975.nxml,first_author_surname,levenshtein,string,0,1,0,0,Bergström,Obstetricia
sobs89-975.grobid-tei.xml,sobs89-975.nxml,author_full_names,exact,set,0,1,0,0,Bo S. Bergström,"Acta Obstetricia, Gynecologica"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,author_full_names,levenshtein,set,0,1,0,0,Bo S. Bergström,"Acta Obstetricia, Gynecologica"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,first_author_full_name,exact,string,0,1,0,0,Bo S. Bergström,Acta Obstetricia
sobs89-975.grobid-tei.xml,sobs89-975.nxml,first_author_full_name,levenshtein,string,0,1,0,0,Bo S. Bergström,Acta Obstetricia
sobs89-975.grobid-tei.xml,sobs89-975.nxml,affiliation_strings,exact,set,0,0,1,0,"Department of Obstetrics & Gynecology, Nordfjord Hospital, Nordfjordeid, Norway",
sobs89-975.grobid-tei.xml,sobs89-975.nxml,affiliation_strings,levenshtein,set,0,0,1,0,"Department of Obstetrics & Gynecology, Nordfjord Hospital, Nordfjordeid, Norway",
sobs89-975.grobid-tei.xml,sobs89-975.nxml,affiliation_institution,exact,set,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,affiliation_institution,levenshtein,set,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,section_titles,exact,list,1,0,0,0,"Introduction, Material and methods, Results, Discussion","Introduction, Material and methods, Results, Discussion"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,section_titles,levenshtein,list,1,0,0,0,"Introduction, Material and methods, Results, Discussion","Introduction, Material and methods, Results, Discussion"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,tables,exact,table,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,tables,levenshtein,table,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,table_strings,exact,list,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,table_strings,levenshtein,list,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,table_labels,exact,list,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,table_labels,levenshtein,list,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,table_captions,exact,list,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,table_captions,levenshtein,list,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,table_label_captions,exact,list,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,table_label_captions,levenshtein,list,0,0,0,1,,
sobs89-975.grobid-tei.xml,sobs89-975.nxml,first_reference_fields,exact,list,0,1,0,0,"[u'1', u'Penfield', u'AJ', u'Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them', u'J Am Assoc Gynecol Laparosc', u'1995', u'2', u'365', u'68', u'9050587']","[u'Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them', u'A', u'J', u'Penfield', u'J Am Assoc Gynecol Laparosc', u'2', u'', u'']"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,first_reference_fields,levenshtein,list,1,0,0,0,"[u'1', u'Penfield', u'AJ', u'Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them', u'J Am Assoc Gynecol Laparosc', u'1995', u'2', u'365', u'68', u'9050587']","[u'Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them', u'A', u'J', u'Penfield', u'J Am Assoc Gynecol Laparosc', u'2', u'', u'']"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,first_reference_title,exact,string,1,0,0,0,Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them,Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them
sobs89-975.grobid-tei.xml,sobs89-975.nxml,first_reference_title,levenshtein,string,1,0,0,0,Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them,Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_fields,exact,list,0,1,0,0,"[u'1', u'Penfield', u'AJ', u'Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them', u'J Am Assoc Gynecol Laparosc', u'1995', u'2', u'365', u'68', u'9050587'], [u'2', u'Almeida', u'OD', u'Jr', u'Current state of office laparoscopic surgery', u'J Am Assoc Gynecol Laparosc', u'2000', u'7', u'545', u'46', u'11044510'], [u'3', u'Bordahl', u'PE', u'Raeder', u'JC', u'Nordentoft', u'J', u'Kirste', u'U', u'Refsdal', u'A', u'Laparoscopic sterilization under local anesthesia or general anesthesia? A randomized study', u'Obstet Gynecol', u'1993', u'81', u'137', u'41', u'8416449'], [u'4', u'Johnson', u'PL', u'Sibert', u'KS', u'Laparoscopy. Gasless vs. CO2 pneumoperitoneum', u'J Reprod Med', u'1997', u'42', u'255', u'59', u'9172113'], [u'5', u'Guido', u'RS', u'Brooks', u'K', u'McKenzie', u'R', u'Gruss', u'J', u'Krohn', u'MA', u'A randomized, prospective comparison of pain after gasless laparoscopy and traditional laparoscopy', u'J Am Assoc Gynecol Laparosc', u'1998', u'5', u'149', u'53', u'9564062'], [u'6', u'WHO Task Force on Female Sterilization', u'Minilaparotomy or laparoscopy for sterilization: a multicenter, multinational randomized study', u'Am J Obstet Gynecol', u'1982', u'143', u'645', u'9', u'6211987'], [u'7', u'Gomel', u'V', u'McComb', u'PF', u'Microsurgery for tubal infertility', u'J Reprod Med', u'2006', u'51', u'177', u'84', u'16674012'], [u'8', u'Palter', u'SF', u'Olive', u'DL', u'Office microlaparoscopy under local anesthesia for chronic pelvic pain', u'J Am Assoc Gynecol Laparosc', u'1996', u'3', u'359', u'64', u'9050656'], [u'9', u'Edwell', u'John RS', u'SpOG', u'A comparative study of hysteroscopic sterilization versus laparoscopic tubal sterilization', u'World Laparosc Hosp', u'2008', u'http://www.laparoscopyhospital.com/A_Comparative_Study_of_Hysteroscopic_Sterilization_versus_Laparoscopic_Tubal_Sterilization.html'], [u'10', u'Yaghoobi', u'Notash A', u'Bahrpeyma', u'SH', u'Modaghegh', u'MH', u'Effectiveness of abdominal wall elevator in reducing intraabdominal pressure and CO2 volume during laparoscopic cholecystectomy', u'Acta Med Iranica', u'2004', u'42', u'131', u'3'], [u'11', u'The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery', u'Surg Endosc', u'2002', u'7', u'1', u'121', u'1143']","[u'Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them', u'A', u'J', u'Penfield', u'J Am Assoc Gynecol Laparosc', u'2', u'', u''], [u'Current state of office laparoscopic surgery', u'O', u'D', u'Almeida', u'Jr', u'J Am Assoc Gynecol Laparosc', u'7', u'', u''], [u'Laparoscopic sterilization under local anesthesia or general anesthesia? A randomized study', u'P', u'E', u'Bordahl', u'J', u'C', u'Raeder', u'J', u'Nordentoft', u'U', u'Kirste', u'A', u'Refsdal', u'Obstet Gynecol', u'81', u'', u''], [u'Gasless vs. CO2 pneumoperitoneum', u'P', u'L', u'Johnson', u'K', u'S', u'Sibert', u'Laparoscopy', u'J Reprod Med', u'42', u'', u''], [u'A randomized, prospective comparison of pain after gasless laparoscopy and traditional laparoscopy', u'R', u'S', u'Guido', u'K', u'Brooks', u'R', u'Mckenzie', u'J', u'Gruss', u'M', u'A', u'Krohn', u'J Am Assoc Gynecol Laparosc', u'5', u'', u''], [u'Minilaparotomy or laparoscopy for sterilization: a multicenter, multinational randomized study', u'WHO Task Force on Female Sterilization', u'', u'143', u''], [u'Microsurgery for tubal infertility', u'V', u'Gomel', u'P', u'F', u'Mccomb', u'J Reprod Med', u'51', u'', u''], [u'Office microlaparoscopy under local anesthesia for chronic pelvic pain', u'S', u'F', u'Palter', u'D', u'L', u'Olive', u'J Am Assoc Gynecol Laparosc', u'3', u'', u''], [u'A comparative study of hysteroscopic sterilization versus laparoscopic tubal sterilization', u'Edwell', u'John', u'R', u'S', u'Spog', u'', u'World Laparosc Hosp', u''], [u'Effectiveness of abdominal wall elevator in reducing intraabdominal pressure and CO2 volume during laparoscopic cholecystectomy', u'Yaghoobi', u'Notash', u'A', u'Bahrpeyma', u'S', u'H', u'Modaghegh', u'M', u'H', u'Acta Med Iranica', u'42', u'', u''], [u'The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery', u'Surg Endosc', u'7', u'', u'']"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_fields,levenshtein,list,0,1,0,0,"[u'1', u'Penfield', u'AJ', u'Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them', u'J Am Assoc Gynecol Laparosc', u'1995', u'2', u'365', u'68', u'9050587'], [u'2', u'Almeida', u'OD', u'Jr', u'Current state of office laparoscopic surgery', u'J Am Assoc Gynecol Laparosc', u'2000', u'7', u'545', u'46', u'11044510'], [u'3', u'Bordahl', u'PE', u'Raeder', u'JC', u'Nordentoft', u'J', u'Kirste', u'U', u'Refsdal', u'A', u'Laparoscopic sterilization under local anesthesia or general anesthesia? A randomized study', u'Obstet Gynecol', u'1993', u'81', u'137', u'41', u'8416449'], [u'4', u'Johnson', u'PL', u'Sibert', u'KS', u'Laparoscopy. Gasless vs. CO2 pneumoperitoneum', u'J Reprod Med', u'1997', u'42', u'255', u'59', u'9172113'], [u'5', u'Guido', u'RS', u'Brooks', u'K', u'McKenzie', u'R', u'Gruss', u'J', u'Krohn', u'MA', u'A randomized, prospective comparison of pain after gasless laparoscopy and traditional laparoscopy', u'J Am Assoc Gynecol Laparosc', u'1998', u'5', u'149', u'53', u'9564062'], [u'6', u'WHO Task Force on Female Sterilization', u'Minilaparotomy or laparoscopy for sterilization: a multicenter, multinational randomized study', u'Am J Obstet Gynecol', u'1982', u'143', u'645', u'9', u'6211987'], [u'7', u'Gomel', u'V', u'McComb', u'PF', u'Microsurgery for tubal infertility', u'J Reprod Med', u'2006', u'51', u'177', u'84', u'16674012'], [u'8', u'Palter', u'SF', u'Olive', u'DL', u'Office microlaparoscopy under local anesthesia for chronic pelvic pain', u'J Am Assoc Gynecol Laparosc', u'1996', u'3', u'359', u'64', u'9050656'], [u'9', u'Edwell', u'John RS', u'SpOG', u'A comparative study of hysteroscopic sterilization versus laparoscopic tubal sterilization', u'World Laparosc Hosp', u'2008', u'http://www.laparoscopyhospital.com/A_Comparative_Study_of_Hysteroscopic_Sterilization_versus_Laparoscopic_Tubal_Sterilization.html'], [u'10', u'Yaghoobi', u'Notash A', u'Bahrpeyma', u'SH', u'Modaghegh', u'MH', u'Effectiveness of abdominal wall elevator in reducing intraabdominal pressure and CO2 volume during laparoscopic cholecystectomy', u'Acta Med Iranica', u'2004', u'42', u'131', u'3'], [u'11', u'The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery', u'Surg Endosc', u'2002', u'7', u'1', u'121', u'1143']","[u'Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them', u'A', u'J', u'Penfield', u'J Am Assoc Gynecol Laparosc', u'2', u'', u''], [u'Current state of office laparoscopic surgery', u'O', u'D', u'Almeida', u'Jr', u'J Am Assoc Gynecol Laparosc', u'7', u'', u''], [u'Laparoscopic sterilization under local anesthesia or general anesthesia? A randomized study', u'P', u'E', u'Bordahl', u'J', u'C', u'Raeder', u'J', u'Nordentoft', u'U', u'Kirste', u'A', u'Refsdal', u'Obstet Gynecol', u'81', u'', u''], [u'Gasless vs. CO2 pneumoperitoneum', u'P', u'L', u'Johnson', u'K', u'S', u'Sibert', u'Laparoscopy', u'J Reprod Med', u'42', u'', u''], [u'A randomized, prospective comparison of pain after gasless laparoscopy and traditional laparoscopy', u'R', u'S', u'Guido', u'K', u'Brooks', u'R', u'Mckenzie', u'J', u'Gruss', u'M', u'A', u'Krohn', u'J Am Assoc Gynecol Laparosc', u'5', u'', u''], [u'Minilaparotomy or laparoscopy for sterilization: a multicenter, multinational randomized study', u'WHO Task Force on Female Sterilization', u'', u'143', u''], [u'Microsurgery for tubal infertility', u'V', u'Gomel', u'P', u'F', u'Mccomb', u'J Reprod Med', u'51', u'', u''], [u'Office microlaparoscopy under local anesthesia for chronic pelvic pain', u'S', u'F', u'Palter', u'D', u'L', u'Olive', u'J Am Assoc Gynecol Laparosc', u'3', u'', u''], [u'A comparative study of hysteroscopic sterilization versus laparoscopic tubal sterilization', u'Edwell', u'John', u'R', u'S', u'Spog', u'', u'World Laparosc Hosp', u''], [u'Effectiveness of abdominal wall elevator in reducing intraabdominal pressure and CO2 volume during laparoscopic cholecystectomy', u'Yaghoobi', u'Notash', u'A', u'Bahrpeyma', u'S', u'H', u'Modaghegh', u'M', u'H', u'Acta Med Iranica', u'42', u'', u''], [u'The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery', u'Surg Endosc', u'7', u'', u'']"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_title,exact,list,0,1,0,0,"Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them, Current state of office laparoscopic surgery, Laparoscopic sterilization under local anesthesia or general anesthesia? A randomized study, Laparoscopy. Gasless vs. CO2 pneumoperitoneum, A randomized, prospective comparison of pain after gasless laparoscopy and traditional laparoscopy, Minilaparotomy or laparoscopy for sterilization: a multicenter, multinational randomized study, Microsurgery for tubal infertility, Office microlaparoscopy under local anesthesia for chronic pelvic pain, A comparative study of hysteroscopic sterilization versus laparoscopic tubal sterilization, Effectiveness of abdominal wall elevator in reducing intraabdominal pressure and CO2 volume during laparoscopic cholecystectomy, The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery","Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them, Current state of office laparoscopic surgery, Laparoscopic sterilization under local anesthesia or general anesthesia? A randomized study, Gasless vs. CO2 pneumoperitoneum, A randomized, prospective comparison of pain after gasless laparoscopy and traditional laparoscopy, Minilaparotomy or laparoscopy for sterilization: a multicenter, multinational randomized study, Microsurgery for tubal infertility, Office microlaparoscopy under local anesthesia for chronic pelvic pain, A comparative study of hysteroscopic sterilization versus laparoscopic tubal sterilization, Effectiveness of abdominal wall elevator in reducing intraabdominal pressure and CO2 volume during laparoscopic cholecystectomy, The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_title,levenshtein,list,0,1,0,0,"Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them, Current state of office laparoscopic surgery, Laparoscopic sterilization under local anesthesia or general anesthesia? A randomized study, Laparoscopy. Gasless vs. CO2 pneumoperitoneum, A randomized, prospective comparison of pain after gasless laparoscopy and traditional laparoscopy, Minilaparotomy or laparoscopy for sterilization: a multicenter, multinational randomized study, Microsurgery for tubal infertility, Office microlaparoscopy under local anesthesia for chronic pelvic pain, A comparative study of hysteroscopic sterilization versus laparoscopic tubal sterilization, Effectiveness of abdominal wall elevator in reducing intraabdominal pressure and CO2 volume during laparoscopic cholecystectomy, The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery","Twenty-two years of office and outpatient laparoscopy: current techniques and why I chose them, Current state of office laparoscopic surgery, Laparoscopic sterilization under local anesthesia or general anesthesia? A randomized study, Gasless vs. CO2 pneumoperitoneum, A randomized, prospective comparison of pain after gasless laparoscopy and traditional laparoscopy, Minilaparotomy or laparoscopy for sterilization: a multicenter, multinational randomized study, Microsurgery for tubal infertility, Office microlaparoscopy under local anesthesia for chronic pelvic pain, A comparative study of hysteroscopic sterilization versus laparoscopic tubal sterilization, Effectiveness of abdominal wall elevator in reducing intraabdominal pressure and CO2 volume during laparoscopic cholecystectomy, The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_year,exact,list,1,0,0,0,"1995, 2000, 1993, 1997, 1998, 1982, 2006, 1996, 2008, 2004, 2002","1995, 2000, 1993, 1997, 1998, 1982, 2006, 1996, 2008, 2004, 2002"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_year,levenshtein,list,1,0,0,0,"1995, 2000, 1993, 1997, 1998, 1982, 2006, 1996, 2008, 2004, 2002","1995, 2000, 1993, 1997, 1998, 1982, 2006, 1996, 2008, 2004, 2002"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_source,exact,list,0,1,0,0,"J Am Assoc Gynecol Laparosc, J Am Assoc Gynecol Laparosc, Obstet Gynecol, J Reprod Med, J Am Assoc Gynecol Laparosc, Am J Obstet Gynecol, J Reprod Med, J Am Assoc Gynecol Laparosc, World Laparosc Hosp, Acta Med Iranica, Surg Endosc","J Am Assoc Gynecol Laparosc, J Am Assoc Gynecol Laparosc, Obstet Gynecol, J Reprod Med, J Am Assoc Gynecol Laparosc, , J Reprod Med, J Am Assoc Gynecol Laparosc, World Laparosc Hosp, Acta Med Iranica, Surg Endosc"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_source,levenshtein,list,0,1,0,0,"J Am Assoc Gynecol Laparosc, J Am Assoc Gynecol Laparosc, Obstet Gynecol, J Reprod Med, J Am Assoc Gynecol Laparosc, Am J Obstet Gynecol, J Reprod Med, J Am Assoc Gynecol Laparosc, World Laparosc Hosp, Acta Med Iranica, Surg Endosc","J Am Assoc Gynecol Laparosc, J Am Assoc Gynecol Laparosc, Obstet Gynecol, J Reprod Med, J Am Assoc Gynecol Laparosc, , J Reprod Med, J Am Assoc Gynecol Laparosc, World Laparosc Hosp, Acta Med Iranica, Surg Endosc"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_volume,exact,list,1,0,0,0,"2, 7, 81, 42, 5, 143, 51, 3, , 42, 7","2, 7, 81, 42, 5, 143, 51, 3, , 42, 7"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_volume,levenshtein,list,1,0,0,0,"2, 7, 81, 42, 5, 143, 51, 3, , 42, 7","2, 7, 81, 42, 5, 143, 51, 3, , 42, 7"
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_fpage,exact,list,0,1,0,0,"365, 545, 137, 255, 149, 645, 177, 359, , 131, 121",", , , , , , , , , , "
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_fpage,levenshtein,list,0,1,0,0,"365, 545, 137, 255, 149, 645, 177, 359, , 131, 121",", , , , , , , , , , "
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_lpage,exact,list,0,1,0,0,"68, 46, 41, 59, 53, 9, 84, 64, , 3, 1143",", , , , , , , , , , "
sobs89-975.grobid-tei.xml,sobs89-975.nxml,reference_lpage,levenshtein,list,0,1,0,0,"68, 46, 41, 59, 53, 9, 84, 64, , 3, 1143",", , , , , , , , , , "
sonc50-621.grobid-tei.xml,sonc50-621.nxml,title,exact,string,1,0,0,0,Management of cutaneous metastases using electrochemotherapy,Management of cutaneous metastases using electrochemotherapy
sonc50-621.grobid-tei.xml,sonc50-621.nxml,title,levenshtein,string,1,0,0,0,Management of cutaneous metastases using electrochemotherapy,Management of cutaneous metastases using electrochemotherapy
sonc50-621.grobid-tei.xml,sonc50-621.nxml,abstract,exact,string,0,1,0,0,"Background. Cutaneous metastases may cause considerable discomfort as a consequence of ulceration, oozing, bleeding and pain. Electrochemotherapy has proven to be highly effective in the treatment of cutaneous metastases. Electrochemotherapy utilises pulses of electricity to increase the permeability of the cell membrane and thereby augment the effect of chemotherapy. For the drug bleomycin, the effect is enhanced several hundred-fold, enabling once-only treatment. The primary endpoint of this study is to evaluate the efficacy of electrochemotherapy as a palliative treatment. Methods. This phase II study is a collaboration between two centres, one in Denmark and the other in the UK. Patients with cutaneous metastases of any histology were included. Bleomycin was administered intratumourally or intravenously followed by application of electric pulses to the tumour site. Results. Fifty-two patients were included. Complete and partial response rate was 68% and 18%, respectively, for cutaneous metastases <3 cm and 8% and 23%, respectively, for cutaneous metastases >3 cm. Treatment was well-tolerated by patients, including the elderly, and no serious adverse events were observed. Conclusions. ECT is an efficient and safe treatment and clinicians should not hesitate to use it even in the elderly.","Background. Cutaneous metastases may cause considerable discomfort as a consequence of ulceration, oozing, bleeding and pain. Electrochemotherapy has proven to be highly effective in the treatment of cutaneous metastases. Electrochemo-therapy utilises pulses of electricity to increase the permeability of the cell membrane and thereby augment the effect of chemotherapy. For the drug bleomycin, the effect is enhanced several hundred-fold, enabling once-only treatment. The primary endpoint of this study is to evaluate the effi cacy of electrochemotherapy as a palliative treatment. Methods. This phase II study is a collaboration between two centres, one in Denmark and the other in the UK. Patients with cutaneous metastases of any histology were included. Bleomycin was administered intratumourally or intravenously followed by application of electric pulses to the tumour site. Results. Fifty-two patients were included. Complete and partial response rate was 68% and 18%, respectively, for cutaneous metastases 3 cm and 8% and 23%, respectively, for cutaneous metastases 3 cm. Treatment was well-tolerated by patients, including the elderly, and no serious adverse events were observed. Conclusions. ECT is an effi cient and safe treatment and clinicians should not hesitate to use it even in the elderly. A cutaneous metastasis can be defi ned as "" a neoplas-tic lesion arising from another neoplasm with which there is no longer continuity "" [1]. Cutaneous metas-tases account for 0.7% to 9% of all metastases [2]. Breast cancer accounts for 51% of the total cases of cutaneous metastases, while malignant melanoma accounts for 18% [3]."
sonc50-621.grobid-tei.xml,sonc50-621.nxml,abstract,levenshtein,string,0,1,0,0,"Background. Cutaneous metastases may cause considerable discomfort as a consequence of ulceration, oozing, bleeding and pain. Electrochemotherapy has proven to be highly effective in the treatment of cutaneous metastases. Electrochemotherapy utilises pulses of electricity to increase the permeability of the cell membrane and thereby augment the effect of chemotherapy. For the drug bleomycin, the effect is enhanced several hundred-fold, enabling once-only treatment. The primary endpoint of this study is to evaluate the efficacy of electrochemotherapy as a palliative treatment. Methods. This phase II study is a collaboration between two centres, one in Denmark and the other in the UK. Patients with cutaneous metastases of any histology were included. Bleomycin was administered intratumourally or intravenously followed by application of electric pulses to the tumour site. Results. Fifty-two patients were included. Complete and partial response rate was 68% and 18%, respectively, for cutaneous metastases <3 cm and 8% and 23%, respectively, for cutaneous metastases >3 cm. Treatment was well-tolerated by patients, including the elderly, and no serious adverse events were observed. Conclusions. ECT is an efficient and safe treatment and clinicians should not hesitate to use it even in the elderly.","Background. Cutaneous metastases may cause considerable discomfort as a consequence of ulceration, oozing, bleeding and pain. Electrochemotherapy has proven to be highly effective in the treatment of cutaneous metastases. Electrochemo-therapy utilises pulses of electricity to increase the permeability of the cell membrane and thereby augment the effect of chemotherapy. For the drug bleomycin, the effect is enhanced several hundred-fold, enabling once-only treatment. The primary endpoint of this study is to evaluate the effi cacy of electrochemotherapy as a palliative treatment. Methods. This phase II study is a collaboration between two centres, one in Denmark and the other in the UK. Patients with cutaneous metastases of any histology were included. Bleomycin was administered intratumourally or intravenously followed by application of electric pulses to the tumour site. Results. Fifty-two patients were included. Complete and partial response rate was 68% and 18%, respectively, for cutaneous metastases 3 cm and 8% and 23%, respectively, for cutaneous metastases 3 cm. Treatment was well-tolerated by patients, including the elderly, and no serious adverse events were observed. Conclusions. ECT is an effi cient and safe treatment and clinicians should not hesitate to use it even in the elderly. A cutaneous metastasis can be defi ned as "" a neoplas-tic lesion arising from another neoplasm with which there is no longer continuity "" [1]. Cutaneous metas-tases account for 0.7% to 9% of all metastases [2]. Breast cancer accounts for 51% of the total cases of cutaneous metastases, while malignant melanoma accounts for 18% [3]."
sonc50-621.grobid-tei.xml,sonc50-621.nxml,keywords,exact,set,0,0,0,1,,
sonc50-621.grobid-tei.xml,sonc50-621.nxml,keywords,levenshtein,set,0,0,0,1,,
sonc50-621.grobid-tei.xml,sonc50-621.nxml,author_surnames,exact,set,0,1,0,0,"Bond, Chalmers, Gehl, Humphreys, Kessell, Matthiessen, Muir, Sainsbury, Veeramani","Bond, Chalmers, Christopher, Gehl, Humphreys, Kessell, Muir, Sainsbury, Veeramani, Wichmann Matthiessen"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,author_surnames,levenshtein,set,0,1,0,0,"Bond, Chalmers, Gehl, Humphreys, Kessell, Matthiessen, Muir, Sainsbury, Veeramani","Bond, Chalmers, Christopher, Gehl, Humphreys, Kessell, Muir, Sainsbury, Veeramani, Wichmann Matthiessen"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,first_author_surname,exact,string,0,1,0,0,Matthiessen,Gehl
sonc50-621.grobid-tei.xml,sonc50-621.nxml,first_author_surname,levenshtein,string,0,1,0,0,Matthiessen,Gehl
sonc50-621.grobid-tei.xml,sonc50-621.nxml,author_full_names,exact,set,0,1,0,0,"Alison Claire Humphreys, David Christopher George Sainsbury, Gareth Kessell, Jane Elisabeth Bond, Julie Gehl, Louise Wichmann Matthiessen, Richard Ling Chalmers, Sivakumar Veeramani, Tobian Muir","Alison Claire Humphreys, David Christopher, Gareth Kessell, George Sainsbury, Jane Elisabeth Bond, Julie Gehl, Louise Wichmann Matthiessen, Richard Ling Chalmers, Sivakumar Veeramani, Tobian Muir"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,author_full_names,levenshtein,set,0,1,0,0,"Alison Claire Humphreys, David Christopher George Sainsbury, Gareth Kessell, Jane Elisabeth Bond, Julie Gehl, Louise Wichmann Matthiessen, Richard Ling Chalmers, Sivakumar Veeramani, Tobian Muir","Alison Claire Humphreys, David Christopher, Gareth Kessell, George Sainsbury, Jane Elisabeth Bond, Julie Gehl, Louise Wichmann Matthiessen, Richard Ling Chalmers, Sivakumar Veeramani, Tobian Muir"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,first_author_full_name,exact,string,0,1,0,0,Louise Wichmann Matthiessen,Julie Gehl
sonc50-621.grobid-tei.xml,sonc50-621.nxml,first_author_full_name,levenshtein,string,0,1,0,0,Louise Wichmann Matthiessen,Julie Gehl
sonc50-621.grobid-tei.xml,sonc50-621.nxml,affiliation_strings,exact,set,0,1,0,0,"Center for Experimental Drug and Gene Electrotransfer (C*EDGE), Department of Oncology, Copenhagen University Hospital Herlev, Denmark, Department of Anaesthesia, James Cook University Hospital, Middlesbrough, UK, Department of Oncology, James Cook University Hospital, Middlesbrough, UK, Department of Reconstructive Plastic Surgery, James Cook University Hospital, Middlesbrough, UK","Department of Anaesthesia, James Cook University Hospital, UK, Department of Oncology, Center for Experimental Drug and Gene Electrotransfer (C*EDGE), Copenhagen University Hospital Herlev, Denmark, Department of Oncology, Copenhagen University Hospital Herlev, Herlev Ringvej 75, DK-2730, Herlev, Denmark, Department of Oncology, James Cook University Hospital, UK, Department of Reconstructive Plastic Surgery, James Cook University Hospital, Middlesbrough, UK"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,affiliation_strings,levenshtein,set,0,1,0,0,"Center for Experimental Drug and Gene Electrotransfer (C*EDGE), Department of Oncology, Copenhagen University Hospital Herlev, Denmark, Department of Anaesthesia, James Cook University Hospital, Middlesbrough, UK, Department of Oncology, James Cook University Hospital, Middlesbrough, UK, Department of Reconstructive Plastic Surgery, James Cook University Hospital, Middlesbrough, UK","Department of Anaesthesia, James Cook University Hospital, UK, Department of Oncology, Center for Experimental Drug and Gene Electrotransfer (C*EDGE), Copenhagen University Hospital Herlev, Denmark, Department of Oncology, Copenhagen University Hospital Herlev, Herlev Ringvej 75, DK-2730, Herlev, Denmark, Department of Oncology, James Cook University Hospital, UK, Department of Reconstructive Plastic Surgery, James Cook University Hospital, Middlesbrough, UK"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,affiliation_institution,exact,set,0,1,0,0,,"Department of Anaesthesia, James Cook University Hospital, Department of Oncology, Center for Experimental Drug and Gene Electrotransfer (C*EDGE), Copenhagen University Hospital Herlev, Department of Oncology, Copenhagen University Hospital Herlev, Department of Oncology, James Cook University Hospital, Department of Reconstructive Plastic Surgery, James Cook University Hospital, Middlesbrough"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,affiliation_institution,levenshtein,set,0,1,0,0,,"Department of Anaesthesia, James Cook University Hospital, Department of Oncology, Center for Experimental Drug and Gene Electrotransfer (C*EDGE), Copenhagen University Hospital Herlev, Department of Oncology, Copenhagen University Hospital Herlev, Department of Oncology, James Cook University Hospital, Department of Reconstructive Plastic Surgery, James Cook University Hospital, Middlesbrough"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,section_titles,exact,list,0,1,0,0,"Patients and methods, Study design, Procedure, Injection of bleomycin, Anaesthesia, Tumour response and safety assessment, Statistical consideration, Results, Patient population, Treatment, Anaesthesia, Choice of electrode, Duration of procedure, Treatment response, Safety, Discussion, Cutaneous metastases: A challenge in cancer treatment, Electrochemotherapy, Electrochemotherapy in routine use, ECT and its place in oncological practice, Conclusion","Patients and methods, Study design, Procedure, Injection of bleomycin, Anaesthesia, Tumour response and safety assessment, Statistical consideration, Results, Patient population, Treatment, Anaesthesia, Management of cutaneous metastases using electrochemotherapy 625, Choice of electrode, Duration of procedure, Safety, Treatment response, Discussion, Cutaneous metastases: A challenge in cancer treatment, Electrochemotherapy, Electrochemotherapy in routine use, ECT and its place in oncological practice, Conclusion"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,section_titles,levenshtein,list,0,1,0,0,"Patients and methods, Study design, Procedure, Injection of bleomycin, Anaesthesia, Tumour response and safety assessment, Statistical consideration, Results, Patient population, Treatment, Anaesthesia, Choice of electrode, Duration of procedure, Treatment response, Safety, Discussion, Cutaneous metastases: A challenge in cancer treatment, Electrochemotherapy, Electrochemotherapy in routine use, ECT and its place in oncological practice, Conclusion","Patients and methods, Study design, Procedure, Injection of bleomycin, Anaesthesia, Tumour response and safety assessment, Statistical consideration, Results, Patient population, Treatment, Anaesthesia, Management of cutaneous metastases using electrochemotherapy 625, Choice of electrode, Duration of procedure, Safety, Treatment response, Discussion, Cutaneous metastases: A challenge in cancer treatment, Electrochemotherapy, Electrochemotherapy in routine use, ECT and its place in oncological practice, Conclusion"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,tables,exact,table,0,1,0,0,"[[["""", ""Patients Total (N = 52)"", ""Patients (%)"", ""Patients Herlev, N = 30"", ""Patients Middlesbrough N = 22""], [""Median age in years (range)"", ""69.6 (38.9-94.7)"", """", ""72.1 (53-89.8)"", ""68.3 (38.9-94.7)""], [""Age distribution 1""], [""80 +"", ""11"", ""11%"", """", """"], [""70 +"", ""25"", ""48%"", """", """"], [""60 +"", ""44"", ""85%"", """", """"], [""50 +"", ""48"", ""92%"", """", """"], [""Sex""], [""Female"", ""35"", ""67%"", ""24"", ""13""], [""Male"", ""17"", ""33%"", ""6"", ""8""], [""ECOG2 performance status""], [""0"", ""35"", ""67%"", ""58%"", ""84%""], [""1"", ""12"", ""23%"", ""33%"", ""5%""], [""2"", ""5"", ""10%"", ""9%"", ""11%""], [""Previous Treatment""], [""Surgery"", ""42"", ""81%"", ""71%"", ""95%""], [""Radiotherapy"", ""20"", ""38%"", ""42%"", ""21%""], [""Chemotherapy"", ""21"", ""40%"", ""42%"", ""37%""], [""No previous treatment"", ""8"", ""15%"", ""21%"", ""0%""], [""Number of metastases treated pr. patient 3""], [""Median (range)"", ""3 (1-7)"", """", ""3 (1-7)"", ""4 (1-7)""], [""Diagnosis 4""], [""Malignant Melanoma"", ""21"", ""40%"", ""36%"", ""47%""], [""Breast Cancer"", ""15"", ""29%"", ""33%"", ""21%""], [""Adenocarcinoma (other than breast)"", ""5"", ""10%"", ""15%"", ""0%""], [""Basocellular Carcinoma"", ""5"", ""10%"", ""9%"", ""11%""], [""Squamous Cell Carcinoma"", ""3"", ""6%"", ""6%"", ""5%""], [""Other"", ""3"", ""5%"", ""0%"", ""16%""], [""Location of metastasis""], [""Chest"", ""79"", ""40"", ""40"", ""41""], [""Lower limbs"", ""54"", ""28"", ""22"", ""36""], [""Head and Neck"", ""30"", ""15"", ""22"", ""6""], [""Scalp"", ""21"", ""11"", ""12"", ""9""], [""Upper limbs"", ""6"", ""3"", ""4"", ""1""], [""Abdomen"", ""5"", ""3"", ""1"", ""5""], [""Back"", ""1"", ""1"", ""0"", ""1""], [""Size of metastases""], [""Median diameter in mm (range)"", ""12 (1-200)"", """", ""15 (2-200)"", ""5 (1-140)""], [""\u22643 cm"", ""138"", """", """", """"], ["">3 cm"", ""24"", """", """", """"]], [[""TREATMENT DATA"", ""All Patients (n = 51)"", ""All Patients (%)"", ""Herlev"", ""Middlesbrough""], [""Chemotherapy""], [""Bleomycin I.T"", ""21"", ""41%"", ""41%"", ""42%""], [""Bleomycin I.V."", ""30"", ""59%"", ""59%"", ""58%""], [""Anaesthesia""], [""Local"", ""23"", ""45%"", ""50%"", ""37%""], [""General"", ""28"", ""55%"", ""50%"", ""63%""], [""ECT session duration1, hours:minutes""], [""Median (range) (hh-mm)"", ""00:16 (00:05-01:27)"", """", ""00:29 (00:08-01:27)"", ""00:18 (00:05-00:35)""], [""Would agree for another session""], [""yes"", ""46"", ""90%"", ""87%"", ""90%""], [""no"", ""4"", ""8%"", ""13%"", ""5%""], [""no answer"", ""1"", ""2%"", ""0"", ""5%""], [""""], [""RESPONSE"", ""All Metastases (n = 97)2"", ""Metastases (%)"", ""Herlev"", ""Middlesbrough""], [""""], [""Response for registered metastases3""], [""CR"", ""58"", ""60%"", ""54%"", ""68%""], [""PR"", ""18"", ""19%"", ""20%"", ""17%""], [""SD"", ""11"", ""11%"", ""18%"", ""2%""], [""PD"", ""7"", ""7%"", ""4%"", ""12%""], [""Not evaluable"", ""3"", ""3%"", ""5%"", ""0%""], [""Time from treatment to CR (days)""], [""Median (range) (days"", ""47 (16-110)"", """", ""41 (16-110)"", ""63 (38-100)""], [""Size of metastases S30 mm (n = 84)""], [""CR"", ""57"", ""68%"", """", """"], [""PR"", ""15"", ""18%"", """", """"], [""SD"", ""5"", ""6%"", """", """"], [""PD"", ""5"", ""6%"", """", """"], [""Not evaluable"", ""2"", ""2%"", """", """"], [""Size of metastases >30 mm (n = 13)""], [""CR"", ""1"", ""8%"", """", """"], [""PR"", ""3"", ""23%"", """", """"], [""SD"", ""6"", ""46%"", """", """"], [""PD"", ""2"", ""15%"", """", """"], [""Not evaluable"", ""1"", ""8%"", """", """"]], [["""", ""Local anaesthesia"", ""General anaesthesia""], [""Location of metastases""], [""Chest"", ""23"", ""32%"", ""56"", ""46%""], [""Lower limbs"", ""31"", ""42%"", ""23"", ""19%""], [""Head and Neck"", ""11"", ""15%"", ""19"", ""15%""], [""Scalp"", ""4"", ""5%"", ""17"", ""14%""], [""Upper limbs"", ""3"", ""4%"", ""3"", ""2%""], [""Abdomen"", ""1"", ""1%"", ""4"", ""3%""], [""Back"", ""0"", ""0"", ""1"", ""1%""], [""Size of metastases""], [""Median (range) (mm)"", ""7.5 (1-60)"", """", ""10 (1-200)"", """"], [""Number of metastases per patient""], [""Median (range)"", ""3"", """", ""4"", """"]]]","[[], [], []]"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,tables,levenshtein,table,0,1,0,0,"[[["""", ""Patients Total (N = 52)"", ""Patients (%)"", ""Patients Herlev, N = 30"", ""Patients Middlesbrough N = 22""], [""Median age in years (range)"", ""69.6 (38.9-94.7)"", """", ""72.1 (53-89.8)"", ""68.3 (38.9-94.7)""], [""Age distribution 1""], [""80 +"", ""11"", ""11%"", """", """"], [""70 +"", ""25"", ""48%"", """", """"], [""60 +"", ""44"", ""85%"", """", """"], [""50 +"", ""48"", ""92%"", """", """"], [""Sex""], [""Female"", ""35"", ""67%"", ""24"", ""13""], [""Male"", ""17"", ""33%"", ""6"", ""8""], [""ECOG2 performance status""], [""0"", ""35"", ""67%"", ""58%"", ""84%""], [""1"", ""12"", ""23%"", ""33%"", ""5%""], [""2"", ""5"", ""10%"", ""9%"", ""11%""], [""Previous Treatment""], [""Surgery"", ""42"", ""81%"", ""71%"", ""95%""], [""Radiotherapy"", ""20"", ""38%"", ""42%"", ""21%""], [""Chemotherapy"", ""21"", ""40%"", ""42%"", ""37%""], [""No previous treatment"", ""8"", ""15%"", ""21%"", ""0%""], [""Number of metastases treated pr. patient 3""], [""Median (range)"", ""3 (1-7)"", """", ""3 (1-7)"", ""4 (1-7)""], [""Diagnosis 4""], [""Malignant Melanoma"", ""21"", ""40%"", ""36%"", ""47%""], [""Breast Cancer"", ""15"", ""29%"", ""33%"", ""21%""], [""Adenocarcinoma (other than breast)"", ""5"", ""10%"", ""15%"", ""0%""], [""Basocellular Carcinoma"", ""5"", ""10%"", ""9%"", ""11%""], [""Squamous Cell Carcinoma"", ""3"", ""6%"", ""6%"", ""5%""], [""Other"", ""3"", ""5%"", ""0%"", ""16%""], [""Location of metastasis""], [""Chest"", ""79"", ""40"", ""40"", ""41""], [""Lower limbs"", ""54"", ""28"", ""22"", ""36""], [""Head and Neck"", ""30"", ""15"", ""22"", ""6""], [""Scalp"", ""21"", ""11"", ""12"", ""9""], [""Upper limbs"", ""6"", ""3"", ""4"", ""1""], [""Abdomen"", ""5"", ""3"", ""1"", ""5""], [""Back"", ""1"", ""1"", ""0"", ""1""], [""Size of metastases""], [""Median diameter in mm (range)"", ""12 (1-200)"", """", ""15 (2-200)"", ""5 (1-140)""], [""\u22643 cm"", ""138"", """", """", """"], ["">3 cm"", ""24"", """", """", """"]], [[""TREATMENT DATA"", ""All Patients (n = 51)"", ""All Patients (%)"", ""Herlev"", ""Middlesbrough""], [""Chemotherapy""], [""Bleomycin I.T"", ""21"", ""41%"", ""41%"", ""42%""], [""Bleomycin I.V."", ""30"", ""59%"", ""59%"", ""58%""], [""Anaesthesia""], [""Local"", ""23"", ""45%"", ""50%"", ""37%""], [""General"", ""28"", ""55%"", ""50%"", ""63%""], [""ECT session duration1, hours:minutes""], [""Median (range) (hh-mm)"", ""00:16 (00:05-01:27)"", """", ""00:29 (00:08-01:27)"", ""00:18 (00:05-00:35)""], [""Would agree for another session""], [""yes"", ""46"", ""90%"", ""87%"", ""90%""], [""no"", ""4"", ""8%"", ""13%"", ""5%""], [""no answer"", ""1"", ""2%"", ""0"", ""5%""], [""""], [""RESPONSE"", ""All Metastases (n = 97)2"", ""Metastases (%)"", ""Herlev"", ""Middlesbrough""], [""""], [""Response for registered metastases3""], [""CR"", ""58"", ""60%"", ""54%"", ""68%""], [""PR"", ""18"", ""19%"", ""20%"", ""17%""], [""SD"", ""11"", ""11%"", ""18%"", ""2%""], [""PD"", ""7"", ""7%"", ""4%"", ""12%""], [""Not evaluable"", ""3"", ""3%"", ""5%"", ""0%""], [""Time from treatment to CR (days)""], [""Median (range) (days"", ""47 (16-110)"", """", ""41 (16-110)"", ""63 (38-100)""], [""Size of metastases S30 mm (n = 84)""], [""CR"", ""57"", ""68%"", """", """"], [""PR"", ""15"", ""18%"", """", """"], [""SD"", ""5"", ""6%"", """", """"], [""PD"", ""5"", ""6%"", """", """"], [""Not evaluable"", ""2"", ""2%"", """", """"], [""Size of metastases >30 mm (n = 13)""], [""CR"", ""1"", ""8%"", """", """"], [""PR"", ""3"", ""23%"", """", """"], [""SD"", ""6"", ""46%"", """", """"], [""PD"", ""2"", ""15%"", """", """"], [""Not evaluable"", ""1"", ""8%"", """", """"]], [["""", ""Local anaesthesia"", ""General anaesthesia""], [""Location of metastases""], [""Chest"", ""23"", ""32%"", ""56"", ""46%""], [""Lower limbs"", ""31"", ""42%"", ""23"", ""19%""], [""Head and Neck"", ""11"", ""15%"", ""19"", ""15%""], [""Scalp"", ""4"", ""5%"", ""17"", ""14%""], [""Upper limbs"", ""3"", ""4%"", ""3"", ""2%""], [""Abdomen"", ""1"", ""1%"", ""4"", ""3%""], [""Back"", ""0"", ""0"", ""1"", ""1%""], [""Size of metastases""], [""Median (range) (mm)"", ""7.5 (1-60)"", """", ""10 (1-200)"", """"], [""Number of metastases per patient""], [""Median (range)"", ""3"", """", ""4"", """"]]]","[[], [], []]"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,table_strings,exact,list,0,1,0,0,"Patients Total (N = 52) Patients (%) Patients Herlev, N = 30 Patients Middlesbrough N = 22 Median age in years (range) 69.6 (38.9-94.7) 72.1 (53-89.8) 68.3 (38.9-94.7) Age distribution 1  80 + 11 11%  70 + 25 48%  60 + 44 85%  50 + 48 92% Sex  Female 35 67% 24 13  Male 17 33% 6 8 ECOG2 performance status  0 35 67% 58% 84%  1 12 23% 33% 5%  2 5 10% 9% 11% Previous Treatment  Surgery 42 81% 71% 95%  Radiotherapy 20 38% 42% 21%  Chemotherapy 21 40% 42% 37%  No previous treatment 8 15% 21% 0% Number of metastases treated pr. patient 3  Median (range) 3 (1-7) 3 (1-7) 4 (1-7) Diagnosis 4  Malignant Melanoma 21 40% 36% 47%  Breast Cancer 15 29% 33% 21%  Adenocarcinoma (other than breast) 5 10% 15% 0%  Basocellular Carcinoma 5 10% 9% 11%  Squamous Cell Carcinoma 3 6% 6% 5%  Other 3 5% 0% 16% Location of metastasis  Chest 79 40 40 41  Lower limbs 54 28 22 36  Head and Neck 30 15 22 6  Scalp 21 11 12 9  Upper limbs 6 3 4 1  Abdomen 5 3 1 5  Back 1 1 0 1 Size of metastases  Median diameter in mm (range) 12 (1-200) 15 (2-200) 5 (1-140)  ≤3 cm 138  >3 cm 24, TREATMENT DATA All Patients (n = 51) All Patients (%) Herlev Middlesbrough Chemotherapy  Bleomycin I.T 21 41% 41% 42%  Bleomycin I.V. 30 59% 59% 58% Anaesthesia  Local 23 45% 50% 37%  General 28 55% 50% 63% ECT session duration1, hours:minutes  Median (range) (hh-mm) 00:16 (00:05-01:27) 00:29 (00:08-01:27) 00:18 (00:05-00:35) Would agree for another session  yes 46 90% 87% 90%  no 4 8% 13% 5%  no answer 1 2% 0 5% RESPONSE All Metastases (n = 97)2 Metastases (%) Herlev Middlesbrough Response for registered metastases3  CR 58 60% 54% 68%  PR 18 19% 20% 17%  SD 11 11% 18% 2%  PD 7 7% 4% 12%  Not evaluable 3 3% 5% 0% Time from treatment to CR (days)  Median (range) (days 47 (16-110) 41 (16-110) 63 (38-100) Size of metastases S30 mm (n = 84)  CR 57 68%  PR 15 18%  SD 5 6%  PD 5 6%  Not evaluable 2 2% Size of metastases >30 mm (n = 13)  CR 1 8%  PR 3 23%  SD 6 46%  PD 2 15%  Not evaluable 1 8%, Local anaesthesia General anaesthesia Location of metastases  Chest 23 32% 56 46%  Lower limbs 31 42% 23 19%  Head and Neck 11 15% 19 15%  Scalp 4 5% 17 14%  Upper limbs 3 4% 3 2%  Abdomen 1 1% 4 3%  Back 0 0 1 1% Size of metastases  Median (range) (mm) 7.5 (1-60) 10 (1-200) Number of metastases per patient  Median (range) 3 4","Patients Total (N 52) Patients (%) Patients Herlev, N 30 Patients Middlesbrough N 22 Median age in years (range) 69.6 (38.9 -94.7) 72.1 (53 -89.8) 68.3 (38.9 -94.7) Age distribution 1 80 11 11% 70 25 48% 60 44 85% 50 48 92% Sex Female 35 67% 24 13 Male 17 33% 6 8 ECOG 2 performance status 0 35 67% 58% 84% 1 12 23% 33% 5% 2 5 10% 9% 11% Previous Treatment Surgery 42 81% 71% 95% Radiotherapy 20 38% 42% 21% Chemotherapy 21 40% 42% 37% No previous treatment 8 15% 21% 0% Number of metastases treated pr. patient 3 Median (range) 3 (1 -7) 3 (1 -7) 4 (1 -7) Diagnosis 4 Malignant Melanoma 21 40% 36% 47% Breast Cancer 15 29% 33% 21% Adenocarcinoma (other than breast) 5 10% 15% 0% Basocellular Carcinoma 5 10% 9% 11% Squamous Cell Carcinoma 3 6% 6% 5% Other 3 5% 0% 16% Location of metastasis Chest 79 40 40 41 Lower limbs 54 28 22 36 Head and Neck 30 15 22 6 Scalp 21 11 12 9 Upper limbs 6 3 4 1 Abdomen 5 3 1 5 Back 1 1 0 1 Size of metastases Median diameter in mm (range) 12 (1 -200) 15 (2 -200) 5 (1 -140) 3 cm 138 3 cm 24, TREATMENT DATA All Patients (n 51) All Patients (%) Herlev Middlesbrough Chemotherapy Bleomycin I.T. 21 41% 41% 42% Bleomycin I.V. 30 59% 59% 58% Anaesthesia Local 23 45% 50% 37% General 28 55% 50% 63% ECT session duration 1 , hours:minutes Median (range) (hh-mm) 00:16 (00:05 -01:27) 00:29 (00:08 -01:27) 00:18 (00:05 -00:35) Would agree for another session yes 46 90% 87% 90% no 4 8% 13% 5% no answer 1 2% 0 5% RESPONSE All Metastases (n 97) 2 Metastases (%) Herlev Middlesbrough Response for registered metastases 3 CR 58 60% 54% 68% PR 18 19% 20% 17% SD 11 11% 18% 2% PD 7 7% 4% 12% Not evaluable 3 3% 5% 0% Time from treatment to CR (days) Median (range) (days 47 (16 -110) 41 (16 -110) 63 (38 -100) Size of metastases 30 mm (n 84) CR 57 68% PR 15 18% SD 5 6% PD 5 6% Not evaluable 2 2% Size of metastases 30 mm (n 13) CR 1 8% PR 3 23% SD 6 46% PD 2 15% Not evaluable 1 8%, Local anaesthesia General anaesthesia Location of metastases Chest 23 32% 56 46% Lower limbs 31 42% 23 19% Head and Neck 11 15% 19 15% Scalp 4 5% 17 14% Upper limbs 3 4% 3 2% Abdomen 1 1% 4 3% Back 0 0 1 1% Size of metastases Median (range) (mm) 7.5 (1 -60) 10 (1 -200) Number of metastases per patient Median (range) 3 4"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,table_strings,levenshtein,list,1,0,0,0,"Patients Total (N = 52) Patients (%) Patients Herlev, N = 30 Patients Middlesbrough N = 22 Median age in years (range) 69.6 (38.9-94.7) 72.1 (53-89.8) 68.3 (38.9-94.7) Age distribution 1  80 + 11 11%  70 + 25 48%  60 + 44 85%  50 + 48 92% Sex  Female 35 67% 24 13  Male 17 33% 6 8 ECOG2 performance status  0 35 67% 58% 84%  1 12 23% 33% 5%  2 5 10% 9% 11% Previous Treatment  Surgery 42 81% 71% 95%  Radiotherapy 20 38% 42% 21%  Chemotherapy 21 40% 42% 37%  No previous treatment 8 15% 21% 0% Number of metastases treated pr. patient 3  Median (range) 3 (1-7) 3 (1-7) 4 (1-7) Diagnosis 4  Malignant Melanoma 21 40% 36% 47%  Breast Cancer 15 29% 33% 21%  Adenocarcinoma (other than breast) 5 10% 15% 0%  Basocellular Carcinoma 5 10% 9% 11%  Squamous Cell Carcinoma 3 6% 6% 5%  Other 3 5% 0% 16% Location of metastasis  Chest 79 40 40 41  Lower limbs 54 28 22 36  Head and Neck 30 15 22 6  Scalp 21 11 12 9  Upper limbs 6 3 4 1  Abdomen 5 3 1 5  Back 1 1 0 1 Size of metastases  Median diameter in mm (range) 12 (1-200) 15 (2-200) 5 (1-140)  ≤3 cm 138  >3 cm 24, TREATMENT DATA All Patients (n = 51) All Patients (%) Herlev Middlesbrough Chemotherapy  Bleomycin I.T 21 41% 41% 42%  Bleomycin I.V. 30 59% 59% 58% Anaesthesia  Local 23 45% 50% 37%  General 28 55% 50% 63% ECT session duration1, hours:minutes  Median (range) (hh-mm) 00:16 (00:05-01:27) 00:29 (00:08-01:27) 00:18 (00:05-00:35) Would agree for another session  yes 46 90% 87% 90%  no 4 8% 13% 5%  no answer 1 2% 0 5% RESPONSE All Metastases (n = 97)2 Metastases (%) Herlev Middlesbrough Response for registered metastases3  CR 58 60% 54% 68%  PR 18 19% 20% 17%  SD 11 11% 18% 2%  PD 7 7% 4% 12%  Not evaluable 3 3% 5% 0% Time from treatment to CR (days)  Median (range) (days 47 (16-110) 41 (16-110) 63 (38-100) Size of metastases S30 mm (n = 84)  CR 57 68%  PR 15 18%  SD 5 6%  PD 5 6%  Not evaluable 2 2% Size of metastases >30 mm (n = 13)  CR 1 8%  PR 3 23%  SD 6 46%  PD 2 15%  Not evaluable 1 8%, Local anaesthesia General anaesthesia Location of metastases  Chest 23 32% 56 46%  Lower limbs 31 42% 23 19%  Head and Neck 11 15% 19 15%  Scalp 4 5% 17 14%  Upper limbs 3 4% 3 2%  Abdomen 1 1% 4 3%  Back 0 0 1 1% Size of metastases  Median (range) (mm) 7.5 (1-60) 10 (1-200) Number of metastases per patient  Median (range) 3 4","Patients Total (N 52) Patients (%) Patients Herlev, N 30 Patients Middlesbrough N 22 Median age in years (range) 69.6 (38.9 -94.7) 72.1 (53 -89.8) 68.3 (38.9 -94.7) Age distribution 1 80 11 11% 70 25 48% 60 44 85% 50 48 92% Sex Female 35 67% 24 13 Male 17 33% 6 8 ECOG 2 performance status 0 35 67% 58% 84% 1 12 23% 33% 5% 2 5 10% 9% 11% Previous Treatment Surgery 42 81% 71% 95% Radiotherapy 20 38% 42% 21% Chemotherapy 21 40% 42% 37% No previous treatment 8 15% 21% 0% Number of metastases treated pr. patient 3 Median (range) 3 (1 -7) 3 (1 -7) 4 (1 -7) Diagnosis 4 Malignant Melanoma 21 40% 36% 47% Breast Cancer 15 29% 33% 21% Adenocarcinoma (other than breast) 5 10% 15% 0% Basocellular Carcinoma 5 10% 9% 11% Squamous Cell Carcinoma 3 6% 6% 5% Other 3 5% 0% 16% Location of metastasis Chest 79 40 40 41 Lower limbs 54 28 22 36 Head and Neck 30 15 22 6 Scalp 21 11 12 9 Upper limbs 6 3 4 1 Abdomen 5 3 1 5 Back 1 1 0 1 Size of metastases Median diameter in mm (range) 12 (1 -200) 15 (2 -200) 5 (1 -140) 3 cm 138 3 cm 24, TREATMENT DATA All Patients (n 51) All Patients (%) Herlev Middlesbrough Chemotherapy Bleomycin I.T. 21 41% 41% 42% Bleomycin I.V. 30 59% 59% 58% Anaesthesia Local 23 45% 50% 37% General 28 55% 50% 63% ECT session duration 1 , hours:minutes Median (range) (hh-mm) 00:16 (00:05 -01:27) 00:29 (00:08 -01:27) 00:18 (00:05 -00:35) Would agree for another session yes 46 90% 87% 90% no 4 8% 13% 5% no answer 1 2% 0 5% RESPONSE All Metastases (n 97) 2 Metastases (%) Herlev Middlesbrough Response for registered metastases 3 CR 58 60% 54% 68% PR 18 19% 20% 17% SD 11 11% 18% 2% PD 7 7% 4% 12% Not evaluable 3 3% 5% 0% Time from treatment to CR (days) Median (range) (days 47 (16 -110) 41 (16 -110) 63 (38 -100) Size of metastases 30 mm (n 84) CR 57 68% PR 15 18% SD 5 6% PD 5 6% Not evaluable 2 2% Size of metastases 30 mm (n 13) CR 1 8% PR 3 23% SD 6 46% PD 2 15% Not evaluable 1 8%, Local anaesthesia General anaesthesia Location of metastases Chest 23 32% 56 46% Lower limbs 31 42% 23 19% Head and Neck 11 15% 19 15% Scalp 4 5% 17 14% Upper limbs 3 4% 3 2% Abdomen 1 1% 4 3% Back 0 0 1 1% Size of metastases Median (range) (mm) 7.5 (1 -60) 10 (1 -200) Number of metastases per patient Median (range) 3 4"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,table_labels,exact,list,0,1,0,0,"Table I, Table II, Table III","Table I . Patients ' characteristics at baseline., Table II . Treatment data and response., Table III . Choice of anaesthesia according to location of metastases and size."
sonc50-621.grobid-tei.xml,sonc50-621.nxml,table_labels,levenshtein,list,0,1,0,0,"Table I, Table II, Table III","Table I . Patients ' characteristics at baseline., Table II . Treatment data and response., Table III . Choice of anaesthesia according to location of metastases and size."
sonc50-621.grobid-tei.xml,sonc50-621.nxml,table_captions,exact,list,0,1,0,0,"Patients' characteristics at baseline., Treatment data and response., Choice of anaesthesia according to location of metastases and size.",", , "
sonc50-621.grobid-tei.xml,sonc50-621.nxml,table_captions,levenshtein,list,0,1,0,0,"Patients' characteristics at baseline., Treatment data and response., Choice of anaesthesia according to location of metastases and size.",", , "
sonc50-621.grobid-tei.xml,sonc50-621.nxml,table_label_captions,exact,list,0,1,0,0,"Table I Patients' characteristics at baseline., Table II Treatment data and response., Table III Choice of anaesthesia according to location of metastases and size.","Table I . Patients ' characteristics at baseline., Table II . Treatment data and response., Table III . Choice of anaesthesia according to location of metastases and size."
sonc50-621.grobid-tei.xml,sonc50-621.nxml,table_label_captions,levenshtein,list,1,0,0,0,"Table I Patients' characteristics at baseline., Table II Treatment data and response., Table III Choice of anaesthesia according to location of metastases and size.","Table I . Patients ' characteristics at baseline., Table II . Treatment data and response., Table III . Choice of anaesthesia according to location of metastases and size."
sonc50-621.grobid-tei.xml,sonc50-621.nxml,first_reference_fields,exact,list,0,1,0,0,"[u'1', u'Schwartz', u'RA', u'Cutaneous metastatic disease', u'J Am Acad Dermatol', u'1995', u'33', u'161', u'82', u'7622642']","[u'Cutaneous metastatic disease', u'R', u'A', u'Schwartz', u'J Am Acad', u'']"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,first_reference_fields,levenshtein,list,0,1,0,0,"[u'1', u'Schwartz', u'RA', u'Cutaneous metastatic disease', u'J Am Acad Dermatol', u'1995', u'33', u'161', u'82', u'7622642']","[u'Cutaneous metastatic disease', u'R', u'A', u'Schwartz', u'J Am Acad', u'']"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,first_reference_title,exact,string,1,0,0,0,Cutaneous metastatic disease,Cutaneous metastatic disease
sonc50-621.grobid-tei.xml,sonc50-621.nxml,first_reference_title,levenshtein,string,1,0,0,0,Cutaneous metastatic disease,Cutaneous metastatic disease
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_fields,exact,list,0,1,0,0,"[u'1', u'Schwartz', u'RA', u'Cutaneous metastatic disease', u'J Am Acad Dermatol', u'1995', u'33', u'161', u'82', u'7622642'], [u'2', u'Rolz-Cruz', u'G', u'Kim', u'CC', u'Tumor invasion of the skin', u'Dermatol Clin', u'2008', u'26', u'89', u'102', u'viii', u'18023773'], [u'3', u'Lookingbill', u'DP', u'Spangler', u'N', u'Helm', u'KF', u'Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patients', u'J Am Acad Dermatol', u'1993', u'29', u'228', u'36', u'8335743'], [u'4', u'Heller', u'R', u'Jaroszeski', u'MJ', u'Reintgen', u'DS', u'Puleo', u'CA', u'DeConti', u'RC', u'Gilbert', u'RA', u'', u'Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin', u'Cancer', u'1998', u'83', u'148', u'57', u'9655305'], [u'5', u'Marty', u'M', u'Sersa', u'G', u'Garbay', u'JR', u'Gehl', u'J', u'Collins', u'CG', u'Snoj', u'M', u'', u'Electrochemotherapy, An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study', u'EJC Supplements', u'2006', u'4', u'3', u'13'], [u'6', u'Mir', u'LM', u'Glass', u'LF', u'Sersa', u'G', u'Teissie', u'J', u'Domenge', u'C', u'Miklavcic', u'D', u'', u'Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy', u'Br J Cancer', u'1998', u'77', u'2336', u'42', u'9649155'], [u'7', u'Gehl', u'J', u'Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research', u'Acta Physiol Scand', u'2003', u'177', u'437', u'47', u'12648161'], [u'8', u'Tounekti', u'O', u'Pron', u'G', u'Belehradek', u'J', u'Jr', u'Mir', u'LM', u'Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized', u'Cancer Res', u'1993', u'53', u'5462', u'9', u'7693342'], [u'9', u'Gehl', u'J', u'Skovsgaard', u'T', u'Mir', u'LM', u'Enhancement of cytotoxicity by electropermeabilization: An improved method for screening drugs', u'Anticancer Drugs', u'1998', u'9', u'319', u'25', u'9635922'], [u'10', u'Orlowski', u'S', u'Belehradek', u'J', u'Jr', u'Paoletti', u'C', u'Mir', u'LM', u'Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs', u'Biochem Pharmacol', u'1988', u'37', u'4727', u'33', u'2462423'], [u'11', u'Jaroszeski', u'MJ', u'Dang', u'V', u'Pottinger', u'C', u'Hickey', u'J', u'Gilbert', u'R', u'Heller', u'R', u'Toxicity of anticancer agents mediated by electroporation in vitro', u'Anticancer Drugs', u'2000', u'11', u'201', u'8', u'10831279'], [u'12', u'Belehradek', u'M', u'Domenge', u'C', u'Luboinski', u'B', u'Orlowski', u'S', u'Belehradek', u'J', u'Jr', u'Mir', u'LM', u'Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial', u'Cancer', u'1993', u'72', u'3694', u'700', u'7504576'], [u'13', u'Campana', u'LG', u'Mocellin', u'S', u'Basso', u'M', u'Puccetti', u'O', u'De Salvo', u'GL', u'Chiarion-Sileni', u'V', u'', u""Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients"", u'Ann Surg Oncol', u'2009', u'16', u'191', u'9', u'18987914'], [u'14', u'Gothelf', u'A', u'Mir', u'LM', u'Gehl', u'J', u'Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation', u'Cancer Treat Rev', u'2003', u'29', u'371', u'87', u'12972356'], [u'15', u'Rodriguez-Cuevas', u'S', u'Barroso-Bravo', u'S', u'Manza-Estrada', u'J', u'Cristobal-Martinez', u'L', u'Gonzalez-Rodriguez', u'E', u'Electrochemotherapy in primary and metastatic skin tumors: Phase II trial using intralesional bleomycin', u'Arch Med Res', u'2001', u'32', u'273', u'6', u'11440782'], [u'16', u'Gehl', u'J', u'Geertsen', u'PF', u'Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy', u'Melanoma Res', u'2000', u'10', u'585', u'9', u'11198481'], [u'17', u'Mir', u'LM', u'Gehl', u'J', u'Sersa', u'G', u'Collins', u'CG', u'Garbay', u'JR', u'Billard', u'V', u'', u'Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes', u'EJC Supplements', u'2006', u'4', u'14', u'25'], [u'18', u'Domenge', u'C', u'Orlowski', u'S', u'Luboinski', u'B', u'De', u'BT', u'Schwaab', u'G', u'Belehradek', u'J', u'Jr', u'', u'Antitumor electrochemotherapy: New advances in the clinical protocol', u'Cancer', u'1996', u'77', u'956', u'63', u'8608490'], [u'19', u'Hall', u'SW', u'Strong', u'JE', u'Broughton', u'A', u'Frazier', u'ML', u'Benjamin', u'RS', u'Bleomycin clinical pharmacology by radioimmunoassay', u'Cancer Chemother Pharmacol', u'1982', u'9', u'22', u'5', u'6183016'], [u'20', u'Mathes', u'DD', u'Bleomycin and hyperoxia exposure in the operating room', u'Anesth Analg', u'1995', u'81', u'624', u'9', u'7544553'], [u'21', u'Therasse', u'P', u'Arbuck', u'SG', u'Eisenhauer', u'EA', u'Wanders', u'J', u'Kaplan', u'RS', u'Rubinstein', u'L', u'', u'New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada', u'J Natl Cancer Inst', u'2000', u'92', u'205', u'16', u'10655437'], [u'22', u'Mir', u'LM', u'Belehradek', u'M', u'Domenge', u'C', u'Orlowski', u'S', u'Poddevin', u'B', u'Belehradek', u'J', u'Jr', u'', u'[Electrochemotherapy, a new antitumor treatment: first clinical trial]', u'C R Acad Sci III', u'1991', u'313', u'613', u'8', u'1723647'], [u'23', u'Quaglino', u'P', u'Mortera', u'C', u'Osella-Abate', u'S', u'Barberis', u'M', u'Illengo', u'M', u'Rissone', u'M', u'', u'Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases', u'Ann Surg Oncol', u'2008', u'15', u'2215', u'22', u'18498012'], [u'24', u'Tijink', u'BM', u'De', u'BR', u'Van Dongen', u'GA', u'Leemans', u'CR', u'How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients', u'Clin Otolaryngol', u'2006', u'31', u'447', u'51', u'17014460'], [u'25', u'Larkin', u'JO', u'Collins', u'CG', u'Aarons', u'S', u'Tangney', u'M', u'Whelan', u'M', u""O'Reily"", u'S', u'', u'Electrochemotherapy: Aspects of preclinical development and early clinical experience', u'Ann Surg', u'2007', u'245', u'469', u'79', u'17435555']","[u'Cutaneous metastatic disease', u'R', u'A', u'Schwartz', u'J Am Acad', u''], [u'', u'Dermatol', u'33', u'', u''], [u'Tumor invasion of the skin', u'G', u'Rolz-Cruz', u'C', u'C', u'Kim', u'Derma'], [u'Cutaneous metastases', u'Viii', u'D', u'P', u'Lookingbill', u'N', u'Spangler', u'K', u'F', u'Helm', u'tol Clin', u'26', u'', u''], [u'in patients with metastatic carcinoma: A retrospective study of 4020 patients', u'J Am Acad Dermatol', u'29', u'', u''], [u'', u'R', u'Heller', u'M', u'J', u'Jaroszeski', u'D', u'S', u'Reintgen', u'C', u'A', u'Puleo', u'R', u'C', u'Deconti', u''], [u'Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin', u'R', u'A', u'Gilbert', u'Cancer', u'83', u'', u''], [u'', u'M', u'Marty', u'G', u'Sersa', u'J', u'R', u'Garbay', u'J', u'Gehl', u'C', u'G', u'Collins', u'M', u'Snoj', u''], [u'An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study', u'EJC Supplements', u'4', u'', u''], [u'Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy', u'L', u'M', u'Mir', u'L', u'F', u'Glass', u'G', u'Sersa', u'J', u'Teissie', u'C', u'Domenge', u'D', u'Miklavcic', u'Br J Cancer', u'77', u'', u''], [u'Electroporation: Theory and methods, perspectives', u'J', u'Gehl', u''], [u'for drug delivery, gene therapy and research', u'Acta Physiol Scand', u'177', u'', u''], [u'Bleomycin, [8] an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized', u'O', u'Tounekti', u'G', u'Pron', u'J', u'Belehradek', u'Jr', u'Mir', u'L', u'M', u'Cancer Res', u'53', u'', u''], [u'Enhancement of cytotoxicity [9] by electropermeabilization: An improved method for screening drugs', u'J', u'Gehl', u'T', u'Skovsgaard', u'L', u'M', u'Mir', u'Anticancer Drugs', u'9', u'', u''], [u'Transient elec[10] tropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs', u'S', u'Orlowski', u'J', u'Belehradek', u'Jr', u'C', u'Paoletti', u'Lm ;', u'Mir', u'M', u'J', u'Jaroszeski', u'V', u'Dang', u'C', u'Pottinger', u'J', u'Hickey', u'R', u'Gilbert', u'Biochem Pharmacol', u'37', u'', u''], [u'Toxicity of anticancer agents mediated by electroporation in vitro', u'R', u'Heller', u'Anticancer Drugs', u'11', u'', u''], [u'', u'M', u'Belehradek', u'C', u'Domenge', u'B', u'Luboinski', u'S', u'Orlowski', u''], [u'Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial', u'J', u'Belehradek', u'Jr', u'L', u'M', u'Mir', u'Cancer', u'72', u'', u''], [u'', u'L', u'G', u'Campana', u'S', u'Mocellin', u'M', u'Basso', u'O', u'Puccetti', u'De', u'Salvo', u''], [u""Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients"", u'G', u'L', u'Chiarion-Sileni', u'V', u'Cancer Treat Rev', u'16', u'', u'', u'Ann Surg Oncol'], [u'', u'S', u'Rodriguez-Cuevas', u'S', u'Barroso-Bravo', u'J', u'Manza-Estrada', u''], [u'Electrochemotherapy in primary and metastatic skin tumors: Phase II trial using intralesional bleomycin', u'Cristobal-Martinez L', u'Gonzalez-Rodriguez', u'E', u'Arch Med Res', u'32', u'', u''], [u'Effi cient palliation of haemorrhaging [16] malignant melanoma skin metastases by electrochemotherapy', u'J', u'Gehl', u'P', u'F', u'Geertsen', u'Melanoma Res', u'10', u'', u''], [u'', u'L', u'M', u'Mir', u'J', u'Gehl', u'G', u'Sersa', u'C', u'G', u'Collins', u'J', u'R', u'Garbay', u'Billard', u''], [u'Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes', u'V', u'EJC Supplements', u'4', u'', u''], [u'', u'C', u'Domenge', u'S', u'Orlowski', u'B', u'Luboinski', u'B', u'T', u'De', u'G', u'Schwaab', u''], [u'Antitumor electrochemotherapy: New advances in the clinical protocol', u'J', u'Belehradek', u'Jr', u'Cancer', u'77', u'', u''], [u'', u'S', u'W', u'Hall', u'J', u'E', u'Strong', u'A', u'Broughton', u'M', u'L', u'Frazier', u'R', u'S', u'Benjamin', u''], [u'Bleomycin clinical pharmacology by radioimmunoassay', u'Cancer Chemother Pharmacol', u'9', u'', u''], [u'Bleomycin and hyperoxia exposure in the oper[20] ating room', u'D', u'D', u'Mathes', u'Anesth Analg', u'81', u'', u''], [u'', u'P', u'Therasse', u'S', u'G', u'Arbuck', u'E', u'A', u'Eisenhauer', u'J', u'Wanders', u'Kaplan', u''], [u'New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada', u'R', u'S', u'Rubinstein', u'L', u'J Natl Cancer Inst', u'92', u'', u''], [u'', u'L', u'M', u'Mir', u'M', u'Belehradek', u'C', u'Domenge', u'S', u'Orlowski', u'Poddevin', u''], [u'', u'B', u'Belehradek', u'J', u'Jr', u'', u'Electrochemotherapy, a new antitumor treatment: fi rst clinical trial'], [u'', u'C R Acad Sci III', u'313', u'', u''], [u'', u'P', u'Quaglino', u'C', u'Mortera', u'S', u'Osella-Abate', u'M', u'Barberis', u''], [u'Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases', u'M', u'Illengo', u'M', u'Rissone', u'Clin Otolaryngol', u'15', u'', u'', u'Ann Surg Oncol'], [u'', u'J', u'O', u'Larkin', u'C', u'G', u'Collins', u'S', u'Aarons', u'M', u'Tangney', u'M', u'Whelan', u''], [u'Aspects of preclinical development and early clinical experience', u'O', u'&apos;reily', u'S', u'Ann Surg', u'245', u'', u'']"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_fields,levenshtein,list,0,1,0,0,"[u'1', u'Schwartz', u'RA', u'Cutaneous metastatic disease', u'J Am Acad Dermatol', u'1995', u'33', u'161', u'82', u'7622642'], [u'2', u'Rolz-Cruz', u'G', u'Kim', u'CC', u'Tumor invasion of the skin', u'Dermatol Clin', u'2008', u'26', u'89', u'102', u'viii', u'18023773'], [u'3', u'Lookingbill', u'DP', u'Spangler', u'N', u'Helm', u'KF', u'Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patients', u'J Am Acad Dermatol', u'1993', u'29', u'228', u'36', u'8335743'], [u'4', u'Heller', u'R', u'Jaroszeski', u'MJ', u'Reintgen', u'DS', u'Puleo', u'CA', u'DeConti', u'RC', u'Gilbert', u'RA', u'', u'Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin', u'Cancer', u'1998', u'83', u'148', u'57', u'9655305'], [u'5', u'Marty', u'M', u'Sersa', u'G', u'Garbay', u'JR', u'Gehl', u'J', u'Collins', u'CG', u'Snoj', u'M', u'', u'Electrochemotherapy, An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study', u'EJC Supplements', u'2006', u'4', u'3', u'13'], [u'6', u'Mir', u'LM', u'Glass', u'LF', u'Sersa', u'G', u'Teissie', u'J', u'Domenge', u'C', u'Miklavcic', u'D', u'', u'Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy', u'Br J Cancer', u'1998', u'77', u'2336', u'42', u'9649155'], [u'7', u'Gehl', u'J', u'Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research', u'Acta Physiol Scand', u'2003', u'177', u'437', u'47', u'12648161'], [u'8', u'Tounekti', u'O', u'Pron', u'G', u'Belehradek', u'J', u'Jr', u'Mir', u'LM', u'Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized', u'Cancer Res', u'1993', u'53', u'5462', u'9', u'7693342'], [u'9', u'Gehl', u'J', u'Skovsgaard', u'T', u'Mir', u'LM', u'Enhancement of cytotoxicity by electropermeabilization: An improved method for screening drugs', u'Anticancer Drugs', u'1998', u'9', u'319', u'25', u'9635922'], [u'10', u'Orlowski', u'S', u'Belehradek', u'J', u'Jr', u'Paoletti', u'C', u'Mir', u'LM', u'Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs', u'Biochem Pharmacol', u'1988', u'37', u'4727', u'33', u'2462423'], [u'11', u'Jaroszeski', u'MJ', u'Dang', u'V', u'Pottinger', u'C', u'Hickey', u'J', u'Gilbert', u'R', u'Heller', u'R', u'Toxicity of anticancer agents mediated by electroporation in vitro', u'Anticancer Drugs', u'2000', u'11', u'201', u'8', u'10831279'], [u'12', u'Belehradek', u'M', u'Domenge', u'C', u'Luboinski', u'B', u'Orlowski', u'S', u'Belehradek', u'J', u'Jr', u'Mir', u'LM', u'Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial', u'Cancer', u'1993', u'72', u'3694', u'700', u'7504576'], [u'13', u'Campana', u'LG', u'Mocellin', u'S', u'Basso', u'M', u'Puccetti', u'O', u'De Salvo', u'GL', u'Chiarion-Sileni', u'V', u'', u""Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients"", u'Ann Surg Oncol', u'2009', u'16', u'191', u'9', u'18987914'], [u'14', u'Gothelf', u'A', u'Mir', u'LM', u'Gehl', u'J', u'Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation', u'Cancer Treat Rev', u'2003', u'29', u'371', u'87', u'12972356'], [u'15', u'Rodriguez-Cuevas', u'S', u'Barroso-Bravo', u'S', u'Manza-Estrada', u'J', u'Cristobal-Martinez', u'L', u'Gonzalez-Rodriguez', u'E', u'Electrochemotherapy in primary and metastatic skin tumors: Phase II trial using intralesional bleomycin', u'Arch Med Res', u'2001', u'32', u'273', u'6', u'11440782'], [u'16', u'Gehl', u'J', u'Geertsen', u'PF', u'Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy', u'Melanoma Res', u'2000', u'10', u'585', u'9', u'11198481'], [u'17', u'Mir', u'LM', u'Gehl', u'J', u'Sersa', u'G', u'Collins', u'CG', u'Garbay', u'JR', u'Billard', u'V', u'', u'Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes', u'EJC Supplements', u'2006', u'4', u'14', u'25'], [u'18', u'Domenge', u'C', u'Orlowski', u'S', u'Luboinski', u'B', u'De', u'BT', u'Schwaab', u'G', u'Belehradek', u'J', u'Jr', u'', u'Antitumor electrochemotherapy: New advances in the clinical protocol', u'Cancer', u'1996', u'77', u'956', u'63', u'8608490'], [u'19', u'Hall', u'SW', u'Strong', u'JE', u'Broughton', u'A', u'Frazier', u'ML', u'Benjamin', u'RS', u'Bleomycin clinical pharmacology by radioimmunoassay', u'Cancer Chemother Pharmacol', u'1982', u'9', u'22', u'5', u'6183016'], [u'20', u'Mathes', u'DD', u'Bleomycin and hyperoxia exposure in the operating room', u'Anesth Analg', u'1995', u'81', u'624', u'9', u'7544553'], [u'21', u'Therasse', u'P', u'Arbuck', u'SG', u'Eisenhauer', u'EA', u'Wanders', u'J', u'Kaplan', u'RS', u'Rubinstein', u'L', u'', u'New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada', u'J Natl Cancer Inst', u'2000', u'92', u'205', u'16', u'10655437'], [u'22', u'Mir', u'LM', u'Belehradek', u'M', u'Domenge', u'C', u'Orlowski', u'S', u'Poddevin', u'B', u'Belehradek', u'J', u'Jr', u'', u'[Electrochemotherapy, a new antitumor treatment: first clinical trial]', u'C R Acad Sci III', u'1991', u'313', u'613', u'8', u'1723647'], [u'23', u'Quaglino', u'P', u'Mortera', u'C', u'Osella-Abate', u'S', u'Barberis', u'M', u'Illengo', u'M', u'Rissone', u'M', u'', u'Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases', u'Ann Surg Oncol', u'2008', u'15', u'2215', u'22', u'18498012'], [u'24', u'Tijink', u'BM', u'De', u'BR', u'Van Dongen', u'GA', u'Leemans', u'CR', u'How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients', u'Clin Otolaryngol', u'2006', u'31', u'447', u'51', u'17014460'], [u'25', u'Larkin', u'JO', u'Collins', u'CG', u'Aarons', u'S', u'Tangney', u'M', u'Whelan', u'M', u""O'Reily"", u'S', u'', u'Electrochemotherapy: Aspects of preclinical development and early clinical experience', u'Ann Surg', u'2007', u'245', u'469', u'79', u'17435555']","[u'Cutaneous metastatic disease', u'R', u'A', u'Schwartz', u'J Am Acad', u''], [u'', u'Dermatol', u'33', u'', u''], [u'Tumor invasion of the skin', u'G', u'Rolz-Cruz', u'C', u'C', u'Kim', u'Derma'], [u'Cutaneous metastases', u'Viii', u'D', u'P', u'Lookingbill', u'N', u'Spangler', u'K', u'F', u'Helm', u'tol Clin', u'26', u'', u''], [u'in patients with metastatic carcinoma: A retrospective study of 4020 patients', u'J Am Acad Dermatol', u'29', u'', u''], [u'', u'R', u'Heller', u'M', u'J', u'Jaroszeski', u'D', u'S', u'Reintgen', u'C', u'A', u'Puleo', u'R', u'C', u'Deconti', u''], [u'Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin', u'R', u'A', u'Gilbert', u'Cancer', u'83', u'', u''], [u'', u'M', u'Marty', u'G', u'Sersa', u'J', u'R', u'Garbay', u'J', u'Gehl', u'C', u'G', u'Collins', u'M', u'Snoj', u''], [u'An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study', u'EJC Supplements', u'4', u'', u''], [u'Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy', u'L', u'M', u'Mir', u'L', u'F', u'Glass', u'G', u'Sersa', u'J', u'Teissie', u'C', u'Domenge', u'D', u'Miklavcic', u'Br J Cancer', u'77', u'', u''], [u'Electroporation: Theory and methods, perspectives', u'J', u'Gehl', u''], [u'for drug delivery, gene therapy and research', u'Acta Physiol Scand', u'177', u'', u''], [u'Bleomycin, [8] an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized', u'O', u'Tounekti', u'G', u'Pron', u'J', u'Belehradek', u'Jr', u'Mir', u'L', u'M', u'Cancer Res', u'53', u'', u''], [u'Enhancement of cytotoxicity [9] by electropermeabilization: An improved method for screening drugs', u'J', u'Gehl', u'T', u'Skovsgaard', u'L', u'M', u'Mir', u'Anticancer Drugs', u'9', u'', u''], [u'Transient elec[10] tropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs', u'S', u'Orlowski', u'J', u'Belehradek', u'Jr', u'C', u'Paoletti', u'Lm ;', u'Mir', u'M', u'J', u'Jaroszeski', u'V', u'Dang', u'C', u'Pottinger', u'J', u'Hickey', u'R', u'Gilbert', u'Biochem Pharmacol', u'37', u'', u''], [u'Toxicity of anticancer agents mediated by electroporation in vitro', u'R', u'Heller', u'Anticancer Drugs', u'11', u'', u''], [u'', u'M', u'Belehradek', u'C', u'Domenge', u'B', u'Luboinski', u'S', u'Orlowski', u''], [u'Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial', u'J', u'Belehradek', u'Jr', u'L', u'M', u'Mir', u'Cancer', u'72', u'', u''], [u'', u'L', u'G', u'Campana', u'S', u'Mocellin', u'M', u'Basso', u'O', u'Puccetti', u'De', u'Salvo', u''], [u""Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients"", u'G', u'L', u'Chiarion-Sileni', u'V', u'Cancer Treat Rev', u'16', u'', u'', u'Ann Surg Oncol'], [u'', u'S', u'Rodriguez-Cuevas', u'S', u'Barroso-Bravo', u'J', u'Manza-Estrada', u''], [u'Electrochemotherapy in primary and metastatic skin tumors: Phase II trial using intralesional bleomycin', u'Cristobal-Martinez L', u'Gonzalez-Rodriguez', u'E', u'Arch Med Res', u'32', u'', u''], [u'Effi cient palliation of haemorrhaging [16] malignant melanoma skin metastases by electrochemotherapy', u'J', u'Gehl', u'P', u'F', u'Geertsen', u'Melanoma Res', u'10', u'', u''], [u'', u'L', u'M', u'Mir', u'J', u'Gehl', u'G', u'Sersa', u'C', u'G', u'Collins', u'J', u'R', u'Garbay', u'Billard', u''], [u'Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes', u'V', u'EJC Supplements', u'4', u'', u''], [u'', u'C', u'Domenge', u'S', u'Orlowski', u'B', u'Luboinski', u'B', u'T', u'De', u'G', u'Schwaab', u''], [u'Antitumor electrochemotherapy: New advances in the clinical protocol', u'J', u'Belehradek', u'Jr', u'Cancer', u'77', u'', u''], [u'', u'S', u'W', u'Hall', u'J', u'E', u'Strong', u'A', u'Broughton', u'M', u'L', u'Frazier', u'R', u'S', u'Benjamin', u''], [u'Bleomycin clinical pharmacology by radioimmunoassay', u'Cancer Chemother Pharmacol', u'9', u'', u''], [u'Bleomycin and hyperoxia exposure in the oper[20] ating room', u'D', u'D', u'Mathes', u'Anesth Analg', u'81', u'', u''], [u'', u'P', u'Therasse', u'S', u'G', u'Arbuck', u'E', u'A', u'Eisenhauer', u'J', u'Wanders', u'Kaplan', u''], [u'New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada', u'R', u'S', u'Rubinstein', u'L', u'J Natl Cancer Inst', u'92', u'', u''], [u'', u'L', u'M', u'Mir', u'M', u'Belehradek', u'C', u'Domenge', u'S', u'Orlowski', u'Poddevin', u''], [u'', u'B', u'Belehradek', u'J', u'Jr', u'', u'Electrochemotherapy, a new antitumor treatment: fi rst clinical trial'], [u'', u'C R Acad Sci III', u'313', u'', u''], [u'', u'P', u'Quaglino', u'C', u'Mortera', u'S', u'Osella-Abate', u'M', u'Barberis', u''], [u'Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases', u'M', u'Illengo', u'M', u'Rissone', u'Clin Otolaryngol', u'15', u'', u'', u'Ann Surg Oncol'], [u'', u'J', u'O', u'Larkin', u'C', u'G', u'Collins', u'S', u'Aarons', u'M', u'Tangney', u'M', u'Whelan', u''], [u'Aspects of preclinical development and early clinical experience', u'O', u'&apos;reily', u'S', u'Ann Surg', u'245', u'', u'']"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_title,exact,list,0,1,0,0,"Cutaneous metastatic disease, Tumor invasion of the skin, Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patients, Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin, Electrochemotherapy, An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study, Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy, Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research, Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized, Enhancement of cytotoxicity by electropermeabilization: An improved method for screening drugs, Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs, Toxicity of anticancer agents mediated by electroporation in vitro, Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial, Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients, Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation, Electrochemotherapy in primary and metastatic skin tumors: Phase II trial using intralesional bleomycin, Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy, Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes, Antitumor electrochemotherapy: New advances in the clinical protocol, Bleomycin clinical pharmacology by radioimmunoassay, Bleomycin and hyperoxia exposure in the operating room, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, [Electrochemotherapy, a new antitumor treatment: first clinical trial], Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases, How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients, Electrochemotherapy: Aspects of preclinical development and early clinical experience","Cutaneous metastatic disease, , , Cutaneous metastases, in patients with metastatic carcinoma: A retrospective study of 4020 patients, , Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin, , An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study, Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy, , for drug delivery, gene therapy and research, Bleomycin, [8] an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized, Enhancement of cytotoxicity [9] by electropermeabilization: An improved method for screening drugs, Transient elec[10] tropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs, Toxicity of anticancer agents mediated by electroporation in vitro, , Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial, , Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients, , Electrochemotherapy in primary and metastatic skin tumors: Phase II trial using intralesional bleomycin, Effi cient palliation of haemorrhaging [16] malignant melanoma skin metastases by electrochemotherapy, , Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes, , Antitumor electrochemotherapy: New advances in the clinical protocol, , Bleomycin clinical pharmacology by radioimmunoassay, Bleomycin and hyperoxia exposure in the oper[20] ating room, , New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, , , , , Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases, , Aspects of preclinical development and early clinical experience"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_title,levenshtein,list,0,1,0,0,"Cutaneous metastatic disease, Tumor invasion of the skin, Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patients, Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin, Electrochemotherapy, An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study, Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy, Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research, Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized, Enhancement of cytotoxicity by electropermeabilization: An improved method for screening drugs, Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs, Toxicity of anticancer agents mediated by electroporation in vitro, Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial, Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients, Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation, Electrochemotherapy in primary and metastatic skin tumors: Phase II trial using intralesional bleomycin, Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy, Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes, Antitumor electrochemotherapy: New advances in the clinical protocol, Bleomycin clinical pharmacology by radioimmunoassay, Bleomycin and hyperoxia exposure in the operating room, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, [Electrochemotherapy, a new antitumor treatment: first clinical trial], Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases, How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients, Electrochemotherapy: Aspects of preclinical development and early clinical experience","Cutaneous metastatic disease, , , Cutaneous metastases, in patients with metastatic carcinoma: A retrospective study of 4020 patients, , Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin, , An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study, Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy, , for drug delivery, gene therapy and research, Bleomycin, [8] an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized, Enhancement of cytotoxicity [9] by electropermeabilization: An improved method for screening drugs, Transient elec[10] tropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs, Toxicity of anticancer agents mediated by electroporation in vitro, , Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial, , Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients, , Electrochemotherapy in primary and metastatic skin tumors: Phase II trial using intralesional bleomycin, Effi cient palliation of haemorrhaging [16] malignant melanoma skin metastases by electrochemotherapy, , Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes, , Antitumor electrochemotherapy: New advances in the clinical protocol, , Bleomycin clinical pharmacology by radioimmunoassay, Bleomycin and hyperoxia exposure in the oper[20] ating room, , New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, , , , , Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases, , Aspects of preclinical development and early clinical experience"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_year,exact,list,0,1,0,0,"1995, 2008, 1993, 1998, 2006, 1998, 2003, 1993, 1998, 1988, 2000, 1993, 2009, 2003, 2001, 2000, 2006, 1996, 1982, 1995, 2000, 1991, 2008, 2006, 2007",", 1995, , 2008, 1993, , 1998, , 2006, 1998, , 2003, 1993, 1998, 1988, 2000, , 1993, , 2003, , 2001, 2000, , 2006, , 1996, , 1982, 1995, , 2000, , , 1991, , 2006, , 2007"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_year,levenshtein,list,0,1,0,0,"1995, 2008, 1993, 1998, 2006, 1998, 2003, 1993, 1998, 1988, 2000, 1993, 2009, 2003, 2001, 2000, 2006, 1996, 1982, 1995, 2000, 1991, 2008, 2006, 2007",", 1995, , 2008, 1993, , 1998, , 2006, 1998, , 2003, 1993, 1998, 1988, 2000, , 1993, , 2003, , 2001, 2000, , 2006, , 1996, , 1982, 1995, , 2000, , , 1991, , 2006, , 2007"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_source,exact,list,0,1,0,0,"J Am Acad Dermatol, Dermatol Clin, J Am Acad Dermatol, Cancer, EJC Supplements, Br J Cancer, Acta Physiol Scand, Cancer Res, Anticancer Drugs, Biochem Pharmacol, Anticancer Drugs, Cancer, Ann Surg Oncol, Cancer Treat Rev, Arch Med Res, Melanoma Res, EJC Supplements, Cancer, Cancer Chemother Pharmacol, Anesth Analg, J Natl Cancer Inst, C R Acad Sci III, Ann Surg Oncol, Clin Otolaryngol, Ann Surg","J Am Acad, Dermatol, , tol Clin, J Am Acad Dermatol, , Cancer, , EJC Supplements, Br J Cancer, , Acta Physiol Scand, Cancer Res, Anticancer Drugs, Biochem Pharmacol, Anticancer Drugs, , Cancer, , Cancer Treat Rev, , Arch Med Res, Melanoma Res, , EJC Supplements, , Cancer, , Cancer Chemother Pharmacol, Anesth Analg, , J Natl Cancer Inst, , , C R Acad Sci III, , Clin Otolaryngol, , Ann Surg"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_source,levenshtein,list,0,1,0,0,"J Am Acad Dermatol, Dermatol Clin, J Am Acad Dermatol, Cancer, EJC Supplements, Br J Cancer, Acta Physiol Scand, Cancer Res, Anticancer Drugs, Biochem Pharmacol, Anticancer Drugs, Cancer, Ann Surg Oncol, Cancer Treat Rev, Arch Med Res, Melanoma Res, EJC Supplements, Cancer, Cancer Chemother Pharmacol, Anesth Analg, J Natl Cancer Inst, C R Acad Sci III, Ann Surg Oncol, Clin Otolaryngol, Ann Surg","J Am Acad, Dermatol, , tol Clin, J Am Acad Dermatol, , Cancer, , EJC Supplements, Br J Cancer, , Acta Physiol Scand, Cancer Res, Anticancer Drugs, Biochem Pharmacol, Anticancer Drugs, , Cancer, , Cancer Treat Rev, , Arch Med Res, Melanoma Res, , EJC Supplements, , Cancer, , Cancer Chemother Pharmacol, Anesth Analg, , J Natl Cancer Inst, , , C R Acad Sci III, , Clin Otolaryngol, , Ann Surg"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_volume,exact,list,0,1,0,0,"33, 26, 29, 83, 4, 77, 177, 53, 9, 37, 11, 72, 16, 29, 32, 10, 4, 77, 9, 81, 92, 313, 15, 31, 245",", 33, , 26, 29, , 83, , 4, 77, , 177, 53, 9, 37, 11, , 72, , 16, , 32, 10, , 4, , 77, , 9, 81, , 92, , , 313, , 15, , 245"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_volume,levenshtein,list,0,1,0,0,"33, 26, 29, 83, 4, 77, 177, 53, 9, 37, 11, 72, 16, 29, 32, 10, 4, 77, 9, 81, 92, 313, 15, 31, 245",", 33, , 26, 29, , 83, , 4, 77, , 177, 53, 9, 37, 11, , 72, , 16, , 32, 10, , 4, , 77, , 9, 81, , 92, , , 313, , 15, , 245"
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_fpage,exact,list,0,1,0,0,"161, 89, 228, 148, 3, 2336, 437, 5462, 319, 4727, 201, 3694, 191, 371, 273, 585, 14, 956, 22, 624, 205, 613, 2215, 447, 469",", , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , "
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_fpage,levenshtein,list,0,1,0,0,"161, 89, 228, 148, 3, 2336, 437, 5462, 319, 4727, 201, 3694, 191, 371, 273, 585, 14, 956, 22, 624, 205, 613, 2215, 447, 469",", , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , "
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_lpage,exact,list,0,1,0,0,"82, 102, 36, 57, 13, 42, 47, 9, 25, 33, 8, 700, 9, 87, 6, 9, 25, 63, 5, 9, 16, 8, 22, 51, 79",", , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , "
sonc50-621.grobid-tei.xml,sonc50-621.nxml,reference_lpage,levenshtein,list,0,1,0,0,"82, 102, 36, 57, 13, 42, 47, 9, 25, 33, 8, 700, 9, 87, 6, 9, 25, 63, 5, 9, 16, 8, 22, 51, 79",", , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , "
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,title,exact,string,0,1,0,0,Resection arthroplasty for luxation of the manubrio-sternal joint in rheumatoid arthritis—a case report,Resection arthroplasty for luxation of the manubrio-sternal joint in rheumatoid arthritis-a case report
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,title,levenshtein,string,1,0,0,0,Resection arthroplasty for luxation of the manubrio-sternal joint in rheumatoid arthritis—a case report,Resection arthroplasty for luxation of the manubrio-sternal joint in rheumatoid arthritis-a case report
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,abstract,exact,string,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,abstract,levenshtein,string,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,keywords,exact,set,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,keywords,levenshtein,set,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,author_surnames,exact,set,0,1,0,0,"Schmitz, de Waal Malefijt, van Heereveld","De Waal Malefijt, Schmitz, Van Heereveld"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,author_surnames,levenshtein,set,1,0,0,0,"Schmitz, de Waal Malefijt, van Heereveld","De Waal Malefijt, Schmitz, Van Heereveld"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,first_author_surname,exact,string,1,0,0,0,Schmitz,Schmitz
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,first_author_surname,levenshtein,string,1,0,0,0,Schmitz,Schmitz
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,author_full_names,exact,set,0,1,0,0,"Hedwig A E M van Heereveld, Maarten C de Waal Malefijt, Marloes W J L Schmitz","E M Van Heereveld, Hedwig A, Maarten C De Waal Malefijt, Marloes W J L Schmitz"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,author_full_names,levenshtein,set,0,1,0,0,"Hedwig A E M van Heereveld, Maarten C de Waal Malefijt, Marloes W J L Schmitz","E M Van Heereveld, Hedwig A, Maarten C De Waal Malefijt, Marloes W J L Schmitz"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,first_author_full_name,exact,string,1,0,0,0,Marloes W J L Schmitz,Marloes W J L Schmitz
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,first_author_full_name,levenshtein,string,1,0,0,0,Marloes W J L Schmitz,Marloes W J L Schmitz
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,affiliation_strings,exact,set,0,1,0,0,"Department of Orthopaedics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, the Netherlands","Departments of 1 Orthopaedics, Rheumatology, Radboud University Nijmegen Medical Centre, the Netherlands"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,affiliation_strings,levenshtein,set,1,0,0,0,"Department of Orthopaedics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, the Netherlands","Departments of 1 Orthopaedics, Rheumatology, Radboud University Nijmegen Medical Centre, the Netherlands"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,affiliation_institution,exact,set,0,1,0,0,"Department of Orthopaedics, Department of Rheumatology, Radboud University Nijmegen Medical Centre","Departments of 1 Orthopaedics, Rheumatology, Radboud University Nijmegen Medical Centre"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,affiliation_institution,levenshtein,set,1,0,0,0,"Department of Orthopaedics, Department of Rheumatology, Radboud University Nijmegen Medical Centre","Departments of 1 Orthopaedics, Rheumatology, Radboud University Nijmegen Medical Centre"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,section_titles,exact,list,0,1,0,0,"Introduction, Discussion",Discussion
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,section_titles,levenshtein,list,0,1,0,0,"Introduction, Discussion",Discussion
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,tables,exact,table,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,tables,levenshtein,table,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,table_strings,exact,list,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,table_strings,levenshtein,list,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,table_labels,exact,list,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,table_labels,levenshtein,list,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,table_captions,exact,list,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,table_captions,levenshtein,list,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,table_label_captions,exact,list,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,table_label_captions,levenshtein,list,0,0,0,1,,
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,first_reference_fields,exact,list,0,1,0,0,"[u'Bogdan', u'A', u'Clark', u'J', u'Manubrio-sternal joint in rheumatoid arthritis', u'Br Med J', u'1950', u'16', u'1361', u'2', u'14792027']","[u'Manubriosternal joint subluxation in rheumatoid arthritis', u'T K', u'Khong', u'P', u'J', u'Rooney', u'J Reumatol', u'9', u'', u'']"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,first_reference_fields,levenshtein,list,0,1,0,0,"[u'Bogdan', u'A', u'Clark', u'J', u'Manubrio-sternal joint in rheumatoid arthritis', u'Br Med J', u'1950', u'16', u'1361', u'2', u'14792027']","[u'Manubriosternal joint subluxation in rheumatoid arthritis', u'T K', u'Khong', u'P', u'J', u'Rooney', u'J Reumatol', u'9', u'', u'']"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,first_reference_title,exact,string,0,1,0,0,Manubrio-sternal joint in rheumatoid arthritis,Manubriosternal joint subluxation in rheumatoid arthritis
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,first_reference_title,levenshtein,string,0,1,0,0,Manubrio-sternal joint in rheumatoid arthritis,Manubriosternal joint subluxation in rheumatoid arthritis
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_fields,exact,list,0,1,0,0,"[u'Bogdan', u'A', u'Clark', u'J', u'Manubrio-sternal joint in rheumatoid arthritis', u'Br Med J', u'1950', u'16', u'1361', u'2', u'14792027'], [u'Holt', u'ME', u'Rooney', u'PJ', u'Manubriosternal joint subluxation in rheumatoid arthritis', u'J Rheumatol', u'1980', u'7', u'260', u'2', u'7373631'], [u'Kelly', u'MC', u'Hopkinson', u'ND', u'Zaphiropoulos', u'GC', u'Manubriosternal joint dislocation in rheumatoid arthritis: the role of thoracic kyphosis', u'Ann Rheum Dis', u'1986', u'45', u'345', u'8', u'3707222'], [u'Khong', u'TK', u'Rooney', u'PJ', u'Manubriosternal joint subluxation in rheumatoid arthritis', u'J Reumatol', u'1982', u'9', u'712', u'5'], [u'Kormano', u'M', u'A micrographic an histological study of the manubrio-sternal joint in rheumatoid arthritis', u'Acta Rheumatol Scand', u'1970', u'16', u'47', u'59', u'5445309'], [u'Laitinen', u'H', u'Saksanen', u'S', u'Suoranta', u'H', u'Involvement of the manubrio-sternal articulation in rheumatoid arthritis', u'Acta Rheumatol Scand', u'1970', u'16', u'40', u'6', u'5445308'], [u'Rapoport', u'RJ', u'Carrera', u'GF', u'Kozin', u'F', u'Manubrio-sternal joint subluxation in rheumatiod arthritis', u'J Reumatol', u'1979', u'6', u'1', u'74', u'7'], [u'Wiseman', u'MJ', u'Dislocation of the manubriosternal joint in rheumatoid arthritis', u'Ann Rheum Dis', u'1981', u'40', u'307', u'8', u'7247475']","[u'Manubriosternal joint subluxation in rheumatoid arthritis', u'T K', u'Khong', u'P', u'J', u'Rooney', u'J Reumatol', u'9', u'', u''], [u'A micrographic an histological study of the manubrio-sternal joint in rheumatoid arthritis', u'M', u'Kormano', u'Acta Rheumatol Scand', u'16', u'', u''], [u'Involvement of the manubrio-sternal articulation in rheumatoid arthritis', u'H', u'Laitinen', u'S', u'Saksanen', u'H', u'Suoranta', u'Acta Rheumatol Scand', u'16', u'', u''], [u'Manubrio-sternal joint subluxation in rheumatiod arthritis', u'R J', u'Rapoport', u'G F', u'Carrera', u'F', u'Kozin', u'J Reumatol', u'6', u'', u''], [u'Dislocation of the manubriosternal joint in rheumatoid arthritis', u'M', u'Wiseman', u'Ann Rheum Dis', u'40', u'', u''], [u'We have not found any reports on the treatment of symptomatic MSJ luxation', u''], [u'Manubrio-sternal joint in rheumatoid arthritis', u'A', u'Bogdan', u'J', u'Clark', u'Br Med J', u'16', u'', u''], [u'Manubriosternal joint subluxation in rheumatoid arthritis', u'M', u'E', u'Holt', u'P', u'J', u'Rooney', u'J Rheumatol', u'7', u'', u''], [u'Manubriosternal joint dislocation in rheumatoid arthritis: the role of thoracic kyphosis', u'M C', u'Kelly', u'N D', u'Hopkinson', u'G', u'Zaphiropoulos', u'Ann Rheum Dis', u'45', u'', u'']"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_fields,levenshtein,list,0,1,0,0,"[u'Bogdan', u'A', u'Clark', u'J', u'Manubrio-sternal joint in rheumatoid arthritis', u'Br Med J', u'1950', u'16', u'1361', u'2', u'14792027'], [u'Holt', u'ME', u'Rooney', u'PJ', u'Manubriosternal joint subluxation in rheumatoid arthritis', u'J Rheumatol', u'1980', u'7', u'260', u'2', u'7373631'], [u'Kelly', u'MC', u'Hopkinson', u'ND', u'Zaphiropoulos', u'GC', u'Manubriosternal joint dislocation in rheumatoid arthritis: the role of thoracic kyphosis', u'Ann Rheum Dis', u'1986', u'45', u'345', u'8', u'3707222'], [u'Khong', u'TK', u'Rooney', u'PJ', u'Manubriosternal joint subluxation in rheumatoid arthritis', u'J Reumatol', u'1982', u'9', u'712', u'5'], [u'Kormano', u'M', u'A micrographic an histological study of the manubrio-sternal joint in rheumatoid arthritis', u'Acta Rheumatol Scand', u'1970', u'16', u'47', u'59', u'5445309'], [u'Laitinen', u'H', u'Saksanen', u'S', u'Suoranta', u'H', u'Involvement of the manubrio-sternal articulation in rheumatoid arthritis', u'Acta Rheumatol Scand', u'1970', u'16', u'40', u'6', u'5445308'], [u'Rapoport', u'RJ', u'Carrera', u'GF', u'Kozin', u'F', u'Manubrio-sternal joint subluxation in rheumatiod arthritis', u'J Reumatol', u'1979', u'6', u'1', u'74', u'7'], [u'Wiseman', u'MJ', u'Dislocation of the manubriosternal joint in rheumatoid arthritis', u'Ann Rheum Dis', u'1981', u'40', u'307', u'8', u'7247475']","[u'Manubriosternal joint subluxation in rheumatoid arthritis', u'T K', u'Khong', u'P', u'J', u'Rooney', u'J Reumatol', u'9', u'', u''], [u'A micrographic an histological study of the manubrio-sternal joint in rheumatoid arthritis', u'M', u'Kormano', u'Acta Rheumatol Scand', u'16', u'', u''], [u'Involvement of the manubrio-sternal articulation in rheumatoid arthritis', u'H', u'Laitinen', u'S', u'Saksanen', u'H', u'Suoranta', u'Acta Rheumatol Scand', u'16', u'', u''], [u'Manubrio-sternal joint subluxation in rheumatiod arthritis', u'R J', u'Rapoport', u'G F', u'Carrera', u'F', u'Kozin', u'J Reumatol', u'6', u'', u''], [u'Dislocation of the manubriosternal joint in rheumatoid arthritis', u'M', u'Wiseman', u'Ann Rheum Dis', u'40', u'', u''], [u'We have not found any reports on the treatment of symptomatic MSJ luxation', u''], [u'Manubrio-sternal joint in rheumatoid arthritis', u'A', u'Bogdan', u'J', u'Clark', u'Br Med J', u'16', u'', u''], [u'Manubriosternal joint subluxation in rheumatoid arthritis', u'M', u'E', u'Holt', u'P', u'J', u'Rooney', u'J Rheumatol', u'7', u'', u''], [u'Manubriosternal joint dislocation in rheumatoid arthritis: the role of thoracic kyphosis', u'M C', u'Kelly', u'N D', u'Hopkinson', u'G', u'Zaphiropoulos', u'Ann Rheum Dis', u'45', u'', u'']"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_title,exact,list,0,1,0,0,"Manubrio-sternal joint in rheumatoid arthritis, Manubriosternal joint subluxation in rheumatoid arthritis, Manubriosternal joint dislocation in rheumatoid arthritis: the role of thoracic kyphosis, Manubriosternal joint subluxation in rheumatoid arthritis, A micrographic an histological study of the manubrio-sternal joint in rheumatoid arthritis, Involvement of the manubrio-sternal articulation in rheumatoid arthritis, Manubrio-sternal joint subluxation in rheumatiod arthritis, Dislocation of the manubriosternal joint in rheumatoid arthritis","Manubriosternal joint subluxation in rheumatoid arthritis, A micrographic an histological study of the manubrio-sternal joint in rheumatoid arthritis, Involvement of the manubrio-sternal articulation in rheumatoid arthritis, Manubrio-sternal joint subluxation in rheumatiod arthritis, Dislocation of the manubriosternal joint in rheumatoid arthritis, , Manubrio-sternal joint in rheumatoid arthritis, Manubriosternal joint subluxation in rheumatoid arthritis, Manubriosternal joint dislocation in rheumatoid arthritis: the role of thoracic kyphosis"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_title,levenshtein,list,0,1,0,0,"Manubrio-sternal joint in rheumatoid arthritis, Manubriosternal joint subluxation in rheumatoid arthritis, Manubriosternal joint dislocation in rheumatoid arthritis: the role of thoracic kyphosis, Manubriosternal joint subluxation in rheumatoid arthritis, A micrographic an histological study of the manubrio-sternal joint in rheumatoid arthritis, Involvement of the manubrio-sternal articulation in rheumatoid arthritis, Manubrio-sternal joint subluxation in rheumatiod arthritis, Dislocation of the manubriosternal joint in rheumatoid arthritis","Manubriosternal joint subluxation in rheumatoid arthritis, A micrographic an histological study of the manubrio-sternal joint in rheumatoid arthritis, Involvement of the manubrio-sternal articulation in rheumatoid arthritis, Manubrio-sternal joint subluxation in rheumatiod arthritis, Dislocation of the manubriosternal joint in rheumatoid arthritis, , Manubrio-sternal joint in rheumatoid arthritis, Manubriosternal joint subluxation in rheumatoid arthritis, Manubriosternal joint dislocation in rheumatoid arthritis: the role of thoracic kyphosis"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_year,exact,list,0,1,0,0,"1950, 1980, 1986, 1982, 1970, 1970, 1979, 1981","1982, 1970, 1970, 1979, 1981, , 1950, 1980, 1986"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_year,levenshtein,list,0,1,0,0,"1950, 1980, 1986, 1982, 1970, 1970, 1979, 1981","1982, 1970, 1970, 1979, 1981, , 1950, 1980, 1986"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_source,exact,list,0,1,0,0,"Br Med J, J Rheumatol, Ann Rheum Dis, J Reumatol, Acta Rheumatol Scand, Acta Rheumatol Scand, J Reumatol, Ann Rheum Dis","J Reumatol, Acta Rheumatol Scand, Acta Rheumatol Scand, J Reumatol, Ann Rheum Dis, , Br Med J, J Rheumatol, Ann Rheum Dis"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_source,levenshtein,list,0,1,0,0,"Br Med J, J Rheumatol, Ann Rheum Dis, J Reumatol, Acta Rheumatol Scand, Acta Rheumatol Scand, J Reumatol, Ann Rheum Dis","J Reumatol, Acta Rheumatol Scand, Acta Rheumatol Scand, J Reumatol, Ann Rheum Dis, , Br Med J, J Rheumatol, Ann Rheum Dis"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_volume,exact,list,0,1,0,0,"16, 7, 45, 9, 16, 16, 6, 40","9, 16, 16, 6, 40, , 16, 7, 45"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_volume,levenshtein,list,0,1,0,0,"16, 7, 45, 9, 16, 16, 6, 40","9, 16, 16, 6, 40, , 16, 7, 45"
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_fpage,exact,list,0,1,0,0,"1361, 260, 345, 712, 47, 40, 74, 307",", , , , , , , , "
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_fpage,levenshtein,list,0,1,0,0,"1361, 260, 345, 712, 47, 40, 74, 307",", , , , , , , , "
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_lpage,exact,list,0,1,0,0,"2, 2, 8, 5, 59, 6, 7, 8",", , , , , , , , "
ORT-1745-3674-81-405.grobid-tei.xml,ORT-1745-3674-81-405.nxml,reference_lpage,levenshtein,list,0,1,0,0,"2, 2, 8, 5, 59, 6, 7, 8",", , , , , , , , "
soto131-469.grobid-tei.xml,soto131-469.nxml,title,exact,string,1,0,0,0,Visualization and assessment of saccular duct and endolymphatic sinus,Visualization and assessment of saccular duct and endolymphatic sinus
soto131-469.grobid-tei.xml,soto131-469.nxml,title,levenshtein,string,1,0,0,0,Visualization and assessment of saccular duct and endolymphatic sinus,Visualization and assessment of saccular duct and endolymphatic sinus
soto131-469.grobid-tei.xml,soto131-469.nxml,abstract,exact,string,1,0,0,0,"Conclusion: The saccular duct and endolymphatic sinus run in the bony groove, before reaching the orifice of the vestibular aqueduct. We first clinically visualized this sulciform groove using three-dimensional (3D) cone beam CT images. This strategy can be useful to assess the condition of the saccular duct and endolymphatic sinus concerning the longitudinal flow system of endolymph. Objective: To assess the saccular duct and endolymphatic sinus in the endolymphatic system in order to advance clinical studies on inner ear dysfunction. Methods: The sulciform groove of the saccular duct and endolymphatic sinus of human subjects was analyzed by cone beam CT and compared with that of a cadaver. Results: We could obtain reconstructed 3D CT images of the sulciform groove of the saccular duct and endolymphatic sinus using several CT window levels.","Conclusion: The saccular duct and endolymphatic sinus run in the bony groove, before reaching the orifice of the vestibular aqueduct. We first clinically visualized this sulciform groove using three-dimensional (3D) cone beam CT images. This strategy can be useful to assess the condition of the saccular duct and endolymphatic sinus concerning the longitudinal flow system of endolymph. Objective: To assess the saccular duct and endolymphatic sinus in the endolymphatic system in order to advance clinical studies on inner ear dysfunction. Methods: The sulciform groove of the saccular duct and endolymphatic sinus of human subjects was analyzed by cone beam CT and compared with that of a cadaver. Results: We could obtain reconstructed 3D CT images of the sulciform groove of the saccular duct and endolymphatic sinus using several CT window levels."
soto131-469.grobid-tei.xml,soto131-469.nxml,abstract,levenshtein,string,1,0,0,0,"Conclusion: The saccular duct and endolymphatic sinus run in the bony groove, before reaching the orifice of the vestibular aqueduct. We first clinically visualized this sulciform groove using three-dimensional (3D) cone beam CT images. This strategy can be useful to assess the condition of the saccular duct and endolymphatic sinus concerning the longitudinal flow system of endolymph. Objective: To assess the saccular duct and endolymphatic sinus in the endolymphatic system in order to advance clinical studies on inner ear dysfunction. Methods: The sulciform groove of the saccular duct and endolymphatic sinus of human subjects was analyzed by cone beam CT and compared with that of a cadaver. Results: We could obtain reconstructed 3D CT images of the sulciform groove of the saccular duct and endolymphatic sinus using several CT window levels.","Conclusion: The saccular duct and endolymphatic sinus run in the bony groove, before reaching the orifice of the vestibular aqueduct. We first clinically visualized this sulciform groove using three-dimensional (3D) cone beam CT images. This strategy can be useful to assess the condition of the saccular duct and endolymphatic sinus concerning the longitudinal flow system of endolymph. Objective: To assess the saccular duct and endolymphatic sinus in the endolymphatic system in order to advance clinical studies on inner ear dysfunction. Methods: The sulciform groove of the saccular duct and endolymphatic sinus of human subjects was analyzed by cone beam CT and compared with that of a cadaver. Results: We could obtain reconstructed 3D CT images of the sulciform groove of the saccular duct and endolymphatic sinus using several CT window levels."
soto131-469.grobid-tei.xml,soto131-469.nxml,keywords,exact,set,1,0,0,0,"CT image, Cochlea, bony groove, endolymphatic duct, endolymphatic hydrops, longitudinal flow, rendering, saccule","CT image, Cochlea, bony groove, endolymphatic duct, endolymphatic hydrops, longitudinal flow, rendering, saccule"
soto131-469.grobid-tei.xml,soto131-469.nxml,keywords,levenshtein,set,1,0,0,0,"CT image, Cochlea, bony groove, endolymphatic duct, endolymphatic hydrops, longitudinal flow, rendering, saccule","CT image, Cochlea, bony groove, endolymphatic duct, endolymphatic hydrops, longitudinal flow, rendering, saccule"
soto131-469.grobid-tei.xml,soto131-469.nxml,author_surnames,exact,set,1,0,0,0,"Anniko, Imoto, Sakamoto, Sunami, Takayama, Yamane","Anniko, Imoto, Sakamoto, Sunami, Takayama, Yamane"
soto131-469.grobid-tei.xml,soto131-469.nxml,author_surnames,levenshtein,set,1,0,0,0,"Anniko, Imoto, Sakamoto, Sunami, Takayama, Yamane","Anniko, Imoto, Sakamoto, Sunami, Takayama, Yamane"
soto131-469.grobid-tei.xml,soto131-469.nxml,first_author_surname,exact,string,1,0,0,0,Yamane,Yamane
soto131-469.grobid-tei.xml,soto131-469.nxml,first_author_surname,levenshtein,string,1,0,0,0,Yamane,Yamane
soto131-469.grobid-tei.xml,soto131-469.nxml,author_full_names,exact,set,1,0,0,0,"Hideo Yamane, Hiramori Sakamoto, Kishiko Sunami, Masahiro Takayama, Matti Anniko, Toshio Imoto","Hideo Yamane, Hiramori Sakamoto, Kishiko Sunami, Masahiro Takayama, Matti Anniko, Toshio Imoto"
soto131-469.grobid-tei.xml,soto131-469.nxml,author_full_names,levenshtein,set,1,0,0,0,"Hideo Yamane, Hiramori Sakamoto, Kishiko Sunami, Masahiro Takayama, Matti Anniko, Toshio Imoto","Hideo Yamane, Hiramori Sakamoto, Kishiko Sunami, Masahiro Takayama, Matti Anniko, Toshio Imoto"
soto131-469.grobid-tei.xml,soto131-469.nxml,first_author_full_name,exact,string,1,0,0,0,Hideo Yamane,Hideo Yamane
soto131-469.grobid-tei.xml,soto131-469.nxml,first_author_full_name,levenshtein,string,1,0,0,0,Hideo Yamane,Hideo Yamane
soto131-469.grobid-tei.xml,soto131-469.nxml,affiliation_strings,exact,set,1,0,0,0,"Department of Otorhinolaryngology and Head & Neck Surgery, Uppsala University Hospital, Uppsala, Sweden, Department of Otorhinolaryngology, Osaka City University Graduate School of Medicine, Osaka, Japan","Department of Otorhinolaryngology and Head & Neck Surgery, Uppsala University Hospital, Uppsala, Sweden, Department of Otorhinolaryngology, Osaka City University Graduate School of Medicine, Osaka, Japan"
soto131-469.grobid-tei.xml,soto131-469.nxml,affiliation_strings,levenshtein,set,1,0,0,0,"Department of Otorhinolaryngology and Head & Neck Surgery, Uppsala University Hospital, Uppsala, Sweden, Department of Otorhinolaryngology, Osaka City University Graduate School of Medicine, Osaka, Japan","Department of Otorhinolaryngology and Head & Neck Surgery, Uppsala University Hospital, Uppsala, Sweden, Department of Otorhinolaryngology, Osaka City University Graduate School of Medicine, Osaka, Japan"
soto131-469.grobid-tei.xml,soto131-469.nxml,affiliation_institution,exact,set,0,1,0,0,,"Department of Otorhinolaryngology and Head & Neck Surgery, Uppsala University Hospital, Department of Otorhinolaryngology, Osaka City University Graduate School of Medicine"
soto131-469.grobid-tei.xml,soto131-469.nxml,affiliation_institution,levenshtein,set,0,1,0,0,,"Department of Otorhinolaryngology and Head & Neck Surgery, Uppsala University Hospital, Department of Otorhinolaryngology, Osaka City University Graduate School of Medicine"
soto131-469.grobid-tei.xml,soto131-469.nxml,section_titles,exact,list,1,0,0,0,"Introduction, Material and methods, Results, Discussion","Introduction, Material and methods, Results, Discussion"
soto131-469.grobid-tei.xml,soto131-469.nxml,section_titles,levenshtein,list,1,0,0,0,"Introduction, Material and methods, Results, Discussion","Introduction, Material and methods, Results, Discussion"
soto131-469.grobid-tei.xml,soto131-469.nxml,tables,exact,table,0,1,0,0,,[[]]
soto131-469.grobid-tei.xml,soto131-469.nxml,tables,levenshtein,table,0,1,0,0,,[[]]
soto131-469.grobid-tei.xml,soto131-469.nxml,table_strings,exact,list,0,1,0,0,,"Hideo Yamane MD, Department of Otorhinolaryngology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka 545-8585, Japan. Tel: +81 6 6645 3871. Fax: +81 6 6646 0515. E-mail: ent-yamane@med.osaka-cu.ac.jp (Received 30 July 2010; accepted 12 October 2010)"
soto131-469.grobid-tei.xml,soto131-469.nxml,table_strings,levenshtein,list,0,1,0,0,,"Hideo Yamane MD, Department of Otorhinolaryngology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka 545-8585, Japan. Tel: +81 6 6645 3871. Fax: +81 6 6646 0515. E-mail: ent-yamane@med.osaka-cu.ac.jp (Received 30 July 2010; accepted 12 October 2010)"
soto131-469.grobid-tei.xml,soto131-469.nxml,table_labels,exact,list,0,1,0,0,,:
soto131-469.grobid-tei.xml,soto131-469.nxml,table_labels,levenshtein,list,0,1,0,0,,:
soto131-469.grobid-tei.xml,soto131-469.nxml,table_captions,exact,list,0,0,0,1,,
soto131-469.grobid-tei.xml,soto131-469.nxml,table_captions,levenshtein,list,0,0,0,1,,
soto131-469.grobid-tei.xml,soto131-469.nxml,table_label_captions,exact,list,0,1,0,0,,:
soto131-469.grobid-tei.xml,soto131-469.nxml,table_label_captions,levenshtein,list,0,1,0,0,,:
soto131-469.grobid-tei.xml,soto131-469.nxml,first_reference_fields,exact,list,0,1,0,0,"[u'1', u'Guild', u'SR', u'The circulation of the endolymph', u'Am J Anat', u'1927', u'39', u'57', u'81']","[u'The circulation of the endolymph', u'S', u'R', u'Guild', u'Am J Anat', u'39', u'', u'']"
soto131-469.grobid-tei.xml,soto131-469.nxml,first_reference_fields,levenshtein,list,1,0,0,0,"[u'1', u'Guild', u'SR', u'The circulation of the endolymph', u'Am J Anat', u'1927', u'39', u'57', u'81']","[u'The circulation of the endolymph', u'S', u'R', u'Guild', u'Am J Anat', u'39', u'', u'']"
soto131-469.grobid-tei.xml,soto131-469.nxml,first_reference_title,exact,string,1,0,0,0,The circulation of the endolymph,The circulation of the endolymph
soto131-469.grobid-tei.xml,soto131-469.nxml,first_reference_title,levenshtein,string,1,0,0,0,The circulation of the endolymph,The circulation of the endolymph
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_fields,exact,list,0,1,0,0,"[u'1', u'Guild', u'SR', u'The circulation of the endolymph', u'Am J Anat', u'1927', u'39', u'57', u'81'], [u'2', u'Kimura', u'RS', u'Schuknecht', u'HF', u'Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac', u'Pract Otorhinolaryngol', u'1965', u'27', u'343', u'54'], [u'3', u'Kitamura', u'K', u'Schuknecht', u'H', u'Kimura', u'R', u'Cochlear hydrops is associated with collapsed saccule and ductus reuniens', u'Ann Otol', u'1982', u'91', u'5', u'13'], [u'4', u'Stahle', u'J', u'Wilbrand', u'H', u""The vestibular aqueduct in patients with Meniere's disease. A tomographic and clinical investigation"", u'Acta Otolaryngol', u'1974', u'78', u'36', u'48', u'4547335'], [u'5', u'Yamamoto', u'E', u'Mizukami', u'C', u'Isono', u'M', u'Ohmura', u'M', u'Hirono', u'Y', u'Observation of the external aperture of the vestibular aqueduct using three-dimensional surface reconstruction imaging', u'Laryngoscope', u'1991', u'101', u'480', u'3', u'2030626'], [u'6', u'Yamane', u'H', u'Takayama', u'M', u'Sunami', u'K', u'Sakamoto', u'H', u'Mchizuki', u'K', u'Inoue', u'Y', u'Three-dimensional images of the reuniting duct using cone beam CT', u'Acta Otolaryngol', u'2009', u'129', u'493', u'6', u'18720066'], [u'7', u'Yamane', u'H', u'Takayama', u'M', u'Sunami', u'K', u'Sakamoto', u'H', u'Anniko', u'M', u'Assessment of the reuniting duct by three-dimensional CT rendering', u'Acta Otolaryngol', u'2009', u'129', u'1166', u'8', u'19863305'], [u'8', u'Yamane', u'H', u'Takayama', u'M', u'Sunami', u'K', u'Sakamoto', u'H', u'Imoto', u'T', u'Anniko', u'M', u""Blockage of reuniting duct in Meniere's disease"", u'Acta Otolaryngol', u'2010', u'130', u'233', u'9', u'19585278'], [u'9', u'Kimura', u'RS', u'Schuknecht', u'HF', u'Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac', u'Pract Otorhinolaryngol', u'1965', u'27', u'343', u'54'], [u'10', u'Schuknecht', u'HF', u'R\xfcther', u'A', u'Blockage of longitudinal flow in the endolymphatic hydrops', u'Eur Arch Otorhinolaryngol', u'1991', u'248', u'209', u'17', u'1859653']","[u'The circulation of the endolymph', u'S', u'R', u'Guild', u'Am J Anat', u'39', u'', u''], [u'Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac', u'R', u'S', u'Kimura', u'H', u'F', u'Schuknecht', u'Pract Otorhinolaryngol', u'27', u'', u''], [u'Cochlear hydrops is associated with collapsed saccule and ductus reuniens', u'K', u'Kitamura', u'H', u'Schuknecht', u'R', u'Kimura', u'Ann Otol', u'91', u'', u''], [u""The vestibular aqueduct in patients with Meniere's disease. A tomographic and clinical investigation"", u'J', u'Stahle', u'H', u'Wilbrand', u'Acta Otolaryngol', u'78', u'', u''], [u'Observation of the external aperture of the vestibular aqueduct using three-dimensional surface reconstruction imaging', u'E', u'Yamamoto', u'C', u'Mizukami', u'M', u'Isono', u'M', u'Ohmura', u'Y', u'Hirono', u'Laryngoscope', u'101', u'', u''], [u'Three-dimensional images of the reuniting duct using cone beam CT', u'H', u'Yamane', u'M', u'Takayama', u'K', u'Sunami', u'H', u'Sakamoto', u'K', u'Mchizuki', u'Y', u'Inoue', u'Acta Otolaryngol', u'129', u'', u''], [u'Assessment of the reuniting duct by threedimensional CT rendering', u'H', u'Yamane', u'M', u'Takayama', u'K', u'Sunami', u'H', u'Sakamoto', u'M', u'Anniko', u'Acta Otolaryngol', u'129', u'', u''], [u""Blockage of reuniting duct in Meniere's disease"", u'H', u'Yamane', u'M', u'Takayama', u'K', u'Sunami', u'H', u'Sakamoto', u'T', u'Imoto', u'M', u'Anniko', u'Acta Otolaryngol', u'130', u'', u''], [u'Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac', u'R', u'S', u'Kimura', u'H', u'F', u'Schuknecht', u'Pract Otorhinolaryngol', u'27', u'', u''], [u'Blockage of longitudinal flow in the endolymphatic hydrops', u'H', u'F', u'Schuknecht', u'A', u'R\xfcther', u'Eur Arch Otorhinolaryngol', u'248', u'', u'']"
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_fields,levenshtein,list,1,0,0,0,"[u'1', u'Guild', u'SR', u'The circulation of the endolymph', u'Am J Anat', u'1927', u'39', u'57', u'81'], [u'2', u'Kimura', u'RS', u'Schuknecht', u'HF', u'Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac', u'Pract Otorhinolaryngol', u'1965', u'27', u'343', u'54'], [u'3', u'Kitamura', u'K', u'Schuknecht', u'H', u'Kimura', u'R', u'Cochlear hydrops is associated with collapsed saccule and ductus reuniens', u'Ann Otol', u'1982', u'91', u'5', u'13'], [u'4', u'Stahle', u'J', u'Wilbrand', u'H', u""The vestibular aqueduct in patients with Meniere's disease. A tomographic and clinical investigation"", u'Acta Otolaryngol', u'1974', u'78', u'36', u'48', u'4547335'], [u'5', u'Yamamoto', u'E', u'Mizukami', u'C', u'Isono', u'M', u'Ohmura', u'M', u'Hirono', u'Y', u'Observation of the external aperture of the vestibular aqueduct using three-dimensional surface reconstruction imaging', u'Laryngoscope', u'1991', u'101', u'480', u'3', u'2030626'], [u'6', u'Yamane', u'H', u'Takayama', u'M', u'Sunami', u'K', u'Sakamoto', u'H', u'Mchizuki', u'K', u'Inoue', u'Y', u'Three-dimensional images of the reuniting duct using cone beam CT', u'Acta Otolaryngol', u'2009', u'129', u'493', u'6', u'18720066'], [u'7', u'Yamane', u'H', u'Takayama', u'M', u'Sunami', u'K', u'Sakamoto', u'H', u'Anniko', u'M', u'Assessment of the reuniting duct by three-dimensional CT rendering', u'Acta Otolaryngol', u'2009', u'129', u'1166', u'8', u'19863305'], [u'8', u'Yamane', u'H', u'Takayama', u'M', u'Sunami', u'K', u'Sakamoto', u'H', u'Imoto', u'T', u'Anniko', u'M', u""Blockage of reuniting duct in Meniere's disease"", u'Acta Otolaryngol', u'2010', u'130', u'233', u'9', u'19585278'], [u'9', u'Kimura', u'RS', u'Schuknecht', u'HF', u'Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac', u'Pract Otorhinolaryngol', u'1965', u'27', u'343', u'54'], [u'10', u'Schuknecht', u'HF', u'R\xfcther', u'A', u'Blockage of longitudinal flow in the endolymphatic hydrops', u'Eur Arch Otorhinolaryngol', u'1991', u'248', u'209', u'17', u'1859653']","[u'The circulation of the endolymph', u'S', u'R', u'Guild', u'Am J Anat', u'39', u'', u''], [u'Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac', u'R', u'S', u'Kimura', u'H', u'F', u'Schuknecht', u'Pract Otorhinolaryngol', u'27', u'', u''], [u'Cochlear hydrops is associated with collapsed saccule and ductus reuniens', u'K', u'Kitamura', u'H', u'Schuknecht', u'R', u'Kimura', u'Ann Otol', u'91', u'', u''], [u""The vestibular aqueduct in patients with Meniere's disease. A tomographic and clinical investigation"", u'J', u'Stahle', u'H', u'Wilbrand', u'Acta Otolaryngol', u'78', u'', u''], [u'Observation of the external aperture of the vestibular aqueduct using three-dimensional surface reconstruction imaging', u'E', u'Yamamoto', u'C', u'Mizukami', u'M', u'Isono', u'M', u'Ohmura', u'Y', u'Hirono', u'Laryngoscope', u'101', u'', u''], [u'Three-dimensional images of the reuniting duct using cone beam CT', u'H', u'Yamane', u'M', u'Takayama', u'K', u'Sunami', u'H', u'Sakamoto', u'K', u'Mchizuki', u'Y', u'Inoue', u'Acta Otolaryngol', u'129', u'', u''], [u'Assessment of the reuniting duct by threedimensional CT rendering', u'H', u'Yamane', u'M', u'Takayama', u'K', u'Sunami', u'H', u'Sakamoto', u'M', u'Anniko', u'Acta Otolaryngol', u'129', u'', u''], [u""Blockage of reuniting duct in Meniere's disease"", u'H', u'Yamane', u'M', u'Takayama', u'K', u'Sunami', u'H', u'Sakamoto', u'T', u'Imoto', u'M', u'Anniko', u'Acta Otolaryngol', u'130', u'', u''], [u'Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac', u'R', u'S', u'Kimura', u'H', u'F', u'Schuknecht', u'Pract Otorhinolaryngol', u'27', u'', u''], [u'Blockage of longitudinal flow in the endolymphatic hydrops', u'H', u'F', u'Schuknecht', u'A', u'R\xfcther', u'Eur Arch Otorhinolaryngol', u'248', u'', u'']"
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_title,exact,list,0,1,0,0,"The circulation of the endolymph, Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac, Cochlear hydrops is associated with collapsed saccule and ductus reuniens, The vestibular aqueduct in patients with Meniere's disease. A tomographic and clinical investigation, Observation of the external aperture of the vestibular aqueduct using three-dimensional surface reconstruction imaging, Three-dimensional images of the reuniting duct using cone beam CT, Assessment of the reuniting duct by three-dimensional CT rendering, Blockage of reuniting duct in Meniere's disease, Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac, Blockage of longitudinal flow in the endolymphatic hydrops","The circulation of the endolymph, Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac, Cochlear hydrops is associated with collapsed saccule and ductus reuniens, The vestibular aqueduct in patients with Meniere's disease. A tomographic and clinical investigation, Observation of the external aperture of the vestibular aqueduct using three-dimensional surface reconstruction imaging, Three-dimensional images of the reuniting duct using cone beam CT, Assessment of the reuniting duct by threedimensional CT rendering, Blockage of reuniting duct in Meniere's disease, Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac, Blockage of longitudinal flow in the endolymphatic hydrops"
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_title,levenshtein,list,1,0,0,0,"The circulation of the endolymph, Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac, Cochlear hydrops is associated with collapsed saccule and ductus reuniens, The vestibular aqueduct in patients with Meniere's disease. A tomographic and clinical investigation, Observation of the external aperture of the vestibular aqueduct using three-dimensional surface reconstruction imaging, Three-dimensional images of the reuniting duct using cone beam CT, Assessment of the reuniting duct by three-dimensional CT rendering, Blockage of reuniting duct in Meniere's disease, Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac, Blockage of longitudinal flow in the endolymphatic hydrops","The circulation of the endolymph, Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac, Cochlear hydrops is associated with collapsed saccule and ductus reuniens, The vestibular aqueduct in patients with Meniere's disease. A tomographic and clinical investigation, Observation of the external aperture of the vestibular aqueduct using three-dimensional surface reconstruction imaging, Three-dimensional images of the reuniting duct using cone beam CT, Assessment of the reuniting duct by threedimensional CT rendering, Blockage of reuniting duct in Meniere's disease, Membranous hydrops in the inner ear of the guinea pig after obliteration of the endolymphatic sac, Blockage of longitudinal flow in the endolymphatic hydrops"
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_year,exact,list,1,0,0,0,"1927, 1965, 1982, 1974, 1991, 2009, 2009, 2010, 1965, 1991","1927, 1965, 1982, 1974, 1991, 2009, 2009, 2010, 1965, 1991"
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_year,levenshtein,list,1,0,0,0,"1927, 1965, 1982, 1974, 1991, 2009, 2009, 2010, 1965, 1991","1927, 1965, 1982, 1974, 1991, 2009, 2009, 2010, 1965, 1991"
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_source,exact,list,1,0,0,0,"Am J Anat, Pract Otorhinolaryngol, Ann Otol, Acta Otolaryngol, Laryngoscope, Acta Otolaryngol, Acta Otolaryngol, Acta Otolaryngol, Pract Otorhinolaryngol, Eur Arch Otorhinolaryngol","Am J Anat, Pract Otorhinolaryngol, Ann Otol, Acta Otolaryngol, Laryngoscope, Acta Otolaryngol, Acta Otolaryngol, Acta Otolaryngol, Pract Otorhinolaryngol, Eur Arch Otorhinolaryngol"
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_source,levenshtein,list,1,0,0,0,"Am J Anat, Pract Otorhinolaryngol, Ann Otol, Acta Otolaryngol, Laryngoscope, Acta Otolaryngol, Acta Otolaryngol, Acta Otolaryngol, Pract Otorhinolaryngol, Eur Arch Otorhinolaryngol","Am J Anat, Pract Otorhinolaryngol, Ann Otol, Acta Otolaryngol, Laryngoscope, Acta Otolaryngol, Acta Otolaryngol, Acta Otolaryngol, Pract Otorhinolaryngol, Eur Arch Otorhinolaryngol"
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_volume,exact,list,1,0,0,0,"39, 27, 91, 78, 101, 129, 129, 130, 27, 248","39, 27, 91, 78, 101, 129, 129, 130, 27, 248"
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_volume,levenshtein,list,1,0,0,0,"39, 27, 91, 78, 101, 129, 129, 130, 27, 248","39, 27, 91, 78, 101, 129, 129, 130, 27, 248"
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_fpage,exact,list,0,1,0,0,"57, 343, 5, 36, 480, 493, 1166, 233, 343, 209",", , , , , , , , , "
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_fpage,levenshtein,list,0,1,0,0,"57, 343, 5, 36, 480, 493, 1166, 233, 343, 209",", , , , , , , , , "
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_lpage,exact,list,0,1,0,0,"81, 54, 13, 48, 3, 6, 8, 9, 54, 17",", , , , , , , , , "
soto131-469.grobid-tei.xml,soto131-469.nxml,reference_lpage,levenshtein,list,0,1,0,0,"81, 54, 13, 48, 3, 6, 8, 9, 54, 17",", , , , , , , , , "
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,title,exact,string,1,0,0,0,Placental programming of blood pressure in Indian children,Placental programming of blood pressure in Indian children
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,title,levenshtein,string,1,0,0,0,Placental programming of blood pressure in Indian children,Placental programming of blood pressure in Indian children
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,abstract,exact,string,0,1,0,0,"Aim To determine whether the size and shape of the placental surface predict blood pressure in childhood. Methods We studied blood pressure in 471 nine-year-old Indian children whose placental length, breadth and weight were measured in a prospective birth cohort study. Results In the daughters of short mothers (<median height), systolic blood pressure (SBP) rose as placental breadth increased (β = 0.69 mmHg/cm, p = 0.05) and as the ratio of placental surface area to birthweight increased (p = 0.0003). In the daughters of tall mothers, SBP rose as the difference between placental length and breadth increased (β = 1.40 mmHg/cm, p = 0.007), that is as the surface became more oval. Among boys, associations with placental size were only statistically significant after adjusting for current BMI and height. After adjustment, SBP rose as placental breadth, area and weight decreased (for breadth β = −0.68 mmHg/cm, p < 0.05 for all three measurements). Conclusions The size and shape of the placental surface predict childhood blood pressure. Blood pressure may be programmed by variation in the normal processes of placentation: these include implantation, expansion of the chorionic surface in mid-gestation and compensatory expansion of the chorionic surface in late gestation.","Aim: To determine whether the size and shape of the placental surface predict blood pressure in childhood. Methods: We studied blood pressure in 471 nine-year-old Indian children whose placental length, breadth and weight were measured in a prospective birth cohort study. Results: In the daughters of short mothers (<median height), systolic blood pressure (SBP) rose as placental breadth increased (b = 0.69 mmHg ⁄ cm, p = 0.05) and as the ratio of placental surface area to birthweight increased (p = 0.0003). In the daughters of tall mothers, SBP rose as the difference between placental length and breadth increased (b = 1.40 mmHg ⁄ cm, p = 0.007), that is as the surface became more oval. Among boys, associations with placental size were only statistically significant after adjusting for current BMI and height. After adjustment, SBP rose as placental breadth, area and weight decreased (for breadth b =)0.68 mmHg ⁄ cm, p < 0.05 for all three measurements)."
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,abstract,levenshtein,string,0,1,0,0,"Aim To determine whether the size and shape of the placental surface predict blood pressure in childhood. Methods We studied blood pressure in 471 nine-year-old Indian children whose placental length, breadth and weight were measured in a prospective birth cohort study. Results In the daughters of short mothers (<median height), systolic blood pressure (SBP) rose as placental breadth increased (β = 0.69 mmHg/cm, p = 0.05) and as the ratio of placental surface area to birthweight increased (p = 0.0003). In the daughters of tall mothers, SBP rose as the difference between placental length and breadth increased (β = 1.40 mmHg/cm, p = 0.007), that is as the surface became more oval. Among boys, associations with placental size were only statistically significant after adjusting for current BMI and height. After adjustment, SBP rose as placental breadth, area and weight decreased (for breadth β = −0.68 mmHg/cm, p < 0.05 for all three measurements). Conclusions The size and shape of the placental surface predict childhood blood pressure. Blood pressure may be programmed by variation in the normal processes of placentation: these include implantation, expansion of the chorionic surface in mid-gestation and compensatory expansion of the chorionic surface in late gestation.","Aim: To determine whether the size and shape of the placental surface predict blood pressure in childhood. Methods: We studied blood pressure in 471 nine-year-old Indian children whose placental length, breadth and weight were measured in a prospective birth cohort study. Results: In the daughters of short mothers (<median height), systolic blood pressure (SBP) rose as placental breadth increased (b = 0.69 mmHg ⁄ cm, p = 0.05) and as the ratio of placental surface area to birthweight increased (p = 0.0003). In the daughters of tall mothers, SBP rose as the difference between placental length and breadth increased (b = 1.40 mmHg ⁄ cm, p = 0.007), that is as the surface became more oval. Among boys, associations with placental size were only statistically significant after adjusting for current BMI and height. After adjustment, SBP rose as placental breadth, area and weight decreased (for breadth b =)0.68 mmHg ⁄ cm, p < 0.05 for all three measurements)."
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,keywords,exact,set,1,0,0,0,"Birth size, Blood pressure, Indian children, Maternal height, Placental surface","Birth size, Blood pressure, Indian children, Maternal height, Placental surface"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,keywords,levenshtein,set,1,0,0,0,"Birth size, Blood pressure, Indian children, Maternal height, Placental surface","Birth size, Blood pressure, Indian children, Maternal height, Placental surface"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,author_surnames,exact,set,0,1,0,0,"Barker, Fall, Hill, Karat, Krishnaveni, Veena, Winder","Correspondence, Fall, Hill, Jp Barker, Krishnaveni, Ls Karat, Veena, Winder"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,author_surnames,levenshtein,set,0,1,0,0,"Barker, Fall, Hill, Karat, Krishnaveni, Veena, Winder","Correspondence, Fall, Hill, Jp Barker, Krishnaveni, Ls Karat, Veena, Winder"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,first_author_surname,exact,string,1,0,0,0,Winder,Winder
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,first_author_surname,levenshtein,string,1,0,0,0,Winder,Winder
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,author_full_names,exact,set,0,1,0,0,"Caroline HD Fall, Chitra LS Karat, David JP Barker, Ghattu V Krishnaveni, Jacqueline C Hill, Nicola R Winder, Sargoor R Veena","Caroline Hd Fall, Chitra Ls Karat, David Jp Barker, Ghattu V Krishnaveni, Jacqueline C Hill, Nicola R Winder, Nicola R Winder Correspondence, Sargoor R Veena"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,author_full_names,levenshtein,set,0,1,0,0,"Caroline HD Fall, Chitra LS Karat, David JP Barker, Ghattu V Krishnaveni, Jacqueline C Hill, Nicola R Winder, Sargoor R Veena","Caroline Hd Fall, Chitra Ls Karat, David Jp Barker, Ghattu V Krishnaveni, Jacqueline C Hill, Nicola R Winder, Nicola R Winder Correspondence, Sargoor R Veena"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,first_author_full_name,exact,string,1,0,0,0,Nicola R Winder,Nicola R Winder
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,first_author_full_name,levenshtein,string,1,0,0,0,Nicola R Winder,Nicola R Winder
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,affiliation_strings,exact,set,0,1,0,0,"Epidemiology Research Unit, CSI Holdsworth Memorial Hospital, Mysore 570021, India, MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK",".MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK, Epidemiology Research Unit, CSI Holdsworth Memorial Hospital, 570021, Mysore, India, MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton. SO16 6YD, UK"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,affiliation_strings,levenshtein,set,0,1,0,0,"Epidemiology Research Unit, CSI Holdsworth Memorial Hospital, Mysore 570021, India, MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK",".MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK, Epidemiology Research Unit, CSI Holdsworth Memorial Hospital, 570021, Mysore, India, MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton. SO16 6YD, UK"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,affiliation_institution,exact,set,0,1,0,0,"Epidemiology Research Unit, CSI Holdsworth Memorial Hospital, MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton",".MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Epidemiology Research Unit, CSI Holdsworth Memorial Hospital, MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,affiliation_institution,levenshtein,set,0,1,0,0,"Epidemiology Research Unit, CSI Holdsworth Memorial Hospital, MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton",".MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Epidemiology Research Unit, CSI Holdsworth Memorial Hospital, MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,section_titles,exact,list,0,1,0,0,"Introduction, Methods, Postnatal follow-up, Analysis sample, Statistical methods, Results, Discussion, Boys, small placental surface, Girls, large placental surface, Girls, oval placental surface, Strengths and limitations of the study, Conclusion","INTRODUCTION, METHODS, Analysis sample, Statistical methods, RESULTS, DISCUSSION, Boys, small placental surface, Girls, large placental surface, Girls, oval placental surface, CONCLUSION"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,section_titles,levenshtein,list,0,1,0,0,"Introduction, Methods, Postnatal follow-up, Analysis sample, Statistical methods, Results, Discussion, Boys, small placental surface, Girls, large placental surface, Girls, oval placental surface, Strengths and limitations of the study, Conclusion","INTRODUCTION, METHODS, Analysis sample, Statistical methods, RESULTS, DISCUSSION, Boys, small placental surface, Girls, large placental surface, Girls, oval placental surface, CONCLUSION"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,tables,exact,table,0,1,0,0,"[[["""", ""n"", ""Mean/[%]"", ""(SD)"", """", """", """", """"], [""Mother""], [""Age (years)"", ""471"", ""23.5"", ""(4.0)"", """", """", """", """"], [""Height (cm) at 30 weeks gestation"", ""471"", ""154.3"", ""(5.2)"", """", """", """", """"], [""Weight (kg) at 30 weeks gestation"", ""471"", ""55.8"", ""(8.7)"", """", """", """", """"], [""Body mass index (BMI) (kg/m2) at 30 weeks gestation"", ""471"", ""23.4"", ""(3.5)"", """", """", """", """"], [""Parity""], [""0"", ""241"", ""[51.2]"", """", """", """", """", """"], [""1"", ""151"", ""[32.0]"", """", """", """", """", """"], [""2 or more"", ""79"", ""[16.8]"", """", """", """", """", """"]], [["""", ""Boys"", ""Girls"", """"], ["""", """", """", """"], ["""", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)"", ""p-value""], [""Placenta""], [""Length (cm)"", ""228"", ""19.6"", ""(2.1)"", ""243"", ""19.4"", ""(2.0)"", ""0.2""], [""Breadth (cm)"", ""228"", ""17.0"", ""(1.8)"", ""243"", ""17.0"", ""(1.8)"", ""0.995""], [""Weight (g)"", ""228"", ""410"", ""(81)"", ""243"", ""407"", ""(85)"", ""0.7""], [""Length\u2013breadth (cm)"", ""228"", ""2.6"", ""(1.8)"", ""243"", ""2.4"", ""(1.5)"", ""0.08""], [""Area (cm2)"", ""228"", ""263.5"", ""(50.1)"", ""243"", ""259.9"", ""(48.2)"", ""0.4""], [""Baby""], [""Gestational age (weeks)"", ""228"", ""39.2"", ""(1.6)"", ""243"", ""39.4"", ""(1.5)"", ""0.2""], [""Weight (g)"", ""228"", ""2898"", ""(467)"", ""243"", ""2804"", ""(387)"", ""0.02""], [""Crown-heel length (cm)"", ""228"", ""48.8"", ""(2.3)"", ""243"", ""48.2"", ""(2.1)"", ""0.004""], [""Head circumference (cm)"", ""228"", ""34.1"", ""(1.4)"", ""243"", ""33.5"", ""(1.2)"", ""<0.0001""], [""Children at 9.5 years""], [""Age (years)"", ""228"", ""9.4"", ""(0.1)"", ""243"", ""9.4"", ""(0.1)"", ""0.29""], [""Systolic B.P (mmHg)"", ""228"", ""102.0"", ""(8.3)"", ""243"", ""99.9"", ""(8.5)"", ""0.008""], [""Diastolic B.P (mmHg)"", ""228"", ""58.5"", ""(6.9)"", ""243"", ""58.0"", ""(6.6)"", ""0.3""], [""Height (cm)"", ""228"", ""131.3"", ""(5.5)"", ""243"", ""130.2"", ""(5.9)"", ""0.05""], [""Weight (kg)"", ""228"", ""25.3"", ""(4.4)"", ""243"", ""24.8"", ""(4.7)"", ""0.3""], [""BMI (kg/m2)"", ""228"", ""14.6"", ""(1.8)"", ""243"", ""14.5"", ""(1.9)"", ""0.8""]], [["""", ""Boys"", ""Girls""], ["""", """", """"], ["""", ""Systolic blood pressure (mmHg)"", ""Diastolic blood pressure (mmHg)"", ""Systolic blood pressure (mmHg)"", ""Diastolic blood pressure (mmHg)""], ["""", """", """", """", """"], [""Placenta"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)""], [""Breadth (cm)""], [""\u226416"", ""68"", ""102.9"", ""(8.9)"", ""68"", ""58.7"", ""(6.5)"", ""83"", ""100.6"", ""(8.4)"", ""83"", ""59.2"", ""(6.3)""], [""17"", ""53"", ""102.6"", ""(7.8)"", ""53"", ""58.9"", ""(7.7)"", ""50"", ""98.4"", ""(8.1)"", ""50"", ""56.1"", ""(7.2)""], [""18"", ""46"", ""100.3"", ""(8.5)"", ""46"", ""58.6"", ""(6.4)"", ""49"", ""98.5"", ""(9.0)"", ""49"", ""58.3"", ""(6.7)""], ["">18"", ""61"", ""101.6"", ""(8.0)"", ""61"", ""58.0"", ""(7.0)"", ""61"", ""101.4"", ""(8.5)"", ""61"", ""57.5"", ""(6.2)""], [""p for trend (unadjusted)"", ""228"", ""0.09"", """", ""228"", ""0.67"", """", ""243"", ""0.50"", """", ""243"", ""0.12"", """"], [""p for trend*"", ""228"", ""0.01"", """", ""228"", ""0.50"", """", ""243"", ""0.83"", """", ""243"", ""0.09"", """"], [""Length (cm)""], [""\u226418"", ""56"", ""101.8"", ""(8.4)"", ""56"", ""58.3"", ""(7.1)"", ""64"", ""99.1"", ""(8.2)"", ""64"", ""58.5"", ""(5.8)""], [""19.5"", ""51"", ""103.2"", ""(8.1)"", ""51"", ""59.4"", ""(5.9)"", ""68"", ""99.8"", ""(8.6)"", ""68"", ""58.7"", ""(8.0)""], [""21"", ""67"", ""101.5"", ""(8.1)"", ""67"", ""58.7"", ""(7.2)"", ""64"", ""99.7"", ""(9.1)"", ""64"", ""56.9"", ""(5.9)""], ["">21"", ""54"", ""101.6"", ""(8.9)"", ""54"", ""57.8"", ""(7.1)"", ""47"", ""101.4"", ""(8.3)"", ""47"", ""57.6"", ""(6.4)""], [""p for trend (unadjusted)"", ""228"", ""0.60"", """", ""228"", ""0.75"", """", ""243"", ""0.07"", """", ""243"", ""0.29"", """"], [""p for trend*"", ""228"", ""0.15"", """", ""228"", ""0.53"", """", ""243"", ""0.59"", """", ""243"", ""0.19"", """"], [""Weight (g)""], [""\u2264350"", ""56"", ""102.5"", ""(8.9)"", ""56"", ""58.5"", ""(7.6)"", ""58"", ""99.4"", ""(8.1)"", ""58"", ""58.6"", ""(7.4)""], [""400"", ""57"", ""101.1"", ""(7.6)"", ""57"", ""58.7"", ""(6.5)"", ""80"", ""99.6"", ""(8.5)"", ""80"", ""58.6"", ""(6.5)""], [""450"", ""58"", ""103.6"", ""(8.5)"", ""58"", ""59.4"", ""(6.6)"", ""44"", ""100.1"", ""(9.3)"", ""44"", ""57.9"", ""(5.6)""], ["">450"", ""57"", ""100.6"", ""(8.2)"", ""57"", ""57.5"", ""(6.8)"", ""61"", ""100.6"", ""(8.6)"", ""61"", ""56.6"", ""(6.6)""], [""p for trend (unadjusted)"", ""228"", ""0.15"", """", ""228"", ""0.24"", """", ""243"", ""0.80"", """", ""243"", ""0.02"", """"], [""p for trend*"", ""228"", ""0.01"", """", ""228"", ""0.12"", """", ""243"", ""0.24"", """", ""243"", ""0.01"", """"], [""Area (cm2)""], [""\u2264225"", ""50"", ""102.4"", ""(8.3)"", ""50"", ""59.2"", ""(7.5)"", ""59"", ""99.7"", ""(8.3)"", ""59"", ""58.9"", ""(5.8)""], [""260"", ""54"", ""102.8"", ""(9.0)"", ""54"", ""58.3"", ""(6.1)"", ""64"", ""99.3"", ""(8.6)"", ""64"", ""58.9"", ""(7.7)""], [""300"", ""74"", ""102.1"", ""(7.6)"", ""74"", ""58.8"", ""(7.1)"", ""67"", ""99.4"", ""(8.7)"", ""67"", ""56.5"", ""(6.3)""], ["">300"", ""50"", ""100.5"", ""(8.6)"", ""50"", ""57.7"", ""(6.8)"", ""53"", ""101.5"", ""(8.5)"", ""53"", ""57.6"", ""(6.2)""], [""p for trend (unadjusted)"", ""228"", ""0.22"", """", ""228"", ""0.70"", """", ""243"", ""0.18"", """", ""243"", ""0.14"", """"], [""p for trend*"", ""228"", ""0.03"", """", ""228"", ""0.49"", """", ""243"", ""0.86"", """", ""243"", ""0.10"", """"], [""Area/birth weight (cm2/kg)""], [""\u226480"", ""62"", ""102.9"", ""(8.9)"", ""62"", ""59.6"", ""(7.5)"", ""49"", ""99.2"", ""(8.5)"", ""49"", ""58.4"", ""(5.6)""], [""90"", ""51"", ""102.6"", ""(8.4)"", ""51"", ""57.9"", ""(7.3)"", ""50"", ""100.2"", ""(7.0)"", ""50"", ""58.3"", ""(6.5)""], [""100"", ""52"", ""101.9"", ""(7.9)"", ""52"", ""58.2"", ""(6.9)"", ""65"", ""98.2"", ""(9.3)"", ""65"", ""57.4"", ""(7.6)""], ["">100"", ""63"", ""100.6"", ""(8.0)"", ""63"", ""58.3"", ""(5.8)"", ""79"", ""101.6"", ""(8.6)"", ""79"", ""57.9"", ""(6.4)""], [""p for trend (unadjusted)"", ""228"", ""0.10"", """", ""228"", ""0.22"", """", ""243"", ""0.01"", """", ""243"", ""0.93"", """"], [""p for trend*"", ""228"", ""0.18"", """", ""228"", ""0.30"", """", ""243"", ""0.004"", """", ""243"", ""0.89"", """"]], [["""", ""Short mothers"", ""Tall mothers""], ["""", """", """"], ["""", ""Systolic blood pressure (mmHg)"", ""Diastolic blood pressure (mmHg)"", ""Systolic blood pressure (mmHg)"", ""Diastolic blood pressure (mmHg)""], ["""", """", """", """", """"], [""Placenta"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)""], [""Breadth (cm)""], [""\u226416"", ""49"", ""98.8"", ""(7.9)"", ""49"", ""58.7"", ""(6.5)"", ""34"", ""103.2"", ""(8.7)"", ""34"", ""60.0"", ""(5.9)""], [""17"", ""25"", ""98.1"", ""(8.4)"", ""25"", ""56.7"", ""(7.0)"", ""25"", ""98.7"", ""(7.9)"", ""25"", ""55.4"", ""(7.5)""], [""18"", ""22"", ""100.6"", ""(8.6)"", ""22"", ""59.2"", ""(7.8)"", ""27"", ""96.8"", ""(9.0)"", ""27"", ""57.4"", ""(5.6)""], ["">18"", ""32"", ""101.7"", ""(9.2)"", ""32"", ""57.8"", ""(6.2)"", ""29"", ""101.1"", ""(7.8)"", ""29"", ""57.3"", ""(6.4)""], [""p for trend (unadjusted)"", ""128"", ""0.049"", """", ""128"", ""0.91"", """", ""115"", ""0.25"", """", ""115"", ""0.03"", """"], [""p for trend*"", ""128"", ""0.11"", """", ""128"", ""0.83"", """", ""115"", ""0.09"", """", ""115"", ""0.02"", """"], [""Length (cm)""], [""\u226418"", ""39"", ""99.0"", ""(7.6)"", ""39"", ""58.5"", ""(5.9)"", ""25"", ""99.3"", ""(9.1)"", ""25"", ""58.5"", ""(5.7)""], [""19.5"", ""36"", ""99.0"", ""(9.4)"", ""36"", ""58.6"", ""(8.8)"", ""32"", ""100.8"", ""(7.6)"", ""32"", ""58.9"", ""(7.1)""], [""21"", ""27"", ""100.4"", ""(8.3)"", ""27"", ""56.0"", ""(5.2)"", ""37"", ""99.2"", ""(9.7)"", ""37"", ""57.5"", ""(6.3)""], ["">21"", ""26"", ""100.9"", ""(8.7)"", ""26"", ""59.3"", ""(5.8)"", ""21"", ""102.00"", ""(7.8)"", ""21"", ""55.4"", ""(6.5)""], [""p for trend (unadjusted)"", ""128"", ""0.17"", """", ""128"", ""0.90"", """", ""115"", ""0.24"", """", ""115"", ""0.07"", """"], [""p for trend*"", ""128"", ""0.37"", """", ""128"", ""0.58"", """", ""115"", ""0.83"", """", ""115"", ""0.02"", """"], [""Weight (g)""], [""\u2264350"", ""34"", ""100.9"", ""(9.0)"", ""34"", ""59.1"", ""(8.4)"", ""24"", ""97.3"", ""(6.2)"", ""24"", ""57.9"", ""(5.8)""], [""400"", ""51"", ""99.5"", ""(8.2)"", ""51"", ""59.1"", ""(6.1)"", ""29"", ""99.9"", ""(9.2)"", ""29"", ""57.6"", ""(7.0)""], [""450"", ""17"", ""97.0"", ""(6.8)"", ""17"", ""54.8"", ""(4.9)"", ""27"", ""102.1"", ""(10.2)"", ""27"", ""59.8"", ""(5.2)""], ["">450"", ""26"", ""100.3"", ""(9.4)"", ""26"", ""57.3"", ""(6.0)"", ""35"", ""100.9"", ""(8.2)"", ""35"", ""56.1"", ""(7.1)""], [""p for trend (unadjusted)"", ""128"", ""0.54"", """", ""128"", ""0.05"", """", ""115"", ""0.34"", """", ""115"", ""0.24"", """"], [""p for trend*"", ""128"", ""0.23"", """", ""128"", ""0.10"", """", ""115"", ""0.92"", """", ""115"", ""0.09"", """"], [""Area (cm2)""], [""\u2264225"", ""36"", ""98.6"", ""(7.5)"", ""36"", ""58.3"", ""(6.0)"", ""23"", ""101.6"", ""(9.3)"", ""23"", ""59.7"", ""(5.6)""], [""260"", ""35"", ""98.7"", ""(9.3)"", ""35"", ""58.7"", ""(8.1)"", ""29"", ""100.1"", ""(7.8)"", ""29"", ""59.2"", ""(7.3)""], [""300"", ""33"", ""99.9"", ""(8.0)"", ""33"", ""56.8"", ""(7.1)"", ""34"", ""98.8"", ""(9.4)"", ""34"", ""56.2"", ""(5.5)""], ["">300"", ""24"", ""102.4"", ""(9.1)"", ""24"", ""59.0"", ""(5.2)"", ""29"", ""100.8"", ""(8.2)"", ""29"", ""56.5"", ""(6.9)""], [""p for trend (unadjusted)"", ""128"", ""0.07"", """", ""128"", ""0.99"", """", ""115"", ""0.97"", """", ""115"", ""0.03"", """"], [""p for trend*"", ""128"", ""0.18"", """", ""128"", ""0.70"", """", ""115"", ""0.40"", """", ""115"", ""0.01"", """"], [""Area/birth weight (cm2/g)""], [""\u2264 80"", ""23"", ""97.2"", ""(6.8)"", ""23"", ""57.1"", ""(4.7)"", ""26"", ""100.9"", ""(9.6)"", ""26"", ""59.6"", ""(6.2)""], [""90"", ""26"", ""99.3"", ""(7.0)"", ""26"", ""58.4"", ""(6.5)"", ""24"", ""101.0"", ""(7.0)"", ""24"", ""58.1"", ""(6.7)""], [""100"", ""39"", ""98.9"", ""(9.4)"", ""39"", ""57.9"", ""(8.1)"", ""26"", ""97.1"", ""(9.1)"", ""26"", ""56.7"", ""(7.0)""], ["">100"", ""40"", ""102.0"", ""(9.0)"", ""40"", ""58.8"", ""(6.7)"", ""39"", ""101.2"", ""(8.4)"", ""39"", ""56.9"", ""(6.1)""], [""p for trend (unadjusted)"", ""128"", ""0.0003"", """", ""128"", ""0.06"", """", ""115"", ""0.83"", """", ""115"", ""0.07"", """"], [""p for trend*"", ""128"", ""0.0002"", """", ""128"", ""0.0499"", """", ""115"", ""0.68"", """", ""115"", ""0.08"", """"]]]","[[], [], []]"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,tables,levenshtein,table,0,1,0,0,"[[["""", ""n"", ""Mean/[%]"", ""(SD)"", """", """", """", """"], [""Mother""], [""Age (years)"", ""471"", ""23.5"", ""(4.0)"", """", """", """", """"], [""Height (cm) at 30 weeks gestation"", ""471"", ""154.3"", ""(5.2)"", """", """", """", """"], [""Weight (kg) at 30 weeks gestation"", ""471"", ""55.8"", ""(8.7)"", """", """", """", """"], [""Body mass index (BMI) (kg/m2) at 30 weeks gestation"", ""471"", ""23.4"", ""(3.5)"", """", """", """", """"], [""Parity""], [""0"", ""241"", ""[51.2]"", """", """", """", """", """"], [""1"", ""151"", ""[32.0]"", """", """", """", """", """"], [""2 or more"", ""79"", ""[16.8]"", """", """", """", """", """"]], [["""", ""Boys"", ""Girls"", """"], ["""", """", """", """"], ["""", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)"", ""p-value""], [""Placenta""], [""Length (cm)"", ""228"", ""19.6"", ""(2.1)"", ""243"", ""19.4"", ""(2.0)"", ""0.2""], [""Breadth (cm)"", ""228"", ""17.0"", ""(1.8)"", ""243"", ""17.0"", ""(1.8)"", ""0.995""], [""Weight (g)"", ""228"", ""410"", ""(81)"", ""243"", ""407"", ""(85)"", ""0.7""], [""Length\u2013breadth (cm)"", ""228"", ""2.6"", ""(1.8)"", ""243"", ""2.4"", ""(1.5)"", ""0.08""], [""Area (cm2)"", ""228"", ""263.5"", ""(50.1)"", ""243"", ""259.9"", ""(48.2)"", ""0.4""], [""Baby""], [""Gestational age (weeks)"", ""228"", ""39.2"", ""(1.6)"", ""243"", ""39.4"", ""(1.5)"", ""0.2""], [""Weight (g)"", ""228"", ""2898"", ""(467)"", ""243"", ""2804"", ""(387)"", ""0.02""], [""Crown-heel length (cm)"", ""228"", ""48.8"", ""(2.3)"", ""243"", ""48.2"", ""(2.1)"", ""0.004""], [""Head circumference (cm)"", ""228"", ""34.1"", ""(1.4)"", ""243"", ""33.5"", ""(1.2)"", ""<0.0001""], [""Children at 9.5 years""], [""Age (years)"", ""228"", ""9.4"", ""(0.1)"", ""243"", ""9.4"", ""(0.1)"", ""0.29""], [""Systolic B.P (mmHg)"", ""228"", ""102.0"", ""(8.3)"", ""243"", ""99.9"", ""(8.5)"", ""0.008""], [""Diastolic B.P (mmHg)"", ""228"", ""58.5"", ""(6.9)"", ""243"", ""58.0"", ""(6.6)"", ""0.3""], [""Height (cm)"", ""228"", ""131.3"", ""(5.5)"", ""243"", ""130.2"", ""(5.9)"", ""0.05""], [""Weight (kg)"", ""228"", ""25.3"", ""(4.4)"", ""243"", ""24.8"", ""(4.7)"", ""0.3""], [""BMI (kg/m2)"", ""228"", ""14.6"", ""(1.8)"", ""243"", ""14.5"", ""(1.9)"", ""0.8""]], [["""", ""Boys"", ""Girls""], ["""", """", """"], ["""", ""Systolic blood pressure (mmHg)"", ""Diastolic blood pressure (mmHg)"", ""Systolic blood pressure (mmHg)"", ""Diastolic blood pressure (mmHg)""], ["""", """", """", """", """"], [""Placenta"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)""], [""Breadth (cm)""], [""\u226416"", ""68"", ""102.9"", ""(8.9)"", ""68"", ""58.7"", ""(6.5)"", ""83"", ""100.6"", ""(8.4)"", ""83"", ""59.2"", ""(6.3)""], [""17"", ""53"", ""102.6"", ""(7.8)"", ""53"", ""58.9"", ""(7.7)"", ""50"", ""98.4"", ""(8.1)"", ""50"", ""56.1"", ""(7.2)""], [""18"", ""46"", ""100.3"", ""(8.5)"", ""46"", ""58.6"", ""(6.4)"", ""49"", ""98.5"", ""(9.0)"", ""49"", ""58.3"", ""(6.7)""], ["">18"", ""61"", ""101.6"", ""(8.0)"", ""61"", ""58.0"", ""(7.0)"", ""61"", ""101.4"", ""(8.5)"", ""61"", ""57.5"", ""(6.2)""], [""p for trend (unadjusted)"", ""228"", ""0.09"", """", ""228"", ""0.67"", """", ""243"", ""0.50"", """", ""243"", ""0.12"", """"], [""p for trend*"", ""228"", ""0.01"", """", ""228"", ""0.50"", """", ""243"", ""0.83"", """", ""243"", ""0.09"", """"], [""Length (cm)""], [""\u226418"", ""56"", ""101.8"", ""(8.4)"", ""56"", ""58.3"", ""(7.1)"", ""64"", ""99.1"", ""(8.2)"", ""64"", ""58.5"", ""(5.8)""], [""19.5"", ""51"", ""103.2"", ""(8.1)"", ""51"", ""59.4"", ""(5.9)"", ""68"", ""99.8"", ""(8.6)"", ""68"", ""58.7"", ""(8.0)""], [""21"", ""67"", ""101.5"", ""(8.1)"", ""67"", ""58.7"", ""(7.2)"", ""64"", ""99.7"", ""(9.1)"", ""64"", ""56.9"", ""(5.9)""], ["">21"", ""54"", ""101.6"", ""(8.9)"", ""54"", ""57.8"", ""(7.1)"", ""47"", ""101.4"", ""(8.3)"", ""47"", ""57.6"", ""(6.4)""], [""p for trend (unadjusted)"", ""228"", ""0.60"", """", ""228"", ""0.75"", """", ""243"", ""0.07"", """", ""243"", ""0.29"", """"], [""p for trend*"", ""228"", ""0.15"", """", ""228"", ""0.53"", """", ""243"", ""0.59"", """", ""243"", ""0.19"", """"], [""Weight (g)""], [""\u2264350"", ""56"", ""102.5"", ""(8.9)"", ""56"", ""58.5"", ""(7.6)"", ""58"", ""99.4"", ""(8.1)"", ""58"", ""58.6"", ""(7.4)""], [""400"", ""57"", ""101.1"", ""(7.6)"", ""57"", ""58.7"", ""(6.5)"", ""80"", ""99.6"", ""(8.5)"", ""80"", ""58.6"", ""(6.5)""], [""450"", ""58"", ""103.6"", ""(8.5)"", ""58"", ""59.4"", ""(6.6)"", ""44"", ""100.1"", ""(9.3)"", ""44"", ""57.9"", ""(5.6)""], ["">450"", ""57"", ""100.6"", ""(8.2)"", ""57"", ""57.5"", ""(6.8)"", ""61"", ""100.6"", ""(8.6)"", ""61"", ""56.6"", ""(6.6)""], [""p for trend (unadjusted)"", ""228"", ""0.15"", """", ""228"", ""0.24"", """", ""243"", ""0.80"", """", ""243"", ""0.02"", """"], [""p for trend*"", ""228"", ""0.01"", """", ""228"", ""0.12"", """", ""243"", ""0.24"", """", ""243"", ""0.01"", """"], [""Area (cm2)""], [""\u2264225"", ""50"", ""102.4"", ""(8.3)"", ""50"", ""59.2"", ""(7.5)"", ""59"", ""99.7"", ""(8.3)"", ""59"", ""58.9"", ""(5.8)""], [""260"", ""54"", ""102.8"", ""(9.0)"", ""54"", ""58.3"", ""(6.1)"", ""64"", ""99.3"", ""(8.6)"", ""64"", ""58.9"", ""(7.7)""], [""300"", ""74"", ""102.1"", ""(7.6)"", ""74"", ""58.8"", ""(7.1)"", ""67"", ""99.4"", ""(8.7)"", ""67"", ""56.5"", ""(6.3)""], ["">300"", ""50"", ""100.5"", ""(8.6)"", ""50"", ""57.7"", ""(6.8)"", ""53"", ""101.5"", ""(8.5)"", ""53"", ""57.6"", ""(6.2)""], [""p for trend (unadjusted)"", ""228"", ""0.22"", """", ""228"", ""0.70"", """", ""243"", ""0.18"", """", ""243"", ""0.14"", """"], [""p for trend*"", ""228"", ""0.03"", """", ""228"", ""0.49"", """", ""243"", ""0.86"", """", ""243"", ""0.10"", """"], [""Area/birth weight (cm2/kg)""], [""\u226480"", ""62"", ""102.9"", ""(8.9)"", ""62"", ""59.6"", ""(7.5)"", ""49"", ""99.2"", ""(8.5)"", ""49"", ""58.4"", ""(5.6)""], [""90"", ""51"", ""102.6"", ""(8.4)"", ""51"", ""57.9"", ""(7.3)"", ""50"", ""100.2"", ""(7.0)"", ""50"", ""58.3"", ""(6.5)""], [""100"", ""52"", ""101.9"", ""(7.9)"", ""52"", ""58.2"", ""(6.9)"", ""65"", ""98.2"", ""(9.3)"", ""65"", ""57.4"", ""(7.6)""], ["">100"", ""63"", ""100.6"", ""(8.0)"", ""63"", ""58.3"", ""(5.8)"", ""79"", ""101.6"", ""(8.6)"", ""79"", ""57.9"", ""(6.4)""], [""p for trend (unadjusted)"", ""228"", ""0.10"", """", ""228"", ""0.22"", """", ""243"", ""0.01"", """", ""243"", ""0.93"", """"], [""p for trend*"", ""228"", ""0.18"", """", ""228"", ""0.30"", """", ""243"", ""0.004"", """", ""243"", ""0.89"", """"]], [["""", ""Short mothers"", ""Tall mothers""], ["""", """", """"], ["""", ""Systolic blood pressure (mmHg)"", ""Diastolic blood pressure (mmHg)"", ""Systolic blood pressure (mmHg)"", ""Diastolic blood pressure (mmHg)""], ["""", """", """", """", """"], [""Placenta"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)"", ""n"", ""Mean"", ""(SD)""], [""Breadth (cm)""], [""\u226416"", ""49"", ""98.8"", ""(7.9)"", ""49"", ""58.7"", ""(6.5)"", ""34"", ""103.2"", ""(8.7)"", ""34"", ""60.0"", ""(5.9)""], [""17"", ""25"", ""98.1"", ""(8.4)"", ""25"", ""56.7"", ""(7.0)"", ""25"", ""98.7"", ""(7.9)"", ""25"", ""55.4"", ""(7.5)""], [""18"", ""22"", ""100.6"", ""(8.6)"", ""22"", ""59.2"", ""(7.8)"", ""27"", ""96.8"", ""(9.0)"", ""27"", ""57.4"", ""(5.6)""], ["">18"", ""32"", ""101.7"", ""(9.2)"", ""32"", ""57.8"", ""(6.2)"", ""29"", ""101.1"", ""(7.8)"", ""29"", ""57.3"", ""(6.4)""], [""p for trend (unadjusted)"", ""128"", ""0.049"", """", ""128"", ""0.91"", """", ""115"", ""0.25"", """", ""115"", ""0.03"", """"], [""p for trend*"", ""128"", ""0.11"", """", ""128"", ""0.83"", """", ""115"", ""0.09"", """", ""115"", ""0.02"", """"], [""Length (cm)""], [""\u226418"", ""39"", ""99.0"", ""(7.6)"", ""39"", ""58.5"", ""(5.9)"", ""25"", ""99.3"", ""(9.1)"", ""25"", ""58.5"", ""(5.7)""], [""19.5"", ""36"", ""99.0"", ""(9.4)"", ""36"", ""58.6"", ""(8.8)"", ""32"", ""100.8"", ""(7.6)"", ""32"", ""58.9"", ""(7.1)""], [""21"", ""27"", ""100.4"", ""(8.3)"", ""27"", ""56.0"", ""(5.2)"", ""37"", ""99.2"", ""(9.7)"", ""37"", ""57.5"", ""(6.3)""], ["">21"", ""26"", ""100.9"", ""(8.7)"", ""26"", ""59.3"", ""(5.8)"", ""21"", ""102.00"", ""(7.8)"", ""21"", ""55.4"", ""(6.5)""], [""p for trend (unadjusted)"", ""128"", ""0.17"", """", ""128"", ""0.90"", """", ""115"", ""0.24"", """", ""115"", ""0.07"", """"], [""p for trend*"", ""128"", ""0.37"", """", ""128"", ""0.58"", """", ""115"", ""0.83"", """", ""115"", ""0.02"", """"], [""Weight (g)""], [""\u2264350"", ""34"", ""100.9"", ""(9.0)"", ""34"", ""59.1"", ""(8.4)"", ""24"", ""97.3"", ""(6.2)"", ""24"", ""57.9"", ""(5.8)""], [""400"", ""51"", ""99.5"", ""(8.2)"", ""51"", ""59.1"", ""(6.1)"", ""29"", ""99.9"", ""(9.2)"", ""29"", ""57.6"", ""(7.0)""], [""450"", ""17"", ""97.0"", ""(6.8)"", ""17"", ""54.8"", ""(4.9)"", ""27"", ""102.1"", ""(10.2)"", ""27"", ""59.8"", ""(5.2)""], ["">450"", ""26"", ""100.3"", ""(9.4)"", ""26"", ""57.3"", ""(6.0)"", ""35"", ""100.9"", ""(8.2)"", ""35"", ""56.1"", ""(7.1)""], [""p for trend (unadjusted)"", ""128"", ""0.54"", """", ""128"", ""0.05"", """", ""115"", ""0.34"", """", ""115"", ""0.24"", """"], [""p for trend*"", ""128"", ""0.23"", """", ""128"", ""0.10"", """", ""115"", ""0.92"", """", ""115"", ""0.09"", """"], [""Area (cm2)""], [""\u2264225"", ""36"", ""98.6"", ""(7.5)"", ""36"", ""58.3"", ""(6.0)"", ""23"", ""101.6"", ""(9.3)"", ""23"", ""59.7"", ""(5.6)""], [""260"", ""35"", ""98.7"", ""(9.3)"", ""35"", ""58.7"", ""(8.1)"", ""29"", ""100.1"", ""(7.8)"", ""29"", ""59.2"", ""(7.3)""], [""300"", ""33"", ""99.9"", ""(8.0)"", ""33"", ""56.8"", ""(7.1)"", ""34"", ""98.8"", ""(9.4)"", ""34"", ""56.2"", ""(5.5)""], ["">300"", ""24"", ""102.4"", ""(9.1)"", ""24"", ""59.0"", ""(5.2)"", ""29"", ""100.8"", ""(8.2)"", ""29"", ""56.5"", ""(6.9)""], [""p for trend (unadjusted)"", ""128"", ""0.07"", """", ""128"", ""0.99"", """", ""115"", ""0.97"", """", ""115"", ""0.03"", """"], [""p for trend*"", ""128"", ""0.18"", """", ""128"", ""0.70"", """", ""115"", ""0.40"", """", ""115"", ""0.01"", """"], [""Area/birth weight (cm2/g)""], [""\u2264 80"", ""23"", ""97.2"", ""(6.8)"", ""23"", ""57.1"", ""(4.7)"", ""26"", ""100.9"", ""(9.6)"", ""26"", ""59.6"", ""(6.2)""], [""90"", ""26"", ""99.3"", ""(7.0)"", ""26"", ""58.4"", ""(6.5)"", ""24"", ""101.0"", ""(7.0)"", ""24"", ""58.1"", ""(6.7)""], [""100"", ""39"", ""98.9"", ""(9.4)"", ""39"", ""57.9"", ""(8.1)"", ""26"", ""97.1"", ""(9.1)"", ""26"", ""56.7"", ""(7.0)""], ["">100"", ""40"", ""102.0"", ""(9.0)"", ""40"", ""58.8"", ""(6.7)"", ""39"", ""101.2"", ""(8.4)"", ""39"", ""56.9"", ""(6.1)""], [""p for trend (unadjusted)"", ""128"", ""0.0003"", """", ""128"", ""0.06"", """", ""115"", ""0.83"", """", ""115"", ""0.07"", """"], [""p for trend*"", ""128"", ""0.0002"", """", ""128"", ""0.0499"", """", ""115"", ""0.68"", """", ""115"", ""0.08"", """"]]]","[[], [], []]"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,table_strings,exact,list,0,1,0,0,"n Mean/[%] (SD) Mother  Age (years) 471 23.5 (4.0)  Height (cm) at 30 weeks gestation 471 154.3 (5.2)  Weight (kg) at 30 weeks gestation 471 55.8 (8.7)  Body mass index (BMI) (kg/m2) at 30 weeks gestation 471 23.4 (3.5) Parity  0 241 [51.2]  1 151 [32.0]  2 or more 79 [16.8], Boys Girls n Mean (SD) n Mean (SD) p-value Placenta  Length (cm) 228 19.6 (2.1) 243 19.4 (2.0) 0.2  Breadth (cm) 228 17.0 (1.8) 243 17.0 (1.8) 0.995  Weight (g) 228 410 (81) 243 407 (85) 0.7  Length–breadth (cm) 228 2.6 (1.8) 243 2.4 (1.5) 0.08  Area (cm2) 228 263.5 (50.1) 243 259.9 (48.2) 0.4 Baby  Gestational age (weeks) 228 39.2 (1.6) 243 39.4 (1.5) 0.2  Weight (g) 228 2898 (467) 243 2804 (387) 0.02  Crown-heel length (cm) 228 48.8 (2.3) 243 48.2 (2.1) 0.004  Head circumference (cm) 228 34.1 (1.4) 243 33.5 (1.2) <0.0001 Children at 9.5 years  Age (years) 228 9.4 (0.1) 243 9.4 (0.1) 0.29  Systolic B.P (mmHg) 228 102.0 (8.3) 243 99.9 (8.5) 0.008  Diastolic B.P (mmHg) 228 58.5 (6.9) 243 58.0 (6.6) 0.3  Height (cm) 228 131.3 (5.5) 243 130.2 (5.9) 0.05  Weight (kg) 228 25.3 (4.4) 243 24.8 (4.7) 0.3  BMI (kg/m2) 228 14.6 (1.8) 243 14.5 (1.9) 0.8, Boys Girls Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Placenta n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Breadth (cm)  ≤16 68 102.9 (8.9) 68 58.7 (6.5) 83 100.6 (8.4) 83 59.2 (6.3)  17 53 102.6 (7.8) 53 58.9 (7.7) 50 98.4 (8.1) 50 56.1 (7.2)  18 46 100.3 (8.5) 46 58.6 (6.4) 49 98.5 (9.0) 49 58.3 (6.7)  >18 61 101.6 (8.0) 61 58.0 (7.0) 61 101.4 (8.5) 61 57.5 (6.2) p for trend (unadjusted) 228 0.09 228 0.67 243 0.50 243 0.12 p for trend* 228 0.01 228 0.50 243 0.83 243 0.09 Length (cm)  ≤18 56 101.8 (8.4) 56 58.3 (7.1) 64 99.1 (8.2) 64 58.5 (5.8)  19.5 51 103.2 (8.1) 51 59.4 (5.9) 68 99.8 (8.6) 68 58.7 (8.0)  21 67 101.5 (8.1) 67 58.7 (7.2) 64 99.7 (9.1) 64 56.9 (5.9)  >21 54 101.6 (8.9) 54 57.8 (7.1) 47 101.4 (8.3) 47 57.6 (6.4) p for trend (unadjusted) 228 0.60 228 0.75 243 0.07 243 0.29 p for trend* 228 0.15 228 0.53 243 0.59 243 0.19 Weight (g)  ≤350 56 102.5 (8.9) 56 58.5 (7.6) 58 99.4 (8.1) 58 58.6 (7.4)  400 57 101.1 (7.6) 57 58.7 (6.5) 80 99.6 (8.5) 80 58.6 (6.5)  450 58 103.6 (8.5) 58 59.4 (6.6) 44 100.1 (9.3) 44 57.9 (5.6)  >450 57 100.6 (8.2) 57 57.5 (6.8) 61 100.6 (8.6) 61 56.6 (6.6) p for trend (unadjusted) 228 0.15 228 0.24 243 0.80 243 0.02 p for trend* 228 0.01 228 0.12 243 0.24 243 0.01 Area (cm2)  ≤225 50 102.4 (8.3) 50 59.2 (7.5) 59 99.7 (8.3) 59 58.9 (5.8)  260 54 102.8 (9.0) 54 58.3 (6.1) 64 99.3 (8.6) 64 58.9 (7.7)  300 74 102.1 (7.6) 74 58.8 (7.1) 67 99.4 (8.7) 67 56.5 (6.3)  >300 50 100.5 (8.6) 50 57.7 (6.8) 53 101.5 (8.5) 53 57.6 (6.2) p for trend (unadjusted) 228 0.22 228 0.70 243 0.18 243 0.14 p for trend* 228 0.03 228 0.49 243 0.86 243 0.10 Area/birth weight (cm2/kg)  ≤80 62 102.9 (8.9) 62 59.6 (7.5) 49 99.2 (8.5) 49 58.4 (5.6)  90 51 102.6 (8.4) 51 57.9 (7.3) 50 100.2 (7.0) 50 58.3 (6.5)  100 52 101.9 (7.9) 52 58.2 (6.9) 65 98.2 (9.3) 65 57.4 (7.6)  >100 63 100.6 (8.0) 63 58.3 (5.8) 79 101.6 (8.6) 79 57.9 (6.4) p for trend (unadjusted) 228 0.10 228 0.22 243 0.01 243 0.93 p for trend* 228 0.18 228 0.30 243 0.004 243 0.89, Short mothers Tall mothers Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Placenta n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Breadth (cm)  ≤16 49 98.8 (7.9) 49 58.7 (6.5) 34 103.2 (8.7) 34 60.0 (5.9)  17 25 98.1 (8.4) 25 56.7 (7.0) 25 98.7 (7.9) 25 55.4 (7.5)  18 22 100.6 (8.6) 22 59.2 (7.8) 27 96.8 (9.0) 27 57.4 (5.6)  >18 32 101.7 (9.2) 32 57.8 (6.2) 29 101.1 (7.8) 29 57.3 (6.4) p for trend (unadjusted) 128 0.049 128 0.91 115 0.25 115 0.03 p for trend* 128 0.11 128 0.83 115 0.09 115 0.02 Length (cm)  ≤18 39 99.0 (7.6) 39 58.5 (5.9) 25 99.3 (9.1) 25 58.5 (5.7)  19.5 36 99.0 (9.4) 36 58.6 (8.8) 32 100.8 (7.6) 32 58.9 (7.1)  21 27 100.4 (8.3) 27 56.0 (5.2) 37 99.2 (9.7) 37 57.5 (6.3)  >21 26 100.9 (8.7) 26 59.3 (5.8) 21 102.00 (7.8) 21 55.4 (6.5) p for trend (unadjusted) 128 0.17 128 0.90 115 0.24 115 0.07 p for trend* 128 0.37 128 0.58 115 0.83 115 0.02 Weight (g)  ≤350 34 100.9 (9.0) 34 59.1 (8.4) 24 97.3 (6.2) 24 57.9 (5.8)  400 51 99.5 (8.2) 51 59.1 (6.1) 29 99.9 (9.2) 29 57.6 (7.0)  450 17 97.0 (6.8) 17 54.8 (4.9) 27 102.1 (10.2) 27 59.8 (5.2)  >450 26 100.3 (9.4) 26 57.3 (6.0) 35 100.9 (8.2) 35 56.1 (7.1) p for trend (unadjusted) 128 0.54 128 0.05 115 0.34 115 0.24 p for trend* 128 0.23 128 0.10 115 0.92 115 0.09 Area (cm2)  ≤225 36 98.6 (7.5) 36 58.3 (6.0) 23 101.6 (9.3) 23 59.7 (5.6)  260 35 98.7 (9.3) 35 58.7 (8.1) 29 100.1 (7.8) 29 59.2 (7.3)  300 33 99.9 (8.0) 33 56.8 (7.1) 34 98.8 (9.4) 34 56.2 (5.5)  >300 24 102.4 (9.1) 24 59.0 (5.2) 29 100.8 (8.2) 29 56.5 (6.9) p for trend (unadjusted) 128 0.07 128 0.99 115 0.97 115 0.03 p for trend* 128 0.18 128 0.70 115 0.40 115 0.01 Area/birth weight (cm2/g)  ≤ 80 23 97.2 (6.8) 23 57.1 (4.7) 26 100.9 (9.6) 26 59.6 (6.2)  90 26 99.3 (7.0) 26 58.4 (6.5) 24 101.0 (7.0) 24 58.1 (6.7)  100 39 98.9 (9.4) 39 57.9 (8.1) 26 97.1 (9.1) 26 56.7 (7.0)  >100 40 102.0 (9.0) 40 58.8 (6.7) 39 101.2 (8.4) 39 56.9 (6.1) p for trend (unadjusted) 128 0.0003 128 0.06 115 0.83 115 0.07 p for trend* 128 0.0002 128 0.0499 115 0.68 115 0.08","n Mean ⁄ [%] (SD), Placenta Boys, Placenta Short mothers Tall mothers Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Breadth (cm) £16 49 98.8 (7.9) 49 58.7 (6.5) 34 103.2 (8.7) 34 60.0 (5.9) 17 25 98.1 (8.4) 25 56.7 (7.0) 25 98.7 (7.9) 25 55.4 (7.5) 18 22 100.6 (8.6) 22 59.2 (7.8) 27 96.8 (9.0) 27 57.4 (5.6) >18 32 101.7 (9.2) 32 57.8 (6.2) 29 101.1 (7.8) 29 57.3 (6.4) p for trend (unadjusted) 128 0.049 128 0.91 115 0.25 115 0.03 p for trend* 128 0.11 128 0.83 115 0.09 115 0.02 Length (cm) £18 39 99.0 (7.6) 39 58.5 (5.9) 25 99.3 (9.1) 25 58.5 (5.7) 19.5 36 99.0 (9.4) 36 58.6 (8.8) 32 100.8 (7.6) 32 58.9 (7.1) 21 27 100.4 (8.3) 27 56.0 (5.2) 37 99.2 (9.7) 37 57.5 (6.3) >21 26 100.9 (8.7) 26 59.3 (5.8) 21 102.00 (7.8) 21 55.4 (6.5) p for trend (unadjusted) 128 0.17 128 0.90 115 0.24 115 0.07 p for trend* 128 0.37 128 0.58 115 0.83 115 0.02 Weight (g) £350 34 100.9 (9.0) 34 59.1 (8.4) 24 97.3 (6.2) 24 57.9 (5.8) 400 51 99.5 (8.2) 51 59.1 (6.1) 29 99.9 (9.2) 29 57.6 (7.0) 450 17 97.0 (6.8) 17 54.8 (4.9) 27 102.1 (10.2) 27 59.8 (5.2) >450 26 100.3 (9.4) 26 57.3 (6.0) 35 100.9 (8.2) 35 56.1 (7.1) p for trend (unadjusted) 128 0.54 128 0.05 115 0.34 115 0.24 p for trend* 128 0.23 128 0.10 115 0.92 115 0.09 Area (cm 2 ) £225 36 98.6 (7.5) 36 58.3 (6.0) 23 101.6 (9.3) 23 59.7 (5.6) 260 35 98.7 (9.3) 35 58.7 (8.1) 29 100.1 (7.8) 29 59.2 (7.3) 300 33 99.9 (8.0) 33 56.8 (7.1) 34 98.8 (9.4) 34 56.2 (5.5) >300 24 102.4 (9.1) 24 59.0 (5.2) 29 100.8 (8.2) 29 56.5 (6.9) p for trend (unadjusted) 128 0.07 128 0.99 115 0.97 115 0.03 p for trend* 128 0.18 128 0.70 115 0.40 115 0.01 Area ⁄ birth weight (cm 2 ⁄ g) £ 80 23 97.2 (6.8) 23 57.1 (4.7) 26 100.9 (9.6) 26 59.6 (6.2) 90 26 99.3 (7.0) 26 58.4 (6.5) 24 101.0 (7.0) 24 58.1 (6.7) 100 39 98.9 (9.4) 39 57.9 (8.1) 26 97.1 (9.1) 26 56.7 (7.0) >100 40 102.0 (9.0) 40 58.8 (6.7) 39 101.2 (8.4) 39 56.9 (6.1) p for trend (unadjusted) 128 0.0003 128 0.06 115 0.83 115 0.07 p for trend* 128 0.0002 128 0.0499 115 0.68 115 0.08 The means are unadjusted. p values were obtained by linear regression using all variables as continuous. *p values adjusted for the child's current body mass index and height. Placenta and childhood blood pressure Winder et al."
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,table_strings,levenshtein,list,0,1,0,0,"n Mean/[%] (SD) Mother  Age (years) 471 23.5 (4.0)  Height (cm) at 30 weeks gestation 471 154.3 (5.2)  Weight (kg) at 30 weeks gestation 471 55.8 (8.7)  Body mass index (BMI) (kg/m2) at 30 weeks gestation 471 23.4 (3.5) Parity  0 241 [51.2]  1 151 [32.0]  2 or more 79 [16.8], Boys Girls n Mean (SD) n Mean (SD) p-value Placenta  Length (cm) 228 19.6 (2.1) 243 19.4 (2.0) 0.2  Breadth (cm) 228 17.0 (1.8) 243 17.0 (1.8) 0.995  Weight (g) 228 410 (81) 243 407 (85) 0.7  Length–breadth (cm) 228 2.6 (1.8) 243 2.4 (1.5) 0.08  Area (cm2) 228 263.5 (50.1) 243 259.9 (48.2) 0.4 Baby  Gestational age (weeks) 228 39.2 (1.6) 243 39.4 (1.5) 0.2  Weight (g) 228 2898 (467) 243 2804 (387) 0.02  Crown-heel length (cm) 228 48.8 (2.3) 243 48.2 (2.1) 0.004  Head circumference (cm) 228 34.1 (1.4) 243 33.5 (1.2) <0.0001 Children at 9.5 years  Age (years) 228 9.4 (0.1) 243 9.4 (0.1) 0.29  Systolic B.P (mmHg) 228 102.0 (8.3) 243 99.9 (8.5) 0.008  Diastolic B.P (mmHg) 228 58.5 (6.9) 243 58.0 (6.6) 0.3  Height (cm) 228 131.3 (5.5) 243 130.2 (5.9) 0.05  Weight (kg) 228 25.3 (4.4) 243 24.8 (4.7) 0.3  BMI (kg/m2) 228 14.6 (1.8) 243 14.5 (1.9) 0.8, Boys Girls Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Placenta n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Breadth (cm)  ≤16 68 102.9 (8.9) 68 58.7 (6.5) 83 100.6 (8.4) 83 59.2 (6.3)  17 53 102.6 (7.8) 53 58.9 (7.7) 50 98.4 (8.1) 50 56.1 (7.2)  18 46 100.3 (8.5) 46 58.6 (6.4) 49 98.5 (9.0) 49 58.3 (6.7)  >18 61 101.6 (8.0) 61 58.0 (7.0) 61 101.4 (8.5) 61 57.5 (6.2) p for trend (unadjusted) 228 0.09 228 0.67 243 0.50 243 0.12 p for trend* 228 0.01 228 0.50 243 0.83 243 0.09 Length (cm)  ≤18 56 101.8 (8.4) 56 58.3 (7.1) 64 99.1 (8.2) 64 58.5 (5.8)  19.5 51 103.2 (8.1) 51 59.4 (5.9) 68 99.8 (8.6) 68 58.7 (8.0)  21 67 101.5 (8.1) 67 58.7 (7.2) 64 99.7 (9.1) 64 56.9 (5.9)  >21 54 101.6 (8.9) 54 57.8 (7.1) 47 101.4 (8.3) 47 57.6 (6.4) p for trend (unadjusted) 228 0.60 228 0.75 243 0.07 243 0.29 p for trend* 228 0.15 228 0.53 243 0.59 243 0.19 Weight (g)  ≤350 56 102.5 (8.9) 56 58.5 (7.6) 58 99.4 (8.1) 58 58.6 (7.4)  400 57 101.1 (7.6) 57 58.7 (6.5) 80 99.6 (8.5) 80 58.6 (6.5)  450 58 103.6 (8.5) 58 59.4 (6.6) 44 100.1 (9.3) 44 57.9 (5.6)  >450 57 100.6 (8.2) 57 57.5 (6.8) 61 100.6 (8.6) 61 56.6 (6.6) p for trend (unadjusted) 228 0.15 228 0.24 243 0.80 243 0.02 p for trend* 228 0.01 228 0.12 243 0.24 243 0.01 Area (cm2)  ≤225 50 102.4 (8.3) 50 59.2 (7.5) 59 99.7 (8.3) 59 58.9 (5.8)  260 54 102.8 (9.0) 54 58.3 (6.1) 64 99.3 (8.6) 64 58.9 (7.7)  300 74 102.1 (7.6) 74 58.8 (7.1) 67 99.4 (8.7) 67 56.5 (6.3)  >300 50 100.5 (8.6) 50 57.7 (6.8) 53 101.5 (8.5) 53 57.6 (6.2) p for trend (unadjusted) 228 0.22 228 0.70 243 0.18 243 0.14 p for trend* 228 0.03 228 0.49 243 0.86 243 0.10 Area/birth weight (cm2/kg)  ≤80 62 102.9 (8.9) 62 59.6 (7.5) 49 99.2 (8.5) 49 58.4 (5.6)  90 51 102.6 (8.4) 51 57.9 (7.3) 50 100.2 (7.0) 50 58.3 (6.5)  100 52 101.9 (7.9) 52 58.2 (6.9) 65 98.2 (9.3) 65 57.4 (7.6)  >100 63 100.6 (8.0) 63 58.3 (5.8) 79 101.6 (8.6) 79 57.9 (6.4) p for trend (unadjusted) 228 0.10 228 0.22 243 0.01 243 0.93 p for trend* 228 0.18 228 0.30 243 0.004 243 0.89, Short mothers Tall mothers Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Placenta n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Breadth (cm)  ≤16 49 98.8 (7.9) 49 58.7 (6.5) 34 103.2 (8.7) 34 60.0 (5.9)  17 25 98.1 (8.4) 25 56.7 (7.0) 25 98.7 (7.9) 25 55.4 (7.5)  18 22 100.6 (8.6) 22 59.2 (7.8) 27 96.8 (9.0) 27 57.4 (5.6)  >18 32 101.7 (9.2) 32 57.8 (6.2) 29 101.1 (7.8) 29 57.3 (6.4) p for trend (unadjusted) 128 0.049 128 0.91 115 0.25 115 0.03 p for trend* 128 0.11 128 0.83 115 0.09 115 0.02 Length (cm)  ≤18 39 99.0 (7.6) 39 58.5 (5.9) 25 99.3 (9.1) 25 58.5 (5.7)  19.5 36 99.0 (9.4) 36 58.6 (8.8) 32 100.8 (7.6) 32 58.9 (7.1)  21 27 100.4 (8.3) 27 56.0 (5.2) 37 99.2 (9.7) 37 57.5 (6.3)  >21 26 100.9 (8.7) 26 59.3 (5.8) 21 102.00 (7.8) 21 55.4 (6.5) p for trend (unadjusted) 128 0.17 128 0.90 115 0.24 115 0.07 p for trend* 128 0.37 128 0.58 115 0.83 115 0.02 Weight (g)  ≤350 34 100.9 (9.0) 34 59.1 (8.4) 24 97.3 (6.2) 24 57.9 (5.8)  400 51 99.5 (8.2) 51 59.1 (6.1) 29 99.9 (9.2) 29 57.6 (7.0)  450 17 97.0 (6.8) 17 54.8 (4.9) 27 102.1 (10.2) 27 59.8 (5.2)  >450 26 100.3 (9.4) 26 57.3 (6.0) 35 100.9 (8.2) 35 56.1 (7.1) p for trend (unadjusted) 128 0.54 128 0.05 115 0.34 115 0.24 p for trend* 128 0.23 128 0.10 115 0.92 115 0.09 Area (cm2)  ≤225 36 98.6 (7.5) 36 58.3 (6.0) 23 101.6 (9.3) 23 59.7 (5.6)  260 35 98.7 (9.3) 35 58.7 (8.1) 29 100.1 (7.8) 29 59.2 (7.3)  300 33 99.9 (8.0) 33 56.8 (7.1) 34 98.8 (9.4) 34 56.2 (5.5)  >300 24 102.4 (9.1) 24 59.0 (5.2) 29 100.8 (8.2) 29 56.5 (6.9) p for trend (unadjusted) 128 0.07 128 0.99 115 0.97 115 0.03 p for trend* 128 0.18 128 0.70 115 0.40 115 0.01 Area/birth weight (cm2/g)  ≤ 80 23 97.2 (6.8) 23 57.1 (4.7) 26 100.9 (9.6) 26 59.6 (6.2)  90 26 99.3 (7.0) 26 58.4 (6.5) 24 101.0 (7.0) 24 58.1 (6.7)  100 39 98.9 (9.4) 39 57.9 (8.1) 26 97.1 (9.1) 26 56.7 (7.0)  >100 40 102.0 (9.0) 40 58.8 (6.7) 39 101.2 (8.4) 39 56.9 (6.1) p for trend (unadjusted) 128 0.0003 128 0.06 115 0.83 115 0.07 p for trend* 128 0.0002 128 0.0499 115 0.68 115 0.08","n Mean ⁄ [%] (SD), Placenta Boys, Placenta Short mothers Tall mothers Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) Breadth (cm) £16 49 98.8 (7.9) 49 58.7 (6.5) 34 103.2 (8.7) 34 60.0 (5.9) 17 25 98.1 (8.4) 25 56.7 (7.0) 25 98.7 (7.9) 25 55.4 (7.5) 18 22 100.6 (8.6) 22 59.2 (7.8) 27 96.8 (9.0) 27 57.4 (5.6) >18 32 101.7 (9.2) 32 57.8 (6.2) 29 101.1 (7.8) 29 57.3 (6.4) p for trend (unadjusted) 128 0.049 128 0.91 115 0.25 115 0.03 p for trend* 128 0.11 128 0.83 115 0.09 115 0.02 Length (cm) £18 39 99.0 (7.6) 39 58.5 (5.9) 25 99.3 (9.1) 25 58.5 (5.7) 19.5 36 99.0 (9.4) 36 58.6 (8.8) 32 100.8 (7.6) 32 58.9 (7.1) 21 27 100.4 (8.3) 27 56.0 (5.2) 37 99.2 (9.7) 37 57.5 (6.3) >21 26 100.9 (8.7) 26 59.3 (5.8) 21 102.00 (7.8) 21 55.4 (6.5) p for trend (unadjusted) 128 0.17 128 0.90 115 0.24 115 0.07 p for trend* 128 0.37 128 0.58 115 0.83 115 0.02 Weight (g) £350 34 100.9 (9.0) 34 59.1 (8.4) 24 97.3 (6.2) 24 57.9 (5.8) 400 51 99.5 (8.2) 51 59.1 (6.1) 29 99.9 (9.2) 29 57.6 (7.0) 450 17 97.0 (6.8) 17 54.8 (4.9) 27 102.1 (10.2) 27 59.8 (5.2) >450 26 100.3 (9.4) 26 57.3 (6.0) 35 100.9 (8.2) 35 56.1 (7.1) p for trend (unadjusted) 128 0.54 128 0.05 115 0.34 115 0.24 p for trend* 128 0.23 128 0.10 115 0.92 115 0.09 Area (cm 2 ) £225 36 98.6 (7.5) 36 58.3 (6.0) 23 101.6 (9.3) 23 59.7 (5.6) 260 35 98.7 (9.3) 35 58.7 (8.1) 29 100.1 (7.8) 29 59.2 (7.3) 300 33 99.9 (8.0) 33 56.8 (7.1) 34 98.8 (9.4) 34 56.2 (5.5) >300 24 102.4 (9.1) 24 59.0 (5.2) 29 100.8 (8.2) 29 56.5 (6.9) p for trend (unadjusted) 128 0.07 128 0.99 115 0.97 115 0.03 p for trend* 128 0.18 128 0.70 115 0.40 115 0.01 Area ⁄ birth weight (cm 2 ⁄ g) £ 80 23 97.2 (6.8) 23 57.1 (4.7) 26 100.9 (9.6) 26 59.6 (6.2) 90 26 99.3 (7.0) 26 58.4 (6.5) 24 101.0 (7.0) 24 58.1 (6.7) 100 39 98.9 (9.4) 39 57.9 (8.1) 26 97.1 (9.1) 26 56.7 (7.0) >100 40 102.0 (9.0) 40 58.8 (6.7) 39 101.2 (8.4) 39 56.9 (6.1) p for trend (unadjusted) 128 0.0003 128 0.06 115 0.83 115 0.07 p for trend* 128 0.0002 128 0.0499 115 0.68 115 0.08 The means are unadjusted. p values were obtained by linear regression using all variables as continuous. *p values adjusted for the child's current body mass index and height. Placenta and childhood blood pressure Winder et al."
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,table_labels,exact,list,0,1,0,0,"Table 1, Table 2, Table 3","Table 1 Characteristics of the mothers, placentas, babies and children in the Mysore Parthenon cohort, Table 2 Blood pressure at 9.5 years among boys and girls according to placental size, Table 3 Blood pressure at 9.5 years among girls according to mother's height and placental size"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,table_labels,levenshtein,list,0,1,0,0,"Table 1, Table 2, Table 3","Table 1 Characteristics of the mothers, placentas, babies and children in the Mysore Parthenon cohort, Table 2 Blood pressure at 9.5 years among boys and girls according to placental size, Table 3 Blood pressure at 9.5 years among girls according to mother's height and placental size"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,table_captions,exact,list,0,1,0,0,"Characteristics of the mothers, placentas, babies and children in the Mysore Parthenon cohort, Blood pressure at 9.5 years among boys and girls according to placental size, Blood pressure at 9.5 years among girls according to mother’s height and placental size",", , "
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,table_captions,levenshtein,list,0,1,0,0,"Characteristics of the mothers, placentas, babies and children in the Mysore Parthenon cohort, Blood pressure at 9.5 years among boys and girls according to placental size, Blood pressure at 9.5 years among girls according to mother’s height and placental size",", , "
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,table_label_captions,exact,list,0,1,0,0,"Table 1 Characteristics of the mothers, placentas, babies and children in the Mysore Parthenon cohort, Table 2 Blood pressure at 9.5 years among boys and girls according to placental size, Table 3 Blood pressure at 9.5 years among girls according to mother’s height and placental size","Table 1 Characteristics of the mothers, placentas, babies and children in the Mysore Parthenon cohort, Table 2 Blood pressure at 9.5 years among boys and girls according to placental size, Table 3 Blood pressure at 9.5 years among girls according to mother's height and placental size"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,table_label_captions,levenshtein,list,1,0,0,0,"Table 1 Characteristics of the mothers, placentas, babies and children in the Mysore Parthenon cohort, Table 2 Blood pressure at 9.5 years among boys and girls according to placental size, Table 3 Blood pressure at 9.5 years among girls according to mother’s height and placental size","Table 1 Characteristics of the mothers, placentas, babies and children in the Mysore Parthenon cohort, Table 2 Blood pressure at 9.5 years among boys and girls according to placental size, Table 3 Blood pressure at 9.5 years among girls according to mother's height and placental size"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,first_reference_fields,exact,list,0,1,0,0,"[u'1', u'Law', u'CM', u'de', u'SM', u'Osmond', u'C', u'Fayers', u'PM', u'Barker', u'DJ', u'Cruddas', u'AM', u'', u'in utero', u'Br Med J', u'1993', u'306', u'24', u'7', u'8435572']","[u'Initiation of hypertension in utero and its amplification throughout life', u'C', u'M', u'Law', u'S', u'M', u'De', u'C', u'Osmond', u'P', u'M', u'Fayers', u'D', u'J', u'Barker', u'A', u'M', u'Cruddas', u'Br Med J', u'306', u'', u'']"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,first_reference_fields,levenshtein,list,0,1,0,0,"[u'1', u'Law', u'CM', u'de', u'SM', u'Osmond', u'C', u'Fayers', u'PM', u'Barker', u'DJ', u'Cruddas', u'AM', u'', u'in utero', u'Br Med J', u'1993', u'306', u'24', u'7', u'8435572']","[u'Initiation of hypertension in utero and its amplification throughout life', u'C', u'M', u'Law', u'S', u'M', u'De', u'C', u'Osmond', u'P', u'M', u'Fayers', u'D', u'J', u'Barker', u'A', u'M', u'Cruddas', u'Br Med J', u'306', u'', u'']"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,first_reference_title,exact,string,1,0,0,0,Initiation of hypertension in utero and its amplification throughout life,Initiation of hypertension in utero and its amplification throughout life
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,first_reference_title,levenshtein,string,1,0,0,0,Initiation of hypertension in utero and its amplification throughout life,Initiation of hypertension in utero and its amplification throughout life
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_fields,exact,list,0,1,0,0,"[u'1', u'Law', u'CM', u'de', u'SM', u'Osmond', u'C', u'Fayers', u'PM', u'Barker', u'DJ', u'Cruddas', u'AM', u'', u'in utero', u'Br Med J', u'1993', u'306', u'24', u'7', u'8435572'], [u'2', u'Adair', u'L', u'Dahly', u'D', u'Developmental determinants of blood pressure in adults', u'Annu Rev Nutr', u'2005', u'25', u'407', u'34', u'16011473'], [u'3', u'Eriksson', u'JG', u'Forsen', u'TJ', u'Kajantie', u'E', u'Osmond', u'C', u'Barker', u'DJP', u'Childhood growth and hypertension in later life', u'Hypertension', u'2007', u'49', u'1415', u'21', u'17452506'], [u'4', u'Barker', u'DJP', u'Fetal origins of coronary heart disease', u'Br Med J', u'1995', u'311', u'171', u'4', u'7613432'], [u'5', u'Barker', u'DJP', u'Mothers, babies and disease in later life', u'1998', u'2nd edn', u'Churchill Livingstone', u'Edinburgh'], [u'6', u'Harding', u'JE', u'The nutritional basis of the fetal origins of adult disease', u'Int J Epidemiol', u'2001', u'30', u'15', u'23', u'11171842'], [u'7', u'Jackson', u'AA', u'All that glitters. Br Nutr Foundation Annual Lecture', u'Nutr Bull', u'2000', u'25', u'11', u'24'], [u'8', u'Tanner', u'JM', u'Fetus into man', u'1989', u'2nd edn', u'Castlemead', u'Ware'], [u'9', u'Duggleby', u'SL', u'Jackson', u'AA', u'Relationship of maternal protein turnover and lean body mass during pregnancy and birth length', u'Clin Sci', u'2001', u'101', u'65', u'72', u'11410116'], [u'10', u'Sibley', u'CP', u'Boyd', u'RDH', u'Polin', u'RA', u'Fox', u'WW', u'Mechanisms of transfer across the human placenta', u'Fetal and neonatal physiology', u'1992', u'Saunders', u'Philadelphia', u'62', u'74'], [u'11', u'Barker', u'DJP', u'Thornburg', u'KL', u'Osmond', u'C', u'Kajantie', u'E', u'Eriksson', u'JG', u'The surface area of the placenta and hypertension in the offspring in later life', u'Int J Dev Biol', u'2010', u'54', u'525', u'30', u'19876839'], [u'12', u'Barker', u'DJP', u'Bull', u'AR', u'Osmond', u'C', u'Simmonds', u'SJ', u'Fetal and placental size and risk of hypertension in adult life', u'Br Med J', u'1990', u'301', u'259', u'62', u'2390618'], [u'13', u'Campbell', u'DM', u'Hall', u'MH', u'Barker', u'DJ', u'Cross', u'J', u'Shiell', u'AW', u'Godfrey', u'KM', u'Diet in pregnancy and the offspring\u2019s blood pressure 40 years later', u'Br J Obstet Gynaecol', u'1996', u'103', u'273', u'80', u'8630314'], [u'14', u'Eriksson', u'J', u'Forsen', u'T', u'Tuomilehto', u'J', u'Osmond', u'C', u'Barker', u'D', u'Fetal and childhood growth and hypertension in adult life', u'Hypertension', u'2000', u'36', u'790', u'4', u'11082144'], [u'15', u'Moore', u'VM', u'Miller', u'AG', u'Boulton', u'TJ', u'Cockington', u'RA', u'Craug', u'IH', u'Magarey', u'AM', u'', u'Placental weight, birth measurements, and blood pressure at age 8 years', u'Arch Dis Child', u'1996', u'74', u'538', u'41', u'8758133'], [u'16', u'Taylor', u'SJC', u'Whincup', u'PH', u'Cook', u'DG', u'Papacosta', u'O', u'Walker', u'M', u'Size at birth and blood pressure; cross sectional study in 8\u201311 year old children', u'Br Med J', u'1997', u'314', u'475', u'80', u'9056797'], [u'17', u'Whincup', u'P', u'Cook', u'D', u'Papacosta', u'O', u'Walker', u'M', u'Birth weight and blood pressure: cross sectional and longitudinal relations in childhood', u'Br Med J', u'1995', u'311', u'773', u'6', u'7580437'], [u'18', u'Hill', u'JC', u'Krishnaveni', u'GV', u'Annamma', u'I', u'Leary', u'SD', u'Fall', u'CHD', u'Glucose tolerance in pregnancy in South India: relationships to neonatal anthropometry', u'Acta Obstet Gynecol Scand', u'2005', u'84', u'159', u'65', u'15683377'], [u'19', u'Eriksson', u'JG', u'Kajantie', u'E', u'Osmond', u'C', u'Thornburg', u'K', u'Barker', u'DJP', u'Boys live dangerously in the womb', u'Am J Hum Biol', u'2010', u'22', u'330', u'5', u'19844898'], [u'20', u'Krishnaveni', u'GV', u'Veena', u'SR', u'Hill', u'JC', u'Kehoe', u'S', u'Karat', u'SC', u'Fall', u'CHD', u'Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in Indian children', u'Diabetes Care', u'2010', u'33', u'402', u'4', u'19918007'], [u'21', u'National High Blood Pressure Educational Program Working Group on High Blood Pressure and Adolescents', u'The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents', u'Pediatrics', u'2004', u'114', u'555', u'76', u'15286277'], [u'22', u'Jansson', u'T', u'Powell', u'TL', u'Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches', u'Clin Sci', u'2007', u'113', u'1', u'13', u'17536998'], [u'23', u'Pedersen', u'JF', u'Ultrasound evidence of sexual differences in fetal size in first trimester', u'Br Med J', u'1980', u'281', u'1253', u'7427655'], [u'24', u'Di Renzo', u'GC', u'Rosati', u'A', u'Sarti', u'RD', u'Cruciani', u'L', u'Cutuli', u'AM', u'Does fetal sex affect pregnancy outcome?', u'Gend Med', u'2007', u'4', u'19', u'30', u'17584623'], [u'25', u'Barker', u'DJP', u'Kajantie', u'E', u'Eriksson', u'JG', u'Alwasel', u'SH', u'Fall', u'CHD', u'Roseboom', u'TJ', u'', u'Burton', u'GJ', u'Barker', u'DJP', u'Moffett', u'A', u'Thornburg', u'K', u'The maternal and placental origins of chronic disease', u'The placenta and human developmental programming', u'2010', u'Cambridge University Press', u'Cambridge', u'5', u'16'], [u'26', u'Kajantie', u'E', u'Thornburg', u'K', u'Eriksson', u'JG', u'Osmond', u'C', u'Barker', u'DJP', u'In preeclampsia, the placenta grows slowly along its minor axis', u'Int J Dev Biol', u'2010', u'54', u'469', u'73', u'19876819'], [u'27', u'Martyn', u'CN', u'Barker', u'DJP', u'Osmond', u'C', u'Mothers pelvic size, fetal growth and death from stroke in men', u'Lancet', u'1996', u'348', u'1264', u'8', u'8909378'], [u'28', u'McCrabb', u'GJ', u'Egan', u'AR', u'Hosking', u'BJ', u'Maternal undernutrition during mid-pregnancy in sheep; variable effects on placental growth', u'J Agric Sci', u'1992', u'118', u'127', u'32']","[u'Initiation of hypertension in utero and its amplification throughout life', u'C', u'M', u'Law', u'S', u'M', u'De', u'C', u'Osmond', u'P', u'M', u'Fayers', u'D', u'J', u'Barker', u'A', u'M', u'Cruddas', u'Br Med J', u'306', u'', u''], [u'Developmental determinants of blood pressure in adults', u'L', u'Adair', u'D', u'Dahly', u'Annu Rev Nutr', u'25', u'', u''], [u'Childhood growth and hypertension in later life', u'J', u'G', u'Eriksson', u'T', u'J', u'Forsen', u'E', u'Kajantie', u'C', u'Osmond', u'Djp', u'Barker', u'Hypertension', u'49', u'', u''], [u'Fetal origins of coronary heart disease', u'Djp', u'Barker', u'Br Med J', u'311', u'', u''], [u'Mothers, babies and disease in later life', u'Djp', u'Barker', u'', u'Edinburgh', u'Churchill Livingstone', u'2nd edn'], [u'Placenta and childhood blood pressure \xaa2011 The Author(s)/Acta Paediatrica \xaa2011 Foundation Acta Paediatrica', u'Winder', u'', u''], [u'The nutritional basis of the fetal origins of adult disease', u'J', u'E', u'Harding', u'Int J Epidemiol', u'30', u'', u''], [u'All that glitters. Br Nutr Foundation Annual Lecture', u'A', u'A', u'Jackson', u'Nutr Bull', u'25', u'', u''], [u'Fetus into man', u'J', u'M', u'Tanner', u'', u'Ware', u'2nd edn. Castlemead'], [u'Relationship of maternal protein turnover and lean body mass during pregnancy and birth length', u'S', u'L', u'Duggleby', u'A', u'A', u'Jackson', u'Clin Sci', u'101', u'', u''], [u'Mechanisms of transfer across the human placenta', u'C', u'P', u'Sibley', u'Rdh', u'Boyd', u'Polin RA and Fox WW', u'', u'', u'Saunders, Philadelphia'], [u'The surface area of the placenta and hypertension in the offspring in later life', u'Djp', u'Barker', u'K', u'L', u'Thornburg', u'C', u'Osmond', u'E', u'Kajantie', u'J', u'G', u'Eriksson', u'Int J Dev Biol', u'54', u'', u''], [u'Fetal and placental size and risk of hypertension in adult life', u'Djp', u'Barker', u'A', u'R', u'Bull', u'C', u'Osmond', u'S', u'J', u'Simmonds', u'Br Med J', u'301', u'', u''], [u""Diet in pregnancy and the offspring's blood pressure 40 years later"", u'D', u'M', u'Campbell', u'M', u'H', u'Hall', u'D', u'J', u'Barker', u'J', u'Cross', u'A', u'W', u'Shiell', u'K', u'M', u'Godfrey', u'Br J Obstet Gynaecol', u'103', u'', u''], [u'Fetal and childhood growth and hypertension in adult life', u'J', u'Eriksson', u'T', u'Forsen', u'J', u'Tuomilehto', u'C', u'Osmond', u'D', u'Barker', u'Hypertension', u'36', u'', u''], [u'Placental weight, birth measurements, and blood pressure at age 8 years', u'V', u'M', u'Moore', u'A', u'G', u'Miller', u'T', u'J', u'Boulton', u'R', u'A', u'Cockington', u'I', u'H', u'Craug', u'A', u'M', u'Magarey', u'Arch Dis Child', u'74', u'', u''], [u'Size at birth and blood pressure; cross sectional study in 811 year old children', u'Sjc', u'Taylor', u'P', u'H', u'Whincup', u'D', u'G', u'Cook', u'O', u'Papacosta', u'M', u'Walker', u'Br Med J', u'314', u'', u''], [u'Birth weight and blood pressure: cross sectional and longitudinal relations in childhood', u'P', u'Whincup', u'D', u'Cook', u'O', u'Papacosta', u'M', u'Walker', u'Br Med J', u'311', u'', u''], [u'Glucose tolerance in pregnancy in South India: relationships to neonatal anthropometry', u'J', u'C', u'Hill', u'G', u'V', u'Krishnaveni', u'I', u'Annamma', u'S', u'D', u'Leary', u'Chd', u'Fall', u'Acta Obstet Gynecol Scand', u'84', u'', u''], [u'Boys live dangerously in the womb', u'J', u'G', u'Eriksson', u'E', u'Kajantie', u'C', u'Osmond', u'K', u'Thornburg', u'Djp', u'Barker', u'Am J Hum Biol', u'22', u'', u''], [u'Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in Indian children', u'G', u'V', u'Krishnaveni', u'S', u'R', u'Veena', u'J', u'C', u'Hill', u'S', u'Kehoe', u'S', u'C', u'Karat', u'Chd', u'Fall', u'Diabetes Care', u'33', u'', u''], [u'National High Blood Pressure Educational Program Working Group on High Blood Pressure and Adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents', u'Pediatrics', u'114', u'', u''], [u'Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches', u'T', u'Jansson', u'T', u'L', u'Powell', u'Clin Sci', u'113', u'', u''], [u'Ultrasound evidence of sexual differences in fetal size in first trimester', u'J', u'F', u'Pedersen', u'Br Med J', u'281', u'1253', u''], [u'Does fetal sex affect pregnancy outcome?', u'Di', u'Renzo', u'G', u'C', u'Rosati', u'A', u'Sarti', u'R', u'D', u'Cruciani', u'L', u'Cutuli', u'A', u'M', u'Gend Med', u'4', u'', u''], [u'The maternal and placental origins of chronic disease', u'Djp', u'Barker', u'E', u'Kajantie', u'J', u'G', u'Eriksson', u'S', u'H', u'Alwasel', u'Chd', u'Fall', u'T', u'J', u'Roseboom', u'The placenta and human developmental programming', u'Burton GJ, Barker DJP, Moffett A, Thornburg', u'Cambridge', u'Cambridge University Press', u'', u''], [u'In preeclampsia, the placenta grows slowly along its minor axis', u'E', u'Kajantie', u'K', u'Thornburg', u'J', u'G', u'Eriksson', u'C', u'Osmond', u'Djp', u'Barker', u'Int J Dev Biol', u'54', u'', u''], [u'Mothers pelvic size, fetal growth and death from stroke in men', u'C', u'N', u'Martyn', u'Djp', u'Barker', u'C', u'Osmond', u'Lancet', u'348', u'', u''], [u'Maternal undernutrition during mid-pregnancy in sheep; variable effects on placental growth', u'G', u'J', u'Mccrabb', u'A', u'R', u'Egan', u'B', u'J', u'Hosking', u'J Agric Sci', u'118', u'', u'']"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_fields,levenshtein,list,0,1,0,0,"[u'1', u'Law', u'CM', u'de', u'SM', u'Osmond', u'C', u'Fayers', u'PM', u'Barker', u'DJ', u'Cruddas', u'AM', u'', u'in utero', u'Br Med J', u'1993', u'306', u'24', u'7', u'8435572'], [u'2', u'Adair', u'L', u'Dahly', u'D', u'Developmental determinants of blood pressure in adults', u'Annu Rev Nutr', u'2005', u'25', u'407', u'34', u'16011473'], [u'3', u'Eriksson', u'JG', u'Forsen', u'TJ', u'Kajantie', u'E', u'Osmond', u'C', u'Barker', u'DJP', u'Childhood growth and hypertension in later life', u'Hypertension', u'2007', u'49', u'1415', u'21', u'17452506'], [u'4', u'Barker', u'DJP', u'Fetal origins of coronary heart disease', u'Br Med J', u'1995', u'311', u'171', u'4', u'7613432'], [u'5', u'Barker', u'DJP', u'Mothers, babies and disease in later life', u'1998', u'2nd edn', u'Churchill Livingstone', u'Edinburgh'], [u'6', u'Harding', u'JE', u'The nutritional basis of the fetal origins of adult disease', u'Int J Epidemiol', u'2001', u'30', u'15', u'23', u'11171842'], [u'7', u'Jackson', u'AA', u'All that glitters. Br Nutr Foundation Annual Lecture', u'Nutr Bull', u'2000', u'25', u'11', u'24'], [u'8', u'Tanner', u'JM', u'Fetus into man', u'1989', u'2nd edn', u'Castlemead', u'Ware'], [u'9', u'Duggleby', u'SL', u'Jackson', u'AA', u'Relationship of maternal protein turnover and lean body mass during pregnancy and birth length', u'Clin Sci', u'2001', u'101', u'65', u'72', u'11410116'], [u'10', u'Sibley', u'CP', u'Boyd', u'RDH', u'Polin', u'RA', u'Fox', u'WW', u'Mechanisms of transfer across the human placenta', u'Fetal and neonatal physiology', u'1992', u'Saunders', u'Philadelphia', u'62', u'74'], [u'11', u'Barker', u'DJP', u'Thornburg', u'KL', u'Osmond', u'C', u'Kajantie', u'E', u'Eriksson', u'JG', u'The surface area of the placenta and hypertension in the offspring in later life', u'Int J Dev Biol', u'2010', u'54', u'525', u'30', u'19876839'], [u'12', u'Barker', u'DJP', u'Bull', u'AR', u'Osmond', u'C', u'Simmonds', u'SJ', u'Fetal and placental size and risk of hypertension in adult life', u'Br Med J', u'1990', u'301', u'259', u'62', u'2390618'], [u'13', u'Campbell', u'DM', u'Hall', u'MH', u'Barker', u'DJ', u'Cross', u'J', u'Shiell', u'AW', u'Godfrey', u'KM', u'Diet in pregnancy and the offspring\u2019s blood pressure 40 years later', u'Br J Obstet Gynaecol', u'1996', u'103', u'273', u'80', u'8630314'], [u'14', u'Eriksson', u'J', u'Forsen', u'T', u'Tuomilehto', u'J', u'Osmond', u'C', u'Barker', u'D', u'Fetal and childhood growth and hypertension in adult life', u'Hypertension', u'2000', u'36', u'790', u'4', u'11082144'], [u'15', u'Moore', u'VM', u'Miller', u'AG', u'Boulton', u'TJ', u'Cockington', u'RA', u'Craug', u'IH', u'Magarey', u'AM', u'', u'Placental weight, birth measurements, and blood pressure at age 8 years', u'Arch Dis Child', u'1996', u'74', u'538', u'41', u'8758133'], [u'16', u'Taylor', u'SJC', u'Whincup', u'PH', u'Cook', u'DG', u'Papacosta', u'O', u'Walker', u'M', u'Size at birth and blood pressure; cross sectional study in 8\u201311 year old children', u'Br Med J', u'1997', u'314', u'475', u'80', u'9056797'], [u'17', u'Whincup', u'P', u'Cook', u'D', u'Papacosta', u'O', u'Walker', u'M', u'Birth weight and blood pressure: cross sectional and longitudinal relations in childhood', u'Br Med J', u'1995', u'311', u'773', u'6', u'7580437'], [u'18', u'Hill', u'JC', u'Krishnaveni', u'GV', u'Annamma', u'I', u'Leary', u'SD', u'Fall', u'CHD', u'Glucose tolerance in pregnancy in South India: relationships to neonatal anthropometry', u'Acta Obstet Gynecol Scand', u'2005', u'84', u'159', u'65', u'15683377'], [u'19', u'Eriksson', u'JG', u'Kajantie', u'E', u'Osmond', u'C', u'Thornburg', u'K', u'Barker', u'DJP', u'Boys live dangerously in the womb', u'Am J Hum Biol', u'2010', u'22', u'330', u'5', u'19844898'], [u'20', u'Krishnaveni', u'GV', u'Veena', u'SR', u'Hill', u'JC', u'Kehoe', u'S', u'Karat', u'SC', u'Fall', u'CHD', u'Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in Indian children', u'Diabetes Care', u'2010', u'33', u'402', u'4', u'19918007'], [u'21', u'National High Blood Pressure Educational Program Working Group on High Blood Pressure and Adolescents', u'The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents', u'Pediatrics', u'2004', u'114', u'555', u'76', u'15286277'], [u'22', u'Jansson', u'T', u'Powell', u'TL', u'Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches', u'Clin Sci', u'2007', u'113', u'1', u'13', u'17536998'], [u'23', u'Pedersen', u'JF', u'Ultrasound evidence of sexual differences in fetal size in first trimester', u'Br Med J', u'1980', u'281', u'1253', u'7427655'], [u'24', u'Di Renzo', u'GC', u'Rosati', u'A', u'Sarti', u'RD', u'Cruciani', u'L', u'Cutuli', u'AM', u'Does fetal sex affect pregnancy outcome?', u'Gend Med', u'2007', u'4', u'19', u'30', u'17584623'], [u'25', u'Barker', u'DJP', u'Kajantie', u'E', u'Eriksson', u'JG', u'Alwasel', u'SH', u'Fall', u'CHD', u'Roseboom', u'TJ', u'', u'Burton', u'GJ', u'Barker', u'DJP', u'Moffett', u'A', u'Thornburg', u'K', u'The maternal and placental origins of chronic disease', u'The placenta and human developmental programming', u'2010', u'Cambridge University Press', u'Cambridge', u'5', u'16'], [u'26', u'Kajantie', u'E', u'Thornburg', u'K', u'Eriksson', u'JG', u'Osmond', u'C', u'Barker', u'DJP', u'In preeclampsia, the placenta grows slowly along its minor axis', u'Int J Dev Biol', u'2010', u'54', u'469', u'73', u'19876819'], [u'27', u'Martyn', u'CN', u'Barker', u'DJP', u'Osmond', u'C', u'Mothers pelvic size, fetal growth and death from stroke in men', u'Lancet', u'1996', u'348', u'1264', u'8', u'8909378'], [u'28', u'McCrabb', u'GJ', u'Egan', u'AR', u'Hosking', u'BJ', u'Maternal undernutrition during mid-pregnancy in sheep; variable effects on placental growth', u'J Agric Sci', u'1992', u'118', u'127', u'32']","[u'Initiation of hypertension in utero and its amplification throughout life', u'C', u'M', u'Law', u'S', u'M', u'De', u'C', u'Osmond', u'P', u'M', u'Fayers', u'D', u'J', u'Barker', u'A', u'M', u'Cruddas', u'Br Med J', u'306', u'', u''], [u'Developmental determinants of blood pressure in adults', u'L', u'Adair', u'D', u'Dahly', u'Annu Rev Nutr', u'25', u'', u''], [u'Childhood growth and hypertension in later life', u'J', u'G', u'Eriksson', u'T', u'J', u'Forsen', u'E', u'Kajantie', u'C', u'Osmond', u'Djp', u'Barker', u'Hypertension', u'49', u'', u''], [u'Fetal origins of coronary heart disease', u'Djp', u'Barker', u'Br Med J', u'311', u'', u''], [u'Mothers, babies and disease in later life', u'Djp', u'Barker', u'', u'Edinburgh', u'Churchill Livingstone', u'2nd edn'], [u'Placenta and childhood blood pressure \xaa2011 The Author(s)/Acta Paediatrica \xaa2011 Foundation Acta Paediatrica', u'Winder', u'', u''], [u'The nutritional basis of the fetal origins of adult disease', u'J', u'E', u'Harding', u'Int J Epidemiol', u'30', u'', u''], [u'All that glitters. Br Nutr Foundation Annual Lecture', u'A', u'A', u'Jackson', u'Nutr Bull', u'25', u'', u''], [u'Fetus into man', u'J', u'M', u'Tanner', u'', u'Ware', u'2nd edn. Castlemead'], [u'Relationship of maternal protein turnover and lean body mass during pregnancy and birth length', u'S', u'L', u'Duggleby', u'A', u'A', u'Jackson', u'Clin Sci', u'101', u'', u''], [u'Mechanisms of transfer across the human placenta', u'C', u'P', u'Sibley', u'Rdh', u'Boyd', u'Polin RA and Fox WW', u'', u'', u'Saunders, Philadelphia'], [u'The surface area of the placenta and hypertension in the offspring in later life', u'Djp', u'Barker', u'K', u'L', u'Thornburg', u'C', u'Osmond', u'E', u'Kajantie', u'J', u'G', u'Eriksson', u'Int J Dev Biol', u'54', u'', u''], [u'Fetal and placental size and risk of hypertension in adult life', u'Djp', u'Barker', u'A', u'R', u'Bull', u'C', u'Osmond', u'S', u'J', u'Simmonds', u'Br Med J', u'301', u'', u''], [u""Diet in pregnancy and the offspring's blood pressure 40 years later"", u'D', u'M', u'Campbell', u'M', u'H', u'Hall', u'D', u'J', u'Barker', u'J', u'Cross', u'A', u'W', u'Shiell', u'K', u'M', u'Godfrey', u'Br J Obstet Gynaecol', u'103', u'', u''], [u'Fetal and childhood growth and hypertension in adult life', u'J', u'Eriksson', u'T', u'Forsen', u'J', u'Tuomilehto', u'C', u'Osmond', u'D', u'Barker', u'Hypertension', u'36', u'', u''], [u'Placental weight, birth measurements, and blood pressure at age 8 years', u'V', u'M', u'Moore', u'A', u'G', u'Miller', u'T', u'J', u'Boulton', u'R', u'A', u'Cockington', u'I', u'H', u'Craug', u'A', u'M', u'Magarey', u'Arch Dis Child', u'74', u'', u''], [u'Size at birth and blood pressure; cross sectional study in 811 year old children', u'Sjc', u'Taylor', u'P', u'H', u'Whincup', u'D', u'G', u'Cook', u'O', u'Papacosta', u'M', u'Walker', u'Br Med J', u'314', u'', u''], [u'Birth weight and blood pressure: cross sectional and longitudinal relations in childhood', u'P', u'Whincup', u'D', u'Cook', u'O', u'Papacosta', u'M', u'Walker', u'Br Med J', u'311', u'', u''], [u'Glucose tolerance in pregnancy in South India: relationships to neonatal anthropometry', u'J', u'C', u'Hill', u'G', u'V', u'Krishnaveni', u'I', u'Annamma', u'S', u'D', u'Leary', u'Chd', u'Fall', u'Acta Obstet Gynecol Scand', u'84', u'', u''], [u'Boys live dangerously in the womb', u'J', u'G', u'Eriksson', u'E', u'Kajantie', u'C', u'Osmond', u'K', u'Thornburg', u'Djp', u'Barker', u'Am J Hum Biol', u'22', u'', u''], [u'Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in Indian children', u'G', u'V', u'Krishnaveni', u'S', u'R', u'Veena', u'J', u'C', u'Hill', u'S', u'Kehoe', u'S', u'C', u'Karat', u'Chd', u'Fall', u'Diabetes Care', u'33', u'', u''], [u'National High Blood Pressure Educational Program Working Group on High Blood Pressure and Adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents', u'Pediatrics', u'114', u'', u''], [u'Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches', u'T', u'Jansson', u'T', u'L', u'Powell', u'Clin Sci', u'113', u'', u''], [u'Ultrasound evidence of sexual differences in fetal size in first trimester', u'J', u'F', u'Pedersen', u'Br Med J', u'281', u'1253', u''], [u'Does fetal sex affect pregnancy outcome?', u'Di', u'Renzo', u'G', u'C', u'Rosati', u'A', u'Sarti', u'R', u'D', u'Cruciani', u'L', u'Cutuli', u'A', u'M', u'Gend Med', u'4', u'', u''], [u'The maternal and placental origins of chronic disease', u'Djp', u'Barker', u'E', u'Kajantie', u'J', u'G', u'Eriksson', u'S', u'H', u'Alwasel', u'Chd', u'Fall', u'T', u'J', u'Roseboom', u'The placenta and human developmental programming', u'Burton GJ, Barker DJP, Moffett A, Thornburg', u'Cambridge', u'Cambridge University Press', u'', u''], [u'In preeclampsia, the placenta grows slowly along its minor axis', u'E', u'Kajantie', u'K', u'Thornburg', u'J', u'G', u'Eriksson', u'C', u'Osmond', u'Djp', u'Barker', u'Int J Dev Biol', u'54', u'', u''], [u'Mothers pelvic size, fetal growth and death from stroke in men', u'C', u'N', u'Martyn', u'Djp', u'Barker', u'C', u'Osmond', u'Lancet', u'348', u'', u''], [u'Maternal undernutrition during mid-pregnancy in sheep; variable effects on placental growth', u'G', u'J', u'Mccrabb', u'A', u'R', u'Egan', u'B', u'J', u'Hosking', u'J Agric Sci', u'118', u'', u'']"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_title,exact,list,0,1,0,0,"Initiation of hypertension in utero and its amplification throughout life, Developmental determinants of blood pressure in adults, Childhood growth and hypertension in later life, Fetal origins of coronary heart disease, , The nutritional basis of the fetal origins of adult disease, All that glitters. Br Nutr Foundation Annual Lecture, , Relationship of maternal protein turnover and lean body mass during pregnancy and birth length, Mechanisms of transfer across the human placenta, The surface area of the placenta and hypertension in the offspring in later life, Fetal and placental size and risk of hypertension in adult life, Diet in pregnancy and the offspring’s blood pressure 40 years later, Fetal and childhood growth and hypertension in adult life, Placental weight, birth measurements, and blood pressure at age 8 years, Size at birth and blood pressure; cross sectional study in 8–11 year old children, Birth weight and blood pressure: cross sectional and longitudinal relations in childhood, Glucose tolerance in pregnancy in South India: relationships to neonatal anthropometry, Boys live dangerously in the womb, Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in Indian children, The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents, Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches, Ultrasound evidence of sexual differences in fetal size in first trimester, Does fetal sex affect pregnancy outcome?, The maternal and placental origins of chronic disease, In preeclampsia, the placenta grows slowly along its minor axis, Mothers pelvic size, fetal growth and death from stroke in men, Maternal undernutrition during mid-pregnancy in sheep; variable effects on placental growth","Initiation of hypertension in utero and its amplification throughout life, Developmental determinants of blood pressure in adults, Childhood growth and hypertension in later life, Fetal origins of coronary heart disease, , , The nutritional basis of the fetal origins of adult disease, All that glitters. Br Nutr Foundation Annual Lecture, , Relationship of maternal protein turnover and lean body mass during pregnancy and birth length, , The surface area of the placenta and hypertension in the offspring in later life, Fetal and placental size and risk of hypertension in adult life, Diet in pregnancy and the offspring's blood pressure 40 years later, Fetal and childhood growth and hypertension in adult life, Placental weight, birth measurements, and blood pressure at age 8 years, Size at birth and blood pressure; cross sectional study in 811 year old children, Birth weight and blood pressure: cross sectional and longitudinal relations in childhood, Glucose tolerance in pregnancy in South India: relationships to neonatal anthropometry, Boys live dangerously in the womb, Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in Indian children, National High Blood Pressure Educational Program Working Group on High Blood Pressure and Adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents, Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches, Ultrasound evidence of sexual differences in fetal size in first trimester, Does fetal sex affect pregnancy outcome?, The maternal and placental origins of chronic disease, In preeclampsia, the placenta grows slowly along its minor axis, Mothers pelvic size, fetal growth and death from stroke in men, Maternal undernutrition during mid-pregnancy in sheep; variable effects on placental growth"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_title,levenshtein,list,0,1,0,0,"Initiation of hypertension in utero and its amplification throughout life, Developmental determinants of blood pressure in adults, Childhood growth and hypertension in later life, Fetal origins of coronary heart disease, , The nutritional basis of the fetal origins of adult disease, All that glitters. Br Nutr Foundation Annual Lecture, , Relationship of maternal protein turnover and lean body mass during pregnancy and birth length, Mechanisms of transfer across the human placenta, The surface area of the placenta and hypertension in the offspring in later life, Fetal and placental size and risk of hypertension in adult life, Diet in pregnancy and the offspring’s blood pressure 40 years later, Fetal and childhood growth and hypertension in adult life, Placental weight, birth measurements, and blood pressure at age 8 years, Size at birth and blood pressure; cross sectional study in 8–11 year old children, Birth weight and blood pressure: cross sectional and longitudinal relations in childhood, Glucose tolerance in pregnancy in South India: relationships to neonatal anthropometry, Boys live dangerously in the womb, Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in Indian children, The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents, Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches, Ultrasound evidence of sexual differences in fetal size in first trimester, Does fetal sex affect pregnancy outcome?, The maternal and placental origins of chronic disease, In preeclampsia, the placenta grows slowly along its minor axis, Mothers pelvic size, fetal growth and death from stroke in men, Maternal undernutrition during mid-pregnancy in sheep; variable effects on placental growth","Initiation of hypertension in utero and its amplification throughout life, Developmental determinants of blood pressure in adults, Childhood growth and hypertension in later life, Fetal origins of coronary heart disease, , , The nutritional basis of the fetal origins of adult disease, All that glitters. Br Nutr Foundation Annual Lecture, , Relationship of maternal protein turnover and lean body mass during pregnancy and birth length, , The surface area of the placenta and hypertension in the offspring in later life, Fetal and placental size and risk of hypertension in adult life, Diet in pregnancy and the offspring's blood pressure 40 years later, Fetal and childhood growth and hypertension in adult life, Placental weight, birth measurements, and blood pressure at age 8 years, Size at birth and blood pressure; cross sectional study in 811 year old children, Birth weight and blood pressure: cross sectional and longitudinal relations in childhood, Glucose tolerance in pregnancy in South India: relationships to neonatal anthropometry, Boys live dangerously in the womb, Intrauterine exposure to maternal diabetes is associated with higher adiposity and insulin resistance and clustering of cardiovascular risk markers in Indian children, National High Blood Pressure Educational Program Working Group on High Blood Pressure and Adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents, Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches, Ultrasound evidence of sexual differences in fetal size in first trimester, Does fetal sex affect pregnancy outcome?, The maternal and placental origins of chronic disease, In preeclampsia, the placenta grows slowly along its minor axis, Mothers pelvic size, fetal growth and death from stroke in men, Maternal undernutrition during mid-pregnancy in sheep; variable effects on placental growth"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_year,exact,list,0,1,0,0,"1993, 2005, 2007, 1995, 1998, 2001, 2000, 1989, 2001, 1992, 2010, 1990, 1996, 2000, 1996, 1997, 1995, 2005, 2010, 2010, 2004, 2007, 1980, 2007, 2010, 2010, 1996, 1992","1993, 2005, 2007, 1995, 1998, 2011100, 2001, 2000, 1989, 2001, 1992, 2010, 1990, 1996, 2000, 1996, 1997, 1995, 2005, 2010, 2010, 2004, 2007, 1980, 2007, 2010, 2010, 1996, 1992"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_year,levenshtein,list,0,1,0,0,"1993, 2005, 2007, 1995, 1998, 2001, 2000, 1989, 2001, 1992, 2010, 1990, 1996, 2000, 1996, 1997, 1995, 2005, 2010, 2010, 2004, 2007, 1980, 2007, 2010, 2010, 1996, 1992","1993, 2005, 2007, 1995, 1998, 2011100, 2001, 2000, 1989, 2001, 1992, 2010, 1990, 1996, 2000, 1996, 1997, 1995, 2005, 2010, 2010, 2004, 2007, 1980, 2007, 2010, 2010, 1996, 1992"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_source,exact,list,0,1,0,0,"Br Med J, Annu Rev Nutr, Hypertension, Br Med J, Mothers, babies and disease in later life, Int J Epidemiol, Nutr Bull, Fetus into man, Clin Sci, Fetal and neonatal physiology, Int J Dev Biol, Br Med J, Br J Obstet Gynaecol, Hypertension, Arch Dis Child, Br Med J, Br Med J, Acta Obstet Gynecol Scand, Am J Hum Biol, Diabetes Care, Pediatrics, Clin Sci, Br Med J, Gend Med, The placenta and human developmental programming, Int J Dev Biol, Lancet, J Agric Sci","Br Med J, Annu Rev Nutr, Hypertension, Br Med J, , , Int J Epidemiol, Nutr Bull, , Clin Sci, , Int J Dev Biol, Br Med J, Br J Obstet Gynaecol, Hypertension, Arch Dis Child, Br Med J, Br Med J, Acta Obstet Gynecol Scand, Am J Hum Biol, Diabetes Care, Pediatrics, Clin Sci, Br Med J, Gend Med, , Int J Dev Biol, Lancet, J Agric Sci"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_source,levenshtein,list,0,1,0,0,"Br Med J, Annu Rev Nutr, Hypertension, Br Med J, Mothers, babies and disease in later life, Int J Epidemiol, Nutr Bull, Fetus into man, Clin Sci, Fetal and neonatal physiology, Int J Dev Biol, Br Med J, Br J Obstet Gynaecol, Hypertension, Arch Dis Child, Br Med J, Br Med J, Acta Obstet Gynecol Scand, Am J Hum Biol, Diabetes Care, Pediatrics, Clin Sci, Br Med J, Gend Med, The placenta and human developmental programming, Int J Dev Biol, Lancet, J Agric Sci","Br Med J, Annu Rev Nutr, Hypertension, Br Med J, , , Int J Epidemiol, Nutr Bull, , Clin Sci, , Int J Dev Biol, Br Med J, Br J Obstet Gynaecol, Hypertension, Arch Dis Child, Br Med J, Br Med J, Acta Obstet Gynecol Scand, Am J Hum Biol, Diabetes Care, Pediatrics, Clin Sci, Br Med J, Gend Med, , Int J Dev Biol, Lancet, J Agric Sci"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_volume,exact,list,0,1,0,0,"306, 25, 49, 311, , 30, 25, , 101, , 54, 301, 103, 36, 74, 314, 311, 84, 22, 33, 114, 113, 281, 4, , 54, 348, 118","306, 25, 49, 311, , , 30, 25, , 101, , 54, 301, 103, 36, 74, 314, 311, 84, 22, 33, 114, 113, 281, 4, , 54, 348, 118"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_volume,levenshtein,list,0,1,0,0,"306, 25, 49, 311, , 30, 25, , 101, , 54, 301, 103, 36, 74, 314, 311, 84, 22, 33, 114, 113, 281, 4, , 54, 348, 118","306, 25, 49, 311, , , 30, 25, , 101, , 54, 301, 103, 36, 74, 314, 311, 84, 22, 33, 114, 113, 281, 4, , 54, 348, 118"
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_fpage,exact,list,0,1,0,0,"24, 407, 1415, 171, , 15, 11, , 65, 62, 525, 259, 273, 790, 538, 475, 773, 159, 330, 402, 555, 1, 1253, 19, 5, 469, 1264, 127",", , , , , , , , , , , , , , , , , , , , , , , , , , , , "
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_fpage,levenshtein,list,0,1,0,0,"24, 407, 1415, 171, , 15, 11, , 65, 62, 525, 259, 273, 790, 538, 475, 773, 159, 330, 402, 555, 1, 1253, 19, 5, 469, 1264, 127",", , , , , , , , , , , , , , , , , , , , , , , , , , , , "
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_lpage,exact,list,0,1,0,0,"7, 34, 21, 4, , 23, 24, , 72, 74, 30, 62, 80, 4, 41, 80, 6, 65, 5, 4, 76, 13, , 30, 16, 73, 8, 32",", , , , , , , , , , , , , , , , , , , , , , , , , , , , "
apa0100-0653.grobid-tei.xml,apa0100-0653.nxml,reference_lpage,levenshtein,list,0,1,0,0,"7, 34, 21, 4, , 23, 24, , 72, 74, 30, 62, 80, 4, 41, 80, 6, 65, 5, 4, 76, 13, , 30, 16, 73, 8, 32",", , , , , , , , , , , , , , , , , , , , , , , , , , , , "
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,title,exact,string,1,0,0,0,On the function of the mammalian renal papilla and the peristalsis of the surrounding pelvis,On the function of the mammalian renal papilla and the peristalsis of the surrounding pelvis
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,title,levenshtein,string,1,0,0,0,On the function of the mammalian renal papilla and the peristalsis of the surrounding pelvis,On the function of the mammalian renal papilla and the peristalsis of the surrounding pelvis
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,abstract,exact,string,1,0,0,0,"This is an informal personal review of the development over time of my ideas about the concentrating mechanism of the mammalian renal papilla. It had been observed that animals with a need to produce a concentrated urine have a long renal papilla. I saw the function of the long papilla in desert rodents as an elongation of the counter-current concentrating mechanism of the inner medulla. This model led me to overlook contrary evidence. For example, in many experiments, the final urine has a higher osmolality than that of the tissue at the tip of the papilla. In addition, we had observations of the peristalsis of the renal pelvis surrounding the papilla. The urine concentration falls if the peristalsis is stopped. I was wrong; together, these lines of evidence show that the renal papilla is not just an elongation of the inner medulla. We are left without a full explanation of the concentrating mechanism of the mammalian renal papilla. It is hoped that other researchers will tackle this interesting problem.","This is an informal personal review of the development over time of my ideas about the concentrating mechanism of the mammalian renal papilla. It had been observed that animals with a need to produce a concentrated urine have a long renal papilla. I saw the function of the long papilla in desert rodents as an elongation of the counter-current concentrating mechanism of the inner medulla. This model led me to overlook contrary evidence. For example, in many experiments, the final urine has a higher osmolality than that of the tissue at the tip of the papilla. In addition, we had observations of the peristalsis of the renal pelvis surrounding the papilla. The urine concentration falls if the peristalsis is stopped. I was wrong; together, these lines of evidence show that the renal papilla is not just an elongation of the inner medulla. We are left without a full explanation of the concentrating mechanism of the mammalian renal papilla. It is hoped that other researchers will tackle this interesting problem."
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,abstract,levenshtein,string,1,0,0,0,"This is an informal personal review of the development over time of my ideas about the concentrating mechanism of the mammalian renal papilla. It had been observed that animals with a need to produce a concentrated urine have a long renal papilla. I saw the function of the long papilla in desert rodents as an elongation of the counter-current concentrating mechanism of the inner medulla. This model led me to overlook contrary evidence. For example, in many experiments, the final urine has a higher osmolality than that of the tissue at the tip of the papilla. In addition, we had observations of the peristalsis of the renal pelvis surrounding the papilla. The urine concentration falls if the peristalsis is stopped. I was wrong; together, these lines of evidence show that the renal papilla is not just an elongation of the inner medulla. We are left without a full explanation of the concentrating mechanism of the mammalian renal papilla. It is hoped that other researchers will tackle this interesting problem.","This is an informal personal review of the development over time of my ideas about the concentrating mechanism of the mammalian renal papilla. It had been observed that animals with a need to produce a concentrated urine have a long renal papilla. I saw the function of the long papilla in desert rodents as an elongation of the counter-current concentrating mechanism of the inner medulla. This model led me to overlook contrary evidence. For example, in many experiments, the final urine has a higher osmolality than that of the tissue at the tip of the papilla. In addition, we had observations of the peristalsis of the renal pelvis surrounding the papilla. The urine concentration falls if the peristalsis is stopped. I was wrong; together, these lines of evidence show that the renal papilla is not just an elongation of the inner medulla. We are left without a full explanation of the concentrating mechanism of the mammalian renal papilla. It is hoped that other researchers will tackle this interesting problem."
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,keywords,exact,set,1,0,0,0,"concentrating mechanism, kidney, peristalsis, renal papilla, renal pelvis, water removal","concentrating mechanism, kidney, peristalsis, renal papilla, renal pelvis, water removal"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,keywords,levenshtein,set,1,0,0,0,"concentrating mechanism, kidney, peristalsis, renal papilla, renal pelvis, water removal","concentrating mechanism, kidney, peristalsis, renal papilla, renal pelvis, water removal"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,author_surnames,exact,set,1,0,0,0,Schmidt-Nielsen,Schmidt-Nielsen
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,author_surnames,levenshtein,set,1,0,0,0,Schmidt-Nielsen,Schmidt-Nielsen
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,first_author_surname,exact,string,1,0,0,0,Schmidt-Nielsen,Schmidt-Nielsen
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,first_author_surname,levenshtein,string,1,0,0,0,Schmidt-Nielsen,Schmidt-Nielsen
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,author_full_names,exact,set,1,0,0,0,"Bent Schmidt-Nielsen, Bodil Schmidt-Nielsen","Bent Schmidt-Nielsen, Bodil Schmidt-Nielsen"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,author_full_names,levenshtein,set,1,0,0,0,"Bent Schmidt-Nielsen, Bodil Schmidt-Nielsen","Bent Schmidt-Nielsen, Bodil Schmidt-Nielsen"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,first_author_full_name,exact,string,1,0,0,0,Bodil Schmidt-Nielsen,Bodil Schmidt-Nielsen
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,first_author_full_name,levenshtein,string,1,0,0,0,Bodil Schmidt-Nielsen,Bodil Schmidt-Nielsen
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,affiliation_strings,exact,set,0,1,0,0,"Department of Physiology, University of Florida, Gainesville, FL, USA, Lexington, MA, USA","Department of Physiology, University of Florida, Gainesville, USA, Loring Rd, Lexington, Lexington, USA, USA"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,affiliation_strings,levenshtein,set,0,1,0,0,"Department of Physiology, University of Florida, Gainesville, FL, USA, Lexington, MA, USA","Department of Physiology, University of Florida, Gainesville, USA, Loring Rd, Lexington, Lexington, USA, USA"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,affiliation_institution,exact,set,0,1,0,0,"Department of Physiology, University of Florida, Lexington",", Department of Physiology, University of Florida"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,affiliation_institution,levenshtein,set,0,1,0,0,"Department of Physiology, University of Florida, Lexington",", Department of Physiology, University of Florida"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,section_titles,exact,list,0,1,0,0,"The peristaltic mechanism, Hypothesis on how the renal pelvic peristaltic pumping of the papilla might contribute to the concentrating mechanism, Conclusion","Abstract, The peristaltic mechanism, Conclusion, Conflicts of interest"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,section_titles,levenshtein,list,0,1,0,0,"The peristaltic mechanism, Hypothesis on how the renal pelvic peristaltic pumping of the papilla might contribute to the concentrating mechanism, Conclusion","Abstract, The peristaltic mechanism, Conclusion, Conflicts of interest"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,tables,exact,table,0,0,0,1,,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,tables,levenshtein,table,0,0,0,1,,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,table_strings,exact,list,0,0,0,1,,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,table_strings,levenshtein,list,0,0,0,1,,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,table_labels,exact,list,0,0,0,1,,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,table_labels,levenshtein,list,0,0,0,1,,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,table_captions,exact,list,0,0,0,1,,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,table_captions,levenshtein,list,0,0,0,1,,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,table_label_captions,exact,list,0,0,0,1,,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,table_label_captions,levenshtein,list,0,0,0,1,,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,first_reference_fields,exact,list,0,1,0,0,"[u'Dantzler', u'WH', u'Unpublished remarks', u'The William H. Dantzler Symposium', u'2006', u'Tucson, AZ', u'April 6\u20137']","[u'Unpublished remarks. The William H. Dantzler Symposium', u'W', u'H', u'Dantzler', u'', u'Tucson, AZ']"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,first_reference_fields,levenshtein,list,0,1,0,0,"[u'Dantzler', u'WH', u'Unpublished remarks', u'The William H. Dantzler Symposium', u'2006', u'Tucson, AZ', u'April 6\u20137']","[u'Unpublished remarks. The William H. Dantzler Symposium', u'W', u'H', u'Dantzler', u'', u'Tucson, AZ']"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,first_reference_title,exact,string,0,0,1,0,Unpublished remarks,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,first_reference_title,levenshtein,string,0,0,1,0,Unpublished remarks,
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_fields,exact,list,0,1,0,0,"[u'Dantzler', u'WH', u'Unpublished remarks', u'The William H. Dantzler Symposium', u'2006', u'Tucson, AZ', u'April 6\u20137'], [u'Knepper', u'MA', u'Saidel', u'GM', u'Hascall', u'VC', u'Dwyer', u'T', u'Concentration of solutes in the renal inner medulla: interstitial hyaluronan as a mechano-osmotic transducer', u'Am J Physiol Renal Physiol', u'2003', u'284', u'F433', u'F446', u'12556362'], [u'Nielsen', u'S', u'Fr\xf8kiaer', u'J', u'Marples', u'D', u'Kwon', u'T-H', u'Agre', u'P', u'Knepper', u'MA', u'Aquaporins in the kidney: from molecules to medicine', u'Physiol Rev', u'2002', u'82', u'205', u'244', u'11773613'], [u'Pruitt', u'MEC', u'Knepper', u'MA', u'Graves', u'B', u'Schmidt-Nielsen', u'B', u'Effect of peristaltic contractions of the renal pelvic wall on solute concentrations of the renal inner medulla in the hamster', u'Am J Physiol Renal Physiol', u'2006', u'290', u'F892', u'F896', u'16234309'], [u'Schmidt-Nielsen', u'B', u'The renal pelvis', u'Kidney Int', u'1987', u'31', u'621', u'628', u'3550232'], [u'Schmidt-Nielsen', u'B', u'August Krogh Lecture. The renal concentrating mechanism in insects and mammals: a new hypothesis involving hydrostatic pressures', u'Am J Physiol Regul Integr Comp Physiol', u'1995', u'268', u'R1087', u'R1100'], [u'Schmidt-Nielsen', u'B', u'Graves', u'B', u'Changes in fluid compartments in hamster renal papilla due to peristalsis in the pelvic wall', u'Kidney Int', u'1982', u'22', u'613', u'625', u'International Society of Nephrology', u'6891728'], [u'Sperber', u'I', u'Studies on the mammalian kidney', u'Zoologiska Bidrag Fr\xe5n Uppsala', u'1944', u'22', u'249', u'431'], [u'Truniger', u'B', u'Schmidt-Nielsen', u'B', u'Intrarenal distribution of urea and related compounds: effects of nitrogen intake', u'Am J Physiol', u'1964', u'207', u'971', u'978', u'14237471'], [u'Zell', u'SR', u'Relationship of the Measured Osmolality in the Mammalian Renal Papilla to the Formation of a Concentrated Urine During Antidiuresis', u'1973', u'Cleveland, OH, USA', u'Case Western Reserve University', u'PhD Thesis']","[u'Unpublished remarks. The William H. Dantzler Symposium', u'W', u'H', u'Dantzler', u'', u'Tucson, AZ'], [u'Concentration of solutes in the renal inner medulla: interstitial hyaluronan as a mechano-osmotic transducer', u'M', u'A', u'Knepper', u'G', u'M', u'Saidel', u'V', u'C', u'Hascall', u'T', u'Dwyer', u'Am J Physiol Renal Physiol', u'284', u'', u''], [u'Aquaporins in the kidney: from molecules to medicine', u'S', u'Nielsen', u'J', u'Fr\xf8kiaer', u'D', u'Marples', u'T.-H', u'Kwon', u'P', u'Agre', u'M', u'A', u'Knepper', u'Physiol Rev', u'82', u'', u''], [u'Effect of peristaltic contractions of the renal pelvic wall on solute concentrations of the renal inner medulla in the hamster', u'M', u'E C', u'Pruitt', u'M', u'A', u'Knepper', u'B', u'Graves', u'B', u'Schmidt-Nielsen', u'Am J Physiol Renal Physiol', u'290', u'', u''], [u'The renal pelvis', u'B', u'Schmidt-Nielsen', u'Kidney Int', u'31', u'', u''], [u'August Krogh Lecture. The renal concentrating mechanism in insects and mammals: a new hypothesis involving hydrostatic pressures', u'B', u'Schmidt-Nielsen', u'Am J Physiol Regul Integr Comp Physiol', u'268', u'', u''], [u'Changes in fluid compartments in hamster renal papilla due to peristalsis in the pelvic wall', u'B', u'Schmidt-Nielsen', u'B', u'Graves', u'International Society of Nephrology', u'22', u'', u'', u'Kidney Int'], [u'Studies on the mammalian kidney', u'I', u'Sperber', u'Zoologiska Bidrag Fr\xe5 n Uppsala', u'22', u'', u''], [u'Intrarenal distribution of urea and related compounds: effects of nitrogen intake', u'B', u'Truniger', u'B', u'Schmidt-Nielsen', u'Am J Physiol', u'207', u'', u''], [u'Relationship of the Measured Osmolality in the Mammalian Renal Papilla to the Formation of a Concentrated Urine During Antidiuresis', u'S', u'R', u'Zell', u'', u'Cleveland, OH, USA', u'Case Western Reserve University', u'PhD Thesis']"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_fields,levenshtein,list,0,1,0,0,"[u'Dantzler', u'WH', u'Unpublished remarks', u'The William H. Dantzler Symposium', u'2006', u'Tucson, AZ', u'April 6\u20137'], [u'Knepper', u'MA', u'Saidel', u'GM', u'Hascall', u'VC', u'Dwyer', u'T', u'Concentration of solutes in the renal inner medulla: interstitial hyaluronan as a mechano-osmotic transducer', u'Am J Physiol Renal Physiol', u'2003', u'284', u'F433', u'F446', u'12556362'], [u'Nielsen', u'S', u'Fr\xf8kiaer', u'J', u'Marples', u'D', u'Kwon', u'T-H', u'Agre', u'P', u'Knepper', u'MA', u'Aquaporins in the kidney: from molecules to medicine', u'Physiol Rev', u'2002', u'82', u'205', u'244', u'11773613'], [u'Pruitt', u'MEC', u'Knepper', u'MA', u'Graves', u'B', u'Schmidt-Nielsen', u'B', u'Effect of peristaltic contractions of the renal pelvic wall on solute concentrations of the renal inner medulla in the hamster', u'Am J Physiol Renal Physiol', u'2006', u'290', u'F892', u'F896', u'16234309'], [u'Schmidt-Nielsen', u'B', u'The renal pelvis', u'Kidney Int', u'1987', u'31', u'621', u'628', u'3550232'], [u'Schmidt-Nielsen', u'B', u'August Krogh Lecture. The renal concentrating mechanism in insects and mammals: a new hypothesis involving hydrostatic pressures', u'Am J Physiol Regul Integr Comp Physiol', u'1995', u'268', u'R1087', u'R1100'], [u'Schmidt-Nielsen', u'B', u'Graves', u'B', u'Changes in fluid compartments in hamster renal papilla due to peristalsis in the pelvic wall', u'Kidney Int', u'1982', u'22', u'613', u'625', u'International Society of Nephrology', u'6891728'], [u'Sperber', u'I', u'Studies on the mammalian kidney', u'Zoologiska Bidrag Fr\xe5n Uppsala', u'1944', u'22', u'249', u'431'], [u'Truniger', u'B', u'Schmidt-Nielsen', u'B', u'Intrarenal distribution of urea and related compounds: effects of nitrogen intake', u'Am J Physiol', u'1964', u'207', u'971', u'978', u'14237471'], [u'Zell', u'SR', u'Relationship of the Measured Osmolality in the Mammalian Renal Papilla to the Formation of a Concentrated Urine During Antidiuresis', u'1973', u'Cleveland, OH, USA', u'Case Western Reserve University', u'PhD Thesis']","[u'Unpublished remarks. The William H. Dantzler Symposium', u'W', u'H', u'Dantzler', u'', u'Tucson, AZ'], [u'Concentration of solutes in the renal inner medulla: interstitial hyaluronan as a mechano-osmotic transducer', u'M', u'A', u'Knepper', u'G', u'M', u'Saidel', u'V', u'C', u'Hascall', u'T', u'Dwyer', u'Am J Physiol Renal Physiol', u'284', u'', u''], [u'Aquaporins in the kidney: from molecules to medicine', u'S', u'Nielsen', u'J', u'Fr\xf8kiaer', u'D', u'Marples', u'T.-H', u'Kwon', u'P', u'Agre', u'M', u'A', u'Knepper', u'Physiol Rev', u'82', u'', u''], [u'Effect of peristaltic contractions of the renal pelvic wall on solute concentrations of the renal inner medulla in the hamster', u'M', u'E C', u'Pruitt', u'M', u'A', u'Knepper', u'B', u'Graves', u'B', u'Schmidt-Nielsen', u'Am J Physiol Renal Physiol', u'290', u'', u''], [u'The renal pelvis', u'B', u'Schmidt-Nielsen', u'Kidney Int', u'31', u'', u''], [u'August Krogh Lecture. The renal concentrating mechanism in insects and mammals: a new hypothesis involving hydrostatic pressures', u'B', u'Schmidt-Nielsen', u'Am J Physiol Regul Integr Comp Physiol', u'268', u'', u''], [u'Changes in fluid compartments in hamster renal papilla due to peristalsis in the pelvic wall', u'B', u'Schmidt-Nielsen', u'B', u'Graves', u'International Society of Nephrology', u'22', u'', u'', u'Kidney Int'], [u'Studies on the mammalian kidney', u'I', u'Sperber', u'Zoologiska Bidrag Fr\xe5 n Uppsala', u'22', u'', u''], [u'Intrarenal distribution of urea and related compounds: effects of nitrogen intake', u'B', u'Truniger', u'B', u'Schmidt-Nielsen', u'Am J Physiol', u'207', u'', u''], [u'Relationship of the Measured Osmolality in the Mammalian Renal Papilla to the Formation of a Concentrated Urine During Antidiuresis', u'S', u'R', u'Zell', u'', u'Cleveland, OH, USA', u'Case Western Reserve University', u'PhD Thesis']"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_title,exact,list,0,1,0,0,"Unpublished remarks, Concentration of solutes in the renal inner medulla: interstitial hyaluronan as a mechano-osmotic transducer, Aquaporins in the kidney: from molecules to medicine, Effect of peristaltic contractions of the renal pelvic wall on solute concentrations of the renal inner medulla in the hamster, The renal pelvis, August Krogh Lecture. The renal concentrating mechanism in insects and mammals: a new hypothesis involving hydrostatic pressures, Changes in fluid compartments in hamster renal papilla due to peristalsis in the pelvic wall, Studies on the mammalian kidney, Intrarenal distribution of urea and related compounds: effects of nitrogen intake, ",", Concentration of solutes in the renal inner medulla: interstitial hyaluronan as a mechano-osmotic transducer, Aquaporins in the kidney: from molecules to medicine, Effect of peristaltic contractions of the renal pelvic wall on solute concentrations of the renal inner medulla in the hamster, The renal pelvis, August Krogh Lecture. The renal concentrating mechanism in insects and mammals: a new hypothesis involving hydrostatic pressures, Changes in fluid compartments in hamster renal papilla due to peristalsis in the pelvic wall, Studies on the mammalian kidney, Intrarenal distribution of urea and related compounds: effects of nitrogen intake, "
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_title,levenshtein,list,0,1,0,0,"Unpublished remarks, Concentration of solutes in the renal inner medulla: interstitial hyaluronan as a mechano-osmotic transducer, Aquaporins in the kidney: from molecules to medicine, Effect of peristaltic contractions of the renal pelvic wall on solute concentrations of the renal inner medulla in the hamster, The renal pelvis, August Krogh Lecture. The renal concentrating mechanism in insects and mammals: a new hypothesis involving hydrostatic pressures, Changes in fluid compartments in hamster renal papilla due to peristalsis in the pelvic wall, Studies on the mammalian kidney, Intrarenal distribution of urea and related compounds: effects of nitrogen intake, ",", Concentration of solutes in the renal inner medulla: interstitial hyaluronan as a mechano-osmotic transducer, Aquaporins in the kidney: from molecules to medicine, Effect of peristaltic contractions of the renal pelvic wall on solute concentrations of the renal inner medulla in the hamster, The renal pelvis, August Krogh Lecture. The renal concentrating mechanism in insects and mammals: a new hypothesis involving hydrostatic pressures, Changes in fluid compartments in hamster renal papilla due to peristalsis in the pelvic wall, Studies on the mammalian kidney, Intrarenal distribution of urea and related compounds: effects of nitrogen intake, "
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_year,exact,list,0,1,0,0,"2006, 2003, 2002, 2006, 1987, 1995, 1982, 1944, 1964, 1973","2006-04-06, 2003, 2002, 2006, 1987, 1995, 1982, 1944, 1964, 1973"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_year,levenshtein,list,0,1,0,0,"2006, 2003, 2002, 2006, 1987, 1995, 1982, 1944, 1964, 1973","2006-04-06, 2003, 2002, 2006, 1987, 1995, 1982, 1944, 1964, 1973"
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_source,exact,list,0,1,0,0,"The William H. Dantzler Symposium, Am J Physiol Renal Physiol, Physiol Rev, Am J Physiol Renal Physiol, Kidney Int, Am J Physiol Regul Integr Comp Physiol, Kidney Int, Zoologiska Bidrag Från Uppsala, Am J Physiol, Relationship of the Measured Osmolality in the Mammalian Renal Papilla to the Formation of a Concentrated Urine During Antidiuresis",", Am J Physiol Renal Physiol, Physiol Rev, Am J Physiol Renal Physiol, Kidney Int, Am J Physiol Regul Integr Comp Physiol, International Society of Nephrology, Zoologiska Bidrag Frå n Uppsala, Am J Physiol, "
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_source,levenshtein,list,0,1,0,0,"The William H. Dantzler Symposium, Am J Physiol Renal Physiol, Physiol Rev, Am J Physiol Renal Physiol, Kidney Int, Am J Physiol Regul Integr Comp Physiol, Kidney Int, Zoologiska Bidrag Från Uppsala, Am J Physiol, Relationship of the Measured Osmolality in the Mammalian Renal Papilla to the Formation of a Concentrated Urine During Antidiuresis",", Am J Physiol Renal Physiol, Physiol Rev, Am J Physiol Renal Physiol, Kidney Int, Am J Physiol Regul Integr Comp Physiol, International Society of Nephrology, Zoologiska Bidrag Frå n Uppsala, Am J Physiol, "
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_volume,exact,list,1,0,0,0,", 284, 82, 290, 31, 268, 22, 22, 207, ",", 284, 82, 290, 31, 268, 22, 22, 207, "
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_volume,levenshtein,list,1,0,0,0,", 284, 82, 290, 31, 268, 22, 22, 207, ",", 284, 82, 290, 31, 268, 22, 22, 207, "
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_fpage,exact,list,0,1,0,0,", F433, 205, F892, 621, R1087, 613, 249, 971, ",", , , , , , , , , "
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_fpage,levenshtein,list,0,1,0,0,", F433, 205, F892, 621, R1087, 613, 249, 971, ",", , , , , , , , , "
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_lpage,exact,list,0,1,0,0,", F446, 244, F896, 628, R1100, 625, 431, 978, ",", , , , , , , , , "
apha0202-0379.grobid-tei.xml,apha0202-0379.nxml,reference_lpage,levenshtein,list,0,1,0,0,", F446, 244, F896, 628, R1100, 625, 431, 978, ",", , , , , , , , , "
